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Abstract
The assessment and appraisal of regenerative medicines and
cell therapy products: an exploration of methods for review,
economic evaluation and appraisal
Robert Hettle,1 Mark Corbett,2 Sebastian Hinde,1 Robert Hodgson,2
Julie Jones-Diette,2 Nerys Woolacott2 and Stephen Palmer1*
1Centre for Health Economics, University of York, York, UK
2Centre for Reviews and Dissemination, University of York, York, UK
*Corresponding author stephen.palmer@york.ac.uk
Background: The National Institute for Health and Care Excellence (NICE) commissioned a ‘mock
technology appraisal’ to assess whether changes to its methods and processes are needed. This report
presents the findings of independent research commissioned to inform this appraisal and the deliberations
of a panel convened by NICE to evaluate the mock appraisal.
Methods: Our research included reviews to identify issues, analysis methods and conceptual differences
and the relevance of alternative decision frameworks, alongside the development of an exemplar case
study of chimeric antigen receptor (CAR) T-cell therapy for treating acute lymphoblastic leukaemia.
Results: An assessment of previous evaluations of regenerative medicines found that, although there
were a number of evidential challenges, none was unique to regenerative medicines or was beyond the
scope of existing methods used to conceptualise decision uncertainty. Regarding the clinical evidence for
regenerative medicines, the issues were those associated with a limited evidence base but were not unique to
regenerative medicines: small non-randomised studies, high variation in response and the intervention subject
to continuing development. The relative treatment effects generated from single-arm trials are likely to be
optimistic unless it is certain that the historical data have accurately estimated the efficacy of the control agent.
Pivotal trials may use surrogate end points, which, on average, overestimate treatment effects. To reduce
overall uncertainty, multivariate meta-analysis of all available data should be considered. Incorporating
indirectly relevant but more reliable (more mature) data into the analysis can also be considered; such data
may become available as a result of the evolving regulatory pathways being developed by the European
Medicines Agency. For the exemplar case of CAR T-cell therapy, target product profiles (TPPs) were
developed, which considered the ‘curative’ and ‘bridging to stem-cell transplantation’ treatment approaches
separately. Within each TPP, three ‘hypothetical’ evidence sets (minimum, intermediate and mature) were
generated to simulate the impact of alternative levels of precision and maturity in the clinical evidence.
Subsequent assessments of cost-effectiveness were undertaken, employing the existing NICE reference case
alongside additional analyses suggested within alternative frameworks. The additional exploratory analyses
were undertaken to demonstrate how assessments of cost-effectiveness and uncertainty could be impacted
by alternative managed entry agreements (MEAs), including price discounts, performance-related schemes
and technology leasing. The panel deliberated on the range of TPPs, evidence sets and MEAs, commenting
on the likely recommendations for each scenario. The panel discussed the challenges associated with the
exemplar and regenerative medicines more broadly, focusing on the need for a robust quantification of the
level of uncertainty in the cost-effective estimates and the potential value of MEAs in limiting the exposure
of the NHS to high upfront costs and loss associated with a wrong decision.
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Conclusions: It is to be expected that there will be a significant level of uncertainty in determining the
clinical effectiveness of regenerative medicines and their long-term costs and benefits, but the existing
methods available to estimate the implications of this uncertainty are sufficient. The use of risk sharing and
MEAs between the NHS and manufacturers of regenerative medicines should be investigated further.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Adverse effect An abnormal or harmful effect caused by and attributable to exposure to a drug, which is
indicated by some result such as death, a physical symptom or visible illness. An effect may be classed as
adverse if it causes functional or anatomical damage, causes irreversible change in the homeostasis of the
organism or increases the susceptibility of the organism to other chemical or biological stress.
Antigen CD19 (cluster of differentiation 19) A protein present on B-cell leukaemias (as well as on
healthy B cells).
Aplasia The failure of an organ or tissue to develop or to function normally.
Autologous Derived from an individual’s own cells.
Between-study variance A measure of statistical heterogeneity that depends on the scale of the
outcome measured. It represents the variation in reported study effects over and above the variation
expected given the within-study variation.
Biologic therapy (biological) Medical preparation derived from a living organism. Includes anti-tumour
necrosis factor drugs and other new drugs that target pathologically active T-cells.
Consolidation chemotherapy Chemotherapy given once a remission is achieved, to sustain a remission.
Cost–benefit analysis An economic analysis that converts the effects or consequences of interventions
into the same monetary terms as the costs and compares them using a measure of net benefit or a
cost–benefit ratio.
Cost-effectiveness analysis An economic analysis that expresses the effects or consequences of
interventions on a single dimension. This would normally be expressed in ‘natural’ units (e.g. cases cured,
life-years gained, additional strokes prevented). The difference between interventions in terms of costs
and effects is typically expressed as an incremental cost-effectiveness ratio (e.g. the incremental cost per
life-year gained).
Cost–utility analysis The same as a cost-effectiveness analysis but the effects or consequences of
interventions are expressed in generic units of health gain, usually quality-adjusted life-years.
Credible interval In Bayesian statistics, a credible interval is a posterior probability interval estimation that
incorporates problem-specific contextual information from the prior distribution. Credible intervals are used
for purposes similar to those that confidence intervals are used for in frequentist statistics.
Fixed-effect model A statistical model that stipulates that the units under analysis (e.g. people in a trial
or study in a meta-analysis) are the ones of interest and thus constitute the entire population of units. Only
within-study variation is taken to influence the uncertainty of the results (as reflected in the confidence
interval) of a meta-analysis using a fixed-effect model.
Graft rejection The rejection of transplanted organs as a result of humoral and cell-mediated responses
by the recipient to specific antigens present in the donor tissue.
Haematological cancers Cancer of blood cells, which can be subdivided into three main diseases:
leukaemia, lymphoma and myeloma.
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Heterogeneity In systematic reviews heterogeneity refers to variability or differences between studies in
the estimates of effects. A distinction is sometimes made between ‘statistical heterogeneity’ (differences in
the reported effects), ‘methodological heterogeneity’ (differences in study design) and ‘clinical heterogeneity’
(differences between studies in key characteristics of the participants, interventions or outcome measures).
Immune reconstitution A condition in which the patient’s immune system begins to recover
after treatment.
Immune reconstitution inflammatory syndrome A condition in which the patient’s immune system
begins to recover after treatment but then reacts later with an overwhelming inflammatory response.
Immunoconjugate An antibody joined to a second molecule, usually a toxin, radioisotope or label, for
use in immunotherapy.
Immunophenotype The protein type expressed by cells.
Immunotherapy A treatment designed to boost the body’s natural defences to fight cancer by utilising
material either from the body or produced in vitro to improve, target or restore immune system function.
Immunotoxin A protein that consists of a targeting portion linked to a toxin, which will bind to a cell and
cause endocytosis, allowing the toxin to kill the cell.
Intention to treat An intention-to-treat analysis is one in which all of the participants in a trial are
analysed according to the intervention to which they were allocated, whether they received it or not.
I-squared (I2) A measure of ‘statistical heterogeneity’ (differences in the reported effects). It varies
between 0 and 1, where 0 indicates that the differences in reported effects are entirely consistent with the
within-study uncertainty, and 1 indicates that the differences in reported effects are entirely explained by
study characteristics that vary across studies.
Medical Devices Directive The Medical Devices Directive is a directive relating to the safety and
performance of medical devices, which were harmonised in the European Union in the 1990s.
Monoclonal antibody An antibody produced in a laboratory from a single clone that recognises only
one antigen.
Open-label study A type of study in which both participants and researchers know which treatment is
being administered.
Orphan designation/status Based on the European Medicines Agency criteria, a medicine can qualify for
orphan status if it is intended for the treatment, prevention or diagnosis of a disease that is life-threatening
or chronically debilitating; the prevalence of the condition in the European Union is not more than 5 in
10,000 or it must be unlikely that marketing of the medicine would generate sufficient returns to justify
the investment needed for its development; and no satisfactory method of diagnosis, prevention or
treatment of the condition concerned can be authorised or, if such a method exists, the medicine must be
of significant benefit to those affected by the condition.
Persistence In treatment intended for direct in vivo administration, persistence may describe how long the
product is effective in treating a targeted disease. It may also be used to refer to the persistence of the
product, for example gene expression or any permanent changes, within the patient as a result of
treatment with the product.
Pharmacodynamic effects The study of how a drug behaves in the body.
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Pharmacokinetic effects The study of the effect that the body has on a drug.
Phase I study Researchers test a new drug or treatment in a small group of people for the first time to
evaluate its safety, determine a safe dosage range and identify side effects.
Phase II study The drug or treatment is given to a larger group of people to see if it is effective and to
further evaluate its safety.
Phase III study The drug or treatment is given to large groups of people to confirm its effectiveness,
monitor side effects, compare it with commonly used treatments and collect information that will allow the
drug or treatment to be used safely.
Phase IV study Study carried out after the drug or treatment has been marketed to gather information
on the drug’s effect in various populations and any side effects associated with long-term use.
Placebo An inactive substance or procedure administered to a patient, usually to compare its effects with
those of a real drug or other intervention, but sometimes for the psychological benefit to the patient
through a belief that he or she is receiving treatment.
Quality-adjusted life-year An index of health gain in which survival duration is weighted or adjusted by
the patient’s quality of life during the survival period. Quality-adjusted life-years have the advantage of
incorporating changes in both quantity (mortality) and quality (morbidity) of life.
Quality of life A concept incorporating all of the factors that might impact on an individual’s life,
including factors such as the absence of disease or infirmity as well as other factors that might affect their
physical, mental and social well-being.
Random-effects model A statistical model sometimes used in meta-analysis in which both within-study
sampling error (variance) and between-study variation are included in the assessment of the uncertainty
(confidence interval) of the results of a meta-analysis.
Randomised controlled trial An experiment in which investigators randomly allocate eligible people into
intervention groups to receive or not receive one or more interventions that are being compared.
Refractory A disease that does not respond to attempted forms of treatment.
Regenerative medicine A field of research and clinical applications dealing with the process of replacing
or regenerating human cells, tissues or organs to restore or establish normal function.
Relative risk (synonym: risk ratio) The ratio of risk in the intervention group to risk in the control
group. The risk (proportion, probability or rate) is the ratio of people with an event in a group to the total
number in the group. A relative risk of 1 indicates no difference between comparison groups. For
undesirable outcomes, a relative risk that is < 1 indicates that the intervention was effective in reducing
the risk of that outcome.
Salvage chemotherapy Chemotherapy given to a patient when all other treatment options are
exhausted.
Sensitivity analysis An analysis used to determine how sensitive the results of a study or systematic
review are to changes in how it was carried out. Sensitivity analyses are used to assess how robust the
results are to uncertain decisions or assumptions about the data and the methods that were used.
Time to relapse Length of first remission.
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Weighted mean difference (in meta-analysis) A method of meta-analysis used to combine measures
on continuous scales when the mean, standard deviation and sample size in each group are known.
The weight given to each study is determined by the precision of its estimate of effect and is equal to
the inverse of the variance. This method assumes that all of the trials have measured the outcome on the
same scale.
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Plain English summary
Regenerative medicines replace or regenerate human cells, tissues or organs to restore or establishnormal function. Potential breakthroughs are eagerly anticipated and expectations are high because
of the possibility of cures (or substantial improvements) for diseases that are deemed chronic or fatal.
Regulatory pathways are evolving to facilitate the early approval of such promising new therapies.
However, the assessment of the long-term costs and benefits of such therapies is more difficult than for
conventional treatments.
In response to an inquiry by the House of Lords into regenerative medicines, an expert group (Regenerative
Medicine Expert Group or RMEG) developed an action plan for the NHS. The RMEG proposed that the
National Institute for Health and Care Excellence (NICE) commission a ‘mock technology appraisal’ to
assess whether changes to its methods and processes are needed.
This report presents the findings of independent research commissioned to inform this appraisal. We
reviewed evaluations of regenerative medicines by NICE and other groups as well as conducting reviews of
the existing literature concerned with the challenges of assessing the therapies. In addition, an exemplar
case study of chimeric antigen receptor (CAR) T-cells for acute leukaemia was constructed to inform the
deliberations of an expert panel set up by NICE.
Our research found that, although evidence about regenerative medicines is expected to be associated
with much uncertainty in determining the long-term costs and benefits to patients and the NHS, the
existing methods available to estimate the implications of this uncertainty are sufficient. Ways of sharing
the risks between the NHS and the therapy manufacturers should be investigated further.
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Scientific summary
Background
Regenerative medicines replace or regenerate human cells, tissues or organs to restore or establish normal
function. Potential breakthroughs in this area of clinical research are eagerly anticipated and expectations
are often high because of the possibility of cures (or substantial improvements) for diseases that are
currently deemed chronic or fatal. However, efficacy, safety and cost-effectiveness evaluations of
regenerative medicines may be difficult compared with evaluations of conventional pharmaceutical
treatments. The Regenerative Medicine Expert Group (RMEG) was tasked to develop a NHS regenerative
medicine delivery readiness strategy and action plan. The RMEG requested an investigation to determine
whether the conceptual differences between regenerative medicines and other types of health technology
require different approaches to the assessment of efficacy, safety and cost-effectiveness.
Objectives
l To test the application of National Institute for Health and Care Excellence (NICE) appraisal
methodology to regenerative medicines.
l To identify specific issues related to the appraisal of regenerative medicines using the current NICE
appraisal process and decision framework.
l To develop a framework for those developing regenerative medicines to facilitate understanding of
how NICE evaluates clinical effectiveness and cost-effectiveness.
Potential issues for the evaluation of clinical effectiveness
Two different approaches were taken to identify and explore issues and challenges that may be associated
with NICE evaluations of regenerative medicines:
1. a broad exploration of the applicability of NICE technology appraisal (TA) methods to regenerative medicines
2. an exemplar NICE appraisal of a hypothetical regenerative medicine product.
Reviews were undertaken to identify and discuss TA methodology issues that may be particularly relevant
to regenerative medicines: a review of European Medicines Agency (EMA), NICE and US Food and Drug
Administration (FDA) assessments of regenerative medicines licensed in the European Union (EU); a review
of the use of surrogate end points in clinical research; and a review of the biases likely to affect the results
of non-randomised studies (NRSs) (with a particular focus on the challenges of using results from single-arm
trials to estimate efficacy).
Several broad issues that may affect uncertainty were apparent from these reviews:
1. It was not universally the case that regenerative medicines are trialled using NRS designs.
2. With single-arm trials, a key consideration when judging levels of uncertainty should be the likelihood
of cure or improvement without experimental treatment.
3. When single-arm trials or case series form the basis of a regulatory submission, the relative treatment
effect generated is likely to be optimistic unless the historical control data are accurate.
4. When single-arm trial data are compared with historical data and adjustment for confounding is made,
the selection of the method used must be explicit; despite advances in statistical techniques, challenges
remain in generating accurate unbiased estimates of effect from non-randomised data.
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5. Pivotal trials in regulatory submissions are likely to report surrogate primary end points. On average,
trials using surrogates report larger treatment effects than trials using final patient-relevant outcomes.
This has implications for effect estimate uncertainty, especially when only surrogate end points are
reported. The choice of surrogate outcomes must be researched, explicit and justified, preferably
through a systematic review. To maximise the use of all available data, and to reduce overall
uncertainty, multivariate meta-analysis methods to analyse data should also be considered.
6. Use of intermediate shorter-term primary outcomes avoids the need for long follow-up but, when
overall survival is a secondary outcome, data are immature at the point of regulatory approval.
7. The high technology status of regenerative medicines may imply greater potential for variation in
response. This is likely to have implications in terms of the generalisability of efficacy and safety
estimates obtained from small single-centre (probably expert-centre) studies, which may produce
larger effect estimates than multicentre studies. In the absence of larger or more varied trials, this
issue might be addressed only by access to individual patient data so that effect modifiers may
be investigated.
8. The availability of confirmatory randomised controlled trials (RCTs) in a similar, larger population [e.g.
B-cell acute lymphocytic (lymphoblastic) leukaemia (B-ALL) patients in first relapse] raises the possibility of
incorporating indirectly relevant but more reliable (and possibly more mature) data into the analysis to
reduce uncertainty; such data may become available as a result of the evolving regulatory pathways
being developed by the EMA.
9. Most regenerative medicines are, by their nature, innovative products that may be subject to continuing
development, with new generations of products having improved efficacy. This may pose problems
when evaluating long-term efficacy and safety: to what extent can the long-term safety data from a
first-generation product be used to inform the long-term safety of a related newly licensed second-
generation product?
Potential issues for the evaluation of cost-effectiveness
Many of the issues associated with regenerative medicines will impact on the level of uncertainty
associated with the cost-effectiveness of the technology when introduced into clinical practice. Even when
products have a significant potential to confer important clinical advances over current therapies, this may
not be known with a high level of certainty at the time of licensing the product. A new technology’s
cost-effectiveness may be more difficult to determine in these circumstances, and schemes or managed
entry agreements (MEAs) that allow the development of further evidence or that entail a risk-sharing
component may be required.
Several studies have concluded that reimbursement decisions and the possible use of MEAs should be
based not only on the expected value of a technology but also on the value of further research, the
anticipated effect of coverage on further research and the costs associated with reversing the decision.
Importantly, provision already exists within NICE’s Guide to the Methods of Technology Appraisal to
accommodate some of these considerations. NICE will also need to consider whether further amendments
to its processes and methods are required.
Exemplar National Institute for Health and Care Excellence
appraisal of chimeric antigen receptor T-cells for relapsed/
refractory B-cell acute lymphoblastic leukaemia
For the exemplar appraisal, the chosen hypothetical product was chimeric antigen receptor (CAR) T-cell
therapy specific to the antigen CD (cluster of differentiation) 19 for treating relapsed (two relapses or
more) or refractory B-ALL.
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Clinical evidence for the efficacy and safety of chimeric antigen receptor
T-cells for relapsed/refractory B-cell acute lymphoblastic leukaemia
The trial data for CAR T-cells are limited to small, single-arm studies. They have the potential to offer
patients a ‘bridge’ to a stem cell transplant or possibly a cure (without transplant), depending on the type
of CAR T-cell therapy. However, potentially serious adverse effects are possible. The relapsed/refractory
B-ALL population is narrowly defined with extremely poor prognosis and limited therapy options. The length
of persistence of CAR T-cells within patients has implications for both efficacy and safety; persistence needs
to be long enough to eradicate malignant cells and short enough to prevent problematic B-cell aplasia.
Length of persistence may dictate how CAR T-cells are used.
The target product profile and hypothetical evidence sets
Based on the available clinical evidence for CAR T-cell and licensed non-regenerative medicines for
relapsed B-ALL, two target product profiles (TPPs) were developed:
1. CAR T-cell therapy used as a ‘bridge to haematopoietic stem cell transplantation (HSCT)’, in which the
primary goal of treatment is to induce the short-term remission of disease to maximise the opportunity
for successful HSCT
2. CAR T-cell therapy used with ‘curative intent’, in which the primary goal of treatment is long-term
remission/cure of disease (with or without HSCT).
To explore the impact of different levels of precision and maturity in the evidence base, three hypothetical
data sets were constructed for each TPP:
1. the minimum set (60–80 patients, median follow-up approximately 10 months) – the minimum data
considered potentially sufficient for CAR T-cell therapy to be granted conditional regulatory approval
2. the intermediate set (60–80 patients, maximum follow-up 5 years) – a variant of the minimum set in
which the efficacy and safety of CAR T-cell therapy has been assessed over a longer follow-up period
3. the mature set (120–140 patients, maximum follow-up 5 years) – a variant of the intermediate set in
which the efficacy and safety of CAR T-cell therapy has been assessed in a larger clinical study but with
a similar follow-up period as in the intermediate set.
Development of the exemplar cost-effectiveness model: summary of
approach and key findings
Two de novo decision models were developed to assess the cost-effectiveness of CAR T-cell therapy within
the two separate TPPs (bridge to HSCT and curative intent) across each of the separate evidence sets.
In the bridge to HSCT scenario, the primary health benefits of treatment with CAR T-cell therapy were
assumed to be driven by an increase in the proportion of patients receiving HSCT and the subsequent
success of HSCT itself. The introduction of an epidemiological ‘link’ between a potential established
surrogate outcome/process and final health benefits [i.e. overall survival and quality-adjusted life-years
(QALYs)] also enabled the use of external evidence to be utilised.
In the curative intent model, the assumption was that the CAR T-cell therapy potentially confers longer-
term and potentially curative benefits without the need to bridge to HSCT. A simple three-state partitioned
survival model was developed to model long-term outcomes through the direct extrapolation of overall
survival data from the evidence sets.
Assumptions, strengths and limitations
A key assumption employed within both models was that, from year 5 onwards, all patients who remained
alive experienced a mortality risk profile consistent with that of a long-term survivor of acute lymphocytic
(lymphoblastic) leukaemia (ALL). Additional follow-up data could be used to test the validity of such an
approach against any claims of longer-term mortality differences.
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In the absence of a commercially available product and published price of CAR T-cell therapy, an
assumption was made that the manufacturer would employ a value-based approach to its pricing, such
that the resulting cost-effectiveness [incremental cost-effectiveness ratio (ICER)] estimate was close to
NICE’s cost-effectiveness threshold. In the context of the exemplar, this was assumed to be based on the
maximum threshold assuming that the existing ‘end-of-life’ (EoL) criteria are met.
Assessment of cost-effectiveness, uncertainty and the value of alternative
policy options: summary of approach and key findings
An important aspect of our work involved investigating how these estimates could inform the NICE TA process.
The sequence of assessments presented started with a conventional assessment of cost-effectiveness based
on the current NICE reference case. Disaggregated estimates of the costs and outcomes were estimated,
together with resulting cost-effectiveness estimates based on the ICER. These results were also expressed
using net health effects (NHEs), representing the difference between any health gained with the intervention
and health forgone elsewhere in the health-care system, expressed either in monetary or in QALY terms.
The impact of uncertainties was explored using conventional one-way sensitivity analyses and
probabilistic approaches.
In addition to the analyses undertaken using the conventional reference case approaches, a series of more
exploratory analyses were also undertaken. In particular, the per-patient assessments were scaled up to
population assessments, requiring an estimate of the number of potentially eligible patients and an
assessment of the period over which the therapy might be utilised within clinical practice.
The results of the population-based analyses were summarised in terms of incremental NHEs and the
probability that CAR T-cell therapy was cost-effective. Alongside these more conventional assessments,
an assessment of the scale of the likely consequences of uncertainty was considered to be potentially
informative in relation to possible research recommendations. An estimate of the consequences of existing
decision uncertainty was subsequently derived, reflecting the potential magnitude of NHEs that could be
gained if uncertainty surrounding this decision could be resolved immediately.
Impact of alternative pricing scenarios
Using the different analyses, the impact of alternative pricing scenarios was explored, including a fixed
price reduction as well as more sophisticated schemes based on pay for performance and leasing
approaches. Similarly, the impact of the alternative evidence sets was explored to establish the implications
of the increased precision and maturity assumed in the intermediate and mature evidence sets.
Quantifying potential uncertainties
An important consideration within this work is the extent to which current NICE methods and processes
are likely to appropriately quantify the potential uncertainties surrounding regenerative medicines and
cell-based therapies to ensure that appropriate policy decisions are made regarding potentially promising
technologies. Our findings show that the conventional assessments requested within the current TA
process may not be sufficient. Estimates of the ICER and associated probabilities that CAR T-cell therapy is
cost-effective at a specific threshold were shown to be virtually identical in one of the TPPs despite being
based on three different evidence sets with varying levels of precision and maturity. Similarly, across both
TPPs, several of the alternative pricing schemes again reported similar estimates of the ICER and associated
probabilities that CAR T-cell therapy is cost-effective. Consequently, it is unclear how these differences
would be reflected within the current TA process.
Consideration of the scale of the consequences for population NHEs provides a clearer distinction between
the different evidence sets and an assessment of the impact of alternative pricing schemes. Consequently,
their more routine application within the TA process for regenerative and cell-based therapies may be an
important consideration for future processes. Such information might provide an important basis for
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discussions between manufacturers, NICE and other relevant parties in terms of how the existing uncertainties
might be appropriately managed, ensuring that risks and benefits are more appropriately shared.
Issues arising from the National Institute for Health and Care
Excellence panel meeting
A separate panel and meeting were convened by NICE to discuss the findings of the exemplar appraisal,
assess the clinical effectiveness and cost-effectiveness evidence informing the separate TPPs and identify
potential issues and challenges for the NICE TA appraisal process and methods. A summary of the clinical
effectiveness and cost-effectiveness evidence was presented to the panel, who were asked to deliberate on
the range of scenarios and to provide ‘hypothetical’ decisions and outline the main considerations for these.
The key consideration relating to the clinical effectiveness evidence was how decisions can be made for
technologies that look highly promising but for which the evidence base is highly uncertain, at a potentially
high but actually unknown risk of bias and which are extremely immature. As appraisals of regenerative
medicines are likely to be conducted in the context of conditional regulatory approval, the panel considered
that it would be important to know what research had been mandated by the regulator and hence what
uncertainty could reasonably be expected to be resolved in the near future. There was concern regarding
the difficulty of decommissioning services following (what later proved to be) incorrect recommendations.
A key consideration regarding the cost-effectiveness results and implications for the ‘hypothetical’ decisions
was whether the panel considered that existing criteria considered within the TA process in relation to EoL
could be applied. The panel accepted that the exemplar met the requirements of the EoL criteria but
concluded that other considerations (e.g. innovation) would not be applied in addition.
The panel raised issues regarding the possible nature and magnitude of any irrecoverable costs that might
be incurred by the NHS and the implications for its decisions. The panel acknowledged that the different
pricing schemes had important impacts both in terms of the ICER and in terms of the allocation of any risk
between the NHS and manufacturers. The concept of the ‘leasing approach’ was identified as a potentially
important option.
The panel acknowledged the challenges and difficulties of generating mature evidence at the point at
which a product is launched. In particular, the panel noted that a comparison of the magnitude of the
incremental NHEs and the consequences of decision uncertainty provided an important starting point for
deliberations in considering the scale of the NHEs that could be achieved by immediate approval and that
which might be achieved by further research.
Summary conclusions
Our research found that the clinical evidence about regenerative medicines is expected to be associated
with much uncertainty. Existing methods are available to adjust for and minimise the risk of bias and
uncertainty in data analyses. Although there will be a significant level of uncertainty in determining the
long-term costs and benefits to patients and the NHS, the existing methods available to estimate the
implications of this uncertainty are sufficient. The use of risk-sharing agreements between the NHS and
manufacturers of regenerative medicines should be investigated further.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction and aims
The term ‘regenerative medicine’ refers to a field of research and clinical applications dealing with theprocess of replacing or regenerating human cells, tissues or organs to restore or establish normal function.1
Regenerative medicine is not a new field of medicine, as it encompasses bone marrow or organ transplants.
However, the development of newer types of regenerative medicine such as cell-based therapies (often using
stem cells or progenitor cells to produce tissues), gene therapy and tissue engineering has raised the possibility
that diseases that are currently deemed chronic or fatal may be curable. Most regenerative medicines will be
classed by the European Medicines Agency (EMA) as ‘advanced-therapy medicinal products’ (ATMPs), which
are essentially treatments based on engineered cells or tissues. Although regenerative medicines may offer
great potential, the route to this new era of medicine might not be straightforward. Product development
and production to commercially viable levels may involve many challenges. Furthermore, efficacy and safety
evaluations of regenerative medicines may be difficult compared with efficacy and safety evaluations of
conventional pharmaceutical treatments. For example, although when pharmaceuticals are discontinued their
adverse effects are likely to improve, some regenerative medicines may cause prolonged toxicities, especially
when cells persist long term; such adverse effects might also not become evident for years.
An inquiry by the House of Lords Science and Technology Committee into regenerative medicine was set
up to pinpoint the UK’s strengths in this area, to identify barriers to translation (applying findings from
basic research to a clinical setting) and commercialisation (primarily delivering treatments in the health-care
market) and to recommend solutions. The report – published in July 20132 – concluded that, although
the UK has a great potential resource in the NHS, which could make it an attractive place for investment,
it is currently underprepared to realise the full potential of regenerative medicine. One of the report’s
recommendations was that the Department of Health should establish a regenerative medicine expert
working group to develop a NHS regenerative medicine delivery readiness strategy and action plan, which
was to report back to the Secretary of State for Health by December 2014.2 In response to this, the
Regenerative Medicine Expert Group (RMEG) was convened and was given the remit to monitor progress
on the government’s response to the House of Lords inquiry and to develop, in partnership with other
stakeholders, a strategy for regenerative medicine in the NHS and provide an action plan. One of the major
discussion areas for the RMEG was that, even when therapies have real potential, this may not be known
with a high level of certainty at the time that an ATMP first comes to market, as the available evidence base
is often limited. In its report (p. 6)3 the RMEG stated that:
In order for NHS patients to benefit from regenerative medicines, robust and effective product
evaluation has to be made to inform commissioning decisions. National Institute for Health and
Care Excellence (NICE) guidance is essential in speeding up the adoption and spread of high value
regenerative medicines in healthcare. However, applying the Institute’s appraisal methodology, based
on cost utility analysis, to products whose true value may not be known for many years can be
challenging, due to the inherent uncertainty of estimating long-term benefit from evidence derived
from short-term studies.
Contains public sector information licensed under the Open Government
Licence v3.0. © Crown Copyright 2015
The assessment of the cost-effectiveness of regenerative medicines may raise particular challenges
compared with the assessment of the cost-effectiveness of other types of technologies. Important
challenges may include the potential curative nature and claims of long-term/lifetime benefits; the
potentially rapid changes that may arise in product characteristics over time; potential longer-term patient
safety issues because of persistence; organisational and scaling issues; and the potentially significant
upfront costs that may arise. Whether the conceptual differences between regenerative medicines and
other types of technologies (e.g. pharmaceuticals and medical devices) mean that a different approach to
the assessment of cost-effectiveness is required needs to be investigated.
DOI: 10.3310/hta21070 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 7
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Hettle et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
1
The RMEG Evaluation and Commissioning Subgroup proposed that the National Institute for Health and
Care Excellence (NICE) commission a ‘mock technology appraisal’ (TA) on an exemplar regenerative
medicine product and develop an outline plan for such a study. This proposal was reflected in the final
report and recommendations of the RMEG (p. 6),3 which stated further that:
We encourage the Institute to consider the findings from these studies with a view to assessing
whether changes to its methods and processes are needed. Evaluation and commissioning, as with all
steps of the product development pathway, need to be supported by clear, up-to-date and accessible
advice and guidance.
Contains public sector information licensed under the Open Government
Licence v3.0. © Crown Copyright 2015
Through RMEG Evaluation and Commissioning Subgroup discussions and further input from the Cell
Therapy Catapult, it was concluded that undertaking a study involving a real commercial product was not
feasible for a number of reasons: there would be significant commercial sensitivities; products undergoing
regulatory review would be candidates for a real appraisal; and using a product at an earlier stage in
clinical development is not helpful as the evidence base would be even less mature and, therefore, it
would not have the attributes of an ‘exemplar’ product. It was therefore proposed to undertake the
evaluation of a hypothetical product: chimeric antigen receptor (CAR) T-cell therapies (see Chapter 3, Clinical
efficacy and safety issues arising from European Medicines Agency, National Institute for Health and Care
Excellence and Food and Drug Administration assessments of licensed regenerative medicines). This decision
was made on the basis that CAR T-cell therapies are quite a new product class – none is currently licensed – for
which there is emerging evidence of clinical benefit. An evaluation of these therapies might also appropriately
exemplify some of the main challenges faced by new regenerative medicines. The Cell Therapy Catapult has
knowledge of and experience with gene-modified T-cells and therefore worked with others on the advisory
group to develop the basis of the target product profile (TPP).
The objectives of this study were to:
l test the application of NICE appraisal methodology to regenerative medicines, identifying challenges
and any areas where methods research and/or adaptation of methodology would be appropriate
l identify specific issues related to the appraisal of regenerative medicines using the current NICE
appraisal process and decision framework
l develop a framework for those developing regenerative medicines to facilitate understanding of how
NICE evaluates clinical effectiveness and cost-effectiveness and to identify the most important evidence
areas to develop before cost-effectiveness can be reasonably estimated.
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Chapter 2 Background
Issues identified by the European Medicines Agency as being
specific to advanced therapy medicinal products
Most of the new, innovative regenerative medicines that are evaluated by the EMA are likely to be categorised
as ATMPs. The Committee for Advanced Therapies (CAT) is the EMA committee responsible for assessing
the quality, safety and efficacy of ATMPs (and for following scientific developments in the field). The EMA
and CAT have issued a range of documents providing guidance regarding the development of ATMPs; one
of these [issued in 2008, based on the requirements of a European Union (EU) regulation] is a guideline for
post-authorisation follow-up entitled Guideline on Safety and Efficacy Follow-up – Risk Management of
Advanced Therapy Medicinal Products.4 Such rules were needed because of the ‘novelty, complexity, and
technical specificity’ of ATMPs (p. 7).4
In this guideline the concerns about risks relate to:
l living donors (where applicable)
l quality characteristics (e.g. origin and characteristics of cells and vectors; quality assurance issues)
l storage and distribution of products (e.g. stability, preservation, thawing)
l administration and readministration procedures (e.g. immune reactions)
l interaction of the product and the patient (e.g. immunogenicity, malignancy)
l scaffolds, matrices and biomaterials (e.g. biodegradation)
l product persistence (e.g. availability of rescue procedures or antidotes)
l health-care professionals, caregivers or other close contacts with the product.
Concerns about the efficacy of ATMPs relate mainly to the uncertainty about how effective they may be in
‘real-life’ settings in the long term and include the following:
l Possible temporal changes in the characteristics of the living material in ATMPs may affect efficacy.
l The time required for new tissue to be fully functional may be several years (use of surrogate end
points needed for marketing authorisation, but confirmation with clinical end points needed in
post-authorisation phase).
l Some ATMPs may be a once in a lifetime treatment and long-term follow-up is needed to demonstrate
the sustainability of efficacy.
l Efficacy may be highly dependent on the quality of the administration procedure (e.g. patient
conditioning, surgery). This may differ between clinical trial and normal health-care settings.
l Cell therapy products with a limited lifetime may require an efficacy follow-up system that monitors the
dynamics of efficacy (this will help to determine need and timing of reapplication).
The issues highlighted in the guideline for the design of the studies needed to monitor long-term safety
and efficacy include careful consideration of:
l sample size (high potential for dropouts over many years of follow-up)
l the dynamics of the disease and the effects of the product (different approaches needed for detecting
early vs. late complications)
l the use of usual clinical practice for follow-up whenever possible to limit additional procedures
and interventions
l the appropriate duration of follow-up of living donors (when applicable)
l the feasibility of follow-up of close contacts and offspring (when applicable).
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Both the safety and efficacy follow-up systems are defined as any systematic collection and collation of
data that is designed in a way that enables learning about safety and/or efficacy of an ATMP. This may
include passive or active surveillance, observational studies or clinical trials. The guideline stresses that both
the efficacy and the safety follow-up systems are not a substitute for the need for adequate data to be
available at the time of authorisation to enable proper benefit–risk evaluation.4
Overview of wider regulatory evidence requirement issues and
the evolving pathways for approval
The ethics, feasibility and reliability of small randomised controlled trials
Although the randomised controlled trial (RCT) is the expected level of evidence needed for regulatory
assessments, it is recognised that for some indications such expectations are unrealistic. Conducting
RCTs in populations with severe or advanced disease may be problematic for a variety of reasons. Such
populations may be very small and, consequently, recruitment into an adequately sized trial would require a
large number of centres and would be very expensive and take a very long time. In addition, when no
alternative treatments exist, patients with life-threatening diseases or severe morbidity typically need, and
desire, accelerated access to innovative new therapies. Patients with more severe or advanced disease may
be more willing to accept the risks of an experimental therapy. In such situations randomisation to a control
treatment may be ethically problematic (because of an absence of clinical equipoise).
A health technology assessment (HTA) review of ethics issues in the design and conduct of RCTs described
numerous situations in which alternative non-randomised designs are morally or practicably preferable.
These included when large differences between treatments are expected; when a disease, if left untreated,
is lethal and for which there is no known effective treatment (i.e. unmet need); and when a disease is rare
and recruitment is slow.5 Additionally, when trial populations are small, it may be difficult to differentiate
a true treatment effect from a chance effect. Important chance imbalances in relevant prognostic factors
between groups at baseline are more likely in small trials. The HTA review highlighted the problem of
underpowered RCTs, which were described as ‘necessarily unethical’ as they were unlikely to produce
clear-cut answers.5 This argument was supported by 15 articles that stipulated the statistical necessity for
random errors in measured effects of treatments to be small in comparison with the size of the therapeutic
effect sought. Other articles in the review discussed the ethics of stopping RCTs early when there is some
evidence of efficacy and the subsequent problems that this may cause, with reduced statistical precision,
clinicians not being persuaded by results and secondary trial aims being compromised being some of the
key problems.
A related HTA review discussed further the ethics issues that may arise when early-phase (e.g. single-arm)
trials produce very encouraging results: it may be unethical to conduct a further trial if the intervention is
apparently effective in a small number of patients.6 In such a situation, the argument for a trial rests on
demonstrating a grey area between a reasonable hope that the intervention is effective in a few patients
and a rational and justified belief that it is effective for the studied patient population more generally
(i.e. the evidence to date has sufficient external validity).
Possible alternatives to the randomised controlled trial
More recently, a framework for using unfamiliar trial designs when rare diseases are studied has outlined
several possible alternative approaches.7 The framework aims to facilitate research when populations
are small. Two of the ‘adaptive’ designs outlined may be particularly relevant for regenerative medicines,
for which treatment intentions may be curative. The first is responsive–adaptive randomisation, which
maximises allocation to the most effective treatment and minimises the required sample size. Outcomes for
previous participants affect the subsequent treatment allocation probabilities. This ‘play the winner’ rule
has the potential to reduce the number of patients who are allocated to less effective treatments and can
therefore reduce the ethical concerns associated with randomisation. However, this design is limited to
studies that assess rapidly available outcomes (as results from previous patients are needed to influence
BACKGROUND
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future allocations). Modified designs have also been outlined to counter the criticism that comparisons may
be obtained in which only one patient has received conventional treatment. The second adaptive design
that may also be useful for studying regenerative medicines is the internal pilot design. This design
eliminates the loss of scarce eligible participants because of participation in a prior pilot study. Once the
pilot phase is finished, a sample size is recalculated with the study continuing until this number is recruited;
patients from the pilot phase are included in the final analysis.
A EMA reflection paper on methodological issues associated with adaptive designs suggested that such
designs ‘would be best utilised as a tool for planning clinical trials in areas where it is necessary to cope
with difficult experimental situations’ (p. 3).8 Cited examples of such situations included ‘small populations
or orphan diseases with constraints to the maximum amount of evidence that can be provided’ and when
there are ‘ethical constraints to experimentation’ (p. 10). However, the US Food and Drug Administration
(FDA)9 raised two principal issues with regard to adaptive design methods more broadly:
1. whether the adaptation process has led to design, analysis or conduct flaws that have introduced bias
which increases the chance of a false conclusion that the treatment is effective (a type I error)
2. whether the adaptation process has led to positive study results that are difficult to interpret,
irrespective of having control of type I error.
This draft FDA guidance document also noted that, for some of the more recently developed adaptive
methods (including adaptive randomisation methods), the magnitude of the risk of bias and the size of the
potential bias, and how to eliminate these effects, are not yet well understood.
Although adaptive designs may be useful in some situations, it is still likely that single-arm trials will form
the basis of many submissions for the regulatory approval of regenerative medicines (because of the nature
of the target populations). Nevertheless, a study that reviewed 31 oncology drugs or biologics approved by
the FDA (between 1973 and 2006) without a randomised trial that incorporated a comparator treatment,
supportive care or placebo arm concluded that such drugs have a reassuring record of long-term safety
and efficacy despite the fact that nearly all of the evidence studies were single-arm Phase II trials.10 The
median number of patients studied per approval was 79 (range 40–413); response rate was the primary end
point for most drugs, and the median objective response rate was 33%. At the time of publication (2009)
all but one of the drugs were still approved; marketing authorisation for gefitinib (Iressa®; AstraZeneca,
Cambridge, UK) was rescinded after a RCT showed no survival improvement. Nineteen drugs have additional
uses, with formal FDA approvals obtained for 11.
Evolving regulatory pathways
Since the late 1980s and early 1990s, regulators and HTA bodies/payers around the world have produced
new approaches to provide patients with timely access to new medicines.11 These new regulatory pathways
can also improve competitiveness; shortened product development times prior to licensing can be very
beneficial and more appealing to emerging small and medium-sized enterprises.
An overview of the relevant EMA regulatory accelerated access pathways is presented in Table 1. The main
mechanism for accelerated access of these pathways is the reduced development time.
The EMA’s most recent development in this area is the adaptive licensing pilot programme, which was
launched in 2014. The programme utilises the regulatory processes within the existing EU legal framework
and is defined as being a prospectively planned adaptive approach to bringing drugs to market. It is more
of a staggered iterative system than previous approval pathways. Such a ‘life-cycle approach’ to acquiring
and (re)assessing evidence will consider the basis of decision-making in the following stages of a product’s
life cycle: development, licensing, reimbursement, monitoring/post-licence evidence and drug utilisation.11
Importantly, the approach encompasses both the authorised indication and the potential further
therapeutic uses of the medicine. The EMA changed the name of the pilot project from ‘adaptive licensing’
to ‘adaptive pathways’ to better reflect the idea of a lifespan approach.
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The pilot project aims to examine whether or not this kind of approach to medicine development and
authorisation will offer advantages in terms of achieving the best balance between the need for timely
patient access and the importance of providing adequate, evolving information on benefits and risks. In so
doing it is expected to develop thinking in the following areas:12
l encourage developers of medicines to consider all regulatory tools and flexibilities within the existing
EU legal framework when planning the life cycle of medicine development
l explore the extent to which regulatory demands for the generation of evidence around efficacy and safety
are compatible with demands around evidence generation from other stakeholders (e.g. HTA bodies,
payers, patient organisations)
l investigate in a timely manner the hurdles that exist in realising the most efficient medicine
development pathways, including the role and limitations of real-world data.
Ideas for refining and improving this lifespan approach are developing at pace. For example, with MAPPs
(Medicines Adaptive Pathways to Patients) the development plan across target populations and indications
will be agreed upfront with the EMA, which distinguishes the MAPPs process from the conventional
indication expansion approach. The MAPPs plan may include a range of studies, such as RCTs, single-arm
TABLE 1 European Medicines Agency regulatory access pathways that allow accelerated access to treatments
Designation
(year of introduction) Use Notes
Approval under exceptional
circumstances (1993)
Medicines with urgent public health
need for which comprehensive data
cannot be provided
Justifications for not being able to provide
comprehensive data include rarity of the
condition, lack of scientific knowledge (e.g.
diagnostic tools) and contrary to medical ethics.
Post-authorisation data collection required, which
usually includes an identified programme of
studies, the results of which form the basis of an
annual reassessment of the benefit–risk profile
Accelerated assessment
(2005)
Medicines of major interest to public
health, particularly those representing
a therapeutic innovation
Review time shortened to 150 days compared
with the standard of 210 days. This pathway has
very rarely been used
Conditional marketing
authorisation (2005)
Seriously debilitating and life-
threatening conditions, medicinal
product for emergency use or orphan
medicinal products; must address
unmet medical need
Authorised for 1 year with the option to renew
as long as benefit–risk profile remains positive.
The condition is that the manufacturer will
initiate or, preferably, continue studies to reduce
uncertainty about benefits and risks to enable
conversion to full authorisation. A periodic safety
update report is required at 6-month intervals
Parallel scientific advice
between EMA and FDA
(2009)
Important medicinal oncology,
vaccine, orphan, paediatric,
nanotechnology, advanced therapy,
pharmacogenomics or blood products.
Products usually have fast-track
designation in the USA
Expected advantages are increased dialogue
between the two agencies and sponsors from the
beginning of the life cycle of a new product, a
deeper understanding of the bases of regulatory
decisions and the opportunity to optimise
product development and avoid unnecessary
testing replication or unnecessary diverse testing
methodologies. Scheduling of parallel scientific
advice can be challenging
Adaptive licensing
(2014 pilot)
Medicines to treat an unmet medical
need for a serious condition, especially
when no alternative therapies exist
Open to interventions in the early stages of
development (during or prior to phase II). Multi-
stakeholder participation desirable. Enhanced
monitoring of drug safety and drug utilisation
controls required after initial authorisation
Using information from Baird et al.11
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studies, pragmatic trials and other forms of real-world study.13 A newly formed public–private project called
ADAPT SMART (Accelerated Development of Appropriate Patient Therapies: a Sustainable, Multi-stakeholder
Approach from Research to Treatment-outcomes), which is funded by the EU Innovative Medicines Initiative,
aims to facilitate and accelerate the availability of MAPPs.14 NICE is one of the 32 international partners that
together represent regulators, patients, academia and industry. The challenge for ADAPT SMART is to
develop a MAPPs model that aligns the needs of all stakeholders, including patients, member state payers,
regulators, medical practitioners and industry. A major task will be the identification of opportunities and
obstacles, and providing a framework for MAPPs that will overcome the latter and seize the former. ADAPT
SMART will address the challenges to the broad implementation of MAPPs by exploring new concepts to
align the various stakeholders and create a consensus on what evidence will be required, how multiple
sources of available data can be best used to facilitate MAPPs and which scientific challenges related to
MAPPs need to be addressed.14
In the UK there is another initiative that may facilitate the pathway to market: the Medicines and
Healthcare products Regulatory Agency (MHRA) operates an early access to medicines scheme (EAMS),
which was launched in April 2014. This voluntary scheme (which does not replace the normal licensing
procedures) is aimed at unlicensed or off-label treatments deemed by the MHRA to be ‘promising
innovative medicines’ (PIMs) for treating life-threatening or seriously debilitating conditions for which there
is unmet need. Once a PIM designation is obtained (stage 1 of the process), the MHRA can then provide
benefit and risk information (stage 2 – scientific opinion) to doctors who may wish to prescribe the
unlicensed medicine under their own responsibility. However, it appears somewhat unclear how the EAMS
assessment output may impact on ongoing or forthcoming EMA assessments of the same therapy (e.g. in
terms of speeding up processes or reducing repetition of information). Further uncertainty around EAMS
exists regarding how therapies with this regulatory status can be funded. As EAMS is not accompanied
by any funding arrangements, meeting the costs of the therapy is currently the responsibility of the
manufacturer; this can act as a barrier to adoption, especially for high-cost therapies produced by small
enterprises.
Regenerative medicines in the new regulatory environment
The experience gleaned from the EMA adaptive licensing pilot so far appears to be quite limited with
respect to regenerative medicines: as of May 2015 one of only three candidate ATMPs had been selected
for a ‘stage II’ proposal.15 By far the most accommodating regulatory environment for developing
regenerative medicines is currently Japan, where, under the new 2014 legislation, regenerative medicines
can receive accelerated conditional approval after a single clinical study, provided the trial has demonstrated
the therapy to be safe, with evidence of a probable therapeutic benefit. This approach aims to dramatically
accelerate patient access and meaningfully shorten clinical development times, thus promoting investment
(as faster, cheaper development, coupled with accelerated commercialisation, would shift the risk–reward
ratio favourably from an investment perspective).16 However, there is concern that this approach may leave
Japan with regenerative medicines that are unrecognised by other countries because of efficacy concerns:
the lack of an explicit plan for determining efficacy during the conditional approval period points to a strong
underlying assumption that regenerative medicines will ultimately prove efficacious, whereas experience
from other areas of clinical research suggests that such optimism may be misplaced.17 The initial
demonstration of safety based on only Phase I trial data is an additional major concern.
The concern raised about the limited evidence that will probably be presented when a product is submitted
for regulatory approval is by no means limited to the Japanese regenerative medicine experience. As many
regenerative medicines will be developed with the initial aim of treating small patient populations in which
there is unmet need, it is likely that they will be evaluated via a regulatory pathway that offers patients
accelerated access to the new treatment. A consequence of this is that many of the studies submitted will
be early-phase, small single-arm trials. Nevertheless, the Japanese regulations excepted, the newer
regulatory pathways being developed across the world do not focus specifically on facilitating the licensing
of regenerative medicines. The newer pathways are primarily aimed at addressing unmet need in serious
conditions for which no alternatives exist, regardless of the type of technology. However, much of the
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focus and expectation for success in this area seems to have been directed at regenerative medicines,
possibly because they may evolve over time and may therefore, ultimately, not be restricted and limited
by having single modes of action. The submission of evidence that is based on single-arm studies appears
to be less to do with regenerative medicines being a ‘special case’ category of interventions, but rather a
consequence of the seriously ill, very small populations of patients with unmet medical needs who are often
the initial target of new regenerative medicines.
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Chapter 3 Technology appraisal methodology
issues that may be particularly relevant to
regenerative medicines
Clinical efficacy and safety issues arising from European Medicines
Agency, National Institute for Health and Care Excellence and Food and
Drug Administration assessments of licensed regenerative medicines
Methods
From the regenerative medicine literature and experts in the field we sought to identify regenerative
medicines that have been granted marketing authorisation in the EU. In addition to EMA assessment
documents, we also sought any NICE or FDA documents. We extracted key details from these reports, with
a primary focus on identifying issues that might be unique, or particular, to regenerative medicines.
Results
We identified six regenerative medicines that are (or have been) licensed in the EU: ChondroCelect®
(TiGenix, Leuven, Belgium), matrix-applied characterised autologous cultured chondrocyte implant (MACI)
(Sanofi, Gentilly, France), Glybera® (alipogene tiparvovec; uniQure, Amsterdam, the Netherlands), Holoclar®
(Holostem Advanced Therapies, Modena, Italy), PROVENGE® (sipuleucel-T; Dendreon Corporation, Seattle,
WA, USA) and ReCell® (Avita Medical, London, UK). No allogeneic therapies were identified – all were
autologous. Summary details are presented in Table 2; more comprehensive details can be found in
Appendix 1 (see Table 42).
ChondroCelect and MACI are both therapies for treating knee cartilage defects. ChondroCelect was the first
ATMP to receive marketing authorisation, in 2009. The marketing authorisation for MACI was suspended in
September 2014 as an authorised manufacturing site no longer existed. Holoclar is a therapy used for
treating corneal lesions resulting from burns to the eye. In 2014 it became the first stem cell-based ATMP to
gain regulatory approval (conditional marketing authorisation was granted). PROVENGE is an active cellular
immunotherapy for asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer
when chemotherapy is not yet indicated; this therapy purportedly helps the immune system to selectively
attack cancer cells (rather than directly attacking tumour cells, as happens with CAR T-cell therapies). EMA
marketing authorisation was granted in June 2013 but withdrawn in May 2015 at the request of the
manufacturer, for commercial reasons. Glybera is used to treat familial lipoprotein lipase deficiency (a rare
genetic disorder) with associated pancreatitis. Its mechanism of action is viral vector delivery of a therapeutic
gene to muscle cells. In 2012 it became the first gene therapy to be approved in Europe or the USA.
The ReCell spray-on skin system is a regenerative medicine device. It harvests a small amount of a patient’s
skin cells, which are then processed to produce a mixed cell population for immediate delivery onto burn
wound surfaces. ReCell can be given rapidly as there is no need for proliferation of the harvested skin cells.
A Conformité Européere (CE) mark was granted in 2005 (under Medical Devices Directive 93/42/EEC28).
Study designs
Randomised trial evidence formed the basis of the regulatory submissions for four of these six regenerative
medicines. This would be expected as, for the four therapies in question (ChondroCelect, MACI, ReCell and
PROVENGE), the disorders being treated were not rare and alternative therapies existed. However, for PROVENGE,
both the European Public Assessment Report (EPAR)24 and NICE Evidence Review Group (ERG) report26 commented
on the lack of blinding and the use of crossover, which allowed placebo patients to receive active treatment
following disease progression, making interpretation of the post-progression overall survival (OS) results difficult.
Nevertheless, there were no design issues for the other three therapies (ChondroCelect, MACI and ReCell),
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demonstrating that ATMP/regenerative medicine status in itself may not necessarily be a barrier to
submitting randomised trial evidence (as discussed at the end of Chapter 2).
Holoclar and Glybera were not studied in RCTs. Both had orphan designations and indications for when
there is unmet medical need; randomised trials were therefore not viable. A single-group study design was
therefore deemed acceptable in both EMA assessments.18,23 However, whereas for Holoclar the CAT
accepted that the condition (eye burns) would not improve spontaneously (making it more plausible that
observed benefits resulted from treatment), for Glybera there were concerns that the reduction of
pancreatitis events may possibly be due to temporal rarity and inherent variability of events over time
(i.e. the resulting apparent benefit may have resulted from chance). Perhaps it is for this reason that these
two therapies took very different routes to approval. Whereas conditional marketing authorisation was
achieved for Holoclar without any prior negative Committee for Medicinal Products for Human Use
(CHMP) decisions, Glybera had a much more difficult route to acquiring marketing authorisation. Negative
CAT and CHMP opinions on Glybera were issued in June 2011. Following a request for re-examination,
the CAT recommended the granting of marketing authorisation under exceptional circumstances in
October 2011, but the CHMP did not recommend approval. Glybera was finally granted approval in July
2012 with a more restricted licence (the approval being for patients with lipoprotein lipase deficiency and
severe or multiple pancreatitis attacks). It appears that EMA concerns about the efficacy of Glybera remain,
prompting Germany’s G-BA [Gemeinsamer Bundesausschuss (Federal Joint Committee for healthcare
regulation)] (which makes reimbursement decisions) to suspend its assessment of Glybera.29
The issue that this comparison of Glybera with Holoclar raises (the likelihood of cure or improvement
without experimental treatment) could be an important consideration for both the design and the
interpretation of future regenerative medicine trials. It is for conditions for which spontaneous cure or
improvement is unlikely that so much is expected of regenerative medicines; the extent of the problems
perceived to result from single-arm trial evidence may well depend on the ‘game-changing’ possibilities of
the therapy being assessed.
Persistence and adverse events
The requirement for, and implications of, long-term persistence of the six licensed therapies in treated
patients varied. For ChondroCelect, MACI, Holoclar and ReCell the aim is for therapeutic cells to become
integrated in recipients for as long as possible and to ultimately produce new cells. Long-term data are
needed for evaluations of true therapeutic success in this respect, and adverse effects associated with
longer-term persistence seem unlikely. Unknown long-term durability was highlighted in the ChondroCelect22
and MACI19 EPARs. Although the negative persistence effects of Glybera were thought to be minimal [the risk
of cancer by integration of viral vector deoxyribonucleic acid (DNA) was thought to be low], the EMA’s
conclusions on efficacy noted that the proposed single treatment was insufficient to provide a durable and
measurable effect on triglycerides, suggesting that the therapy did not persist in recipients for long enough.18
Little information could be found on the implications of the long-term persistence of PROVENGE within
patients.24 However, prior to infusion into patients, PROVENGE is associated with a very short shelf life. An
overview of the manufacturing and scale-up issues that may be encountered with regenerative medicines can
be found in this report’s discussion.
The only other adverse events that were noteworthy in terms of informing evaluations of future regenerative
medicine studies were immune reactions. For patients receiving Glybera, the use of immunosuppression did
not result in a reduction of unwanted immunogenicity.18 Acute infusion reactions were identified as a risk in
patients who had received PROVENGE and the risk of autoimmune reactions in non-prostatic tissues could
not be ruled out.24
Use of surrogate outcomes
Both surrogate and real clinical outcomes were evaluated for five of the six regenerative medicines;
the ReCell studies did not need to use surrogates, with all outcomes having clear clinical importance.27 The
use of surrogate outcomes was most problematic in the assessment of PROVENGE, as the OS results were
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not supported by the progression-free survival (PFS) or the time-to-progression (TTP) results.24 Many
members of the CHMP felt strongly that, in light of these seemingly contradictory results, the efficacy
evidence should be convincing and ideally corroborated by other secondary end points, which was not the
case. The NICE ERG report also highlighted the lack of consistency between the surrogate outcomes and
OS. Surrogate outcomes are discussed more broadly in Review of the use of surrogate end points as
primary outcome measures in definitive effectiveness trials of new therapeutic agents.
Evolving therapies
A key difference between regenerative medicines and conventional medicines is the likelihood that specific
treatments may change or evolve over time. The only example of this issue in the reports identified in this
section related to the cartilage cell (chondrocytes) treatments for cartilage defects of the knee (MACI and
ChondroCelect).19–22 When both were assessed by NICE they were third-generation products. The ERG
report noted the ‘general problem when long-term results are needed but the technology continues to
evolve’ (p. 148),20 the implication being that, by the time long-term trials results become available, the
therapy may well have been superseded by a (apparently superior) next-generation treatment.
Summary
The key issues arising from the reports of licensed regenerative medicines, that is, the issues that may be
beneficial to consider when appraising future regenerative medicines, were:
l the importance of considering the likelihood of cure or improvement without experimental treatment
when evaluating the results of single-arm studies
l the positive and negative implications of long-term persistence of therapies within patients
l the use of reliable surrogate outcomes (i.e. the need for validation of the relationship between
surrogates and real clinical outcomes)
l the problems of long-term evaluations when therapies evolve over time
l none of the six regenerative medicines approved for use in the EU to date was an allogeneic therapy.
Study biases: an overview of their importance and methods to
quantify and adjust for their impact
Regenerative medical technologies will often seek (and receive) EMA/FDA approval with limited or no data
from randomised experiments. In such cases, estimates of effectiveness will be based on observational data
and single-arm experimental studies. Recent examples include Holoclar, which received EMA authorisation
based on retrospective case series (combined n = 148),23 and Glybera, which was licensed based on
single-arm studies (combined n = 27).18
The focus of this section is therefore on making comparisons using historical controls and non-randomised
evidence more generally, as this is likely to represent the typical way in which single-arm studies will be
used in any future regenerative medicine submissions when evidence from randomised trials is unavailable.
This section will provide an overview of the reliability of using observational data and data from single-arm
trials and current methods used to minimise potential confounding bias. Most manufacturer submissions to
NICE are likely to be based on efficacy evidence from randomised trials; this overview is therefore important
as it may highlight areas in which NICE might consider that methods development research is needed to
enhance the TA programme. Specifically, this section seeks to address the following three questions.
1. To what extent do estimates of effectiveness obtained from non-randomised studies (NRSs) agree with
those obtained from randomised trials? (i.e. the quantification of bias)
2. What techniques are available to adjust for confounding bias in NRSs and how reliable are they?
3. What are the specific challenges of using single-arm studies to estimate treatment effectiveness?
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Methods
Pragmatic surveys of the literature were carried out to address these research questions. One review
addressed the reliability of obtaining treatment effectiveness estimates in comparative NRSs. Two further
separate reviews were carried out with respect to the second research question: one focusing on methods
to adjust for bias in the evidence synthesis process and a second on methods of analysing individual
patient data (IPD) from NRSs. A final review explored the literature relating specifically to single-arm
studies. For each review a number of key articles were identified using unstructured searches of MEDLINE
and studies known to the team. Based on these key studies snowballing techniques were then applied in
which citation searches were carried out and references checked for relevant studies. Citations and
references of any additional studies identified were then also checked until no further relevant studies
were identified.
Records identified in both the searches of MEDLINE and citation searches were screened by a single
reviewer and the full texts of those deemed potentially relevant were obtained and also screened by a
single reviewer.
Results
Quantification of bias in observational studies
A total of 14 studies were identified as relevant to the first research question (quantification of bias in
observational studies).30–43 A summary of the methods and findings of each the 14 identified studies is
presented in Appendix 2 (see Table 42).
All 14 studies relevant to the quantification of bias in observational studies sought to quantify the extent
of bias in NRSs by comparing the results of RCTs with those of NRSs. In six of the studies,33–35,37,38,41 data
were sourced from published meta-analyses that included both RCTs and NRSs. Five other studies30,32,39,40,42
took a different approach and searched for NRSs that compared treatment effects and then carried out
a further search to locate relevant RCTs. Beynon et al.31 took a similar sampling approach, randomly
selecting RCTs from the Cochrane Central Register of Controlled Trials database and then conducting
searches for NRSs that had addressed the same topic.
The method of analysis in the majority of studies involved pooling the evidence from randomised and
non-randomised sources separately. The resulting summary effects from the randomised and non-randomised
evidence were then compared. Despite these similarities in approach, a considerable range of methods was
used to compare summary estimates of effect, with multiple outcome measures often being employed.
Common outcomes included:
l assessment of direction of effect
l subjective assessment of overlap of confidence intervals (CIs) and proximity of summary estimates
l tests of statistical difference in summary estimates of effect obtained from randomised and
non-randomised evidence
l the calculation of ratios of odds or risk ratios.
The lack of a common method of comparison is problematic as it presents a significant barrier to making
comparisons across studies and indicates a lack of consensus around how to measure the degree of
concordance between results obtained from randomised studies and those obtained from NRSs.
Furthermore, the employment of multiple methods of comparison in many studies can be considered a
potential source of bias, as no attempt was made to adjust comparisons for multiple testing.
Of the 14 included studies, seven30,35,37,38,40–42 concluded that there were no systematic differences in either
the size or the direction of effect estimates obtained from NRSs compared with those from RCTs. Five
studies31,32,34,39,43 concluded that effect estimates obtained from NRSs were systematically larger than those
obtained from RCTs. This included the largest study by Ioannidis et al.,34 which contained RCTs and NRSs
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from 45 topic areas. The authors of the other two studies33,36 felt unable to draw any meaningful
conclusions about the comparability of estimates obtained from RCTs and NRSs.
Study design and study quality were investigated in a number of the studies and were discussed in nearly
all of the studies included in this review. Study design was identified as a likely factor in determining the
reliability of estimates of clinical effectiveness obtained from NRSs.
Two studies excluded NRSs that used historical control groups.37,42 Concato et al.37 justified this exclusion
based on previous evidence presented in Sacks et al.,39 who reported that 79% of interventions tested
were considered effective in trials with historical controls, whereas only 20% were considered effective
in RCTs. Further empirical evidence of the potential for bias in studies using historical controls is also
presented in Ioannidis et al.,34 Algra and Rothwell40 and Golder et al.,41 who all found that there were
fewer discrepancies between the results of RCTs and NRSs when studies with historical controls were
excluded. Ioannidis et al.34 also found that results from prospective NRSs contained fewer discrepancies
compared with effect estimates from randomised studies than did retrospective studies, either with current
or historical controls. Investigations into broader measures of quality have also revealed similar results.
MacLehose et al.35 classified NRSs as being of either high or low quality and observed that comparisons
between randomised evidence and high-quality NRSs tended to show much smaller discrepancies than
comparisons between randomised studies and low-quality NRSs.
Adjustment for bias in non-randomised studies
A total of 28 studies44–71 were identified as relevant to the second research question on the techniques
available to adjust for confounding bias in NRSs (details of these reviews are presented in Appendix 2).
A key factor in the reliability of estimates of effectiveness based on observational data is the statistical
analysis used; a large number of studies have sought to develop and evaluate methods for adjusting and
eliminating bias resulting from confounding. A summary of the studies that have looked at methods of
adjustment for confounding bias in NRSs and how reliable they are62–70 is presented in Appendix 3. Overall,
it is unclear which methods are most appropriate in certain circumstances and further research is needed.
Furthermore, adjusting for bias when comparing single-arm trials with historical controls requires IPD; this
can be difficult to access, although approaches for recreating IPD data have been developed, such as the
algorithm by Guyot et al.72 Consequently, results generated from NRSs will be subject to an unknown
degree of uncertainty, even after adjustment for confounding.
Challenges of using single-arm trials to estimate effectiveness
A total of 10 articles were identified as being relevant to the issue of using single-arm trials to estimate
effectiveness.73–82 One of these was a recent review paper73 that discusses both the opportunities and the
challenges involved in using studies without a control group. Single-arm designs have the advantage of
requiring fewer patients, all of whom receive the experimental treatment, thereby reducing the cost of
trials in terms of patients, funding and effort. This section discusses the issues of making comparisons
using single-arm studies and how comparable results from single-arm studies and comparative randomised
studies are.
Making comparisons using single-arm studies
Without a direct, concurrent comparator in single-group studies, both explicit and implicit comparisons
are frequently made.73 Implicit comparisons are made when the expected outcomes in the absence of the
intervention of interest are believed to be well known and the expected effect size from the intervention is
large. Explicit comparisons are made when the investigators compare the single group of subjects before
and after an intervention or when the investigators choose to incorporate a historical comparator in the
analysis (e.g. historical data from the research institution or from an external cohort or existing database).
Each of these alternative study designs has particular challenges and advantages. The particular challenges
are discussed in the following sections.
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Implicit comparisons Implicit comparison is acceptable when the natural history of the disease is known
with (near) certainty, the study participants are representative of the broader patient population in terms of
disease severity and prognosis (in the absence of treatment) and the outcomes in untreated patients are
well known, with a large observed effect in the study group.73 Examples can be seen in the recent TAs
of new drugs for hepatitis C by NICE, for which, because of the objective outcome and large treatment
benefit, regulatory approval had been granted based on short-term single-arm trials.83 However, even
for diseases with an apparently uniform prognosis, there may be subtle yet clinically relevant differences
between patients who are enrolled in the single-arm trial and those who do not qualify and also between
those in the trial and the historical controls. Careful review of the study population and eligibility criteria is
needed to make an assessment concerning external validity.73
When considering clinical effectiveness based on single-arm trials, the comparison is often made implicitly:
a survey found that roughly half of Phase II studies did not cite the source of their historical response
rates.74 This is never sufficient for the purposes of a cost-effectiveness analysis, in which it is essential to
have some reasonable estimate of the treatment’s effectiveness relative to a control. This requirement has
the implication that such implicit comparisons are likely to be rarely of relevance to submissions to NICE,
which will by necessity always contain an economic component.
Before-and-after designs Studies that use before-and-after designs (sometimes referred to as pre–post
designs) assess the difference in response before and after the administration of an intervention in a single
group of patients. Patients therefore serve as their own controls. For before-and-after designs to provide
unbiased estimates of effectiveness it is necessary to eliminate all alternative explanations for observed
treatment effects. It is therefore necessary to eliminate the possibility of improvement as a result of adjunctive
therapies administered concurrently or carryover effects from therapies administered before the intervention
of interest should be considered. Furthermore, natural recovery presents another potential explanation for
an observed before–after improvement in a health outcome in a single-group comparison. Drawing valid
and meaningful inferences about treatment effect using single-group observational studies is therefore
problematic when evaluating conditions that are fluctuating or intermittent and this limits their applicability.
Further to the above, before-and-after designs can be subject to the effects of regression to the mean, which
can simulate improvements in disease outcomes but which result from the elective sampling of patients at a
peak severity in the natural history of disease, which has a tendency to return to average severity levels over
time regardless of interventions administered.75 Before-and-after designs are therefore most appropriate for
chronic conditions in which disease status is stable over time or in which the natural history of the disease
is certain, such that any variation in disease status/progression is likely to result from the intervention.
Before-and-after designs consequently are most commonly used for the evaluation of surgical interventions and
other irreversible interventions. Before-and-after studies can also be useful when a disease is rare (as fewer patients
need be recruited) or when ethical issues mean that using a control group would be inappropriate, such as in
end-of-life (EoL) care and childhood diseases. In these cases, however, the weaknesses highlighted above
are likely to remain, but can be mitigated by the inability to carry out comparative studies.
Historical controls Comparative estimates of effectiveness can be generated from single-arm data sets
by comparing results with historical data obtained either from the same research institution or from an
external cohort or database. The interpretation of single-group studies with historical controls is, however,
complicated by specific challenges to the validity of historical comparisons resulting from differences
between patients selected as historical controls and those recruited to the single-arm studies. Differences
between the patient populations of a single treated group and historical controls can arise for a variety
of reasons, including differences among accrual sites or over time in patient characteristics (e.g. age,
performance status or other prognostic factors). For example, more recently diagnosed patients may have
milder manifestations of a condition because of improved (and therefore commonly increased) diagnostic
sensitivity. Treatment effects may also be attributable to secular trends in clinical care (e.g. changes in
diagnostic methods, classification criteria or outcome ascertainment).
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There are many additional reasons why patients in a single-arm Phase II study may not be comparable to
those in some hypothetical historical group.76 Phase II trials involving new agents are typically undertaken
in large academic medical centres, where the patient population may vary in many ways from that in a
subsequent Phase III trial (e.g. the population may be more mobile or more heavily pretreated or have a
better socioeconomic status or receive better supportive care). For new agents there is a natural enthusiasm
among the investigators for the new agent and a desire for it to ‘look good’. This enthusiasm may manifest
itself in various ways, such as setting the historical response rate at a low value74 or enrolling only patients
who look in some sense ‘promising’. These aspects cause problems in an uncontrolled Phase II study, but
not in a randomised Phase II study.
However, if historical data are available from previous randomised Phase III trials, the historical estimate of
the response rate for the standard treatment may be more accurate than the estimate obtained from the
control arm of a randomised Phase II trial, which is based on a smaller sample size.76
To address the problem of reliable historical benchmarks for single-arm Phase II trials, efforts have been
made to amass historical databases and derive historical control data for future trials in specific disease
sites. Examples include stage IV melanoma77 and advanced pancreatic cancer.78 The availability of these
kinds of data is extremely important for better evaluation and analysis of data from single-arm trials and is
essential to generate the estimates of relative effectiveness needed in economic models for the assessment
of cost-effectiveness.
Comparability of results from single-arm studies and randomised designs
There is a growing body of literature on whether Phase II trials should be single arm or randomised (which
is now the more common approach), with the focus on which design is most efficiently associated with
success in Phase III RCTs, particularly in the context of cancer drug development. From one perspective this
appears not to be directly relevant to the issue of the product development of regenerative medicines, for
which the issue is not which design best helps companies decide which drugs to take on to a Phase III trial,
but rather how companies and regulators can manage development when the long-established expectations
for pivotal evidence are unlikely to be met. This body of literature, however, includes a number of studies
that have sought to evaluate the reliability of estimates of effectiveness from single-arm studies and their
relative performance compared with those from randomised trials.
A simulation study79 investigated the difference between randomised Phase II trials and single-arm Phase II
trials under realistic statistical parameters and with a historical control success rate of 20% and a target
success rate of 40%. The study found that both designs produced similar results when there was no variation
in historical control success rate but that even a modest variation in historical control success rate inflated the
false-positive rate in single-arm trials. Furthermore, increasing the size of the single-arm trial inflated the false
positive rate. Another simulation study80 aimed to quantify the impact of a policy of all single-arm Phase II
trials compared with randomised Phase II trials on the number of Phase III trials conducted using active
agents. The parameters modelled in this study included between-institution variability in the standard
care response rate, treatment effect and estimate of historical control rate; the presence of historical bias
(over- or under-estimation of the response rate in the historical controls as a result of changing care); and the
proportion of Phase II trials conducted using active agents. The study found that single-arm trials resulted in a
higher percentage of Phase III trials conducted using active agents when there was a minimal standard of
care activity (i.e. high unmet need) or when the historical control rate was overestimated (with a high control
rate a randomised trial was less likely to identify a treatment benefit). Randomised Phase II trials performed
better when the historical control rate was underestimated or when it was highly variable. These results
reflect those of Tang et al.79 in demonstrating that historical bias has a large impact on the reliability of
results from single-arm trials. Similar findings were reported when a Bayesian approach was used to compare
single-arm and randomised studies, based on a binary response variable, in terms of their abilities to reach
the correct decision about a new treatment.81 The study found that the accuracy of the estimate of the
success rate for the standard agent, obtained from historical data, has a crucial role: when the response rate
for the standard agent is correctly estimated, the single-arm studies are preferred but, as the magnitude of
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the misspecification increases or as the total number of patients accrued get larger, two-arm studies tend to
be preferred.
A more recent publication investigated the superiority of randomised Phase II trials over single-arm Phase II
trials to predict success at Phase III for oncology drugs.82 In this study, published Phase III trials testing
systemic cancer therapy were identified through a MEDLINE search. Statistical analysis was performed
using the generalised estimating equation method, correlating Phase II features with Phase III outcome.
The results found that of 189 eligible Phase III trials the primary outcome was positive in 79 (41.8%)
(success) and these were supported by 336 Phase II trials, including 66 randomised Phase II trials; positive
Phase II outcome, randomised or not, correlated with positive Phase III outcome (p = 0.03). Randomised
Phase II trials were not superior to single-arm Phase II trials at predicting Phase III study success. The
authors concluded that, given the added resources required to conduct randomised Phase II trials, further
research into Phase II trial designs is required.
In summary, these studies confirm that results from single-arm trials can be considered as reliable indicators
of treatment benefit only when the disease natural history is very well known, the patient population is
homogeneous and the control (standard care) treatment has little impact on outcomes. It is interesting that
increasing the size of single-arm trials is not helpful.
Effect estimates from single-centre compared with multicentre trials
Single-centre trials may produce significantly larger effect estimates than multicentre trials. Although
no publications were found examining this effect in NRSs, there are relevant publications for RCTs.
Overestimation of treatment effect in single-centre RCTs has been discussed and quantified in critical
care medicine;84,85 a relative overestimation of 36% was found in a study that compared 41 single-centre
studies (median n = 40) with 41 multicentre studies (median n = 223).84 Trial- or review-specific examples
of this effect have also been reported in neonatology.86
Possible reasons for the larger effect estimates may be that single-centre studies:
l are more prone to bias than multicentre studies84
l recruit fewer patients than multicentre studies (smaller studies tend to report larger effects)
l may have treatment effect magnitudes that are affected by the high levels of centre expertise
l may recruit populations that are unduly homogeneous.
These factors may limit the reliability or the external validity (generalisability) of single-arm trial results.
Relevance to future regenerative medicine submissions
Although RCTs continue to be the dominant method for evaluating treatment effectiveness, a large
number of studies has been conducted devoted to establishing the relatability of evidence from NRSs. This
sizable literature demonstrates both the value and the challenges of using observational data. Although
the evidence is mixed regarding the reliability of observational data for evaluating treatment effectiveness,
the existing studies do seem to indicate that, in some cases at least, confounding is a potential issue and
will impact on treatment effectiveness estimates. Furthermore, the current evidence suggests that
retrospective studies and, in particular, historical control studies are more likely to result in biased estimates
of effect. As observed in Clinical efficacy and safety issues arising from European Medicines Agency,
National Institute for Health and Care Excellence and Food and Drug Administration assessments of
licensed regenerative medicines, many recent regenerative medicine submissions have been based on data
from single-arm studies, which have been compared with historical controls. The findings of this review
therefore suggest that a degree of caution is necessary in interpreting estimates from these comparisons,
as bias in estimates of effectiveness from historical comparisons will add additional uncertainty not
accounted for in the CIs/credible intervals presented. A key factor in the reliability of estimates of
effectiveness based on observational data is the statistical analysis used, and a large number of studies
have similarly sought to develop and evaluate methods for adjusting and eliminating bias resulting from
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confounding. Despite this, it is unclear which methods are most appropriate in certain circumstances and
further research is needed. Consequently, results generated from NRSs will be subject to an unknown
degree of uncertainty, even after adjustment for confounding. Single-arm trials are reliable indicators of
treatment benefit only when the natural history of the disease is very well known, the patient population is
homogeneous and the control treatment has little impact on outcomes. It is interesting that increasing the
size of single-arm trials is not always helpful.
If regenerative medicines continue to be targeted at tightly defined conditions, with a narrow population
to minimise heterogeneity, when patients have little or no chance of recovery/improvement otherwise, the
use of NRSs and, in particular, single-arm studies may be adequate. To complement the data from such
trials, robust accurate evidence of the outcomes achieved with standard care must be provided. When
appropriate, methods to adjust for confounding should be employed, with the selection of the method
used being explicit and based on sound reasoning. Confidence in estimates of effect may also increase
by utilising multiple methods of adjustment, although care should be taken to ensure that methods are
appropriate to the decision problem in question. However, many regenerative medicines may require
highly skilled and specialised facilities for optimum delivery. Consequently, the evidence on their efficacy
and safety may be derived from only small, single-centre studies, which (more often than not) might
overestimate effect estimates or which might lack the external validity needed to support more widespread
uptake of the intervention.
In terms of NICE methods and processes, methods research may be considered to inform guidance both
for manufacturers (e.g. minimum reporting requirements for analysis methods for comparing single-arm
trial data with historical control data) and for ERGs (e.g. checklists for appraising how historical control
data were identified and analysed by manufacturers).
Review of the use of surrogate end points as primary outcome
measures in definitive effectiveness trials of new therapeutic agents
Introduction
As discussed earlier (see Clinical efficacy and safety issues arising from European Medicines Agency,
National Institute for Health and Care Excellence and Food and Drug Administration assessments of
licensed regenerative medicines), it can be anticipated that almost all of the pivotal trials of regenerative
medicines submitted for assessment for marketing authorisation will utilise a surrogate or intermediate
outcome (or end point). A surrogate may be either a laboratory or a physiological measure of the patients’
experience that could be used to predict or provide an early measure of therapeutic effect. This section
presents an overview of surrogate outcome measures and their use in clinical research and highlights
issues pertinent to the development and appraisal of regenerative medicines.
Methods
To describe the use of surrogate end points as primary outcome measures in trials of new therapeutic
agents a review of the most relevant and up-to-date literature was performed. The review was not
systematic but was designed more as a pragmatic rapid review to assimilate current information and
opinion on the use and suitability of surrogates in therapeutic trials. The review began with a search of key
guidelines on the use of surrogate end points produced by the FDA, NICE DSU (Decision Support Unit)
(University of Sheffield) and European Network for Health Technology Assessment (EUnetHTA) and survey
results produced by the National Institute for Health Research (NIHR) HTA programme on the cost-effective
use of surrogate outcomes. Citation and reference searches followed, which produced a library of relevant
peer-reviewed publications and statistical reports on evidence for the use of surrogate end points in
medicine. All relevant studies identified are presented in Appendix 4 (see Table 44).
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Definition and examples of surrogate outcomes
Ideally, it is expected that the relative effectiveness of drugs and treatments will be based on final clinical
end points,87 that is, an outcome that the patient, the clinician and other stakeholders hope to avoid such
as morbidity, impaired quality of life and/or death.88 RCTs with large sample sizes and extended follow-up
periods are often required to capture the statistical significance of a treatment’s or an intervention’s
impact on a patient-relevant outcome.87 However, the requirements of RCTs are often impractical when
considered alongside pressures of time for products to go to market and in particular the urgent need for
new treatments for patients with chronic but life-threatening diseases. The principal rationale for the use
of a surrogate outcome is a more rapid assimilation of data without the need for large and lengthy trials in
patients for whom mortality rates are high or treatment options are few.89
For example, OS is considered the gold standard to measure benefit in many clinical trials as it provides
a precise and statistically and clinically meaningful end point. However, mature OS data are difficult to
achieve because of the length of time needed and the number of deaths required for appropriate statistical
analyses. Furthermore, OS as a measure of therapeutic success becomes less useful as the course and duration
of diseases such as cancer move from being acute to more chronic; longitudinal effects of chronic disease
such as comorbidities and additional ongoing treatments add further limitations to OS as an outcome.90,91
As a solution, there has recently been a steady move (by regulatory bodies) away from OS as a clinical end
point measure and towards more short-term surrogate measures.
A generally accepted definition of a surrogate has followed that of Temple (p. 4):92 ‘a laboratory measurement
or physical sign used as a substitute for a clinically meaningful endpoint that measures directly how a patient
feels, functions or survives’. However, chronic disease programmes and patient-reported outcomes have
meant that a broader definition is now needed to better fit the HTA perspective.93,94 Although the term
‘intermediate end point’ is sometimes used synonymously with surrogate end point,95 it is often used to refer
to more patient-relevant outcomes than those typically thought of as surrogates. However, for the purposes
of this report, the term ‘surrogate outcome’ will be used in its broadest sense.
Examples of approved drugs based on the use of validated surrogate end points include antihypertensives
and blood pressure in stroke research, cholesterol-lowering agents and serum cholesterol and treatments
for glaucoma and intraocular pressure;96 CD4 count for acquired immunodeficiency syndrome (AIDS)
or death in human immunodeficiency virus (HIV) infection;97 and bone density for bone fracture in
osteoporosis.89 However, occasionally such approvals have to be revised when long-term data become
available. The drug gefitinib was approved in the USA in 2003 for patients with non-small-cell lung cancer
based on tumour response rate, a surrogate end point. When, in 2005, the results from later studies
showed no significant benefit in terms of survival, the FDA withdrew approval for its use in new patients.
Therefore, although surrogate end points offer the potential of real benefit – in providing patients with
faster access to treatments and saving triallists time and resources – they may also have important
drawbacks. Most notably (as the gefitinib example demonstrates), there may be uncertainty about the
relationship between surrogate and real clinical end points and this may result in treatment efficacies being
overestimated. A meta-epidemiological study that compared 84 trials that used surrogate outcomes with
101 trials that used patient-relevant outcomes showed that trials reporting surrogate end points had larger
treatment effects: on average, trials using surrogate outcomes reported treatment effects that were
28–48% higher than those of trials using final patient-relevant outcomes and this result was consistent
across sensitivity and secondary analyses.98 The study characteristics of trials using surrogate outcomes and
those of trials using patient-relevant outcomes were well balanced except for median sample size (371 vs.
741) and single-centre status (23% vs. 9%). Their risks of bias did not differ. This finding illustrates the
importance of surrogate end points being appropriately validated and of quantifying the level of certainty
of association of treatment effect between the surrogate and patient-relevant final outcomes.98
Validation
Surrogate outcomes can be unreliable without sufficient validation; for example, two major antiarrhythmic
drugs, encanaide and flecanaide, reduced arrhythmia but caused a more than threefold increase in overall
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mortality99 and cardiac inotropes improved short-term cardiac haemodynamic function but can increase
mortality.100 Such examples may fuel uncertainty about the validity of surrogates. The results of a questionnaire
study of 74 stakeholders in the drug development of cardio-renal disease indicated that, although the use of
surrogates is not opposed, most are not considered valid.101 Out of the four surrogate outcomes suggested as
an end point for trials – blood pressure, glycated haemoglobin (HbA1c), albuminuria or C-reactive protein (CRP) –
only use of blood pressure was considered moderately accurate. Questionnaire responders from industry valued
the accuracy of surrogates consistently higher than academic and regulatory responders.
General principles of validation
For a surrogate to be a reliable outcome measure it is generally accepted that the measure must be on the
‘causal pathway’ from the intervention to the clinical outcome.89 The possible reasons for treatment or trial
failure associated with surrogate end points have been discussed by Fleming and DeMets102 and more
recently by Taylor and Elston:89
l the surrogate is not on the causal pathway of the disease process
l of several causal pathways of disease, the intervention affects only the pathway mediated by
the surrogate
l the surrogate is not on the pathway of the intervention’s effect or is insensitive to its effect
l the intervention has mechanisms of action independent of the disease process (and so its effect will not
be captured by a surrogate outcome).
A number of guidelines have been proposed for assessing the validity of surrogate end points87,89,100,102 and
further work has also been published on scoring schemas for the value of surrogates.103
As a result of a review, Elston and Taylor88 recommended that, before a surrogate outcome is accepted, a
systematic review of the evidence for the validation of the surrogate/final outcome relationship should be
conducted. Furthermore, the evidence on surrogate validation should be presented according to an explicit
hierarchy, such as:
l level 1 – evidence demonstrating that treatment effects on the surrogate correspond to effects on the
patient-related outcome (from clinical trials)
l level 2 – evidence demonstrating a consistent association between surrogate outcome and final
patient-related outcome (from epidemiological/observational studies)
l level 3 – evidence of biological plausibility of the relationship between surrogate and final patient-
related outcome (from pathophysiologic studies and/or understanding of the disease process).
Methods for the statistical validation of surrogates as outcome measures have also developed.99,104,105
Validation of specific surrogate outcomes
Surrogate outcomes in oncology
A recently published systematic review of trial-level meta-analyses of randomised trials quantifying the
association between surrogate and final outcomes in cancer included 36 studies.106 The review found that
all validation studies used only a subset of the available trials and that the evidence supporting the use of
surrogate outcomes in cancer trials is limited. The results are summarised in Table 3.
The results of the review indicate that little research effort has been invested in validating tumour response
as a surrogate for clinical outcomes; the available evidence suggests that better tumour-level surrogate
outcomes are required. The clinical outcome surrogates (intermediate outcomes) for OS, particularly PFS,
have been better studied and appear to perform better. However, the range of results for PFS indicates
that the validation of a surrogate in one disease and setting cannot be assumed to hold for other diseases
and settings.
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Progression-free survival or time to progression
The suitability of PFS or TTP as an appropriate surrogate measure in advanced or metastatic cancer
research has been reviewed.94 The review identified 19 papers covering eight different tumour types. Data
sets included the relationship between the measures within aggregated trial data and the effect on
individuals within IPD. The studies employed a variety of different data sets and statistical techniques, but
the lack of standardisation across the studies made it very difficult for the review to identify any consistent
relationship between the surrogate and the overall outcome measure.
In a recent review of current statistical approaches to surrogate end point validation based on meta-
analysis in various advanced-tumour settings,107 the suitability of PFS and TTP was assessed using three
validation frameworks: Elston and Taylor’s framework, the German Institute of Quality and Efficiency in
Health Care’s (IQWiG) framework and the Biomarker Surrogacy Evaluation Schema (BSES3). The findings
suggested that the strength of the association between the two surrogates and OS was generally low.
The level of evidence (observation level vs. treatment level) available varied considerably by cancer type
and evaluation tools and was not always consistent, even within one specific cancer type. This study
emphasises the challenges of surrogate end point validation and the importance of building consensus on
the development of evaluation frameworks.
A recently published study analysed the degree of difference in treatment effects between surrogate
end points and OS in RCTs of pharmacological therapies in advanced colorectal cancer.108 Univariate and
multivariate random-effects meta-analyses were used to estimate pooled summary treatment effects.
The ratio of hazard ratios (HRs) to odds ratios (ORs) and differences in medians were used to quantify the
degree of difference in treatment effects between the surrogate end points and OS. The study found a
larger treatment effect for the surrogates than for OS. The authors suggested that previous surrogacy
relationships observed between PFS/TTP and OS in selected settings may not apply across other classes or
lines of therapy.108
Minimal residual disease
Minimal residual disease (MRD) is a surrogate outcome that has been accepted by a regulatory agency, the
FDA. With current intensive treatments, many acute leukaemia patients will enter morphological complete
remission (CR). This is typically defined as patients having < 5% blasts (abnormal, immature cells) in the
bone marrow. If no further therapy is given after entering CR, most patients will relapse, demonstrating
that microscopy-based evaluations are incapable of detecting all tumour cells. However, diagnostic
techniques can now quantify and monitor MRD, which is invisible to the trained eye, in patients in CR.
The ability to quantitatively measure the amount of MRD at various times after achieving CR can guide
subsequent treatment.109 Studies have shown that MRD before stem cell transplantation is a strong
TABLE 3 Summary of the results from a systematic review of trial-level meta-analyses of randomised trials
quantifying the association between surrogate and final outcomes in cancer
Surrogate and clinical outcome
Number
of studies
Range of correlation
coefficients
Level of correlation
(low, medium or high)
Pathological complete response for event-free survival 2 0.17–0.28 Low
Pathological complete response for OS 2 0.30–0.49 Low
Response rate for OS 11 0.32–0.68 Low to medium
Locoregional control for OS 2 0.52–0.84 Medium to high
Event-free survival for OS 3 0.79–0.86 High
Disease-free survival for OS 7 0.62–0.98 High
PFS for OS 30 0.29–0.99 Low to high
TTP for OS 3 0.54–0.69 Medium
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independent predictor of subsequent relapse in children with high-risk or very high-risk acute lymphocytic
(lymphoblastic) leukaemia (ALL).110,111
Threshold levels for MRD may vary depending on the population being considered. For children receiving
first-line chemotherapy for ALL, leukaemia cell concentrations of 0.01% (1 in 10,000) have been described
as optimal for identifying higher-risk patients for potential intervention.112 For children with ALL who have
had a previous relapse, the best MRD threshold for predicting disease-free survival (DFS) at 10 years has
been reported as 0.001%.113 The FDA has concluded that the evidence base to indicate that early MRD
status is the strongest predictor of long-term event-free survival (EFS) in ALL is unequivocal.114 It added
that the magnitude of the importance of its critical role in risk stratification for treatment decisions has
furthered the consideration of its potential as a surrogate end point for clinical trials of investigational
therapeutic interventions. However, results from the UKALL R3 trial, which compared different
chemotherapy treatments for children in first relapse, showed that the longer-term outcome of having
MRD-negative status in patients who have already had one relapse may well vary according to how the
status was achieved.115 There is, therefore, some uncertainty in how MRD negativity correlates to long-term
outcomes in relapsed populations.
Current issues for health technology assessment and cost-effectiveness models
Regulatory bodies find it acceptable for trials to be shorter, to have fewer participants and to use surrogate
outcomes when populations are rare and there is a high unmet clinical need. However, a commitment
to ongoing research is mandatory to receive longer-term approval; if research is not continued or if it is
continued but efforts to validate the surrogate fail, the approval will be withdrawn.96 From a regulatory
and HTA perspective, the absence of data on clinical end points might be acceptable when a clinical end
point is difficult or impossible to study. The EUnetHTA summarised its findings into eight recommendations
for end points used in the relative effectiveness assessment (REA) of pharmaceuticals:87
1. Efficacy assessments of pharmaceuticals should be based whenever possible on final patient-relevant
clinical end points (e.g. morbidity, overall mortality).
2. Biomarkers and intermediate end points will be considered as surrogate end points if they can reliably
substitute for a clinical end point and predict its clinical benefit.
3. Surrogate end points should be adequately validated and this must have been demonstrated based on
biological plausibility and empirical evidence.
4. Validation of a surrogate is normally undertaken in a specific population and for a specific drug
intervention. Demonstration of surrogate validation both within and across drug classes should be
thoroughly justified.
5. The availability of a sufficiently large safety database is particularly important and evidence on safety
outcomes should always be reported.
6. The absence of data on clinical end points might be acceptable when a clinical end point is difficult or
impossible to study (very rare or delayed) or the target population is too small to obtain meaningful
results on relevant clinical end points even after very long follow-up (very slowly progressive and/or rare
diseases). However, these exceptions need to be carefully argued and agreed in advance.
7. Reassessment requirements for further data should be clearly defined when an assessment has been
previously made based on surrogate end points.
8. Further methodological research on the use of surrogate outcomes is needed to inform future REA
approaches for the handling of surrogates.
Similarly, Elston and Taylor88 recommended that a HTA or cost-effectiveness model based on a surrogate
outcome should be undertaken only when it is not possible to base the assessment of clinical effectiveness
and cost-effectiveness on final patient-related outcomes [i.e. mortality, important clinical events and
health-related quality of life (HRQoL)]. In such cases, a systematic review of the evidence for the validation
of the surrogate/final outcome relationship should be performed and the evidence on surrogate validation
should be presented according to an explicit hierarchy.
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Given the difficulty in validating surrogate outcomes, which conflicts with the need to use such outcomes
in clinical research, Ciani and Taylor93 commented on the requirement to recognise the need for pragmatic
high-level evidence, preferably from meta-analyses and regression modelling using both surrogate and
final outcomes for HTA. This is demonstrated by a study conducted to illustrate the potential to reduce
uncertainty around the clinical outcome by estimating it from a multivariate meta-analysis.116 Bayesian
multivariate meta-analysis was used to synthesise data on correlated outcomes in rheumatoid arthritis.
Estimates from the Health Assessment Questionnaire (HAQ) were mapped onto the HRQoL measure, the
EuroQol-5 Dimensions (EQ-5D) questionnaire, and the effect was compared with mapping the HAQ
obtained from the univariate approach. The results showed that use of multivariate meta-analysis can lead
to reduced uncertainty around the effectiveness parameter. By allowing all of the relevant data to be
incorporated in estimating clinical effectiveness outcomes, including data from surrogate outcomes,
multivariate meta-analysis can improve the estimation of health utilities through mapping methods.
In their review of HTA and cost-effectiveness models, Taylor and Elston89 found that only one of the four
reports undertook a systematic review to specifically seek the evidence base for the association between
surrogate and final outcomes. Furthermore, this was the only report to provide level 1 surrogate–final
outcome validation evidence (i.e. RCT data) showing a strong association between the change in surrogate
outcome (biopsy-confirmed acute rejection) and the change in final outcome (graft survival) at an
individual patient level. The outcome of the review was to make recommendations for the evaluation of
surrogate end points in a HTA (these are listed in Appendix 4, Table 44).
Taylor and Elston’s89 HTA publication has been key to providing insight into the use of surrogates within
the HTA and cost-effectiveness models framework and presents the range of approaches. This includes HR
calculation, transition probabilities within a model of natural history and predictive risk equations, used by
researchers to quantify the relationship between surrogate and clinical end points.88
In addition to calls for the validation of commonly used surrogate outcomes, there is a need for novel,
more appropriate, more valid outcomes. An editorial in the Journal of Clinical Oncology117 commented on
the large number of novel anti-tumour agents currently being tested in ever smaller groups of patients
with increasingly specific tumour characteristics. Cancer types will continue to be divided into many
subentities that differ from each other in terms of genetic make-up, natural course and sensitivity to systemic
treatments. This, together with the limited number of patients who are available for clinical studies, means
that a new approach to oncology research is needed. The editorial called for more intensive efforts at the
preclinical stage to better understand the mode of action of potential new agents and for this information to
be used to select more precisely the target population and appropriate and valid surrogate outcomes. By so
doing it should be possible to achieve a higher success rate in Phase III studies, with smaller numbers of
patients needed.
Summary
l Studies looking at surrogates for OS demonstrate how difficult it is to validate even commonly
used surrogates.
l On average, it seems that trials using surrogate outcomes report larger treatment effects (28–48%)
than trials using final patient-relevant outcomes.
l However, a desire to get regenerative medicines to market quickly means that manufacturer submissions
are likely to be supported by short-term trials reporting primary outcomes that are surrogates.
l Regulatory agencies may accept evidence based on surrogate outcomes; for example, the FDA accepts
that MRD is the strongest predictor of long-term EFS in ALL, although there is considerable uncertainty
about its value in relapsed populations.
l The choice of surrogate outcomes must be researched, explicit and justified. Ideally, a systematic review
of the evidence for the validation of the surrogate/final outcome relationship should be performed and
the evidence on surrogate validation should be presented according to an explicit hierarchy.
l Analyses, at whatever stage of development and maturity of data, should include all available outcome
data to minimise uncertainty.
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Scoping review of potential cost-effectiveness issues
The assessment of the cost-effectiveness of regenerative medicines and cell therapies may raise additional
challenges compared with the assessment of the cost-effectiveness of other types of technologies. A focused
scoping review was undertaken to help to identify potential conceptual differences between regenerative
medicines/cell therapy products and other more conventional technologies. The objective of the scoping review
was to identify possible characteristics that could make any assessment of cost-effectiveness, uncertainty and
the value of further evidence different from that for other technologies. These characteristics also provided a
basis for subsequent exploratory work to assess the appropriateness of existing decision frameworks for health
technologies. A related objective was to identify areas in which additional methodological development may
be required.
The scoping review was based on completed and ongoing NICE TAs for regenerative medicines and
broader literature that has attempted to identify potential challenges.
Previous regenerative medicine evaluations evaluated within the National Institute for
Health and Care Excellence technology appraisal process
Methods
A review of previous NICE TAs of regenerative medicines and cell therapy products was conducted. The
primary aim of the review was to identify any common themes and potential analytical challenges relating
to the assessment of the cost-effectiveness of regenerative medicines and cell therapy products.
Results
The National Institute for Health and Care Excellence has previously evaluated two regenerative medicines
within the existing TA process: autologous chondrocyte implantation (ACI) for the treatment of cartilage
defects in the knee joints118–120 and sipuleucel-T (PROVENGE) for treating asymptomatic or minimally
symptomatic metastatic hormone-relapsed prostate cancer.121
Autologous chondrocyte implantation
Autologous chondrocyte implantation has now been appraised on three separate occasions by NICE:
originally in 2000 (TA16)119 and as separate re-reviews in 2005 (TA89)120 and 2015 (as part of an ongoing
review).118 The original guidance in TA16 has since been replaced by TA89 and documentation from the
initial appraisal has been removed from NICE’s website. Hence, our review focused on the separate
re-reviews. However, it was reported in the final appraisal determination (FAD) for TA89 that, when the
original guidance was produced in 2000, data from completed RCTs for ACI were not available.
For the re-review in 2005,120 four controlled trials were subsequently considered, two comparing ACI
with microplasty (n = 40 and n = 100) and two comparing ACI with microfracture (n = 80 and n = 66).
Follow-up across the trials varied between 1 and 2 years. Three publications relating to a Swedish
longer-term case series for ACI were also identified, describing outcomes for up to 11 years after surgery.
In reviewing the various documents for TA89 there appears to be no specific reference made to any
distinct challenges of evaluating ACI based on its classification as a regenerative medicine or any specific
discussion related to possible innovation. However, the lack of medium- to long-term outcomes associated
with ACI and their durability was highlighted as a key limitation in the FAD. The committee also noted
concerns that the comparative trial evidence had a follow-up of only 1–2 years and longer-term case series
data appeared to show similar benefits for most treatment modalities.
Although uncertainties surrounding long-term outcomes are clearly not unique to regenerative medicines,
the Assessment Group (AG) concluded in TA89 that there was insufficient evidence for ACI to produce a
robust cost per quality-adjusted life-year (QALY) estimate for ACI. Instead, the AG undertook ‘illustrative
modelling’ of the cost-effectiveness of ACI in three ‘increasingly speculative’ stages, incorporating
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alternative assumptions relating to the short term (2 years), medium term (10 years) and long term (up to
50 years). The conventional NICE reference case for cost-effectiveness was applied,122 although deterministic
approaches (i.e. point estimates were assumed for input parameters) were applied. A discount rate of 1.5%
for health benefits and 6% for costs were applied in line with the recommended rates at the time of
the appraisal.123
The cost-effectiveness results were sensitive to the time horizon and the assumptions employed within the
chosen periods. In both the short-term and medium-term analyses, ACI was reported to be dominated by
the current standard of care (microfracture/mosaicplasty). In the long-term analyses, the possible avoidance
of knee replacements was taken into account and the incremental cost-effectiveness ratio (ICER) of ACI
compared with microfracture was reported to be between £3200 and £3650 per QALY.
Autologous chondrocyte implantation was subsequently not recommended in TA89120 for routine use,
being given an only in research (OIR) recommendation.
As of 23 November 2016 this re-review is still ongoing.118 The rapid evolvement of ACI over time was
highlighted in the appraisal consultation document (ACD) and the branded MACI product being appraised
was now classified as a third-generation ACI.
The AG undertook a ‘review of reviews’ comparing the effectiveness of ACI (any generation) with that of
microfracture. In total, 12 systematic reviews were identified. Studies within the reviews were reported by
the AG to be heterogeneous, with follow-up of between 6.5 months and 7.5 years. The AG considered
the results of the reviews to be inconclusive on the effectiveness of ACI compared with microfracture.
The National Institute for Health and Care Excellence received separate submissions for ChondroCelect
(Swedish Orphan Biovitrum, Stockholm, Sweden), MACI (Aastrom, now called Vericel Corporation,
Cambridge, MA, USA) and OsCell (Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, UK).118
Although both ChondroCelect and MACI had EMA approval, the submission by OsCell was based on
a product provided via the hospital exemption licence, which allows provision for OsCell to supply
chondrocytes for use in ACI under the professional responsibility of a medical practitioner. There was
a marked difference in list prices (excluding value-added tax) between the products: £18,301 for
ChondroCelect, £16,226 for MACI and £4135 for OsCell. However, costs were also noted to vary in
different settings because of negotiated procurement discounts.
The manufacturer submission supporting ChondroCelect provided evidence of clinical effectiveness from
four new sources not considered in TA89: a RCT (n = 118) with up to 5 years’ follow-up; a ‘compassionate
use’ case series (n = 370); an ongoing registry-based cohort study (n = 308) with up to 3 years’ follow-up;
and data from a Belgian reimbursement scheme (254 procedures undertaken over a 3-year period).
The submission supporting MACI described new clinical evidence from two RCTs (n = 144 and n = 60,
both with up to 2 years’ follow-up) and a subsequent ongoing extension study (up to 3 years’ additional
follow-up, with interim data reported for the first year).
The OsCell submission reported interim (up to 5 years’ follow-up) clinical effectiveness evidence from a
UK RCT [ACTIVE (Autologous Chondrocyte Transplantation/Implantation Versus Existing treatments) trial
(n = 390), including first-, second- and third-generation ACI] and evidence from a separate cohort study
(n = 366) with up to 3 years’ follow-up.
Separate cost-effectiveness analyses were presented by the manufacturers of ChondroCelect and OsCell
and the AG. A discount rate of 3.5% for both health benefits and costs was applied in line with the
recommended rates at the time of the appraisal.122 The base-case ICERs for ACI compared with
microfracture in the manufacturers’ and AG models were approximately £6000–7000 and £16,000 per
QALY gained, respectively.
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In the ACD, the committee concluded that, although there was more clinical effectiveness data than at
the time of the previous NICE TA guidance, the evidence base for the technology is still emerging and
no comparative clinical effectiveness data had been reported beyond 5 years. Innovation was formally
considered and the committee agreed that ACI, albeit not new, is technically innovative. However, the
committee concluded that the uncertainties in clinical effectiveness were such that the technologies could
not be considered innovative in the context of a NICE appraisal.118
In relation to the cost-effectiveness evidence, the committee considered that OsCell had underestimated its
cell costs and that the true cost may approach that of MACI and ChondroCelect. The committee concluded
that, although the cost to the NHS of providing the cells for ACI was somewhat uncertain, the cost estimate
used within the AG and the ChondroCelect model were reasonable for the purposes of decision-making.
The committee concluded that a lifetime horizon was preferable because it captured all of the costs and
consequences of treatment, but the lack of long-term data with which to populate a model generated large
uncertainties. The committee concluded that there was no ICER available that included the assumptions
that it considered plausible. Furthermore, it was not persuaded that ACI was proven to be a cost-effective
treatment and neither did it consider that the available data robustly supported ACI being better than
other treatments.
The committee therefore issued a provisional OIR recommendation because the clinical effectiveness and
cost-effectiveness of ACI remains uncertain. Hence, ACI was not recommended for routine use in the NHS
unless it is part of existing or new clinical studies. It was stated that ‘these studies should generate robust
outcome data and include both interventional and observational studies’ (p. 45 of the ACD).118
Sipuleucel-T
The National Institute for Health and Care Excellence issued guidance for sipuleucel-T in February 2015.121
The appraisal was subsequently withdrawn in May 2015 following the withdrawal of the marketing
authorisation for sipuleucel-T. However, prior to this NICE had conducted a full appraisal of the technology,
rejecting it because of the cost-effectiveness estimates exceeding the threshold considered to represent
value for money to the NHS.122
Clinical effectiveness evidence was based on three Phase III, double-blind, multicentre RCTs conducted in
the USA and Canada that compared sipuleucel-T with placebo (n = 512, n = 127 and n = 98). The primary
end point for the pivotal [Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT)] trial was OS
and the median follow-up was 34 months. The main secondary end point was TTP. The risk of death was
reported to be statistically significantly lower in the sipuleucel-T group than in the placebo group (HR 0.78,
95% CI 0.61 to 0.98). The trial also demonstrated that patients randomised to sipuleucel-T survived for
longer (median 25.8 months) than patients randomised to placebo (median 21.7 months), with a
difference of 4.1 months.
Subgroup analysis suggested important clinical differences based on baseline prostate-specific antigen
(PSA) concentration, with a difference of 13 months (HR 0.51, 95% CI 0.31 to 0.85) in median survival for
the quartile of patients with the lowest baseline PSA concentration compared with 2.8 months (HR 0.84,
95% CI 0.55 to 1.29) for the quartile with the highest PSA concentration. The manufacturer suggested
that sipuleucel-T has a delayed onset of action because it is an immunotherapy, so giving it early in the
course of disease progression (as indicated by a low PSA) could provide patients with more time to benefit
from sipuleucel-T. However, the ERG cautioned that the subgroup of patients in the IMPACT trial with the
lowest quartile baseline PSA level had been identified in a post hoc analysis, with no clinical significance
attached to the specific PSA concentration in this group.
A conventional Markov (partitioned-survival) model was submitted by the manufacturer to inform cost-
effectiveness with a lifetime time horizon (10 years). Parametric survival analyses were used to extrapolate
the trial data to the lifetime horizon. Conventional discount rates (3.5% for costs and benefits) were applied.
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In the manufacturer’s base-case analysis, the ICER for sipuleucel-T compared with best supportive care
was £124,875 per QALY gained. In the subgroup with the lowest quartile baseline PSA level, the ICER for
sipuleucel-T compared with best supportive care was £48,672 per QALY gained. The manufacturer also
conducted sensitivity analyses with an alternative comparator (abiraterone rather than best supportive care;
Zytiga®, Janssen Biotech Inc., Horsham, PA, USA) and applied assumed discounts to the price of abiraterone
of ≥ 30%; these analyses resulted in ICERs for sipuleucel-T compared with abiraterone of at least £511,663
per QALY gained.
The ERG noted uncertainty surrounding the extrapolation of survival data and chose an alternative survival
distribution for OS in its exploratory analyses alongside other proposed amendments. In the ERG’s base
case, the ICER for sipuleucel-T compared with BSC was £111,417 per QALY gained. The ERG’s analysis for
the low PSA concentration subgroup resulted in an ICER of £61,381 per QALY gained for sipuleucel-T
compared with BSC.
In considering the cost data and assumptions within the manufacturer’s submission, it was noted that
the acquisition cost of sipuleucel-T included the costs of leukapheresis, patient tests associated with
leukapheresis, transportation of white blood cells and the manufacture and transportation of sipuleucel-T.
However, given the complex administration of sipuleucel-T and the lack of experience in the UK of using
the treatment, the committee was unsure whether the NHS would incur additional costs of using
sipuleucel-T that were not included in the economic model. The committee also considered that there may
be patient travel costs associated with sipuleucel-T treatment because of its provision within specialist
centres, which had not been included in the model. These issues were considered to add uncertainty to
the estimates of cost-effectiveness.
In considering the clinical relevance of the subgroups, the committee heard that the clinical experts were
unable to identify a single PSA value that was currently used for guiding treatment decisions. The committee
considered that registry data could have been used to assess whether outcomes after treatment with
sipuleucel-T in clinical practice were similar to those in the IMPACT trial for patients with low baseline PSA
concentrations, but they were not presented with this information by the manufacturer. The manufacturer
reported that such a registry had been established (PROCEED – A Registry of Sipuleucel-T Therapy in Men
With Advanced Prostate Cancer) but that data were considered too immature to inform OS.
In relation to potential innovation, the committee reported that it was aware that sipuleucel-T is an
autologous cellular immunotherapy and is the first treatment for this indication that is not cytotoxic or
based on hormone therapy. However, the committee concluded that no evidence had been presented for
any specific additional benefits that were not already captured in the QALY estimates.121
The committee concluded that there were areas of considerable uncertainty in the results generated by the
model and noted that all of the ICERs estimated by the manufacturer and the ERG fell substantially above
the range normally considered cost-effective (£20,000–30,000 per QALY gained).121
Issues and common themes
The existing NICE TAs raise a number of issues and several common themes emerge. The innovative nature
of ACI (most recent ACD only) and sipuleucel-T were acknowledged by both committees. However, these
considerations appear to relate more to an appreciation of the technical nature of the innovations than to
any specific attributes of the innovations that might lead to a distinct benefit that may not be appropriately
reflected in the reference case measure of QALYs. Importantly, no evidence was presented in either
appraisal that led the committee to consider that these specific attributes of innovation were relevant.
The high levels of uncertainty surrounding the cost-effectiveness results were highlighted in both appraisals.
In the most recent appraisal of ACI,118 this led the committee to conclude that there was no ICER available
that included the assumptions that it considered plausible; neither was it persuaded that ACI was ‘proven’ to
be a cost-effective treatment. The committee appraising sipuleucel-T concluded that, despite the considerable
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uncertainty in the results generated by the model, all of the ICERs estimated by the manufacturer and the ERG
appeared to be substantially above the range normally considered cost-effective.121 The difference in the
committee’s subsequent recommendations (i.e. OIR for ACI and reject for sipuleucel-T) suggests that the
committees may have reached different conclusions on the potential of both products to be cost-effective
despite the inherent uncertainties.
The rapidly changing nature of regenerative medicines and challenges raised by this is evident across the
series of appraisals for ACI. Over the 15-year period that the separate appraisals have been undertaken,
the initial first-generation ACI products (ACI-C) have been superseded by second- and third-generation
products. This has resulted in potential challenges in relation to quantifying the long-term uncertainties as
newer generations emerge – during the time over which longer-term evidence has emerged, newer
generations of ACI have also arrived. The generalisability of the longer-term evidence to the newer
generations has raised additional issues and challenges. For example, the AG in the most recent ACI
appraisal excluded longer-term evidence available from the first-generation of ACI products on the basis
that these products had now been superseded by newer generations.118 This approach effectively assumes
that existing evidence cannot be generalised across different generations of products. If such a position
were routinely taken, this may pose a potential challenge to manufacturers in terms of providing data that
are considered sufficiently robust within a time frame that permits sufficient commercial return to warrant
their research and development (R&D) expenditure. The extent to which evidence can be generalised or
transferred between generations remains an important consideration.
Similar uncertainties arise for more conventional technologies in relation to the constant evolution of
knowledge over time and subsequent challenges for HTA and cost-effectiveness assessments. The
challenge of determining when evidence is sufficiently ‘robust’ within a technology’s overall life cycle to
undertake a HTA/cost-effectiveness assessment is summarised by what has been termed ‘Buxton’s law’
(i.e. it is always too early until, unfortunately, it’s suddenly too late).124 These challenges have led to an
increased appreciation of the importance of employing an iterative approach to cost-effectiveness
assessments, such that, as new evidence emerges, progressively more certain estimates are derived and
earlier policy decisions can be subsequently reconsidered.125,126 However, as highlighted by the ACI appraisal,
more specific challenges may arise for appraising newer generations of products in relation to the extent to
which evidence is considered generalisable or transferable across different product generations.
Furthermore, the potential high upfront costs and the scale of any irrecoverable costs, as discussed in more
detail in later sections, may be important additional considerations within these iterative assessments.
Additional uncertainties were also identified across both appraisals in relation to the costs that would be
incurred by the NHS. Within the ACI appraisal, uncertainties were identified surrounding the acquisition
costs of the technologies themselves (i.e. because of local price negotiations and concerns regarding the
proposed cost of the product provided under hospital exemption), as well as the appropriate cost or tariff
to apply to other elements of the overall procedure.118 The complexity of provision and lack of experience
in the UK of using the product was also identified as an issue within the appraisal of sipuleucel-T.121
Uncertainties arising from this, alongside the proposed provision within specialist centres and the possible
impact on travel costs for patients, led the committee to conclude that additional uncertainties existed
surrounding whether all relevant costs had been appropriately included within the model.
Importantly, the RCTs that informed the basis of the regulatory submissions for ChondroCelect, MACI and
sipuleucel-T were also central to the subsequent submissions to NICE and the economic models developed to
support these.121 Follow-up ranged from between 2 and 5 years for ChondroCelect and MACI and additional
evidence was also submitted from ongoing extension studies and other registries. In the case of sipuleucel-T,
the pivotal (IMPACT) trial was powered on OS with a median follow-up time of 34 months. Consequently,
neither appraisal provides an indication of any additional challenges that may be raised for regenerative
medicines or cell therapies that have received regulatory approval based on uncontrolled studies or employing
surrogate outcomes. However, it seems reasonable to conclude that the uncertainties expressed in relation to
cost-effectiveness within the existing appraisals are likely to be magnified in this eventuality.
DOI: 10.3310/hta21070 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 7
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Hettle et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
29
Broader consideration of potential conceptual differences and possible
methodological challenges for cost-effectiveness analyses
A separate review of known references and key citations of these was undertaken to identify other
potential conceptual differences between regenerative medicine and cell therapies and more conventional
medicines to identify potential methodological challenges for cost-effectiveness assessments.
During the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference held
in November 2014, a workshop was held to discuss potential HTA and reimbursement challenges for
regenerative medicines and curative treatments. As part of the workshop, Towse127 argued that many of
the challenges for curative therapies appear similar to those for disease-modifying therapies for chronic
diseases, sharing several associated problems, most notably (1) the use of short-term trials using surrogate
outcomes that may not produce relevant clinical outcomes, (2) the use of outcomes that may not be
sustained over time and (3) safety problems that may emerge over time.
In considering how these uncertainties might be formally incorporated within policy decisions regarding
reimbursement, Towse127 acknowledged that value of information approaches provide a potential
analytical framework. This framework formally evaluates the potential trade-off between the net health
benefits to current patients from early access to the technology and those to future patients from
withholding access to the technology until additional research has been conducted. The framework can
then be used to help guide more appropriate policy choices between (1) adopt and reimburse now,
(2) delay adoption/reimbursement and undertake further research (i.e. OIR) and (3) adopt/reimburse now
and undertake further research [akin to coverage with evidence development (CED) or approve with
research (AWR)].128 Towse127 also acknowledged the importance of risk-sharing approaches and particularly
how these could enhance the value of CED/AWR.
As discussed in Clinical efficacy and safety issues arising from European Medicines Agency, National
Institute for Health and Care Excellence and Food and Drug Administration assessments of licensed
regenerative medicines, assessments of the clinical effectiveness and cost-effectiveness of regenerative
medicines and cell-based therapies, particularly early in their life cycle, may be less extensive and lower in
quantity than evidence for more conventional pharmaceuticals. Under these circumstances it may become
even more critical to consider conditional reimbursement and possible risk-sharing agreements between
the manufacturer and the payer.
Towse127 concluded that the main reimbursement challenges for regenerative medicines relate more to
their financing than to the methodology of HTA and cost-effectiveness. In particular, concern was raised
by Towse regarding whether health-care systems could cope with the potential high upfront costs of a
curative treatment that appeared cost-effective using conventional thresholds, thereby presenting a
potential barrier to adoption.
In the same workshop, Faulkner129 explored differences between regenerative medicines/cell therapies and
conventional biologics. Specific reference was made to the more limited understanding by physicians and
payers, leading to potentially greater requirements being made for longer-term data collection to more
robustly demonstrate value. The multiple procedural steps required for some therapies were identified as
another potential challenge, as these may be subject to different regulatory and reimbursement processes.
Similar concerns were raised by another speaker, Husereau,130 who highlighted that regenerative medicines
can be considered as both a biologic and a device/procedure, with many countries also having different
reimbursement procedures, often based on cost minimisation for the funding of procedures because of
fixed Healthcare Resource Group (HRG) pricing. In common with the arguments made by Towse, both
Husereau and Faulkner also highlighted the challenge of applying a single financing approach
for reimbursement.
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The potential to enable a disease cure or prolonged therapeutic effect was also identified as a relevant
characteristic by both Faulkner129 and Husereau.130 However, Husereau130 identified a specific challenge
surrounding the classification of a cure and its distinction from a prolonged therapeutic effect. To be
considered curative, a therapy needed to demonstrate ‘no chance of re-entering suboptimal health state
from same disease’. In reality, it seems unlikely that a new therapy can be definitively classified as curative
prospectively, as many of the required elements cannot be demonstrated until a full lifetime of a cohort of
treated patient has passed.
Husereau130 also raised the question of whether there is anything specific regarding curative therapies
relative to standard treatments that could be perceived as providing additional benefits to patients beyond
the current QALY framework. This was further considered in a subsequent publication.131 Husereau reported
that, although there was limited direct empirical evidence to address this specific question, important
insights could be generated from the large literature exploring valuation issues for treatment (which he
noted was often labelled as ‘cure’ within these studies) compared with prevention. Husereau reported a
potential disconnect between existing literature reporting individual preferences and that reporting societal
preferences. When given a choice between prevention and treatment, individuals appear to state a
preference for prevention. However, similar preferences are not apparent when (societal) willingness to pay
is considered. This disconnect was attributed to separate psychological factors including time, certainty of
individual decisions and the valuation of identifiable compared with statistical lives. Husereau concluded
that if a similar disconnect exists for curative therapies relative to standard treatments this could lead to
considerable public debate and that further research was required.
Importantly, several of these issues and challenges highlighted in the workshop do not appear to be
unique to regenerative medicines and cell-based therapies and similar challenges are often present when
appraising more conventional biologics, companion diagnostics and devices more generally. However,
it appears reasonable to conclude that these issues will be more commonly faced within evaluations
concerning regenerative medicines and cell therapies. Furthermore, as many regenerative medicines and
cell therapies will be considered as both a biologic and a device/procedure, manufacturers may have to
address the specific regulatory and reimbursement challenges faced by both pharmaceutical and device
manufacturers internationally.
Because of the personalised nature of regenerative medicines, the manufacturing and production process
is typically more complex than that for traditional drug therapies. Current pharmaceutical manufacture is
largely based around drugs being prepared, tested and manufactured in bulk at a consistent quality in
advance of need, using automated processes. In contrast, many regenerative medicines require significant
personalisation at the point of need. The complexity of the process, and the high level of personalisation
required, may result in significantly higher marginal costs of production than for conventional pharmaceuticals
or biologics. Inevitably, these additional complexities are likely to lead to higher upfront costs to health-care
systems. However, high-upfront-cost therapies are not limited to regenerative medicine. A recent example is
Sovaldi® (sofosbuvir; Gilead Sciences, Foster City, CA, USA) for hepatitis C, which was recommended by NICE
in some genotypes of the disease despite its high initial cost.132
This complexity and personalisation is likely to be coupled with a requirement for the provision of additional
health-care services within the overall process. The additional demands raise issues around the impact on
the wider health-care setting, both at a marginal cost and wider infrastructure level. These demands may
differ according to the extent of the services provided by the manufacturer and those requiring separate
funding by the health-care system. In the sipuleucel-T appraisal,121 the lack of experience in the UK of using
the treatment raised additional uncertainties about whether the NHS would incur additional costs that were
not reflected in any of the scenarios evaluated, raising an additional source of uncertainty.
As the provision of regenerative medicines and cell-based therapies often entails multiple procedural
steps (e.g. cell extraction, processing and administration) and may be undertaken alongside additional
procedures (e.g. leukapheresis in the case of sipuleucel-T and arthrotomy for ACI), additional uncertainties
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are likely to be raised concerning the generalisability and transferability of evidence between different
settings. That is, separating out the specific effect of the regenerative medicine or cell therapy from the
effect of broader health provision, which itself may be subject to significant variation across different
health-care systems, represents an important challenge to HTAs and cost-effectiveness assessments.
Many regenerative medicines and cell therapies also appear likely to share similar ‘unique’ characteristics to
those reported for medical devices.133 For example, particular parts of the procedural process may change
significantly over time, experiencing incremental or step changes as new processes and infrastructure
develops. Additionally, the requirement for highly specialised infrastructure and staff indicates the
potential for a learning curve over time both for manufacturers and for health-care providers. Although
increased automation methods and the ‘scaling out’ of services may subsequently reduce the need for
highly specialised staff (and lower the marginal costs of production), the infrastructure requirements and
implications for possible learning curve effects are likely to be an important consideration when assessing
the cost-effectiveness of regenerative medicines and cell therapies.
In addition to issues related to uncertainty, issues of irrecoverable costs may pose an additional challenge.
Irrecoverable costs are those costs that once committed cannot be recouped if changes occur at a later
time, most commonly thought of as investment costs associated with the capital expenditure on
equipment, new facilities or training and learning costs. These are likely to be most significant when the
introduction of a new regenerative medicine or cell therapy imposes additional infrastructure requirements
on the health system. Within economic evaluations, these costs are commonly annuitised and allocated as
‘per-patient’ costs by spreading the cost over the number of patients likely to be treated during the lifetime
of the equipment. However, if reimbursement decisions about the technology change before the end of
the lifetime of the equipment (e.g. approval is withdrawn), then these costs may not be recovered and
hence need to be explicitly considered.
The risks of these more conventional types of irrecoverable costs to the health system may be more limited
if the manufacturer provides the necessary infrastructure and associated training. However, irrecoverable
costs also potentially exist at the patient level. Regenerative and cell therapies are developed, by design,
to have a significant (if not permanent) period of effect, during which they may be neither removable nor
reversible. The irreversibility of these therapies implies that any uncertainty associated with the long-term
efficacy and adverse event profile has a greater potential significance than for treatments that can easily be
reversed or switched.
Potential approaches to addressing health technology assessment challenges
Many of the issues associated with regenerative medicines will inevitably impact on the level of uncertainty
associated with the cost-effectiveness of the technology when introduced into clinical practice. Even when
products have a significant potential to confer important clinical advances over current therapies, this may
not be known with a high level of certainty at the time at which a regenerative medicine is licensed.
Inevitably, a new technology’s cost-effectiveness may be more difficult to determine in these circumstances
and schemes that allow the development of further evidence or entail a risk-sharing component may
be required.
Managed entry agreements (MEAs) are an increasingly common policy response to dealing with uncertainty
in the evidence base of new health technologies entering the market. MEAs are also commonly referred to
as performance-based risk-sharing agreements and patient access schemes (PASs). A taxonomy provided by
Walker et al.134 makes an important distinction between MEAs based on reductions in the effective price
(e.g. akin to the majority of PASs implemented currently alongside NICE guidance) and those associated
with evidence generation (e.g. OIR, CED). Both approaches have the aim of reducing risk and decision
uncertainty to the health-care system, albeit through separate mechanisms. Walker et al.134 concluded that
reimbursement decisions and the possible use of MEAs should be based not only on the expected value of a
technology but also on the value of further research, the anticipated effect of coverage on further research
and the costs associated with reversing the decision (i.e. irrecoverable costs).
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Similar conclusions are reflected in NICE’s current Guide to the Methods of Technology Appraisal (pp. 69–70),122
which outlines several factors that need to be considered (e.g. the need for and value of further research
as well as the feasibility of obtaining trials) when clinical effectiveness is considered limited or weak.
How to determine when efficiency is sufficiently weak or uncertain, such that MEAs are appropriate policy
responses, remains a key methodological issue that has important implications both for policy making and
research investments made by the regenerative medicine industry. A more formal framework has recently
been proposed that has established the key principles of the assessments needed.128 NICE’s DSU has also
recently published a report outlining potential methods for assessing MEAs within the TA programme.135
Concerns surrounding the potential high upfront costs of regenerative medicines and their affordability to
health-care systems have also received particular attention in the literature, leading several authors to
conclude that alternative financing approaches may also have to be considered. For example, Towse127
outlined three alternative financing routes: (1) pay for performance, (2) amortisation and (3) innovative
financing schemes. The potential issues and challenges related to alternative financing approaches in the
context of regenerative medicine and cell-based therapies are discussed in the following sections.
Fixed price schemes
The simplest and most common approach to reimbursement is the payment of a fixed price at the time
of treatment, potentially subject to discounts agreed via a PAS. This approach has the benefit of being
relatively manageable and low cost to implement. Furthermore, subject to uncertainties concerning the
eligible patient population size and subsequent uptake rates, the budget impact is also largely predictable.
However, if the therapy is expensive and/or the patient population is large, the total budget impact to the
funder may raise issues concerning system ‘affordability’ (i.e. the ability to displace sufficient activities
elsewhere in the health-care system to provide the additional funds necessary to provide the new
treatment). This may have implications for subsequent implementation.
Although ‘affordability’ is not explicitly considered by NICE, the committee is requested to take ‘account
of how the incremental cost-effectiveness of the technology being appraised relates to other interventions
or technologies currently or potentially applied in the NHS’ (p. 65).122 When significant uncertainty exists
surrounding future outcomes, a fixed price scheme exposes the funder to the risk of overpayment for
outcomes that may not be realised. A fixed pricing mechanism may be potentially optimal in situations in
which there is little uncertainty about the long-term outcomes; there are high costs of patient follow-up;
and/or the resulting budget impact is likely to represent a marginal change to overall NHS spend.
Amortisation
Amortisation has been raised as an alternative financing approach for curative treatments, particularly
for chronic diseases.127,136 Gottlieb and Carino136 identified that most health-care finance systems are not
currently structured to be able to pay to rapidly cure everyone of a chronic disease using a treatment that
may be priced much higher than the existing chronic therapies. Payment models were therefore advocated
that could more easily spread the potentially high upfront costs of a curative treatment and be more
closely aligned to the time period over which health and economic benefits are realised. Such financing
schemes are common for the payment of medical devices and other capital equipment. However, for a
regenerative medicine or cell therapy, instead of spreading out payment over the lifetime of the capital
equipment, amortisation would spread payment over the expected duration of benefits.
Gottlieb and Carino136 highlighted several issues and challenges relating to operationalising such a scheme.
These included the potential need for another financial intermediary to act as a third party to the transactions,
the need to alter accounting standards and potential conflict with the manufacturer’s desire to secure
immediate revenue to maximise return on its investment. The magnitude of the initial R&D costs compared
with the ongoing marginal costs of production might also influence the interest rate that the funder would
have to offer to sufficiently incentivise both existing and future manufacturers.
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Pay for performance
Although the use of an amortisation approach to financing might address the constraints imposed within
current financial structures, this approach does not reduce the risk to health-care systems of uncertain
future health benefits that may not be realised in routine clinical practice.
In contrast, a pay-for-performance-type mechanism ensures that the total price paid is more directly related
to the performance of the therapy in clinical practice. This mechanism requires agreement between the
funder and the manufacturer on the measure of performance (e.g. response, relapse or mortality), the
programme of data collection and analyses required to monitor performance and the payment mechanism
itself (e.g. fixed price at time of treatment with rebate, retrospective reimbursement for treatment
‘successes’ or amortised payments directly linked to performance over time).
As with amortisation, the potential to spread repayments over the longer term reduces the short-term
budget impact. This financing approach also potentially addresses the uncertainties surrounding the
potential health benefits and the risk of overpayment (i.e. when the opportunity costs are subsequently
revealed to be greater than the acquisition cost) by the funder. Inevitably, such a mechanism is likely to
be both more complex and more expensive to implement than a simple PAS or amortisation approach.
However, there are examples of existing PASs within the NICE TA programme that already incorporate
performance assessments, and discontinuation rules are commonly applied within NICE appraisals to
‘optimise’ cost-effectiveness and reduce decision uncertainty.
A pay-for-performance mechanism is potentially optimal if there is large uncertainty about long-term
outcomes, a relatively low cost of patient follow-up and monitoring of the outcome(s) of interest (relative
to the level of uncertainty) and a large total budget impact that, as with amortisation, can be spread over
time. The potential challenges concern how performance in clinical practice would be monitored and
evaluated and whether a simple assessment of continued treatment ‘success’ is feasible or not.
A recent paper by Edlin et al.137 proposed a leasing approach for innovative technologies as an alternative
payment strategy combining elements of amortisation with pay-for-performance approaches. The
advantages of this approach is that it both addresses the funding constraints caused by existing finance
structures and ensures that the risks associated with uncertain future health benefits are more
appropriately shared between the funder and the manufacturer.
Edlin et al.137 proposed that, having established the price at which the technology is expected to be
cost-effective, the ‘lease’ payment due for each period of health delivered could be established by calculating
a stream of payments over the expected lifetime of the technology that has the same expected net present
value as the agreed price. The subsequent leasing scheme would work by paying the manufacturer for each
period of time that health is delivered at the individual patient level, that is, if the observed effectiveness in
clinical practice was equal to the expected effectiveness, the manufacturer would receive the full value of the
technology over the agreed period. However, if observed effectiveness was less than expected, payment
would stop and the risk to the health system of overpayment would be limited. Furthermore, manufacturers
would be rewarded for technologies that resulted in better health outcomes than expected by receiving
additional payments over extended periods of time.
Using trastuzumab (Herceptin®, Genetech, San Francisco, CA, USA) in early breast cancer as an exemplar,
and linking the lease to relapse-free survival (RFS), Edlin et al.137 demonstrated that the scheme not only
reduced the total budgetary impact but also resulted in a more appropriate share of risk between the
manufacturer and the funder, while simultaneously reducing the value of further research. Edlin et al.137
concluded that such a scheme could help to promote the rapid adoption of innovative technologies into
routine clinical practice.
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Innovative financing
Several authors have argued for even more innovative approaches to pricing to be considered, seeking
inspiration from the wider financial world, for example innovative licensing and the issuing of bonds, by
which third-party payers cover the costs of treatment, benefiting from the respective interest rate paid
by the health-care funder.131 Such mechanisms have had some success in the provision of vaccination
programmes in developing nations (through the International Finance Facility for Immunisation scheme),
appealing to investors seeking ethical investments. An alternative mechanism, considerably closer to a
pay-for-performance mechanism, is the Health Impact Fund, in which manufacturers distribute innovations
at cost but are rewarded with performance-based bonuses.
Possible implications for National Institute for Health and Care Excellence
methods and processes
In considering the potential characteristics of regenerative medicines and cell-based therapies and
associated challenges for HTA, NICE will need to consider whether changes to its current processes and
methods are required or not. Importantly, some of the potential challenges highlighted are already
considered within the existing methods guide.122 For example, the committee is already requested to
recognise that the evidence base will necessarily be weaker for some technologies, such as those used
to treat patients with very rare diseases. If considered appropriate, this could be extended to include
regenerative and cell therapies. Similarly, although the magnitude of the budget impact is stated not to
determine the appraisal committee’s decision, the existing methods guide indicates that the committee
may require more robust evidence on the effectiveness and cost-effectiveness of technologies that are
expected to have a large impact on NHS resources. However, a potential conflict may arise between the
certainty required for interventions with a large budget impact and subsequent deliberations regarding the
acceptability of ‘weaker’ evidence.
The National Institute for Health and Care Excellence’s existing processes also make separate provision for
specific disease and technology characteristics, which may be relevant to many regenerative medicines and
cell therapies. NICE’s current EoL criteria allow the committee, when considering the overall health benefits,
to explore a QALY weighting that is different from that of the reference case, assuming that all of the stated
criteria are met. The methods guide also states that this approach can be used in other circumstances when
instructed by the NICE board. Further research may be warranted to determine whether a similar weighting
approach might be appropriate for regenerative medicines and cell therapies. However, there remains an
issue regarding whether such a weight should be based on product-specific characteristics or patient-specific
characteristics (i.e. not confined to product type).
Within the provisions and regulations of the Health and Social Care Act 2012138 relating to NICE, due
regard is also required concerning ‘the desirability of promoting innovation in providing health services or
social care in England’ (see Chapter 6).122 This is currently incorporated within the committee’s deliberative
process for situations in which the most plausible ICER exceeds £20,000 per QALY gained. In this situation,
the innovative nature of the technology, specifically if it adds ‘demonstrable and distinctive benefits of a
substantial nature which may not have been adequately captured in the reference case QALY measure’
(p. 68) is accounted for.122 Importantly, neither of the previous regenerative medicines appraised by NICE
to date were considered to demonstrate such benefits.118,121
The NICE methods guide also permits separate provision to be made via the specific discount rate that it
applies.122 Within the NICE reference case for cost-effectiveness analysis, the same annual discount rate is
required to be used for both costs and benefits (currently 3.5%). However, the use of a non-reference case
discount of 1.5% for both costs and health effects is permitted in cases in which treatment restores people
who would otherwise die or have a very severely impaired life to full or near full health and when this is
sustained over a very long period (normally at least 30 years) and is highly likely to be achieved. Hence,
certain regenerative medicines and cell therapies may be considered to meet these criteria. However,
uncertainties remain regarding how the likelihood of achieving these long-term health benefits will be
considered by the committee, particularly in the context of the uncertainties outlined in this section.
DOI: 10.3310/hta21070 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 7
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Hettle et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
35
Furthermore, the stipulation that the committee will also need to be satisfied that the introduction of the
technology does not commit the NHS to significant irrecoverable costs raises additional issues about
whether these criteria will be met.
Issues of discounting have been widely considered in the economic literature in relation to preventative
treatments and, particularly, vaccination programmes. The appropriateness of employing different discount
rates and/or different rates over time is an area that requires further consideration, particularly for
potentially curative regenerative medicines and cell-based therapies. Westra et al.139 explored the impact of
employing alternative discount rate approaches for human papillomavirus vaccination based on different
time-varying methods: a stepwise approach (a constant rate is applied for a set period and lowered in
subsequent periods), a hyperbolic approach (the discount rate declines over time) and a time-shifted
approach. A recent review by Jit and Mibei140 also noted that the UK Treasury currently recommends
stepwise discounting to all public sector bodies, but at a very slowly declining rate (3.5% for the first
30 years, declining to 3.0% from year 31, with further declines from year 76). Although the use of
discounting seeks to incorporate social preferences rather than to alleviate uncertainty, further
consideration could be given to its application to regenerative medicines and cell therapies.
Another approach commonly employed to better characterise the uncertainties surrounding longer-term
benefits and to inform the committee’s deliberations relates to the time horizon of the analysis and the
methods of extrapolation. Within NICE’s current methods guide,122 alternative scenarios are requested
to be routinely considered to compare the implications of different methods for the extrapolation of
the results. Several other country-specific guidelines for cost-effectiveness analyses request the presentation
of alternative scenarios based on different time horizons and comparing within-trial results with
extrapolated results.141–143
Alteration of the time horizon of the evaluation, away from the lifetime analysis recommended by NICE
when appropriate, acts to reduce the uncertainty by excluding the impact of costs and outcomes that
occur in the long term, when uncertainty is likely to be greatest. Although such analyses are potentially
informative in terms of understanding how influential particular assumptions are over the period of
extrapolation, restricting the horizon risks omitting important costs and outcomes related to a particular
technology and simply shifts the risk associated with particular uncertainties from the health system to
the manufacturer.
Similarly, separating the within-trial results from the extrapolated results (or considering alternative
scenarios for extrapolation) has been argued to allow separation of the uncertainty associated with
downstream consequences from other sources of uncertainty. Mortimer144 suggested that this approach
could enable decision-makers to assign a weight to the results of the extrapolation to take account of
various uncertainties. However, it was also acknowledged that such a comparison is not always explicitly
made and that implicit comparisons were often problematic, as the relationship between the within-trial
and extrapolation period may not be predictable. Issues of predictability may be a particular challenge for
regenerative medicines and cell therapies. Although it is commonly argued that a within-trial analysis is
conservative with respect to cost-effectiveness estimates, the author identified situations in which this may
not be true, for example when long-term adverse effects offset any initial gains or when increased survival
is associated with additional costs related to the disease and/or other unrelated diseases. Mortimer144 also
highlighted that the relativity in results between within-trial analysis and the results of extrapolation was
made even more problematic when uncertainty as a result of future technological change was introduced.
Several key factors were highlighted as affecting the relativity of results between within-trial and extrapolated
analysis, including the timing of potential technological advances, the proportion of patients who could
benefit when the new technology becomes available and the effectiveness of the new technology.
Conclusions
The review has identified a number of common themes and potential challenges in relation to HTAs and
assessments of cost-effectiveness for regenerative medicines and cell therapies. Some of the challenges
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identified do not appear to be unique to these types of therapies and are also faced by manufacturers of
more conventional pharmaceuticals, biologics and devices. However, it seems likely that these challenges
may be faced more routinely for regenerative medicines and cell therapies.
There is already provision within NICE’s methods guide to accommodate some of these aspects,122
although potential challenges may arise in ensuring that this is consistently applied between committees
and understood by manufacturers. NICE will also need to consider whether further amendments to its
processes and methods are required. Broader consideration will also need to be given to approaches that
may extend beyond NICE’s existing remit, for example alternative funding approaches. Consequently, other
bodies and manufacturers themselves may also have an important role in identifying more innovative
approaches to seeking reimbursement that recognise the inherent uncertainties and lead to a more
efficient sharing of associated risk.
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Chapter 4 Exemplar technology appraisal of a
regenerative medicine
Selection of exemplar
Following RMEG subgroup discussions and further input from the Cell Therapy Catapult, it was decided
that undertaking an exemplar appraisal involving a real commercial product was not feasible for a number
of reasons: there would be significant commercial sensitivities; products undergoing regulatory review
would be candidates for a real appraisal; and using a product at an earlier stage in clinical development
would not be helpful as the evidence base would be even less mature and therefore would not have
the attributes of an ‘exemplar’ product. It was therefore proposed to undertake the evaluation of a
hypothetical product.
As a result of both RMEG subgroup discussions and technical meeting discussions, the type of regenerative
medicine chosen as the hypothetical product was CAR T-cell therapy specific to the antigen CD19 (cluster
of differentiation 19). The chosen indication was relapsed or refractory ALL. This specific combination was
selected based on the existence of relatively mature data sets in the context that none of the currently
available CAR T-cell products is licensed.
About chimeric antigen receptor T-cell therapies
Chimeric antigen receptor T-cell therapies have been under development for around 20 years. The specific
CAR T-cell therapies considered in this appraisal consist of autologous (i.e. the treated individual’s) T-cells
that are genetically modified to redirect the target of the T-cell receptors. These receptors target specific
proteins found on the surface of leukaemia cells, in this case the protein CD19, which is present on B-cell
leukaemias as well as on healthy B cells, but which is not found on haematopoietic stem cells (which are
situated in the bone marrow) or on other tissues.145 The activated T-cells can then attack and destroy the
leukaemia B cells. Persistence of a given CAR T-cell therapy within the body is linked to the properties of
the T-cell from which the cells were derived as well as the immune environment into which they are infused.
CAR T-cell therapies have already begun to evolve, with second-generation therapies currently being trialled
in Phase II studies. Research efforts at developing future generations are focused on addressing the key
challenges of T-cell target specificity, persistence and ability to exert the desired anti-tumour effects as well
as identifying new target antigens.146 CAR T-cell therapies have recently emerged as regenerative medicines
with promising potential to treat haematological cancers. In July 2014 the FDA granted ‘breakthrough
therapy’ status to the CAR T-cell therapy CTL019 (manufactured by Novartis, Basel, Switzerland) for the
treatment of adult and paediatric relapsed or refractory ALL.147
Although CAR T-cell therapies may offer relapsed or refractory B-cell acute lymphocytic (lymphoblastic)
leukaemia (B-ALL) patients a ‘bridge’ to stem cell transplantation, or possibly even a cure for B-ALL, it is
likely that patients will need to be monitored for some key adverse effects that are often reported. These
include cytokine release syndrome (CRS) and B-cell aplasia (an absence of B cells). CRS occurs as a result of
cytokines being released from the successfully targeted cancer cells and can result in various symptoms
such as fever, headache, nausea and a rash. The severity of CRS appears to be proportional to the tumour
burden. Although CRS is an adverse effect of CAR T-cell therapy, there may be a correlation between the
development of CRS and response to therapy; patients who do not develop CRS may be less likely to
benefit from CAR T-cells, whereas those who develop CRS often respond to the therapy. Although there
may be some correlation between developing CRS and efficacy, there does not appear to be a strong
correlation between the degree of CRS and response to therapy.148
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B-cell aplasia is an expected adverse effect of successful CAR T-cell therapies, which eliminate normal
mature and precursor B cells. As long as CAR T-cells persist, B-cell aplasia continues (which provides
what appears to be a highly accurate pharmacodynamic marker of CAR function).148 B-cell aplasia is a
manageable disorder; patients may be treated with intravenous immunoglobulin (IVIG), although this is
an expensive treatment. Persistent B-cell aplasia could result in an increased risk of infection even with
replacement therapy.149
Overview of disease
B-cell acute lymphoblastic leukaemia is a subtype of ALL. ALL is a cancer that starts from the immature
lymphocytes in the bone marrow and then invades the blood fairly quickly, spreading to other parts of the
body including the lymph nodes, liver, spleen, central nervous system (brain and spinal cord) and testicles
(in males). The term ‘acute’ means that the leukaemia can progress quickly and, if not treated, is probably
fatal within a few months. The American Cancer Society has estimated that, including both children and
adults, in 2015 there were about 6250 new cases of ALL (3100 in males and 3150 in females) and around
1450 deaths from ALL (800 in males and 650 in females).150 The risk for developing ALL is highest in
children aged < 5 years. Although most cases of ALL occur in children, most deaths from ALL (about four
out of five) occur in adults.150
UK statistics presents a similar picture. Statistics for the incidence of ALL in the UK (2009–11) are provided
by Cancer Research UK,151 based on data sourced from the UK Office for National Statistics (ONS),
Information Services Division Scotland, the Welsh Cancer Intelligence and Surveillence Unit and the
Northern Ireland Cancer Registry. Across all ages in 2011 there were 654 new cases reported in the UK
(377 in males and 277 in females), with crude incidence rates of 1.2 for males and 0.9 for females
(per 100,000). Incidence is strongly related to age, but ALL is unusual as it does not follow the pattern of
increasing incidence with age seen for most cancers; instead, the highest incidence rates are in children,
teenagers and young adults. In the UK between 2009 and 2011, an average of 65% of cases were
diagnosed in people aged < 25 years and only 6% of cases were diagnosed in those aged ≥ 75 years.
Age-specific incidence rates are highest in infants aged 0–4 years and drop sharply through childhood,
adolescence and young adulthood, reaching their lowest point at age 35–39 years and increasing slightly
thereafter. Incidence rates are similar between males and females in all age groups except for those aged
15–19 years, when age-specific rates are significantly higher in males (male-to-female ratio of around
22 : 10). Averaged across all patients aged < 30 years the mean number of cases of ALL per year is 462.
There are subtypes of ALL based on the type of lymphocyte (B cell or T cell) and how mature these
leukaemia cells are.150 About 80–85% of ALL cases are B-ALL. There are several subtypes of B-ALL: early
precursor B-ALL (early pre-B-ALL, also called pro-B-ALL); common ALL; pre-B-ALL; and mature B-ALL (also
called Burkitt leukaemia). This last type is rare, accounting for only about 2–3% of childhood ALL; it is
essentially the same as Burkitt lymphoma and is treated differently from most leukaemias. T-cell acute
lymphocytic (lymphoblastic) leukaemia (T-ALL) constitutes about 15–20% of cases of ALL. This type of
leukaemia affects males more than females and generally affects older children more than does B-ALL.
It often causes an enlarged thymus (a small organ in front of the windpipe), which can sometimes cause
breathing problems. It may also spread to the cerebrospinal fluid (the fluid that surrounds the brain and
spinal cord) early in the course of the disease.
Based on an estimate of 82.5% of cases of ALL being B-ALL, there will be 540 cases of B-ALL in the
UK per year, of which 381 will be in those aged < 30 years. Approximately 20% of these cases will be
refractory to treatment or relapse,152 giving an estimate for young people with relapsed/refractory B-ALL in
the UK of 76.
Overview of current practice
Although the management of ALL in adults and children is similar, the prognosis is different, with that in
adults (aged > 30 years) being much poorer than that in the younger age group. Hence, they are generally
considered as two distinct clinical groups.
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With stepwise improvements in risk-adapted chemotherapy and supportive care over the past five decades,
current overall cure rates of newly diagnosed ALL are approaching 90% in the developed world in children
and around 50% in adults.153 Treatment involves induction with combination chemotherapy for the attainment
of CR (both clinical and haematological) followed by post-remission maintenance therapy with or without
haematopoietic stem cell transplantation (HSCT) (which enhances relapse prevention, particularly in patients
aged < 35 years). However, because of the morbidity and mortality risks associated with transplant, HSCT is
usually reserved for high-risk patients.
US National Comprehensive Cancer Network guidelines for first-line treatment are based on risk stratification
and age, as follows:154
l Philadelphia chromosome-positive (Ph+) ALL (adolescents and young adults) – chemotherapy and
tyrosine kinase inhibitor (TKI), followed by allogeneic stem cell transplantation (ASCT) if an appropriate
donor is available; if transplantation is not feasible, continue multiagent chemotherapy and a TKI
l Ph+ ALL (adults aged < 65 years) – chemotherapy and TKI; consider ASCT if an appropriate donor
is available and the patient has a good performance status and no or limited comorbidities;
if transplantation is not feasible, continue multiagent chemotherapy and a TKI
l Ph+ ALL (adults aged ≥ 65 years or with substantial comorbidities) – TKI and corticosteroids or TKI and
chemotherapy (evaluate end-organ reserve, end-organ dysfunction and performance status)
l Philadelphia chromosome-negative (Ph–) ALL (adolescents and young adults) – paediatric-style
multiagent chemotherapy
l Ph– ALL (adults aged < 65 years) – multiagent chemotherapy
l Ph– ALL (adults aged ≥ 65 years or with substantial comorbidities) – multiagent chemotherapy or
corticosteroids (evaluate end-organ reserve and end-organ dysfunction).
However, little progress has been made in the treatment of relapsed ALL. Following initial induction and
maintenance therapy most adults will relapse and long-term leukaemia-free survival is achieved in only
20–30% of cases; following relapse, response rates to further chemotherapy are low at around 20–30%
and long-term OS rates of 3–24% have been reported.155 From a UK study of 608 adult patients, OS at
5 years in newly diagnosed patients was 38% (95% CI 36% to 41%) but after relapse was only 7%
(95% CI 4% to 9%).156
Relapse is less common in paediatric ALL but accounts for the highest proportion of cancer deaths in
children.157 Studies of Nordic and Austrian data found that, of children with ALL, 25% had a first relapse,
8% had a second relapse158,159 and 2% had a third relapse.159 Around 50% of relapsed ALL in children
does not respond to salvage therapy and for these patients survival rates are < 10%.159 In children, age
and white blood cell count at primary diagnosis of ALL are the most important prognostic factors for
relapse: age < 1 year or ≥ 10 years is associated with the worst prognosis. In addition, site of relapse and
duration of first remission are the major criteria for the classification of patients after first relapse.157
Therapy after relapsed ALL consists of re-induction chemotherapy followed by consolidation chemotherapy
and/or HSCT. Time to relapse (length of first remission), site of relapse and ALL immunophenotype are
established factors that are prognostic at first relapse and can be used to determine further treatment.157
B-ALL has a better prognosis than T-ALL. Various regimens have been investigated and re-induction
remission rates of 71–95% have been reported; the higher rates are generally associated with later first
relapse. Patients who are refractory to re-induction therapy or who have a further relapse have a poor
prognosis, with survival rates of < 10%.159 Failure to achieve CR after late re-induction chemotherapy is
associated with previous failures to achieve CR or short remission. The proportion of patients achieving
CR has been shown to reduce with subsequent relapses: in a study of 225 patients with ALL (including
195 patients with B-ALL), the mean (standard error) CR rates were 83% (4%) for early first marrow
relapse, 93% (3%) for late first marrow relapse, 44% (5%) for second marrow relapse and 27% (6%) for
third marrow relapse.152 Five-year DFS rates in second CR and third CR were 27% (4%) and 15% (7%),
respectively. Although some therapies with curative intent are capable of inducing a second remission in
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patients refractory to previous therapy, these are often associated with high treatment-related morbidity,
mortality and minimal survival.160 Such patients are eligible for innovative therapies in Phase I or Phase II
trials. Therapies for relapsed B-ALL that have been licensed by the EMA or the FDA are discussed in
Review of licensed treatments for relapsed/refractory B-cell acute lymphoblastic leukaemia. In particular,
clofarabine (Evoltra®; Genzyme Europe, Naarden, the Netherlands), a purine nucleoside anti-metabolite,
(which affects DNA elongation, synthesis and repair), was granted EMA marketing authorisation in 2006
for use in children and young adults with a second or greater relapse (or refractory patients). The pivotal
trial of clofarabine (n = 61 with second or greater relapse) reported an overall remission rate of 20%
(12/61 patients), with 16% (10/61) of patients going on to receive HSCT.161 Clofarabine had been studied
only in single-arm trials and marketing authorisation was granted ‘under exceptional circumstances’.
As discussed in Chapter 3 (see Review of the use of surrogate end points as primary outcome measures
in definitive effectiveness trials of new therapeutic agents), the use of CR as an outcome is not specific at
predicting which patients might subsequently relapse. In recent years, evaluation of response to therapy
in B-ALL patients has become more precise with the development of methods to detect MRD. Although
the FDA has concluded that the evidence base to indicate that early MRD status is the strongest predictor
of long-term EFS in ALL is unequivocal, there is some uncertainty surrounding how MRD correlates with
long-term outcomes in relapsed populations. The use of MRD as a surrogate end point is discussed further
in Chapter 3.
Haematopoietic stem cell transplantation
Allogeneic HSCT is a potentially curative treatment option and a number of studies have demonstrated
improved outcomes compared with chemotherapy. However, there are difficulties in the interpretation of
the findings of many such trials, with issues such as patient selection bias, the specific nature of the HSCT,
the source of the donor cells and the adverse effects associated with various specific transplant therapies.157
The risks associated with transplant include graft rejection, delayed immune reconstitution, graft versus
host disease and vulnerability to infections. In addition, there is significant toxicity associated with the
chemoradiotherapy conditioning required before transplant.157 The adverse effects of HSCT are not limited
to those occurring in the short term. One study investigated long-term survival and late deaths among
1458 ALL patients who were disease free 2 years after allogeneic HSCT; the median follow-up was around
80 months.162 Of the 167 deaths, new cancers accounted for around 10% of the primary causes of death,
with graft versus host disease accounting for 23% of deaths.
One study examined the impact of MRD status in 157 patients with ALL in morphological remission
undergoing allogeneic HSCT following a myeloablative conditioning regimen (12 patients were post two or
more relapses).163 The 3-year OS for those who were MRD negative pre transplant was 68% and for those
who were MRD positive was 40%, whereas the probabilities of relapse were 16% and 33% for the two
groups, respectively. The trend towards increased relapse in those with MRD was seen in patients with
B-ALL (HR 2.87) and in those with T-ALL (HR 7.07); the small number of T-ALL patients (n = 24) meant that
it could not be determined if the effect was statistically significantly larger in T-ALL patients. Post transplant,
among those with any sample positive for MRD, the risk of subsequent relapse was higher (HR 3.21) as
was the risk for overall mortality (HR 2.54). Similar findings were reported in a study that included a slightly
larger sample of those post second or later relapse (n = 18).110 Based on these and other studies, there is the
suggestion of benefits through MRD-directed therapies, although controlled trials are needed to define
their value.109
Immunotherapies are showing promise and are being investigated. These therapies are targeted at specific
surface antigens expressed on the target cells: naked and unconjugated antibodies; immunoconjugates
and immunotoxins; bi-specific T-cell-engaging (BiTE) therapy [Blincyto® (blinatumomab; Amgen, Thousand
Oaks, CA, USA)]; and CAR T-cells. The last two target CD19.155
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Decision problem
The key aspects of the decision problem to be addressed were identified and agreed at a meeting
between the academic group and a subgroup of the project advisory group (topic experts). These were
based on discussion of the Phase I/II CAR T-cell trials in B-ALL,164–166 which had been identified by literature
searches performed by Cell Therapy Catapult. The agreed components of the decision problem were
as follows:
l Intervention – CD19 CAR T-cell therapies.
l Indication – patients with B-ALL who have relapsed (with no further planned curative chemotherapy or
HSCT) or who are refractory to standard chemotherapy. As described in Overview of current practice,
the treatment pathways and prognosis for patients aged < 30 years and > 30 years are very different.
Consequently, the indication considered in this assessment has focused on those aged < 30 years.
l Subgroups – sources of heterogeneity such as relapsed/refractory status, previous HSCT, CAR design,
dose, conditioning chemotherapy, tumour burden at the time of therapy or age of the patients may
be explored.
l Comparators – best supportive care (e.g. salvage chemotherapy).
l Efficacy outcomes – response criteria such as CR, partial response/remission (PR) and MRD; OS;
progression and/or EFS; persistence of CAR T-cells; HRQoL; and rates of HSCT.
l Adverse event outcomes – CRS, B-cell aplasia, febrile neutropenia and neurological effects.
Review of evidence of clinical effectiveness: chimeric antigen
receptor T-cell therapies
Methods
Initially, studies of CD19 CAR T-cells in B-ALL were identified by staff at Cell Therapy Catapult (who are
part of the project advisory group, being experts in cell-based regenerative medicines). PubMed was
searched using the search terms ‘CD19’, ‘chimeric antigen receptor’, ‘CAR’ and ‘CD19 CAR’ with a cut-off
date of 21 October 2014. The ClinicalTrials.gov trials registry and relevant published reviews of CAR T-cell
therapies were also searched.
To identify any further relevant clinical trials we performed update searches in MEDLINE and EMBASE up to
May 2015, using the same search terms as those previously described. One reviewer performed an initial
screen of the abstracts and those deemed potentially relevant were then screened by a second reviewer.
Google (Google Inc., Mountain View, CA, USA) searches to identify further data on already-identified trials
were also undertaken. Our clinical advisor was also contacted regarding any relevant 2015 conferences
where new data may have been presented. To further inform the study design details of the hypothetical
data sets, the ClinicalTrials.gov trials registry was searched for ongoing trials that had commercial
involvement: the focus was on trials designed with the likely aim of acquiring marketing authorisation.
Overview of studies
Three published papers were identified from the Cell Therapy Catapult searches.164–166 No further studies
were identified from the MEDLINE and EMBASE update searches. Two conference abstracts167,168 (relating
to two of the published studies) and one conference video169 (relating to one of the published studies) with
more up-to-date data were identified from the Google searches.
Of the planned or (other) ongoing CAR T-cell studies identified on ClinicalTrials.gov, seven had commercial
involvement: three were Phase II trials, all with estimated enrolments of 67 patients; one was a Phase I/II trial
with an estimated enrolment of 80 patients; and three were Phase I trials (Table 4). All were single-arm studies.
Two of the Phase II trials were multicentre studies (i.e. they listed more than one centre for recruitment in
the contacts and locations field) and three had a primary outcome that assessed response or remission; the
time frames stated for these outcomes ranged from 9 weeks to 1 year. Only one trial reported the collection
of longer-term survival data, with a stated time frame of 5 years for OS, EFS and RFS.
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TABLE 4 Ongoing commercial CAR T-cell trials registered on ClinicalTrials.gov
ClinicalTrials.gov
identifier, start
date and
estimated end
date Study name
Phase and
design
Estimated
enrolment
Primary outcome(s)
and time frame
Secondary outcomes
and time frame
NCT02228096,
August 2014–
November 2017
Study of efficacy and
safety of CTL019 in
pediatric ALL patients
(relapsed/refractory)
II; single arm,
open label,
multicentre
67 Overall response rate,
which includes CR and
CRi, as determined by
assessments of
peripheral blood,
bone marrow and
central nervous system
symptoms, physical
examination and
cerebrospinal fluid
(1 year)
Adverse events and
laboratory abnormalities
(type, frequency and
severity) (1 year)
NCT02167360,
June 2016–June
2017
Study of efficacy and
safety of CTL019 in
adult ALL patients
(relapsed/refractory)
II; single arm,
open label,
multicentre
67 Safety (1 year) None reported
NCT02435849,
April 2015–April
2021
Determine efficacy
and safety of
CTL019 in paediatric
patients with
relapsed and
refractory B-ALL
II; single arm,
open label,
multicentre
67 Overall remission rate,
which includes CR and
CRi, as determined by
independent review
committee assessment
(6 months)
Percentage of patients
who achieve CR or CRi at
month 6 without stem
cell transplant between
CTL019 infusion and
the month 6 response
assessment; percentage
of patients who achieve
CR or CRi and proceed to
stem cell transplant while
in remission before the
month 6 response
assessment; duration of
remission (60 months);
percentage of patients
who achieve CR or CRi
with MRD-negative bone
marrow (60 months);
RFS (60 months); EFS
(60 months); OS
(60 months); in vivo
cellular pharmcokinetic
profile (levels, persistence,
trafficking) of CTL019
cells (60 months);
prevalence/incidence of
immunogenicity to
CTL019 (60 months)
NCT01840566,
April 2013–April
2016
High dose therapy
and autologous stem
cell transplantation
followed by infusion
of chimeric antigen
receptor (CAR)
modified T-cells
directed against
CD19+ B-cells for
relapsed and
refractory aggressive
B cell non-Hodgkin
lymphoma
I; single arm,
open label
18 Maximum tolerated
dose; safety
(2 years)
2-year PFS; OS (2 years)
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Efficacy results
Details of the three trials identified from the Cell Therapy Catapult searches are presented in Table 5. Two
of the studies were Phase I trials164,166 and one was categorised as a Phase I/IIA trial165 (on ClinicalTrials.gov);
safety was the primary outcome in all trials (one study also had maximum tolerated dose as a co-primary
outcome164). All trials had recruited < 40 patients, although two were ongoing.165,166
As can be seen from Table 5, notable clinical heterogeneity was evident both within and across trials.
One study was of children and adults165 and one studied children and young adults.164 The remaining
study included only adults166 and so ultimately was not of further use for the assessment. Most patients
had had a previous relapse following remission; a small proportion of patients were refractory to previous
treatments. In two studies the CAR T-cell treatments were mostly used to enable patients to receive HSCT
(i.e. used as a bridging therapy).164,166 The remaining study appeared to recruit a more difficult-to-treat
population, with most patients having two or more relapses and previous HSCT; here, the treatment
intention may possibly have been curative.165 CAR T-cell design also varied, with either the CD28 or the
4-1BB co-stimulatory domains being used, a difference that might explain the more prolonged persistence
of circulating CAR T-cells seen in one of the studies.165 Persistence of CAR T-cell therapies in the body can
result in benefit and risk, depending on the duration of persistence.
TABLE 4 Ongoing commercial CAR T-cell trials registered on ClinicalTrials.gov (continued )
ClinicalTrials.gov
identifier, start
date and
estimated end
date Study name
Phase and
design
Estimated
enrolment
Primary outcome(s)
and time frame
Secondary outcomes
and time frame
NCT01430390,
September
2011–September
2016
In vitro expanded
allogeneic
Epstein–Barr virus
specific cytotoxic
T-lymphocytes
(EBV-CTLs)
genetically targeted
to the CD19 antigen
in B-cell malignancies
I; single arm,
open label
26 Safety (3 years);
persistence of
escalating doses
(3 years)
Assess the effects of the
adoptively transferred
CD19-specific T-cells on
the progression of
leukaemia (3 years);
quantitate the number of
CAR-positive T-cells in
the blood at defined
intervals post infusion to
determine their survival
and proliferation in the
host (3 years); assess the
long-term status of
treated patients (15 years)
NCT01683279
(PLAT-01),
December
2012–January
2016
A pediatric trial of
genetically modified
autologous T cells
directed against
CD19 for relapsed
CD19+ acute
lymphoblastic
leukemia
I; single arm,
open label
18 Number of
participants with
adverse events
(42 days)
Persistence of the CD19
CAR+ T-cells (42 days);
determine whether there
is anti-leukaemic activity
of the CD19 CAR+ T-cells
(42 days)
NCT02028455
(PLAT-02), January
2014–January
2017
A pediatric and
young adult trial of
genetically modified
T-cells directed
against CD19 for
relapsed/refractory
CD19+ leukemia
I/II; single
arm, open
label
80 Safety (30 days);
MRD-negative CR
(63 days); releasable
cell product generated
(28 days)
Persistence of the CD19
CAR+ T-cells (63 days);
number of participants
with recrudescence or
development of acute
graft versus host disease
(63 days); number of
participants who have
T-cells ablated with
cetuximab (3 years)
CRi, complete remission with incomplete blood count recovery.
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Two surrogate end points were reported in all three trials: CR and MRD. Rates of CR ranged from around
70% to 90%. As would be expected, the rates of achieving a status of MRD were lower, ranging from
around 60% to 80%, although only one trial stated the MRD threshold used, which was 0.01% (i.e. one
cancer cell in 10,000 normal cells).164 All three trials reported OS data. In one trial the probability of OS
was 52% at 9.7 months.164 The other two trials reported probabilities of OS at 6 months, which were
58%168 and 78%, respectively.165
Adverse events
The key adverse events noted in the trials were CRS, B-cell aplasia, febrile neutropenia and various neurological
effects. In two studies most patients had mild to moderate CRS,164,165 although a greater incidence of
severe CRS was evident in the trial in adults.166 Affected patients were treated with steroids or tocilizumab.
Two of the three studies reported the incidence of B-cell aplasia. In one study prolonged B-cell aplasia did
not occur164 and in the other B-cell aplasia occurred in all patients who had a response and persisted for up
to 1 year after CAR T-cells were no longer detectable.165 Significant proportions of patients had febrile
neutropenia or neurological adverse effects such as hallucinations or altered mental status (see Table 5).
Summary issues for the target product profile and hypothetical data sets
l The B-ALL population is narrowly defined with extremely poor prognosis and limited alternative therapy
options. This is likely to be typical of regenerative medicines.
l Therapy potentially offers a ‘cure’.
l There are potentially serious adverse effects of therapy.
l Limited data are available (single-arm studies).
l Appropriate comparator and control data need to be identified/generated.
Review of licensed treatments for relapsed/refractory B-cell
acute lymphoblastic leukaemia
A pragmatic review of the other treatments for relapsed/refractory B-ALL that have been licensed by
the EMA or the FDA was undertaken. This was carried out to further inform decisions to help construct
the CAR T-cell therapy hypothetical data sets and to help to put them in context. Three treatments
were quickly identified from the B-ALL literature and EMA/FDA websites: Evoltra (clofarabine), Blincyto
(blinatumomab) and Marqibo® (vincristine sulphate liposome injection; Talon Therapeutics, San Francisco,
CA, USA). This number of treatments was deemed sufficient for the purposes of this exercise.
Evoltra – known as Clolar® in the USA – was granted EMA marketing authorisation under exceptional
circumstances in 2006. It is a purine nucleoside anti-metabolite (which affects DNA elongation, synthesis
and repair). Blincyto and Marqibo were both licensed by the FDA under the accelerated approval
programme (in 2014 and 2012, respectively); in this programme, drugs for serious conditions that fill an
unmet medical need may be approved based on a surrogate end point. Blincyto, which has also been
granted a ‘breakthrough therapy’ designation, is a monoclonal antibody designed to specifically attach to
CD19 proteins on leukaemia cells. Marqibo provides targeted delivery of vinicristine, which involves
encapsulation of vinicristine in nanoparticle liposomes.
Marqibo and Blincyto are licensed for use in adults and Evoltra for use in children and young adults.
All three treatments have an orphan product designation, all claim to meet unmet medical need and the
submissions for all were primarily based on data from Phase II single-arm trials.170–173 However, whereas
Marqibo and Evoltra are licensed for patients with a second or greater relapse (or refractory patients), the
approval for Blincyto is broader, covering patients with Ph– relapsed or refractory B-cell precursor ALL; over
half of the patients in the pivotal Blincyto study172 had had only one relapse. A consequence of these
different populations can be seen in the pivotal trial sample sizes, with smaller study sample sizes for
Marqibo (n = 65)173 and Evoltra (n = 61)170,171 and a larger sample size for Blincyto (n = 189).172
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Primary outcomes for all three trials were based on remission status (CR and/or overall remission). All
studies also reported OS. For the second or greater relapse populations, treatment with Evoltra resulted
in an overall remission rate of 20% (12/61 patients), with 16% (10/61) of patients going on to receive
HSCT;170,171 treatment with Marqibo resulted in a CR rate of 15% (10/65 patients) (although the figure
was 12% based on the FDA’s assessment), with 18% (12/65) receiving HSCT.173 However, most of these
patients did not achieve CR with Marqibo. As would be expected, a higher rate of CR was seen in the
Blincyto trial (42%)172 than in the Marqibo173 and Evoltra170,171 trials, as most patients were at first relapse.
Further results and other assessment details are presented in Appendix 5.
The EMA review of Evoltra stated that, given the efficacy seen early on in the clinical programme, studies
using a placebo comparator were considered clinically unethical.170 Active comparator studies were also not
deemed to be appropriate as there were no other recognised therapeutic options available: ‘The indication
is encountered so rarely that the applicant cannot reasonably be expected to provide comprehensive data
on clinical efficacy and safety’ (p. 35).170 Marketing authorisation was therefore granted ‘under exceptional
circumstances’.170 The All Wales Medicines Strategy Group (AWMSG) recommended Evoltra only if the
intended use was as a bridge to HSCT (and recommended that it should not be used with palliative
intent).171 The FDA approval of Marqibo seemed less straightforward; committee members consistently
stated that the proposed Phase III trial was critical in assessing the benefit of Marqibo.173 Some members
indicated that the trial should be completed before approval, whereas several indicated that accelerated
approval may be appropriate but with the expectation that this approval would be withdrawn if the Phase III
trial failed to confirm clinical benefit. The post-approval study was a multicentre Phase III randomised trial
comparing standard vinicristine with Marqibo in older adults with newly diagnosed untreated Ph– ALL;
the proposed sample size was 348.
For Blincyto, a confirmatory Phase III RCT was required to compare Blincyto with standard care
chemotherapy in relapsed/refractory adults; this was ongoing at the time of submission to the FDA.172 A
2 : 1 randomisation ratio was used, with more patients receiving blinatumomab. Around 400 patients were
expected to be enrolled and the primary end point is OS.
Single-arm B-cell acute lymphoblastic leukaemia trials: identifying
appropriate control data
As discussed in Chapter 3 (see Study biases: an overview of their importance and methods to quantify and
adjust for their impact), although the results of single-arm trials can be compared with historical control
data, the results of such comparisons can be considered as reliable indicators of treatment benefit only
when the disease natural history is very well known, the patient population is homogeneous and the
standard of care treatment has little impact on outcomes. For Evoltra, Blincyto and Marqibo, different
approaches were used to devise a control data set.
For Blincyto a weighted analysis of patient-level data from 694 retrospective controls (1990–2014) was
performed.174 This study, which was of relapsed/refractory adults treated with standard of care therapy,
utilised databases in several EU countries and the USA. The manufacturer of Blincyto (Amgen) also
conducted a model-based meta-analysis of clinical study data to project the effect of Blincyto relative to
existing therapies. For its ongoing trial in children, Amgen cited both a key paper on prognostic factors in
B-ALL152 and the CR rates seen with Clolar (clofarabine), stating that the primary efficacy end point would
be met if the CR + CRh (complete remission with incomplete haematological recovery) rate was at least
22.5% (suggesting efficacy similar to or greater than that for clofarabine).172 For the Marqibo FDA
submission, literature searches were performed to identify response rates in relevant patients.173 The
study reporting the best historical comparison data still had some key differences with regard to the
Marqibo trial population, most notably in terms of line of treatment, eligibility for transplant and site of
adjudication.175 Comparisons were made with the closest matched subgroup of patients in the historical
study: patients who received third-line single-agent treatment.173 Clofarabine was assessed in 2006 and
thus the aforementioned O’Brien study175 was not available. Instead, data were obtained from German
and Dutch cancer registries; simple comparisons of median survival results were presented to the EMA.170
DOI: 10.3310/hta21070 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 7
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Hettle et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
51
Summary
l Studies that form the basis of regulatory submissions for treatments for patients with second or greater
relapsed/refractory B-ALL will be small (around 65 patients), Phase II, single-arm trials.
l Primary end points will be surrogate end points such as CR.
l Confirmatory randomised trials may be appropriate and viable in related larger populations for whom
other treatment options exist.
l For very small patient populations it is likely to be difficult to identify published prognostic studies that
have suitable historical control data. Other strategies may therefore be needed, such as seeking access
to national patient databases (in order to perform new studies).
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Chapter 5 The target product profile and
hypothetical data sets
Summary of issues to consider to inform the creation of the
target product profiles and hypothetical data sets
The innovative nature of regenerative medicines, together with the indications that many of them will be
expected to target initially (populations with high levels of unmet medical need), means that there is a
collective desire to expedite their approval and appraisal. This ambition may run counter to the need for
additional vigilance relating to robust evidence and long-term outcomes. Regulatory bodies must therefore
endeavour to balance urgency of patient need with the requirement for robust evidence on efficacy and
safety. This can be managed through a combination of regulatory approval based on limited – although
promising – data, combined with post-approval requirements for continued data collection. From the
perspective of NICE appraisals, this means that the evidence base available at the time of product approval
may be highly uncertain; the cost of this uncertainty has to be a key part of the decision-making process.
The reviews have identified several broad issues relevant to uncertainty around the clinical evidence for the
creation of the TPPs and hypothetical data sets for the exemplar.
l It is not universally the case that regenerative medicines (or ATMPs) will be tested using NRS designs.
Rather, submitted pivotal studies may well in fact be randomised, notably when levels of unmet need
are low and diseases/conditions are not rare; in such cases, the maturity of data (which would be
available at the time of a NICE appraisal) has been up to 5 years’ duration.
l When single-arm trials, or case series, do form the basis of a regulatory submission, a key consideration
when judging uncertainty should be the likelihood of cure or improvement without experimental
treatment. However, it may be very difficult to identify published prognostic studies that have suitable
historical control data. Other strategies for obtaining historical data may well be needed, such as
seeking access to national patient databases.
l When single-arm trial data are compared with historical data and appropriate methods to adjust for
confounding are employed, the selection of the method used must be explicit and based on sound
reasoning; despite advances in statistical techniques, clear challenges remain in generating accurate
unbiased estimates of effect from non-randomised data.
l Results from single-arm trials can be considered as reliable indicators of treatment benefit only when
the disease natural history is very well known, the patient population is homogeneous and the control
(standard of care) treatment has little impact on outcomes.
l Although more mature evidence, such as confirmatory RCTs, may sometimes be viable in the specific
population, it might also be expected only in larger, similar populations (e.g. B-ALL patients in first
relapse). This raises the possibility of incorporating indirectly relevant but more reliable (and possibly
more mature) data into the analysis, to reduce uncertainty.
l The high technology status of regenerative medicines may imply greater potential for variation in
response across both individuals and centres. This is likely to have implications in terms of the
generalisability of efficacy and safety estimates obtained from small single-centre (probably expert
centre), single-arm studies; in the absence of larger or more varied trials, this might be addressed only
by access to IPD so that potential predictors of response or effect modifiers may be investigated.
l Another key issue is that pivotal trials in regulatory submissions are likely to report primary end points
that are surrogates for real clinical end points. On average, trials using surrogates report larger
treatment effects than trials using final patient-relevant outcomes. This has implications for effect
estimate uncertainty, especially when only surrogate end points are reported; the choice of surrogate
outcomes used should be researched, explicit and justified. Nevertheless, to maximise the use of all
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available data, and to reduce overall uncertainty, multivariate meta-analysis methods to analyse data
should be considered, whatever the maturity of the evidence base.
l Related to the issue of surrogates as primary outcomes is that of duration of follow-up: use of
intermediate shorter-term outcomes avoids the need for long follow-up. The consequence of this is
that, even when OS data are recorded, these data are immature at the point of regulatory approval.
l Regenerative medicines are by their nature innovative products and may be subject to continuing
development, with new generations having improved efficacy. This may pose problems when
evaluating long-term efficacy and safety, for example when determining to what extent the long-term
safety data from a first-generation product can be used to inform the long-term safety of a related
newly licensed second-generation product. This may mean that, as well as bioavailability-type studies,
key trials conducted earlier in the development process may have to be replicated or adjustments may
have to be made in the analyses of trial data to account for their indirectness.
For the specific purpose of deciding what to include in the exemplar hypothetical data sets, the best
information to begin with comes from the published and ongoing trials for CAR T-cells, together with the
EMA-/FDA-licensed non-regenerative medicines for relapsed B-ALL. These indicate that a minimum data set
would consist of a small (around 65 patients), Phase II, single-arm trial, with a surrogate end point such as
CR as the primary end point. MRD, the surrogate end point that is the strongest predictor of long-term
EFS in ALL, is also likely to be reported, although there is considerable uncertainty about its value in
relapsed populations.
Historical control data must be identified, which should reflect the treatment that B-ALL patients would
receive in the absence of CAR T-cell therapies being available. This is necessary to utilise the hypothetical
trial evidence within the economic analyses. A key challenge for constructing the historical control group
would therefore be identifying the population included within the single-arm studies and selecting an
appropriate control group: any selected control group is unlikely to exactly match the tiny population
included in the single-arm studies and so comparisons would therefore be subject to confounding.
To mitigate the effects of any such bias, a second challenge would be to identify and apply the most
appropriate methods to adjust for confounding.
The small sample sizes available from the trials of CAR T-cell therapies in relapsed/refractory B-ALL imply
that estimates of effect are likely to be inexact and imprecise and this should be considered when creating
the more mature data sets.
More mature data sets would be expected to have larger (tending towards appropriately powered) sample
sizes to reduce the width of the CI around any effect estimate. It should be noted that this would not
influence the magnitude of any potential bias and may lead to increased confidence in an incorrect
estimate of effect. Increasing the sample size may, however, also allow for a wider range of statistical
methods to mitigate the effects of confounding and therefore have an indirect effect on reducing any bias
in the effect estimate.
A RCT could be included in a more mature data set or the availability of data from a RCT in B-ALL patients
in first relapse could be proposed. This latter possibility raises methodological questions of how the results
of confirmatory RCTs in an indirect population might be used to re-evaluate the uncertainty of the direct
evidence base.
Background to developing the target product profiles and
evidence sets
Data from the three published trials for CAR T-cell therapies164–166 were discussed at a meeting of the
project advisory group on 24 June 2015. Based on these discussions it was decided that, for the purposes
of the exemplar, the population would comprise children and young adults who had experienced two or
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more relapses or who were refractory to treatment (with older adults excluded). It was further decided that
the exemplar would explore both of the therapeutic goals of the CAR T-cell therapy, encompassing
bridging and remission/curative intents.
Two TPPs were subsequently developed to be considered as part of the exemplar appraisal:
1. CAR T-cell therapy used as a bridge to HSCT, in which the primary goal of treatment is to induce
short-term remission of disease to maximise the opportunity for successful HSCT
2. CAR T-cell therapy used with curative intent, in which the primary goal of CAR T-cell treatment is
long-term remission/cure of disease (with or without HSCT).
These two approaches to treatment with CAR T-cell therapy imply two potentially different contexts in
which therapy may be appraised. Consequently, there are separate implications arising from the different
applications, which require their consideration as two distinct scenarios.
In the bridge to HSCT scenario, the survival benefits of treatment are determined primarily by the subsequent
receipt of HSCT and the associated benefits that stem from this. As such, the health benefits of CAR T-cell
therapy are closely linked to the HSCT status of the cohort in the immediate period following CAR T-cell
therapy. From a regulatory and reimbursement standpoint, the primary determinant of treatment efficacy is
likely to include short-term end points such as remission and, potentially, MRD status. These data may also
be supported by data on the outcomes of HSCT after CAR T-cell therapy. Marketing approval may therefore
be achieved through demonstrating clinical benefit in terms of remission, MRD status (potentially) and
subsequent rates of HSCT.
In the curative intent scenario, the survival benefit of treatment is considered to be as a direct result of
CAR T-cell therapy itself. In this context, there is no separate surrogate treatment or process (i.e. HSCT)
that determines the long-term benefits of therapy. From a regulatory standpoint, the primary determinant
of the efficacy of treatment in this scenario is likely to include longer-term clinical end points such as EFS
and OS, and increased levels of data maturity may be required.
New technologies are submitted to licensing agencies to seek regulatory approval and are subject to
NICE appraisal at various stages of development of the supporting evidence base. To explore the impact
of different levels of precision and maturity in the evidence base, three hypothetical data sets were
constructed for each TPP:
1. the minimum set – the minimum data considered potentially sufficient for CAR T-cell therapy to be
granted conditional regulatory approval
2. the intermediate set – a variant of the minimum set in which the efficacy and safety of CAR T-cell
therapy have been assessed over a longer follow-up period
3. the mature set – a variant of the intermediate set in which the efficacy and safety of CAR T-cell therapy
have been assessed in a larger clinical study but with a similar follow-up period as in the intermediate set.
In developing the TPPs, it was not our intention to directly compare the separate scenarios or to use these
to infer differences between the alternative CAR T-cell therapies currently being developed. Neither were
the different evidence sets intended to be prescriptive regarding the sufficiency of evidence for the
purposes of regulatory or reimbursement processes. Instead, the hypothetical TPPs were developed to
provide an exploration of potential issues and challenges associated with varying levels of precision and
maturity in the underlying evidence base and the potential impact that these might have on subsequent
assessments of cost-effectiveness and associated decision uncertainty.
In total, six evidence sets were developed spanning the separate TPPs (three sets for bridge to HSCT and
three sets for curative intent). Each of the six evidence sets included hypothetical efficacy and safety data
for CAR T-cell therapy and for a historical control. The efficacy and safety estimates in the bridge to HSCT
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and curative intent TPPs were derived from data from Lee et al.164 and Maude et al.,165 respectively,
reflecting the clinical heterogeneity and the potentially different treatment intentions reported in Chapter 4
(see Review of evidence of clinical effectiveness: chimeric antigen receptor T-cell therapies).
Defining a historical control
The lack of control data within existing CAR T-cell studies necessitated the selection of a historical control
from existing published literature to inform the TPPs and economic model. As discussed in Chapter 3
(see Study biases: an overview of their importance and methods to quantify and adjust for their impact),
the use of a historical control introduces potential bias as observed or unobserved confounders other than
the treatments may impact the outcomes of interest. As such, a direct comparison of the CAR T-cell results
and historical control data may be subject to bias.
Observable sources of confounding can be potentially adjusted for in a number of ways, either at a
single-study level or through the synthesis of evidence from a number of studies (as discussed in Appendix 2).
A key source of potential observable confounding relates to differences in patient characteristics, which are
known to be related to subsequent prognosis. To identify prognostic factors that might provide a basis
for adjusting a historical control to account for potential prognostic imbalance, a pragmatic search was
conducted using Google and Google Scholar to identify previously published multivariate prognostic models
for patients with ALL.
The search identified 12 potentially relevant studies. However, five of these did not report sufficient detail
on the results to be considered further.159,160,175–177 A summary of the patient characteristics in the
remaining seven studies is provided in Appendix 6. None of the prognostic models specifically focused on
the population of interest. In addition, there appeared to be little consistency across the prognostic factors
selected for inclusion in the multivariate analyses, with no single factor considered across all models and
only a few of which could be applied to the patient characteristics reported within existing CAR T-cell
studies. Hence, although formal adjustment for potential bias is desirable, the lack of access to IPD meant
that this was not considered feasible within the exemplar.
A separate pragmatic search was subsequently conducted using Google and Google Scholar to identify
possible historical control studies that might be more generalisable to the population of interest (i.e. based
on age and previous history of relapse) and which might minimise the potential for bias in the absence of
a formal adjustment for confounding. This search identified two studies considered to be potentially
generalisable to the population considered within the exemplar evaluation.160,178 Jeha et al.178 reported
on a Phase II, open-label study of clofarabine in paediatric patients with refractory or relapsed ALL. Von
Stackelberg et al.160 conducted a retrospective analysis of outcomes in children and adolescents with ALL
who had not responded to salvage therapy and evaluated the OS of the patient population given different
treatment modalities (curative, palliative and no therapy).
For consistency across TPPs and evidence sets, the same historical control intervention and informative
data were implemented in both scenarios. Clofarabine and the study by Jeha et al.178 were subsequently
selected to act as the control treatment and source of historical control data for the following reasons:
l Clofarabine is considered a standard of care chemotherapy for B-cell relapsed refractory ALL, alongside
other chemotherapies such as fludarabine, cytarabine, granulocyte colony-stimulating factor and
idarubicin (Zavedos, Pfizer, New York City, NY, USA) (FLAG-IDA).
l It is the only EMA-licensed treatment available for ALL in paediatric patients who have relapsed or who
are refractory after receiving at least two prior regimens and for whom there is no other treatment
option anticipated to result in a durable response.
THE TARGET PRODUCT PROFILE AND HYPOTHETICAL DATA SETS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
56
l Although clofarabine has not been appraised by NICE for this indication, clofarabine is currently funded
through the Cancer Drugs Fund (CDF). At the time of writing, clofarabine was the only treatment for
relapsed and refractory B-ALL approved by the CDF.
l The Phase II study population was also considered to be broadly consistent with populations enrolled in
the studies by Maude et al.165 and Lee et al.164
Developing the evidence sets and target product profiles
The first step in developing the hypothetical evidence was to define the sample size and maturity of the
evidence (i.e. follow-up) for the minimum, intermediate and mature evidence sets. The second step
involved generating the efficacy and safety data conditional on the sample and maturity levels specified for
each of the evidence sets. This involved the synthesis of data reported in the existing CAR T-cell historical
control studies and simulation modelling.
Defining the sample size and maturity of evidence in the evidence
sets studies
Current evidence on the efficacy of CAR T-cell therapies is limited to early Phase I/II studies with patient
numbers of between 16 and 30.164,165,179 It is anticipated that larger clinical studies will be needed to meet
the minimum requirements for positive regulatory approval. This evidence is expected to come from a
series of Phase II/III studies. Several previous pharmaceutical treatments for ALL have been granted
regulatory approval based on efficacy and safety data from single-arm Phase II studies with sample sizes
ranging from 61 to 189. This appears to be reflected in the design of planned and ongoing CAR T-cell
studies in ALL. According to the ClinicalTrials.gov trials registry, there are currently three registered Phase II
trials investigating the efficacy and safety of CAR T-cell therapies. The planned sample size of these trials is
67 patients (see Table 4). There is also one Phase I/II trial with an estimated enrolment of 80 patients.
The expected minimum data requirement for regulatory approval of CAR T-cell therapy was therefore set
in the region of 60–80 patients. This sample size was used in both the minimum and the intermediate
evidence sets. The mature evidence set was assumed to be based on trial evidence derived from a larger
sample of patients than in the minimum and intermediate evidence sets. This evidence set was designed
to reflect a scenario in which the evidence base for CAR T-cell therapy could include data from a more
conventional RCT (or alternatively a larger uncontrolled study) with sufficient duration of follow-up to
determine the longer-term efficacy for key clinical end points including OS. In practice, the sample size and
maturity for such a study would be determined by a number of factors, including conventional statistical
power calculations, likely accrual rates, the competitive landscape and overall study costs. In the time
available, it was not feasible to formally consider these elements in estimating the anticipated sample size
for this study. Instead, the sample size was based on the planned enrolment size of an ongoing Phase III
trial of blinatumomab in adult ALL, identified from previous hand-searching of ClinicalTrials.gov.180 In this
study, the planned enrolment was for 400 patients to be randomised to blinatumomab or standard of care
at a ratio of 2 : 1. As such, of the total 400 randomised patients, 133 would be randomised to the control
arm and 267 would be randomised to blinatumomab. For the mature set, the study sample size was
therefore set in the region of 120–140 patients per treated group (240–280 in total).
In using this specific sample size for the mature evidence set, we recognise that there are differences between
the patients recruited into the blinatumomab trial and the specific population being considered here both in
terms of age and previous history of relapse. However, for the purposes of a hypothetical exemplar this was
considered to provide a reasonable basis for investigating the potential impact of increased precision.
The intermediate and mature evidence sets were also assumed to be based on trial evidence, with longer
efficacy follow-up durations than the minimum set. For the minimum set, trial follow-up was based on
a similar duration to that reported within existing CAR T-cell studies, with a median follow-up of
approximately 10 months. For the intermediate and mature sets, trial follow-up was based on the
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maximum planned study duration for all Phase II CAR T-cell trials registered on the ClinicalTrials.gov trials
registry. Across these studies, the longest planned follow-up period was 5 years.
A summary of the targeted sample size and level of evidence maturity considered across each of the
evidence sets is provided in Table 6.
Estimating the efficacy of chimeric antigen receptor T-cell and comparator
treatments in the evidence sets
For all dichotomous outcomes, including response, remission and use of HSCT, parameter estimates were
extracted directly from the existing CAR T-cell and clofarabine publications. The effect of increased sample
size on the variance parameter for each dichotomous outcome was modelled using a beta distribution.
As these outcomes tend to be measured during the first few months of a study, it is expected that longer
follow-up would not directly impact these parameter estimates.
For the OS end point, parameter estimates were derived by digitising the Kaplan–Meier (KM) curves
reported in the main study publications and using the algorithm by Guyot et al.72 to impute the
patient-level time-to-event and event-type (censored or event) data. These data were then analysed using
conventional semiparametric survival modelling techniques using the statistical programming platform R
(version 3.0.2; The R Foundation for Statistical Computing, Vienna, Austria).181 This included assessments
of landmark survival probabilities at 6, 12 and 60 months and derivation of the HR for CAR T-cell
therapy compared with standard of care therapies and restricted mean survival times (i.e. in the event
of non-proportional hazards, formally tested using the Schoenfeld residual test).
Using the studies by Maude et al.165 and Lee et al.,164 it was possible to generate samples of between
21 and 30 patients treated with CAR T-cell therapy. However, the expected minimum sample size for
regulatory approval may be in the region of 60–80 patients. Therefore, it was necessary to increase the
size of the imputed data sets from between 21 and 30 to between 60 and 80. This was achieved by
replicating each of the imputed data sets until the total sample size was between 60 and 80 patients for
the minimum/intermediate evidence sets and between 120 and 140 patients for the mature evidence set.
By creating the pooled sets in this way, the mean survival probabilities and KM plots for OS remained
consistent across evidence sets, whereas the variance around those estimates was allowed to vary in line
with the sample size.
For the mature and intermediate data sets it was also necessary to simulate an increase in the duration of
study follow-up to account for a scenario in which CAR T-cell studies had a longer follow-up duration, up
to a maximum of 5-years. This adjustment was made by adding survival time to the imputed patient records,
which were censored after the last recorded event in each study. These patients were subsequently assumed
to be re-censored at their new survival time. The same approach was applied in both the CAR T-cell and the
clofarabine arms. By extending the study time of patients who were censored after the last recorded event,
the following assumptions were made:
l patients who were alive and censored at the end of the studies were likely to be ‘cured’ of ALL,
such that they would also be alive and censored at the end of the longer follow-up period
l patients who were censored prior to the last event were assumed to have been lost to follow-up,
such that additional trial follow-up would not lead to further information on the timing of death
(or re-censoring) in those individual patients.
TABLE 6 Summary of the sample size and maturity of trial evidence assumed in the three evidence sets
Variable Minimum data set Intermediate data set Mature data set
Sample size 60–80 60–80 120–140
Study follow-up (months) 10 (median) 60 (maximum) 60 (maximum)
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This approach ensured that the KM curves remained consistent across the evidence sets. The net result of this
adjustment is that the more mature evidence sets contain more information on the long-term survival of those
alive and censored at the end of the current studies. An illustration of this approach is provided in Figure 1.
It is important to highlight that, in practice, additional follow-up time points in trials would be likely to
result in changes to the KM curves and estimates of survival benefit. To predict these changes would
require access to IPD to elicit the characteristics of patients who are censored at shorter follow-up
times and to then predict the unobserved event time for the censored patients, conditional on their
characteristics. With the imputed data it is not possible to identify the characteristics of those who are
censored and there are too few data to develop a prediction equation for the unobserved event times.
Finalised target product profiles
Bridge to haematopoietic stem cell transplantation target product profiles
Data on the evidence sets assumed for the clinical efficacy of CAR T-cell therapy as a bridge to HSCT are
reported in Table 7 (OS) and Table 8 (dichotomous end points, adverse events). The associated KM plots
are reported in Figure 2.
Minimum data set
In terms of OS, CAR T-cell therapy was assumed to be associated with improved probabilities of survival at
months 6 (66.8%) and 12 (51.6%) compared with standard of care therapy (32.0% at 6 months and
20.7% at 12 months). Treatment with CAR T-cell therapy was associated with a statistically significant
improvement in the time to death, with a HR of 0.33 (95% CI 0.203 to 0.539).
In a restricted mean survival time analysis, treatment with CAR T-cell therapy was associated with a mean
extension to life expectancy of 5.39 months (95% CI 3.18 to 7.60 months) compared with standard of
care therapy. The median follow-up in the minimum set was 11.3 months.
Intermediate data set
Given the consistency in the assumptions and the KM data assumed across the evidence sets, similar
results were observed in the intermediate set as were reported in the minimum set. However, evidence
was now also assumed to be reported on the survival benefits up to 5 years, with assumed 5-year
landmark survival probabilities of 51.6% and 20.7% for CAR T-cell and standard of care therapy,
respectively. Treatment with CAR T-cell therapy was associated with a statistically significant improvement
in the time to death, with a HR of 0.31 (95% CI 0.19 to 0.50).
Time since randomisation
Time of last event
X = additional time from
last censored patient to
maximum of 5 years
T = maximum follow-up
current studies
Censored patient
Patient with event
FIGURE 1 Illustration of adjustment to the data sets to account for additional study maturity.
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FIGURE 2 Kaplan–Meier plots of time from randomisation to death for CAR T-cell and standard of care therapies
in the different scenarios: (a) Bridge to HSCT – current trial follow-up; (b) curative intent – current trial follow-up;
(c) bridge to HSCT – mature trial follow-up; and (d) curative intent – mature trial follow-up. (continued )
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FIGURE 2 Kaplan–Meier plots of time from randomisation to death for CAR T-cell and standard of care therapies
in the different scenarios: (a) Bridge to HSCT – current trial follow-up; (b) curative intent – current trial follow-up;
(c) bridge to HSCT – mature trial follow-up; and (d) curative intent – mature trial follow-up.
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With increased data maturity compared with the minimum set, there was a greater trend towards
non-proportional hazards. In the restricted mean survival time analysis, treatment with CAR T-cell therapy was
associated with a mean improvement in life expectancy of 22.06 months (95% CI 12.87 to 31.25 months)
compared with standard of care therapy. The median follow-up in the intermediate data set was 53.6 months.
Mature data set
With increased precision and data maturity compared with the minimum set, treatment with CAR T-cell
therapy was associated with a statistically significant improvement in the time to death, with a HR of 0.31
(95% CI 0.22 to 0.43). In the restricted mean survival time analysis, treatment with CAR T-cell therapy was
associated with a mean improvement in life expectancy of 22.06 months (95% CI 15.56 to 28.57 months)
compared with standard of care therapy. The increased sample size is reflected in a more precise estimate
of the mean life expectancy in this evidence set compared with the intermediate set, evidenced by the
tighter CIs reported. The median follow-up in the mature data set was 53.6 months.
Curative intent target product profiles
Data on the evidence sets assumed for the clinical efficacy of CAR T-cell therapy as a curative treatment
option are reported in Table 9 (OS) and Table 10 (dichotomous end points, adverse events). The associated
KM plots are reported in Figure 2.
Minimum data set
Chimeric antigen receptor T-cell therapy was assumed to be associated with improved probabilities of
survival at months 6 (78.5%) and 12 (72.5%) compared with standard of care therapy (32.0% and 20.7%
at 6 and 12 months, respectively). Treatment with CAR T-cell therapy was associated with a statistically
significant improvement in the time to death, with a HR of 0.20 (95% CI 0.11 to 0.37).
In a restricted mean survival time analysis, treatment with CAR T-cell therapy was associated with a mean
extension to life expectancy of 10.47 months (95% CI 7.59 to 13.34 months) compared with standard of
care therapy. The median follow-up in the minimum set was 10.03 months.
Intermediate data set
Five-year landmark survival probabilities of 72.5% and 20.7% for CAR T-cell therapy and standard of care
therapy were assumed, respectively. Treatment with CAR T-cell therapy was associated with a statistically
significant improvement in the time to death, with a HR of 0.18 (95% CI 0.10 to 0.33).
In contrast to the bridge to HSCT intermediate data set, there was no apparent trend towards
non-proportional hazards over time. In the restricted mean survival time analysis, CAR T-cell therapy was
associated with a mean improvement in life expectancy of 32.94 months (95% CI 24.38 to 41.43 months)
compared with standard of care therapy. The median follow-up in the intermediate data set was 45.2 months.
Mature data set
Treatment with CAR T-cell therapy was associated with a statistically significant improvement and a more
precise estimated HR than in the minimum and intermediate data sets (HR 0.179, 95% CI 0.117 to 0.272).
In the restricted mean survival time analysis, treatment with CAR T-cell therapy was associated with a
similar mean extension to life expectancy as in the intermediate set but with increased precision. The
estimate of the improvement in life expectancy was 32.94 months (95% CI 26.87 to 38.93 months)
compared with standard of care therapy. The median follow-up in the mature data set was 45.2 months.
A summary of the six evidence sets across the two separate TPPs is provided in Table 11.
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TABLE 11 Summary of the key attributes of the six evidence sets
Attribute Minimum data set Intermediate data set Mature data set
TPP: bridge to HSCT
Median time to censoring (follow-up)
(months)
11.3 53.6 53.6
OS: HR (95% CI); difference in restricted
mean survival time (95% CI) (months)
0.331 (0.203 to 0.539);
5.4 (3.2 to 7.6)
0.309 (0.190 to 0.503);
22.1 (12.9 to 31.3)
0.307 (0.218 to 0.434);
22.1 (15.6 to 28.6)
CR (95% CI)
CAR T-cell therapy 64.9 (52.6 to 76.5) 64.9 (52.6 to 76.5) 65.7 (57.7 to 73.6)
Standard of care – clofarabine 12.5 (6.1 to 21.5) 12.5 (6.1 to 21.5) 12.0 (6.9 to 18.1)
MRD negative (95% CI) (%)
CAR T-cell therapy 54.7 (42.8 to 67.7) 54.7 (42.8 to 67.7) 56.0 (47.6 to 64.7)
Standard of care – clofarabine 2.7 (0.4 to 7.5) 2.7 (0.4 to 7.5) 2.3 (0.5 to 5.4)
CRS (95% CI) (%)
CAR T-cell therapy 28.9 (19.0 to 40.7) 28.9 (19.0 to 40.7) 28.2 (20.8 to 36.1)
Standard of care – clofarabine 1.5 (0.0 to 5.3) 1.5 (0.0 to 5.3) 0.9 (0.0 to 3.3)
Febrile neutropenia (95% CI) (%)
CAR T-cell therapy 33.8 (22.8 to 45.0) 33.8 (22.8 to 45.0) 33.2 (24.8 to 41.6)
Standard of care – clofarabine 48.6 (36.7 to 61.0) 48.6 (36.7 to 61.0) 49.1 (40.5 to 58.2)
TPP: curative intent
Median time to censoring (follow-up)
(months)
10.03 45.2 45.2
OS: HR (95% CI); difference in restricted
mean survival time (95% CI) (months)
0.204 (0.113 to 0.370);
10.5 (7.6 to 13.3)
0.180 (0.099 to 0.327);
32.9 (24.4 to 41.4)
0.179 (0.117 to 0.272);
32.9 (26.9 to 38.9)
CR (95% CI) (%)
CAR T-cell therapy 90.0 (81.3 to 96.2) 90.0 (81.3 to 96.2) 90.0 (84.0 to 94.7)
Standard of care – clofarabine 11.5 (4.7 to 20.6) 11.5 (4.7 to 20.6) 11.5 (6.5 to 17.8)
MRD negative (95% CI) (%)
CAR T-cell therapy 73.4 (61.5 to 83.7) 73.4 (61.5 to 83.7) 73.4 (65.2 to 80.8)
Standard of care – clofarabine 1.6 (0.0 to 6.0) 1.6 (0.0 to 6.0) 1.6 (0.0 to 4.5)
CRS (95% CI) (%)
CAR T-cell therapy 27.0 (16.6 to 38.9) 27.0 (16.6 to 38.9) 27.0 (19.5 to 35.3)
Standard of care – clofarabine 1.5 (0.0 to 5.3) 1.5 (0.0 to 5.3) 0.9 (0.0 to 3.3)
Febrile neutropenia (95% CI) (%)
CAR T-cell therapy 73.0 (61.2 to 83.3) 73.0 (61.2 to 83.3) 73.0 (64.8 to 80.5)
Standard of care – clofarabine 48.6 (36.7 to 61.0) 48.6 (36.7 to 61.0) 49.1 (40.5 to 58.2)
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Chapter 6 Review of cost-effectiveness evidence
for chimeric antigen receptor T-cell therapy and other
interventions for acute lymphocytic leukaemia
Methods
No previously published studies on the potential cost-effectiveness of CAR T-cell therapy for ALL were
identified in our searches (see Appendix 7). To inform the conceptualisation and development of the
economic model, a separate review of published studies evaluating the cost-effectiveness of other
treatments for ALL was conducted. The primary aim of the review was to inform key structural
assumptions and potential parameter sources required for the model. Hence, the review focused on the
main methodological approaches taken in the studies identified, rather than the specific results reported.
A two-part approach was taken, consisting of a systematic review and a more pragmatic search. Details of
the search strategy employed to inform the systematic review are provided in Appendix 8 (see Table 47).
The pragmatic search searched for any publicly available reports considering the cost-effectiveness of any
intervention in ALL using Google and Google Scholar; in addition, the relevant websites for NICE and
AWMSG were searched to identify previous appraisals for ALL.
Results
The systematic search identified 489 records, 11 of which were deemed potentially relevant after a review
of their titles and abstracts. However, after obtaining the full articles, none of these studies was found to
be a full economic evaluation and hence these studies were not subsequently considered within the model
conceptualisation stage. The pragmatic search using Google and Google Scholar found two papers
deemed relevant to the primary aim of the review.182,183
Costa et al.182 conducted a cost-effectiveness evaluation of unrelated stem cell transplantation for adults
with acute leukaemia (ALL and acute myeloid leukaemia) structured around a 20-year Markov model. The
study concluded that the two forms of transplantation considered (cord blood and bone marrow/peripheral
blood stem cells) were cost-effective compared with no transplantation. The study found that, despite the
high initial cost and short-term mortality associated with the transplantation procedures, the resulting
life-year gains achieved by surviving patients were significant.
Lis et al.183 considered the cost-effectiveness of clofarabine combined with chemotherapy in children and
adolescents with ALL who have failed at least two previous therapies compared with nelarabine (Atriance®,
GlaxoSmithKline, Brentford, UK) and FLAG-IDA, through the use of a lifetime Markov model. After the
initial treatments, a proportion of patients was assumed to subsequently receive HSCT; this proportion
varied given the response to initial treatment (complete, partial, complete without platelet recovery or no
response) and the treatment arm. A patient who survived for 2 years post HSCT was assumed to be cured
of ALL; no cure was possible without HSCT. The authors found clofarabine to be cost-effective compared
with both comparators. The result was driven by the success of a therapy in achieving a bridge to HSCT and
thus a potential cure. As clofarabine was associated with a greater proportion of patients experiencing an
initial CR, it had the greatest proportion of patients undergoing HSCT and thus cured patients.
The search of NICE and AWMSG appraisals found that the only appraisal by NICE for ALL (dasatinib,
ID386)184 was discontinued in 2008 because of the low number of patients anticipated to be treated.
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By contrast, the AWMSG provided details of four separate appraisals in ALL, although one of these
(imatinib, no. 2014) did not receive a formal submission by the manufacturer.171,185–187 Of the remaining
AWMSG appraisals, only the final appraisal recommendations (FARs) are made publicly available, limiting
the detail available on the evaluative approaches. Only two of the appraisals (clofarabine171 and
nelarabine185) provided sufficient detail to review.
Clofarabine171 was recommended by the AWMSG for children and adolescents with ALL who are relapsed
or refractory after at least two previous regimens and for whom no other treatment is anticipated. Within
the FAR, an important restriction was placed on the recommendation such that clofarabine should be
given only to patients in whom there is an intention to proceed to HSCT. This recommendation was based
on the findings that clofarabine did not appear to be cost-effective for patients who did not subsequently
receive HSCT. In the submission, clofarabine was compared with palliative care alone. Palliative care was
assumed to be associated with a very short median survival time (9–10 weeks) based on historical
control data.
Although limited details of the modelling approach are reported, it is evident that the primary structural
driver within the model is the bridging role of clofarabine to HSCT, with potentially significant gains in
life-years assumed for patients who subsequently receive HSCT. The manufacturer assumed that the
success of HSCT in achieving long-term remission (and cure) was driven by the achievement of remission
(complete, with platelet involvement or partial) at the time of transplantation. Hence, improved rates of
remission achieved with clofarabine compared with palliative care directly equate to long-term survival.
The model submitted assumed that patients who received HSCT and survived for 1 year were cured,
returning to the mortality risks and utilities of the general population.
Nelarabine185 was recommended by the AWMSG for the treatment of patients with T-ALL and T-cell
lymphoblastic leukaemia whose disease has not responded to, or has relapsed, following treatment with at
least two chemotherapy regimens. Best supportive care was used as the main comparator and clofarabine
was considered in a separate scenario based on indirect comparisons. In common with the restriction
previously applied within its recommendations for clofarabine in ALL, the AWMSG also restricted treatment to
patients for whom there is an intention to proceed to HSCT. This restriction was based on a similar finding
that the cost-effectiveness of nelarabine was closely related to the assumed increase in the proportion of
patients subsequently receiving HSCT (and their related long-term health gains). The base-case analysis
presented survival based on within-trial estimates with no extrapolation conducted. This was considered to be
an extremely conservative estimate. Separate scenarios were presented considering the long-term survival of
post-HSCT patients and were found to have a major impact on the results. The base-case ICER of £102,281
per QALY gained was subsequently reduced to £51,169 if post-HSCT survival was assumed to be 2 years and
to £25,523 if normal life expectancy was assumed in patients who survived for > 1 year (i.e. cure at 1 year).
Implications for model conceptualisation
The systematic and pragmatic searches highlighted a number of potential implications for our evaluation.
Within existing studies, it is clear that the main benefit of existing treatments has been related to their
ability to provide a ‘bridge’ to HSCT. The primary factor determining cost-effectiveness in the reviewed
literature was the increased likelihood of receiving HSCT with a new treatment and the associated
assumptions made regarding subsequent health gains associated with transplantation. Only a limited
survival gain was attributed to patients who did not subsequently receive HSCT, such that none of the
treatments reviewed appeared to be cost-effective as a palliative option.
The key structural assumptions employed within these studies were the potentially curative effect of HSCT
and the short life expectancy assumed for the comparator treatments (best supportive care/palliative
treatment alone) derived from historical controls. The majority of studies assumed a ‘cure point’ associated
with HSCT, although the timing was different across studies. The ‘cure point’ was assumed to represent
the time at which patients are assumed to no longer be at risk of disease relapse. The study by Costa
et al.182 assumed that at 5 years post transplantation the patient will be free of any procedural mortality
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risk or any risk of disease recurrence. In Lis et al.183 and the AWMSG appraisal of nelarabine185 this cure
point was assumed to be 2 years after HSCT, whereas in the AWMSG appraisal of clofarabine171 the
cure point was assumed to be 1 year after HSCT.
The studies also differed in the assumptions made concerning subsequent survival after the ‘cure point’.
Costa et al.182 acknowledged that long-term ALL survivors are likely to be subject to significant
comorbidities over their remaining lifetime despite being leukaemia free. To account for the impact of
comorbidities, an assumption was made that the long-term survival of ALL patients would be 50% less
than that in the general population. The authors acknowledge that this was an arbitrary adjustment
because of the lack of data on the long-term mortality rate in long-term survivors of ALL reported at the
time. In contrast, the study reported by Lis et al.183 and the clofarabine submission171 effectively assumed
no additional comorbidities (i.e. beyond those experienced by the general population) beyond the ‘cure
point’. Hence, patients were subsequently assumed to return to the age-adjusted mortality risk and utility
of the general population. The AWMSG raised concerns that, not only was this assumption insufficiently
justified but, also, the model was very sensitive to changes in the long-term survival probability.
In the absence of RCT data, each model incorporated historical control data as the basis to inform
outcomes associated with the comparator (best supportive care, palliative care and clofarabine within a
scenario for the submission for nelarabine).171,185–187 However, insufficient details were reported regarding
the source of the historical control data used and whether attempts were made to identify possible biases
or to formally account for potential confounding.
The existing cost-effectiveness literature is limited in ALL. No completed NICE appraisals of licensed
treatments for ALL were identified. Furthermore, of the studies published, none was reported in sufficient
detail to provide a suitable basis for informing the exemplar application. In the absence of previous NICE
appraisals or sufficient reporting within existing publications, the development of a de novo model to
inform the exemplar application was considered necessary. Full details of this are reported in the
next chapter.
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Chapter 7 The exemplar economic model
Overview
There are several distinct issues and challenges relating to the modelling of costs and outcomes that arise
from the separate TPPs:
1. In the bridge to HSCT TPP, the primary health benefits of treatment are gained by enabling more
patients to successfully undergo HSCT, an established intervention that has known curative potential.
For economic modelling purposes it may therefore be desirable to introduce a structural link between
HSCT and overall treatment benefit (i.e. survival) in the model. The introduction of a link between a
potential established surrogate outcome or process and final health benefits also enables the use of
evidence external to the CAR T-cell evidence sets (i.e. survival post HSCT). This structural link may also
provide decision-makers with greater confidence surrounding the modelled health benefits of treatment
for survival, given that model projections would depend largely on the established benefits of HSCT.
In terms of decision uncertainty, this approach would also mean that the uncertainty surrounding the
cost-effectiveness of CAR T-cell therapy is partly determined by the maturity and sample size of the
evidence sets and partly by the maturity, sample size and acceptability of external evidence obtained
from other sources.
2. In the curative intent TPP, the case for introducing a structural link between final health benefits and a
surrogate outcome or process such as HSCT is more limited than in the bridge to HSCT case, given that
it is primarily CAR T-cell therapy itself that is expected to provide the curative benefits. In this context, it
may be more appropriate to model long-term outcomes through the direct extrapolation of EFS and OS
data from the CAR T-cell trial evidence sets, as opposed to modelling long-term outcomes through a
separate surrogate process. In this case, the decision uncertainty surrounding the cost-effectiveness of
treatment would be determined solely by the maturity and sample size of data from the evidence sets.
Patient population
In this evaluation we assessed the cost-effectiveness of CAR T-cell therapy in the treatment of children and
young adults with two or more relapses or refractory ALL. The baseline demographic characteristics of this
patient group are summarised in Table 12.
Comparator
The comparator treatment to CAR T-cell therapy was defined as standard of care. In the base case, the
standard of care treatment was assumed to be clofarabine. The mean cost for a course of clofarabine
treatment is approximately £43,200 per patient.171
As part of a separate sensitivity analysis, the standard of care treatment was assumed to be FLAG-IDA. The
mean cost for a course of FLAG-IDA treatment is approximately £3803 per patient (see Administration and
monitoring costs).
TABLE 12 Baseline characteristics of patients
Scenario Characteristic Parameter Source/application
Bridge to HSCT Mean baseline age (years) 14.0 Lee et al.164
Female (%) 33
Curative intent Mean baseline age (years) 14.0 Maude et al.165
Female (%) 40
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Model development
The approaches to modelling the cost-effectiveness of CAR T-cell therapy varied between the separate
scenarios. Therefore, two de novo decision models were developed and used to assess the
cost-effectiveness of CAR T-cell therapy across the two scenarios:
1. bridge to HSCT model – based on a landmark responder model consisting of two related
decision models:
i. a short-term decision tree to predict the remission and transplant status of the population in the
immediate period following CAR T-cell or comparator therapy
ii. a series of partitioned survival (or area under the curve) models to predict the longer-term survival of
patients conditional on remission and transplant status
2. curative intent model – based on a simple three-state (alive and event free, alive post event, dead)
partitioned survival model.
The two models share a number of common features, which are outlined in Table 13.
Further details specific to each of the two model structures are reported in the following sections.
Bridge to haematopoietic stem cell transplantation scenario
Key structural assumptions
The bridge to HSCT model consists of a decision tree model (days 0–56) and a series of partitioned
survival models (day 56 to lifetime) that, when combined, provide an estimate of the lifetime costs and
effectiveness of treatment in ALL. An illustration of the structure of the model is provided in Figure 3.
The short-term decision tree component of the model consists of three chance nodes that represent a
series of clinically relevant events that may occur during the first 56 days (2 months) of treatment:
1. remission status at day 28 (remission, no remission or death)
2. MRD status at day 28 (negative or positive)
3. transplantation status at day 56 (HSCT or no HSCT).
TABLE 13 Key common features of the de novo economic models
Factor Chosen values Justification
Time horizon Lifetime horizon (up to a
maximum age of 100 years)
Necessary to capture the potential lifetime impacts of
short-term and potentially ongoing mortality benefit
Cycle length 1 month Sufficient length to capture relevant transitions in the model
Mid- or half-cycle
correction
Mid-cycle correction employed To guard against over- or under-predicting state occupancy in
the model
Measure of health
effects
QALYs In accordance with the current NICE reference case for
cost-effectiveness.122 Necessary to quality short-term and
potentially ongoing mortality benefits and associated adverse
events
Discounting 3.5% for costs and health
effects over the lifetime horizon
In accordance with the current NICE reference case.
Alternative discounting rates explored using sensitivity analysis
Perspective NHS/PSS In accordance with the current NICE reference case
PSS, Personal Social Services.
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These events are considered to be prognostic of the duration and quality of life of patients with ALL and
were therefore included in the model to link short-term measures of trial efficacy to longer-term health
outcomes. The three nodes of the decision tree are sequenced in the order of remission, MRD status and
transplantation status.
At the first chance node, the hypothetical cohort are distributed across three states: remission, no
remission or death. In the model, remission is defined using the criteria applied in the CAR T-cell and
clofarabine clinical trials.164,178 CR is defined as < 5% marrow blasts by flow cytometry, an absence of
circulating blasts and no extramedullary sites of disease with an absolute neutrophil count of ≥ 1000/µl
and a platelets count of ≥ 100,000/µl. In accordance with both the Lee et al.164 study and the Jeha et al.178
study, remission status is determined at day 28 (month 1) of the simulation.
At the second chance node, patients with remission are reassigned to one of two states: remission and
MRD negative or remission and MRD positive. A MRD-negative status is defined as < 0.01% marrow blasts
and a MRD-positive status is determined by marrow blasts of between 0.01% and 5% (at > 5% patients
are no longer in remission).
At the third and final node (day 56), all patients are assigned to states corresponding to the use of HSCT
(HSCT vs. no HSCT). The final determination of health status (remission – MRD – HSCT) was assumed to
occur at day 56 (month 2) of the simulation. This time period was chosen based on the mean time from
CAR T-cell therapy to HSCT estimated from data reported in the study by Lee et al.164 (mean 54 days, 95%
CI 45 to 77 days).
At the end of the decision tree phase, the cohort is assigned to six mutually exclusive states (presented in
order of best prognosis):
1. HSCT – remission and MRD negative
2. HSCT – remission and MRD positive
3. HSCT – no remission
4. no HSCT – remission
5. no HSCT – no remission
6. death.
After day 56, the long-term survival of the cohort is modelled through a series of related partitioned
survival models (see Figure 3) that are used to model the long-term outcomes of treatment (day 56 to
lifetime). The model includes four distinct partitioned survival models that are used to evaluate survival in
the following groups:
1. HSCT – remission and MRD negative
2. HSCT – remission and MRD positive
3. HSCT – no remission
4. no HSCT.
Haematopoietic stem cell transplantation recipients with MRD-negative status prior to transplantation are
assumed to have the best prognosis in terms of long-term survival. An increasing level of marrow blasts is
assumed to be associated with a lower probability of long-term survival, such that HSCT recipients with
MRD-positive status have (on average) a worse survival prognosis than MRD-negative patients. HSCT
recipients who fail to achieve remission prior to transplantation are assumed to have the poorest prognosis
of all HSCT patients.
For patients who did not receive HSCT, the probability of OS was significantly lower than for HSCT patients.
It was assumed that CR was not associated with improved probabilities of survival in non-HSCT patients.
This assumption was made on the basis that in the bridging scenario it is through HSCT (and not remission
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in the absence of HSCT) that meaningful gains in survival can be achieved. The impact of this assumption on
the results of the evaluation was tested in the one-way sensitivity analyses, in which it was assumed that
non-remission non-HSCT patients had an inferior survival prognosis to remission non-HSCT patients.
At year 5 of the simulation, those who were alive were subsequently assumed to be long-term survivors of
ALL. From this point forward, the cohort was considered to be effectively ‘cured’ of ALL and experienced
the mortality risk profile consistent with that of a long-term survivor of ALL. The mortality risks after year 5
were therefore modelled based on general population age- and sex-adjusted all-cause risks of mortality
adjusted for excess morbidity and mortality reported in cohorts of long-term survivors of ALL.188 The
approach is more formally described in Model development.
The model also included treatment-related adverse events. These include events such as CRS,
encephalopathy, hypotension, febrile neutropenia, neutropenia, anaemia, thrombocytopenia, leukopenia,
hypokalaemia and hypophosphataemia. The costs and consequences of these events were assumed to
occur at the start of the evaluation. As prolonged B-cell aplasia did not occur in the Lee et al.164 study, the
costs and consequences of this were not included within the bridge to HSCT scenario. The key structural
assumptions applied in the model are outlined in Table 14.
Clinical justification for the structure of the model
The conceptual structure of the bridge to HSCT model is based on an assumed relationship between HSCT
use and final clinical benefits and the assumption that the effectiveness of HSCT is dependent on MRD
status prior to transplantation.
TABLE 14 Summary of the key modelling assumptions in the bridge to HSCT responder model
Input Assumption
Surrogate relationship between
MRD status and HSCT
A lower marrow blast status prior to transplantation (as captured through MRD status)
is associated with a higher probability of experiencing sustained remission and
long-term survival benefits in ALL
HSCT All HSCT events were assumed to occur at day 56 of the simulated time horizon. No
further HSCT events were permitted after this point
Survival during the first 5 years
of the evaluation time horizon
Survival post HSCT was modelled based on the constant transition probability. There is
no difference in survival between remission non-HSCT patients and non-remission
non-HSCT patients
Survival after the first 5 years of
the evaluation time horizon
All patients alive at 5 years post HSCT are considered to be long-term survivors of the
disease. Long-term survivors of ALL experience excess morbidity and mortality
compared with the general population
Treatment/retreatment In the base case it was assumed that each patient would receive a single full course of
therapy. Retreatment with CAR T-cell therapy or standard of care therapy was not
permitted in the base case but was considered in the sensitivity analysis
Treatment effect Compared with standard of care therapy, CAR T-cell therapy improves the probability
of remission, the probability of a MRD-negative status and the probability of successful
HSCT. The clinical parameter estimates used to inform the models and TPPs can be
generalised to the UK NHS
Patient follow-up After HSCT, patients receive ongoing care and rehabilitation up to 2 years post HSCT.
Patients who do not receive HSCT are assumed to require hospitalisation prior to death
Adverse events Treatment-related adverse events were considered in the evaluation and included
events such as CRS, the incidence of which is expected to increase with the use of
CAR T-cell therapy. The costs and health consequences of adverse events were
accrued at the start of the evaluation
HRQoL Patients who achieve remission status are assigned a higher utility weight than patients
who do not achieve remission. Transplantation is associated with a one-off decrement
to HRQoL
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Allogeneic HSCT is a potentially curative treatment option in patients with ALL. However, the long-term
benefits of HSCT are uncertain, with some patients experiencing long-term benefits, including the effective
cure/suppression of ALL, and other patients experiencing relapse and/or mortality shortly after transplantation.
In this evaluation, survival benefits are established through remission and MRD status prior to HSCT.
Several studies have investigated the relationship between remission/MRD status prior to HSCT and the
long-term outcomes of HSCT therapy.110,111,189 These studies have shown, to varying degrees, that MRD
status prior to HSCT appears to be an important prognostic determinant of long-term RFS and OS,
with MRD-negative (< 0.01% marrow blasts) patients experiencing superior survival compared with
MRD-positive (> 0.01% to 5% marrow blasts) patients, including within studies of children with relapsed
ALL. These data support the assumption of a continuous relationship between MRD level prior to HSCT
and 5-year survival probability.
For patients who do not receive HSCT, the long-term outcomes of treatment are generally poor. In the
study by von Stackelberg et al.,160 the median survival in refractory patients who failed to respond to
induction therapy and who went on to receive palliative care was 89 days (equivalent to 3.17 months).
In the model, it was assumed that all patients who did not receive HSCT (including remission and non-remission
patients) went on to receive palliative care, having exhausted all treatment strategies that may be curative.
Remission status was not considered to be prognostic of survival in the non-HSCT population, such that
non-HSCT patients who achieved remission were assumed to be at the same risk of mortality as non-HSCT
patients who failed to achieve remission. However, as discussed later in Model inputs: utilities, all patients
with remission were assigned an improved health utility compared with those who failed to achieve remission.
These benefits were, however, assumed not to extend to improved life expectancy.
In previous economic evaluations in ALL (reviewed in Chapter 6), it had been assumed that survivors of ALL
experience the same mortality risk profile as that of the general population. This assumption implies that
there is no excess mortality or morbidity risk associated with their previous illness. This assumption is not
supported by the published literature, which generally reports excess mortality and morbidity among the
long-term ALL survivor population compared with match-adjusted individuals without ALL (i.e. siblings).190,191
In the model, the risk of mortality assigned to survivors of ALL was set equal to the general population
background all-cause mortality risk profile, with an adjustment for an increased mortality risk among
survivors of ALL.
The point at which patients were assumed to be long-term survivors of ALL (5 years) was based on the
definition used in a number of published studies reporting long-term survival data in ALL. None of these
studies provides an explicit rationale for selecting 5 years as the cure point and, to our knowledge, there
appears to have been no published attempts to empirically justify the widespread use of the 5-year cure
point. However, across a number of studies, the KM curves for post-HSCT survival appear to stabilise within
the 5-year time frame, such that the curve becomes flat and the incidence of death reduces to near zero.
Efficacy parameter estimates
In the decision tree component of the model, the data for remission, MRD and HSCT status of the
modelled cohort were derived from the separate evidence sets reported in Chapter 5 (see Bridge to
haematopoietic stem cell transplantation target product profiles). The key assumptions required to
generate the estimates for the evidence sets are outlined in Table 15. A continuity correction was applied
to particular estimates to take account of the low numbers (e.g. when 0 events were recorded) in the
probabilistic analysis.
Figure 4 presents the proportion of patients occupying each state at the end of the decision tree model.
The model predicts that 48% of patients receiving CAR T-cell therapy and 15% of patients receiving
standard of care treatment will receive HSCT. All patients who underwent HSCT following CAR T-cell
therapy were assumed to have a MRD-negative status. In contrast, most patients who underwent HSCT
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after receiving clofarabine had not achieved remission (11.5%) prior to transplantation, with only a small
proportion of patients receiving HSCT after CR (1.6% MRD negative, 1.6% MRD positive).
With the structural link included within the model, it was necessary to use external data rather than the
evidence sets themselves for the purposes of extrapolation and estimating lifetime mortality. This was
necessary because the existing survival data for CAR T-cell therapy were not reported in terms of being
conditional on remission, MRD or HSCT status. Hence, the parameter estimates for the partitioned survival
analyses were sourced from two external studies: Leung et al.111 for the post-HSCT survival probabilities
and von Stackelberg et al.160 for the non-HSCT survival probabilities. A summary of the survival rates is
provided in Table 16.
In the base case it was assumed that all transplant recipients in remission and with a MRD-negative status
prior to HSCT reverted to the same mortality rates as seen in long-term survivors of ALL, from the time
point of HSCT. Employing this assumption, as opposed to using the data reported in Leung et al.111 for
this population, provided a more consistent prediction of survival data from Lee et al.,164 in which it was
reported that all 10 HSCT recipients with a MRD-negative status were leukaemia free and alive at the end
of study follow-up.
Transplant recipients in remission and with a MRD-positive status were assumed to have an inferior
long-term survival prognosis compared with those who were MRD negative. Similarly, recipients who failed
to respond to therapy were assumed to have an inferior long-term prognosis compared with those who
responded (including MRD-positive and MRD-negative recipients). Parameter estimates were obtained from
Leung et al.111 and were modelled assuming an exponential distribution for time to death.
The Leung et al.111 data were used in the base-case analysis as this was the only study identified in the
literature review that reported post-HSCT survival in patients who failed to achieve remission (marrow
blasts > 5.0%). The parameter estimate for no-remission HSCT patients forms an important part of
predicting the long-term survival benefits of standard of care therapy, as approximately 11% of the
standard of care population underwent HSCT, despite having failed to achieve CR (vs. 0% of the CAR
T-cell trial population).
For patients who do not receive HSCT (including remission and non-remission patients), long-term survival
was modelled using data from von Stackelberg et al.160 A series of parametric survival functions was fitted
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to estimates of patient-level data generated from the published KM curve. According to goodness-of-fit
statistics, the best-fitting distribution was the log-normal. However, when the function was applied in
the model, the predicted OS for the total CAR T-cell and standard of care populations became visibly
disjointed, with the risk of mortality in the decision tree phase being significantly greater than the risk
being applied at the start of the partition survival phase. Consequently, there was an uncharacteristic
‘plateau’ in the modelled survival curve between day 56 (month 2) and day 84 (month 3). This plateau
effect was caused by an initially low probability of death predicted from the von Stackelberg et al.160 data.
Because of the implausible nature of the survival curve, an alternative survival distribution for von Stackelberg
et al.160 was selected in the base case. To be consistent with the approach used in modelling post-HSCT
survival,111 the exponential distribution was chosen for the base-case analysis. The mean time to death with
the exponential function was 0.35 years, which is consistent with the mean time to death estimated using
the log-normal distribution (0.34 years).
The validation of the responder model in predicting the outcomes of the Lee et al.164 and Jeha et al.178
studies was assessed by comparing the predicted survival probabilities from the model with the KM data
extracted from these studies. As shown in Figure 5, the final model appears to provide an accurate
prediction of reported survival for both CAR T-cell therapy and the comparator.
The background all-cause mortality risks were obtained from the interim life tables published by the
UK ONS.188 The ONS data report annual all-cause mortality rates by sex and age (yearly increments from
0 to 100 years). A sex-averaged mortality risk was derived based on a cohort that was 33.3% female
(n = 7/21).164 An adjustment factor for excess mortality in ALL survivors was also incorporated and modelled
using data from MacArthur et al.191 [standardised mortality ratio (SMR) 9.1, 95% CI 7.8 to 10.5]. These data
were combined using the following equation:
TP(age) = 1− e − MR(female,age) × P(female) +MR(male,age) × P(male)
 
× 112 × SMR
 
, (1)
where TP(x) is the monthly transition probability for the cohort with average age x, MR(y, x) is the ONS
all-cause mortality rate for sex y and average age x, P(y) is the proportion of the cohort with sex y, and
SMR is the SMR for long-term ALL survivors compared with the general population. The factor of 1/12 was
included to convert the annualised mortality rates from the ONS to monthly rates, and probabilities, for use
in the model. The mortality risk was assumed to remain constant within each year of the cohort’s age.
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Curative intent model
Structural assumptions
A simple three-state partitioned survival model was developed to assess the cost-effectiveness of CAR T-cell
therapy used with curative intent. The three health states included in the model were alive and event free,
alive with relapsed disease and death. An illustration of the structure of the model is provided in Figure 6.
The health state of alive and event free included all patients who either had stable disease or had
responded to therapy. The health state of alive with relapsed disease included patients who had failed
induction therapy, had relapsed after previously responding to treatment or had developed second
malignancies. This definition is based on the criteria used in the UK ALL study.115
State occupancy in the model was derived using the partitioned survival technique. This involved the direct
extrapolation of EFS and OS curves, which were then used to estimate the proportion of patients occupying
each of the three states using the following equations:
alive and event free (t) = P(EFS, t), (2)
alive with relapsed disease (t) = (P(OS, t)− P(EFS, t), (3)
death (t) = 1− P(OS, t), (4)
where P(event,t) is the cumulative survival probability for the event at time t.
Data on EFS were not available from either the CAR T-cell164 or the clofarabine178 studies. In the absence of
data, the EFS curve was derived from the available OS data, through assuming a proportional relationship
between EFS and OS. This relationship is justified on the basis that EFS is highly correlated with OS as it
includes death prior to recurrence.
In the short term it was assumed that the cumulative hazard function for EFS would be proportional to
the cumulative hazard function for OS. This was modelled based on data from the UK ALL study.115 The
proportional relationship between EFS and OS is not expected to continue indefinitely, given the potential
for cure of disease and the expectation that after a finite period of time all patients alive in the simulation
would also be free of relapsed disease (EFS =OS). This is equivalent to saying that, at some point in
time, all patients who are alive are long-term survivors of ALL. Therefore, in the model, the proportional
relationship between EFS and OS was assumed to continue up to year 5 of the simulation (the assumed
point of ‘effective’ cure in ALL). After year 5, the cumulative survival probabilities for EFS were assumed to
be flat up to the point at which EFS is equal to OS. In all cases, EFS was always assumed to be less than or
equal to OS to avoid a negative number of patients being assigned to the relapsed disease state.
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FIGURE 6 Illustration of the partitioned survival model structure. (a) Illustration of the state structure; and
(b) illustration of partitioned survival.
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In common with the bridge to HSCT scenario, at year 5 of the simulation, those who were alive in the
curative intent model were also subsequently assumed to be long-term survivors of ALL. From this point
forward, the cohort was considered to be effectively ‘cured’ of ALL and experienced the mortality risk
profile consistent with a long-term survivor of ALL. The mortality risks after year 5 were also modelled
based on general population age- and sex-adjusted all-cause risks of mortality adjusted for excess
morbidity and mortality reported in cohorts of long-term survivors of ALL.
The model evaluation also included the costs and consequences of treatment-related adverse events,
which included CRS and B-cell aplasia, whose occurrence is specifically associated with CAR T-cell therapy.
Other events captured in the model include encephalopathy, hypotension, febrile neutropenia, neutropenia,
anaemia, thrombocytopenia, leukopenia, hypokalaemia and hypophosphataemia. All events, with the
exception of B-cell aplasia, were assumed to occur at the time of treatment initiation and to resolve within
the first year of therapy. The cost–consequences of these events were therefore captured at the start of
the evaluation.
The occurrence of B-cell aplasia in patients treated with CAR T-cells is an expected consequence of CAR
T-cell therapy and is linked to the proliferation of CAR T-cells and the associated durability of the clinical
effect. Consequently, for some patients, treatment of B-cell aplasia is expected to persist beyond the first
year post CAR T-cell therapy. To capture this in the model, a series of survival models was fitted to data on
the time to CD19 positivity or relapse reported in Maude et al.165 and used to predict the proportion of
patients requiring treatment for B-cell aplasia. The primary assumptions made in the curative intent model
scenario are summarised in Table 17.
Efficacy parameter estimates: partitioned survival model
The primary data sources for OS in the curative intent model were the same imputed patient data used to
derive the evidence sets reported in Chapter 5 (see Curative intent target product profiles). Each separate
evidence set was then analysed using parametric survival modelling to inform the 5-year survival estimates
and projections applied within the cost-effectiveness analyses. The parametric analyses were undertaken
using the FlexSurv package in the statistical programming platform R (version 3.0.2).
TABLE 17 Summary of key modelling assumptions: curative intent scenario
Input Assumption
Survival during the first 5 years Survival was modelled based on a weighted average survival distribution
Survival after the first 5 years All patients alive at 5 years are considered to be long-term survivors of the disease.
Long-term survivors of ALL experience excess morbidity and mortality compared with
the general population
Treatment/retreatment In the base case it was assumed that all patients received a single full course of therapy.
Retreatment with CAR T-cell therapy or standard of care therapy was not permitted in
the base case, but was considered in the sensitivity analysis
Treatment effect Treatment with CAR T-cell therapy is assumed to lead to an increase in the number of
patients achieving a sustained cure for ALL and therefore extend the life expectancy of
patients with ALL. The clinical parameter estimates used to inform the models and TPPs
can be generalised to the UK NHS
Adverse events Treatment-related adverse events were considered in the evaluation and included CRS
and B-cell aplasia. The costs and health consequences of all adverse events except B-cell
aplasia were accrued at the start of the evaluation. The costs of B-cell aplasia were
modelled by estimating the probability of patients having B-cell aplasia over time, using
data from Maude et al.165
HRQoL Patients who are event free are assigned a higher utility weight than patients who have
relapsed disease. Transplantation is associated with a one-off adjustment to utilities
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A series of survival distributions was considered in the analysis, including exponential, log-normal, Weibull
and Gompertz. Because of the potential curative nature of CAR T-cell therapy (and therefore the potential
for an unconventional hazard function), a series of flexible cubic spline models was also considered in the
analysis. The cubic spline models were based on those developed by Royston and Parmar.192 Cubic spline
models expressed on the proportional odds scale were used as they appeared to converge to an optimised
solution more frequently than the proportional hazards or probit variants of the cubic spline model.
A series of one-, two-, three- and four-knot spline models was considered. The knots were evenly
distributed across the time scale of the study, as per the default settings for the FlexSurv package in R.
Separate curves were fitted to the hypothetical CAR T-cell data and the comparator data to allow both the
shape and the scale of the distribution to vary between these. Alternative options include fitting proportional
hazards models to a data set containing both treatments and including a covariate in the regression for
treatment assignment. This alternative approach was not considered here, given that an earlier assessment
of the validity of the proportional hazards assumption illustrated that this assumption may not consistently
hold across all evidence sets.
Within cost-effectiveness studies it is common practice to use a single survival distribution in the base-case
analysis. This is chosen based on goodness-of-fit statistics, the fit of each distribution to the KM curves and
the clinical plausibility of subsequent model projections over the full time horizon. However, it is unlikely
that a single survival distribution can adequately characterise uncertainties over the longer-term extrapolation
period. The robustness of the ICER estimates to alternative distributions can be considered within separate
sensitivity analyses or scenarios. However, transparency concerns may exist regarding this approach if their
weighting is not explicitly specified in subsequent policy decisions.
To more formally account for the uncertainty surrounding choice of survival distribution, a model-averaging
approach was adopted using the methods outlined in Jackson et al.193 This technique involves the
parameterisation of uncertainty surrounding the choice of distribution through including all plausible
survival functions as part of a weighted distribution and sampling both the parametric uncertainty
associated within each distribution and the uncertainty (or weights) surrounding the choice of preferred
method. Through the probabilistic analysis, it is therefore possible to estimate the joint distribution of
uncertainty around the parameter estimates and the choice of survival function.
Each model is assigned a weight that represents the adequacy of that distribution in predicting the lifetime
survival of the modelled cohort in comparison to all other distributions considered in the model. There are
a number of measures of model adequacy that can be considered. Examples include statistical adequacy
measures such as the Akaike information criterion (AIC) and Bayesian information criterion and expert
judgement. The weights considered in this evaluation were based on AIC scores. As outlined in Jackson
et al.,193 the AIC value reported from each survival distribution was converted to a probability weight (wk)
using the following equations:
Ak = e(−0:5×AIC), (5)
wk =
Ak
Σ Ak
. (6)
The weighted distribution was then applied in the base-case analysis. Different model weights and parameter
estimates were considered across the three different data sets, as outlined in the following sections.
Minimum data set
A summary of the goodness-of-fit statistics for each distribution fitted to the imputed survival data across
each of the evidence sets is provided in Table 18.
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According to the AIC statistic, the distribution with the best goodness of fit to the CAR T-cell data was the
spline model with a single knot (AIC = 121.02), followed by the spline model with two knots (AIC = 122.97).
The spline model with a single knot was assigned the highest single weight of 60.1% and was followed by
the two-knot (22.7%), three-knot (8.5%) and four-knot (4.0%) spline configurations. A visual comparison
of the survival data based on the weighted distribution and several single distributions is reported in
Figure 7.
Because of the limited maturity in the minimum data set, there was considerable variation in the predicted
long-term survival of the modelled cohort, as shown by the spread of survival trajectories in Figure 7.
Although the ‘best-fitting’ spline models appeared to generate a robust fit to the data over the first 3
months of the study, the functions were not able to accurately predict the tail of the distribution. In this
case, the ‘best-fitting’ model underestimated the KM probabilities from month 18 of the simulated time
horizon. The weak fit of the model to the tail of the KM curve is partly driven by the limited data available
to support the continued flattening of the curve. As shown in the following section, with additional data
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FIGURE 7 Plot comparing fit of weighted distribution and key single distributions to CAR T-cell data: curative
intent scenario.
TABLE 18 Summary of goodness-of-fit statistics and weights for survival distributions: minimum set
Distribution
CAR T-cell therapy Standard of care
AIC AIC-based weight (%) AIC AIC-based weight (%)
Exponential 127.91 1.9 302.15 0.1
Weibull 129.88 0.7 303.31 0.0
Gamma 129.91 0.7 304.09 0.0
Gompertz 139.21 0.0 303.01 0.0
Log-normal 128.70 1.3 291.00 13.8
Spline with a single knot 121.02 60.1 288.65 44.6
Spline with two knots 122.97 22.7 290.41 18.5
Spline with three knots 124.93 8.5 291.32 11.7
Spline with four knots 126.44 4.0 291.42 11.2
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maturity, the parametric models tend to provide a better prediction of the tail of the KM curve as there are
more data to support the long-term flattening of the survival curve.
In the standard of care group, the distribution with the optimal predictive validity as judged using the AIC
was also the spline model with a single knot (AIC = 288.65). A weight of 44.6% was assigned to the
spline model with a single knot, followed by weights of 18.5% for the spline model with two knots and
13.8% for the log-normal model. A visual comparison of the survival data based on the weighted
distribution and several single distributions is reported in Figure 8.
Intermediate and mature data sets
Summaries of the goodness-of-fit statistics and weights are reported for the intermediate and mature
evidence sets in Tables 19 and 20, respectively.
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FIGURE 8 Plot comparing fit of weighted distribution and key single distributions to standard of care data: curative
intent scenario.
TABLE 19 Summary of goodness-of-fit statistics and AIC-based weights for survival distributions: intermediate set
Distribution
CAR T-cell therapy Standard of care
AIC AIC-based weight (%) AIC AIC-based weight (%)
Exponential 157.43 0.0 345.45 0.0
Weibull 147.51 0.0 329.54 0.0
Gamma 148.64 0.0 337.70 0.0
Gompertz 161.81 0.0 343.38 0.0
Log-normal 143.41 0.0 308.08 0.1
Spline with a single knot 125.18 61.2 296.00 56.0
Spline with two knots 126.95 25.3 298.08 19.7
Spline with three knots 128.84 9.8 299.58 9.4
Spline with four knots 130.84 3.6 298.66 14.8
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The additional maturity of the data in these evidence sets and the superior AIC statistics associated with
the flexible spline models resulted in none of the standard distributions being assigned a weight > 0.1%.
The different levels of precision resulted in small differences in the weights assigned to the spline models
across the intermediate and mature evidence sets.
Visual comparisons of the survival data based on the weighted distribution and several single distributions
are reported in Figure 9.
In comparing across evidence sets, the survival models fitted to the intermediate and mature evidence sets
appear to have a shallower slope than those fitted to the minimum evidence set, resulting in a longer tail
to the predicted survival curves. This is driven by the assumption that in the more mature evidence sets
there is greater certainty over the ‘curative’ benefit of treatment because of additional evidence on patient
survival up to month 60 of the hypothetical evidence set (vs. maximum survival of approximately 24 months
in the minimum data set). This is broadly equivalent to saying that, in the intermediate and mature evidence
sets, there is greater certainty over the flattening of the KM curve.
When comparing across competing survival models, the intermediate and mature evidence sets are also
associated with a more consistent set of survival projections than the minimum data set. This leads
to a narrower range of potential survival probabilities being predicted at later time points in both the
intermediate data set and the mature data set. Therefore, unlike the bridge to HSCT model, additional
evidence maturity in the curative model leads to a different projection of survival benefit, as well as
impacting on the parametric uncertainty surrounding model extrapolations.
There are slight differences in the survival curves predicted from the intermediate and mature evidence sets
because of differences in the weights applied to different functions. These differences cannot be clearly
seen on the plots as the difference in weights is marginal. The key difference between these evidence sets
is the additional sample size assigned to the mature data set, which primarily impacts on the uncertainty/
precision surrounding survival estimates, which is not shown on these plots.
Adverse events: B-cell aplasia
A series of survival models was fitted to data on the time to CD19 positivity or relapse reported in Maude
et al.165 and used to predict the proportion of patients requiring treatment for B-cell aplasia. The best-fitting
distribution was the Weibull distribution.
TABLE 20 Summary of goodness-of-fit statistics and AIC-based weights for survival distributions: mature set
Distribution
CAR T-cell therapy Standard of care
AIC AIC-based weight (%) AIC AIC-based weight (%)
Exponential 312.85 0.0 688.89 0.0
Weibull 291.02 0.0 655.07 0.0
Gamma 293.28 0.0 671.39 0.0
Gompertz 339.75 0.0 644.99 0.0
Log-normal 282.81 0.0 612.15 0.0
Spline with a single knot 244.36 60.3 586.00 34.0
Spline with two knots 245.89 28.0 588.17 11.5
Spline with three knots 247.65 11.7 589.17 7.0
Spline with four knots NA NA 585.32 47.6
NA, not applicable.
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FIGURE 9 Plot comparing fit of weighted distribution and key single distributions to KM curves across the data
sets: curative intent scenario. (a) CAR T-cell therapy minimum data set; (b) standard of care minimum data set;
(c) CAR T-cell therapy intermediate/mature data set; and (d) standard of care intermediate/mature data set.
(continued )
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The accuracy of the partitioned survival model in predicting the outcomes of the Maude et al.165 and Jeha
et al.178 studies was assessed by comparing the predicted survival probabilities from the model with the KM
data. As shown in Figure 10, the final models appear to provide an accurate prediction of the extracted
KM curve for OS in both studies.
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FIGURE 9 Plot comparing fit of weighted distribution and key single distributions to KM curves across the data
sets: curative intent scenario. (a) CAR T-cell therapy minimum data set; (b) standard of care minimum data set;
(c) CAR T-cell therapy intermediate/mature data set; and (d) standard of care intermediate/mature data set.
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FIGURE 10 Model prediction (lines) vs. extracted KM curves (markers) of OS in all patients across the three evidence
sets: (a) minimum data set; (b) intermediate data set; and (c) mature data set.
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Resource use and costs: bridge to haematopoietic stem cell
transplantation and curative models
The resource use and costs incorporated within each separate model were based on the following
components:
l treatment acquisition costs
l administration and monitoring costs
l adverse events
l HSCT
l long-term costs.
Treatment acquisition costs
Chimeric antigen receptor T-cell therapy
The complex nature of regenerative medicines and the treatment pathway makes it necessary to disentangle
the separate procedural elements of the CAR T-cell treatment process and to make assumptions concerning
those elements that would be included within the acquisition cost of the therapy itself and those that might
represent additional procedural costs that would need to be separately provided and funded by the NHS
itself.
Levine et al.145 summarises the CAR T-cell process as follows: separating the processes of leukapheresis,
conditioning chemotherapy and infusion from the transduction and expansion. We assumed the same
separation to represent those components of care that would be provided (and funded separately) by the
NHS and those that would be undertaken by the manufacturer and included within the acquisition cost of
CAR T-cell therapy. Hence, we assumed that the acquisition cost of CAR T-cell therapy would not include
the cost to the NHS of providing leukapheresis, conditioning chemotherapy or cell infusion and that these
are assumed to represent additional costs to the NHS.
In the absence of licensed products being available, there are currently no commercially available estimates
of the acquisition cost of CAR T-cell therapy. Informal sources have indicated that future acquisition
costs may be in the region of US$150,000–500,000.194 Within the exemplar, we have assumed that the
manufacturer would employ a value-based approach to pricing, such that the acquisition cost would be
set at a level such that the resulting cost-effectiveness (ICER) estimates would be close to NICE’s current
threshold range. In the context of the specific population considered, we have assumed that this would be
in line with the £50,000 per QALY estimate based on NICE’s current approach to treatments at the EoL.195
We subsequently explored the impact of alternative prices and payment schemes using separate scenarios.
Full details of the hypothetical prices assumed across the separate scenario are reported in Chapter 8.
The acquisition cost of conditioning therapy (£329.86) was estimated from the regimen used in the study
by Lee et al.,164 which was 25 mg/m2 per day of fludarabine on days –4, –3 and –2 and 900 mg/m2 per day
of cyclophosphamide on day –2.
The acquisition cost associated with clofarabine was derived from the AWMSG appraisal of clofarabine,171
which reported a cost of £43,200 per patient treated based on the average costs of the drug volumes
used in the CLO-212 study178 (based on 1.8 cycles of treatment, a patient body surface area of 1.2 m2 and
the licensed dose of 52 mg/m2/5-day treatment cycle).
The acquisition costs of FLAG-IDA were considered as part of a separate sensitivity analysis and were
estimated by applying unit costs from the British National Formulary196 to a dosing guide published by the
Royal Surrey NHS Trust.197 Assuming an average body surface area of 1.2 m2 and an average of 1.76 cycles
of treatment198 gives the estimate of £3809 per patient.
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Administration and monitoring costs
In addition to the acquisition costs, it is important to consider the resource use and costs associated with
administration and subsequent monitoring. All patients regardless of subsequent treatment are assumed to
require an initial non-elective hospitalisation. For clofarabine and FLAG-IDA it is assumed that the costs of
this hospitalisation also include all costs associated with the monitoring and administration of treatment.
For CAR T-cell therapy, the same initial hospitalisation is assumed to occur for the administration of the
conditioning therapy. However, because of the additional production period required to manufacture the
CAR T-cells (in the region of 11 days currently), an additional elective hospitalisation is also assumed during
which CAR T-cells are subsequently administered and the patient monitored. The cost of a single
leukapheresis procedure is also applied to CAR T-cell patients.
Table 21 reports these per-patient costs and the sources and associated assumptions.
TABLE 21 Model inputs: costs
Parameter Cost Source/assumption
1. Acquisition costs
1a. CAR T-cell therapy
Acquisition cost of CAR T-cell
therapy
Threshold analysis Threshold price analysis based on three approaches
detailed in the accompanying text
Conditioning therapy £329.86 per patient Acquisition costed directly from Lee et al.164 assuming
full use of 2 × 50-mg fludarabine vials and 1 × 500-mg
and 1 × 1-g vials of cyclophosphamide and a body
surface area of 1.2 m2;198 infusion costs assumed
included in CAR T-cell therapy administration costs
1b. Clofarabine
Acquisition cost of clofarabine £43,200 per patient Cost presented in AWMSG FAR for clofarabine,171
excluding costs of administration
1c. FLAG-IDA
Acquisition cost of FLAG-IDA £3808.57 per patient Cost per cycle estimated from the Royal Surrey NHS
Trust guide,197 average body surface area of 1.2 m2
and the average number of cycles of FLAG-IDA of
1.76198
2. Administration and monitoring costs
2a. CAR T-cell therapy
Leukapheresis £1627 per patient Weighted average of HRGs for stem cell and bone
marrow harvest199
Initial hospitalisation for
conditioning
£7179.99 HRG paediatric ALL admissions weighted average
non-elective long stay199
Additional hospitalisation for
CAR T-cell treatment
£5831.72 HRG paediatric ALL admissions weighted average
elective inpatient199
2b. Clofarabine
Hospitalisation over treatment
period
£7179.99 HRG paediatric ALL admissions weighted average
non-elective long stay199
2c. FLAG-IDA
Hospitalisation over treatment
period
£7179.99 HRG paediatric ALL admissions weighted average
non-elective long stay199
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Adverse events
The individual costing of each adverse event for the alternative treatments could entail double counting,
as some aspects of these may already be included in the hospitalisation costs used for the administration
and monitoring costs of each treatment. Therefore, an assumption is made that all grade 3 and 4 adverse
events (except CRS and B-cell aplasia, as discussed below) require an extension of hospitalisation by 1 day,
with a cost based on the excess bed-day HRG cost as shown in Table 21.
For CRS, a combination of the acquisition cost of cytokine inhibitor drugs and the cost of an admission to
a paediatric intensive care unit is assumed for all cases of grade 4 or severe CRS.
B-cell aplasia is assumed to be treated with a regimen of IVIG, given at a dose of 0.5 g/kg every 4 weeks
until the patient is no longer in need of treatment (i.e. CD19 positivity, relapse or death). We assumed the
population treated to have an average weight of 49.5 kg. Rounding down of each dose to the nearest vial
in line with national prescribing recommendations201 (i.e. 20-g vial per dose), the cost per vial is estimated
as £850. In addition, an administration cost of £225 per dose is assumed.
TABLE 21 Model inputs: costs (continued )
Parameter Cost Source/assumption
3. Adverse events
CRS £2857.99 per patient per
grade 4 or severe CRS event
Combination of the drug cost (£1193 HRG for cytokine
inhibitor drugs) plus cost of ICU hospitalisation
(£1664.99 HRG weighted ALL advanced critical care
paediatric ICUs)199
B-cell aplasia £1075 per month per patient
for the first 3 months
Dose of 0.5 g/kg of IVIG every 4 weeks until the
patient is no longer in need of treatment (i.e. CD19
positivity, relapse or death)196
Febrile neutropenia £0 Assumed included in CRS costs
Encephalopathy £539.24 per patient per
adverse event
HRG paediatric ALL admissions weighted excess
bed-day non-elective inpatient stay199
Hypotension
Neutropenia
Anaemia
Thrombocytopenia
Leukopenia
Hypokalaemia
Hypophosphataemia
4. HSCT
Transplantation £89,879.15 per patient Weighted average of paediatric transplant HRGs,
elective inpatients only199
Follow-up costs £61,965 per living patient Sum of follow-up costs from UK Stem Cell Strategy
Oversight Committee report200 (< 6 months = £28,390,
6–12 months = £19,502, 12–24 months = £14,073).
In the model these will be included as time and OS
dependent
5. Long-term costs
Post non-HSCT population £7179.77 at point of death HRG paediatric ALL admissions weighted average
non-elective long stay199
Curative model population £7179.77 at point of
recurrence
HRG paediatric ALL admissions weighted average
non-elective long stay199
ICU, intensive care unit.
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Haematopoietic stem cell transplantation
Three potential sources of cost estimates of HSCT were identified and considered:
1. NHS reference costs.199 This provides estimates of completed HRG activity and unit costs across six
different paediatric allogeneic transplantation categories. Although intuitively appealing because of the
relevance to our population and UK context, concerns have been raised200 that these do not capture the
full cost of HSCT because of their focus on a single admission period.
2. London Specialised Commissioning Group report.202 This report estimated a national tariff for adult
blood and bone marrow transplants based on the phases of transplantation from decision to transplant
to 100 day post-transplantation follow-up care. However, no details are given on how the estimate was
derived. In addition, the estimate considers only an adult population.
3. UK Stem Cell Strategy Oversight Committee report.200 This report used the results from a Dutch study
published in 2002 that reported the cost of allogeneic adult unrelated bone marrow transplantation.
This estimate includes all initial costs of the transplantation as well as follow-up costs for up to 2 years
after the transplantation. The inclusion of the longer-term follow-up costs addresses the primary
concern around existing NHS reference costs. However, there is uncertainty about the generalisability of
the cost to the specific population considered here.
To take account of the limitations around each of the three data sources, the model combines estimates
from both the NHS reference costs and the UK Stem Cell Strategy Oversight Committee report. The
London Specialised Commissioning Group report was discounted because of a lack of detail on how the
estimate was derived.
The cost of HSCT is considered in two parts: (1) the cost of the procedure and associated hospitalisation
and (2) the cost of long-term care. Although all three sources provide an estimate of the cost of the
procedure, both the London Specialised Commissioning Group and the UK Stem Cell Strategy Oversight
Committee focus on adult populations. Existing HRG costs report a higher cost of the procedure for
paediatric patients, with paediatric HRG costs of between £21,622 and £74,434 more than the equivalent
adult HRG costs across the four different forms of allogeneic transplantation reported.199 Therefore, the
cost of the procedure has been estimated as the weighted average (by frequency of HRG) of all paediatric
allogeneic transplantations from the HRG costs.
As previously noted, the HRG costs include only the costs accrued during the admission in which the
transplantation occurred. Hence, any longer-term costs will not be included. To estimate the longer-term
costs, an estimate of post-transplantation costs from the UK Stem Cell Strategy Oversight Committee
report was used.200 No further adjustment was made to the estimate. In using this estimate the same
assumptions were made about the appropriateness of the original source of the costs.203 It was additionally
assumed that, unlike the cost of the procedure, long-term costs are independent of type of transplantation
and age of patient at the time of transplantation.
Model inputs: utilities
Literature review
A pragmatic approach was taken to identify potentially relevant sources for health utilities. Google and
Google Scholar were used to search for publicly available utility estimates, alongside a search of known
economic evaluations and HTA appraisals in ALL (see Appendix 7). The search focused on utility estimates
for children with ALL, regardless of treatment provided. Two systematic reviews of utility studies in
paediatric ALL were identified.204,205
Van Litsenburg et al.205 reviewed the measurement of HRQoL (used synonymously with utilities) in
paediatric patients with ALL using the Health Utilities Index (HUI). The study identified 15 studies reporting
utilities in this population using both HUI2 and HUI3. The van Listenburg et al.205 review has several issues
that limit its relevance to our model. First, no attempt was made to meta-analyse the results, with the
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review summarising only the individual utility estimates from each study. In addition, the results were
reported by phase of care, often focusing on specific time points in the treatment pathway rather than on
specific health states relevant to our modelling. Given the time constraints in our work, a more detailed
consideration of each study was not considered feasible.
Kelly et al.204 undertook a decision analysis of cranial radiation therapy for paediatric T-ALL patients,
including a systematic review of utility studies to inform this. Although the study focused on T-ALL, the
review of utilities did not stipulate type of ALL and hence included all forms of ALL. The study used existing
mapping functions to convert generic HRQoL measures [Short Form questionnaire-36 items (SF-36) and
Child Health Rating Inventories (CHRIs)] to preference-based utility estimates (HUI2 and EQ-5D). Of particular
relevance to our model were the states of ‘in the state of relapse’ and ‘cured after relapse’, with mean utility
estimates of 0.75 (range 0.44–1) and 0.91 (0.87–0.95), respectively.
In addition, the pragmatic search also identified a number of published economic evaluations that had
used utility estimates.171,182,183,185
Of the three AWMSG FARs related to ALL, one did not report any utility results from the manufacturer’s
submission (dasatinib).186 The clofarabine FAR171 reported that all patients who survived post 1 year after
HSCT were assumed to have the utility of the general population. All other states modelled were varied
between 0.2 and 1 as scenario analyses to demonstrate that the results were not sensitive to the utility
values of those who do not survive long term. The nelarabine FAR185 reported that non-responders and
untreated patients were assumed to have a utility of 0.64. This value was referenced from Health
Outcomes Data Repository data from patients with lymphoid leukaemia and, as such, represents patients
in secondary care. In addition, all patients who undergo successful transplantation were assumed to have a
utility of 0.92 based on the study by Sung et al.206
The study by Sung et al.206 considers physician-elicited estimates of utility for acute myeloid leukaemia
patients who have survived without recurrent disease post transplantation. Sung et al.206 additionally
present estimates of disutility (i.e. decrement associated with an event) associated with treatment with
chemotherapy and transplantation, estimated as 0.42 (plausible range 0.16–0.83) and 0.57 (plausible
range 0.31–0.87), respectively. No estimates of the duration of these disutilities are presented.
Similar to the study by Sung et al.,206 the economic evaluation of clofarabine for paediatric ALL conducted
by Lis et al.183 included an elicitation exercise involving physicians because of a lack of relevant utility
estimates available at the time. Lis et al.183 reported utility estimates for treatment with palliative care
(0.26), clofarabine without HSCT (0.34) and clofarabine with HSCT but surviving for < 1 year (0.48),
as well as for survival post HSCT for 1 year (0.80), 2 years (0.85) and beyond (0.88).
Although these values appear to be generally consistent with the results reported within the systematic
reviews, the magnitude of the treatment disutilities appears higher. It is plausible that this discrepancy may
be the result of the use of physician rather than patient utility elicitation.
Informing the model states
All model utility inputs applied in the model are summarised in Table 22.
Treatment disutilities
Because of a lack of literature on the short-term impacts on health utility associated with both chemotherapy
and HSCT, we based our estimates on the study by Sung et al.206 A decrement in utility of 0.57 for HSCT and
0.42 for all forms of chemotherapy was assumed. Both estimates were assumed to incorporate all short-term
adverse events associated with both treatments. However, Sung et al.206 failed to report any estimate of
duration associated with the estimated disutility for either treatment. Therefore, we assumed that disutilities
apply for 1 year post treatment initiation. As the disutility estimate for all forms of chemotherapy is the same
in both treatment arms, the impact will cancel out and was therefore excluded from our model.
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Adverse events
As discussed in the previous section, all HSCT and chemotherapy adverse events are assumed to be
incorporated in the treatment disutility estimates applied. The only additional adverse events to consider
are those specifically associated with CAR T-cell therapy. As discussed in the cost section, only CRS and
B-cell aplasia are expected to be associated with a potential additional burden not considered elsewhere
in the model. The pragmatic literature review was unable to find any specific estimates of disutility or
duration associated with either adverse event.
For severe (grade 4) CRS it was assumed that, because of the severity of initial onset of the event and
associated intensive care admission, a utility of 0 is incurred for 1 week. For B-cell aplasia, although there is
a large cost burden associated with its management, there is little evidence of any significant impact on
patient utility. In existing CAR T-cell studies, B-cell aplasia appears to be either well managed or short-lived,
with no reported cases of associated intensive care hospitalisation. Therefore, no disutility was assumed for
cases of B-cell aplasia.
Short-term health-related quality of life
The model considers the short-term response as either relapse or remission. The utility estimates to inform
these states were derived from the study by Kelly et al.,204 with a utility of 0.75 assigned to the relapse
state and 0.91 to the remission state.
Long-term health-related quality of life
Patients with the severe form of ALL considered in the model are likely to experience long-term
comorbidities associated with the disease and associated disutility. As such, the utility score estimated for
the state of remission was applied with an additional age-related decrement.
Conclusions
Two de novo decision models were developed to assess the cost-effectiveness of CAR T-cell therapy within
the two separate TPPs (bridge to HSCT and curative intent) across each of the separate evidence sets.
Although a number of common inputs and assumptions were employed across both models, the two
TABLE 22 Model inputs: utilities
Parameter Utility (95% CI) Source/assumption
Treatment disutilities
HSCT disutility 0.57 for 1 year (0.33 to 0.87) Sung et al.:206 ‘disutility of undergoing BMT’ expert VAS elicitation
Adverse events
CRS 0 for 1 week Assume severity of ICU hospitalisation associated with utility of 0
Short-term utility
Relapse 0.75 (0.44 to 1) Kelly et al.:204 ‘in the state of relapse’ mapped value from CHRIs
to EQ-5D
Remission 0.91 (0.87 to 0.95) Kelly et al.:204 ‘cured after relapse-all relapsed patients treated
with CRT’ mapped value from SF-36 to HUI2; need to assume no
long-term disutility adverse events from CRT
Long-term utility
Long-term disutility Remission utility (0.91) with
age-adjusted decrement
To reflect ageing of cohort
BMT, bone marrow transplantation; CRT, cranial radiation therapy; ICU, intensive care unit.
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models had important structural differences that led to differences both in the underlying modelling
approach and in the use of external evidence.
In the bridge to HSCT scenario, the primary health benefits of treatment with CAR T-cell therapy were
assumed to be driven by an increase in the proportion of patients receiving HSCT and the subsequent
success of HSCT itself (based on remission and MRD status). The introduction of an epidemiological ‘link’
between a potential established surrogate outcome and/or process (i.e. MRD and HSCT status) and final
health benefits (i.e. OS and QALYs) also enabled the use of external evidence to be utilised alongside the
separate hypothetical evidence sets generated. A landmark response model was developed utilising
evidence from the hypothetical evidence sets to inform short-term outcomes of remission, HSCT and MRD
status and external evidence to estimate OS conditional on these shorter-term outcomes. Hence, the key
assumption employed within this scenario is that external evidence substantiating the relationship between
MRD and HSCT status in studies in which CAR T-cells have not been used can be generalised to patients in
whom CAR T-cells have been used. Importantly, the results of our validation work appear to demonstrate
that, with minor calibration and adjustment, the combination of trial-reported evidence on short-term
outcomes (remission, HSCT and MRD status) and external evidence on their relationship to OS appeared to
closely match the OS estimates directly reported within the studies used to generate the evidence sets for
CAR T-cell therapy and the comparator (clofarabine).
In the curative intent model a different assumption was employed, specifically that the CAR T-cell therapy
itself potentially confers longer-term and potentially curative benefits without the need to bridge to HSCT.
In this context, the case for use of a structural link between final health benefits and a surrogate outcome
or process such as HSCT appears more limited. Instead, a simple three-state partitioned survival model was
developed to model long-term outcomes through the direct extrapolation of OS data from the evidence
sets. An important consideration within this model was whether or not the use of conventional parametric
survival functions (e.g. exponential, Weibull, log-normal) would adequately capture the potential for a less
conventional hazard function that might be observed for a curative treatment and how this might be
affected by different levels of precision and maturity of evidence. Consequently, our work considered the
goodness of fit of conventional survival functions and more flexible survival models (e.g. spline-based
models developed by Royston and Parmar192). A key finding was that the more flexible survival models
appeared to more closely approximate the observed hazard function across each of the evidence sets.
To our knowledge, although the use of these more flexible survival models is briefly discussed within
existing NICE technical support documents,207 we are not aware of any examples of their use to date by
manufacturers or AGs within the NICE TA process. Consequently, further research may be required to
more formally consider the appropriateness of alternative survival modelling approaches to regenerative
medicines and cell-based therapies, including more flexible models and cure fraction models.208
The importance of the level of data maturity in deriving robust survival projections for the economic model
was evident in our results. Although the ‘best-fitting’ spline models appeared to generate a robust fit to
the data over the first 3 months of the KM estimate used in the minimum data set, the functions were not
able to accurately predict the tail of the distribution. Furthermore, considerable variation was evident in the
predicted long-term survival of the modelled cohort, with a significant spread in the projected survival
trajectories employing different parametric functions. Consequently, we concluded that it was unlikely that
a single survival distribution could adequately characterise uncertainties over the longer-term extrapolation
period. Although the robustness of the ICER estimates to alternative distributions can be explored in
separate sensitivity analyses or scenarios, concerns may exist regarding the transparency of subsequent
decisions if the weighting of these is not explicitly specified in subsequent policy decisions.
To more formally account for the uncertainty surrounding choice of survival distribution, a model-averaging
approach was adopted. This technique involves the parameterisation of uncertainty surrounding the choice
of distribution, combining results from a series of alternative survival functions as part of a weighted
distribution. This approach samples both the parametric uncertainty associated within each distribution and
the uncertainty (or weights) surrounding the choice of preferred method. Through the probabilistic analysis,
DOI: 10.3310/hta21070 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 7
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Hettle et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
99
it is therefore possible to estimate the joint distribution of uncertainty around the parameter estimates and
the choice of survival function.
In contrast to the minimum set, the additional data maturity in the intermediate and mature evidence
sets results in greater certainty over the long-term survival benefits of treatment. This leads to reduced
variability in the potential trajectories for the survival benefits of treatment. In addition, with more mature
evidence, the fitted survival models are better able to predict the tail of the KM curve. Therefore, unlike
the bridge to HSCT model, additional evidence maturity in the curative model leads to different projections
of survival benefit, as well as impacting on the parametric uncertainty surrounding model extrapolations.
The weights in the exemplar model were based on standard measures of statistical fit. However, these
weights could also be informed by clinical judgement and the committee’s deliberations.
Given the inevitable uncertainties that are likely to exist regarding the longer-term benefits of regenerative
medicines and cell-based therapies and their implications for the robustness of subsequent cost-effectiveness
estimates, further methodological research could be usefully undertaken to help inform how these
uncertainties might be appropriately quantified in a transparent manner to inform subsequent decisions.
A key consideration here would be the extent to which these weights can be defined prior to the
committee’s deliberations or whether they should be more directly informed by them. Given the potential
complexity in both undertaking these analyses and communicating the results, more efforts should be
made to ensure that informal judgements can be more explicitly incorporated in a timely and transparent
manner.209
A key assumption employed within both models is that from year 5 onwards all patients who remained
alive were assumed to experience a similar mortality risk profile as that of a long-term survivor of ALL.
Hence, the mortality risks assumed in both models after year 5 were based on matched general population
estimates of the all-cause risk of mortality adjusted for excess morbidity and mortality reported in cohorts
of long-term survivors of ALL. As data were not assumed to be available beyond 5 years, it is not possible
to determine the possible direction and/or magnitude of any possible bias that this approach might
introduce. However, this period is consistently utilised within existing studies of ALL and appears clinically
to represent an important time point for patients to reach without subsequent relapse. Hence, for the
purposes of extrapolation and the exemplar, it was considered a reasonable basis for informing subsequent
longer-term extrapolations. This assumption also impacted on reducing some of the longer-term
uncertainties that would inevitably arise from the extrapolation of the data beyond the maximum reported
follow-up across the evidence sets considered for CAR T-cell therapies. Clearly, if additional follow-up data
were available, then the validity of such an approach could be more formally considered and any claims of
longer-term benefits could be more robustly substantiated.
Our searches to inform other model parameters identified other important uncertainties. The existing
HRQoL data on ALL were limited and several assumptions were required. Importantly, no existing
CAR T-cell study had incorporated measures of HRQoL that could be considered directly in the model. In
the absence of these data, assumptions were made based on external studies to account for the possible
magnitude of HRQoL benefits of achieving remission, alongside any negative impacts resulting from the
model of therapy (i.e. HSCT, chemotherapy) and other specific adverse events. Our model focused
specifically on the impact of CRS and B-cell aplasia. Importantly, no studies were identified on the potential
HRQoL impact of these specific events, which are likely to be associated with CAR T-cell therapy,
necessitating the use of potentially arbitrary assumptions. Further research to generate more robust
estimates of HRQoL appropriate for cost-effectiveness analysis is clearly required, together with more
specific research that more formally demonstrates the impact of specific therapeutic modalities (including
CAR T-cell therapy).
Finally, our research also identified important uncertainties regarding both the likely acquisition costs of
CAR T-cells and the other key elements of the process (e.g. costs of leukapheresis, costs of conditioning
therapies, level of hospitalisation required for different aspects such as conditioning, subsequent
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administration and monitoring costs). Furthermore, no account was taken of the potential costs incurred
by patients and their families. Based on previous NICE TA appraisals, additional evidence would need to be
provided by manufacturers to more robustly determine the potential costs to the NHS to avoid these
uncertainties regarding the costing assumptions being raised. An important uncertainty identified related
to the costs of HSCT and any additional costs that may arise from longer-term management of patients.
A variety of possible sources were identified in our review and important differences were observed across
these. Further studies would be useful to more formally cost the short-term and longer-term implications
of HSCT in paediatric populations and also to determine the generalisability of studies reporting estimates
from outside the UK.
Although the existence of possible learning curves was identified as an important issue in the conceptual
review, these were not directly considered within the exemplar. Some aspects of these may become more
apparent as larger studies report, particularly those involving centres with different levels of expertise. Hence,
some aspects of learning may be reflected within the results from larger studies and/or specific factors may
become more apparent in terms of how these might be incorporated within cost-effectiveness assessments.
For example, as experience with using CAR T-cell therapies develops, this may have important implications
for both the identification and the management of potential adverse events, as well as the provision of the
therapy itself. An assumption is made in the exemplar model that the different stages of CAR T-cell therapy
would require separate hospitalisations (i.e. for the initial conditioning therapy and later for the subsequent
administration of the CAR T-cells and ensuring monitoring). However, as experience and knowledge
continues to develop, aspects of the process may evolve over time such that the subsequent administration
and monitoring may be undertaken in a less resource-intensive setting. Although the existence of learning
curves has received significant attention in the clinical literature, to date, their implications for and
application within cost-effectiveness analysis remain limited and warrant further investigation.133
Finally, an important assumption made within the exemplar relates to the acquisition cost of CAR T-cell
therapy itself. In the absence of a commercially available product and published price, an assumption was
made that the manufacturer would employ a value-based approach to its decision such that the resulting
cost-effectiveness (ICER) estimate was close to NICE’s cost-effectiveness threshold. In the context of the
exemplar, this was assumed to be based on the maximum range of the threshold considered by NICE,
assuming that the existing EoL criteria are met. Importantly, this price is not considered to be indicative of
the final acquisition cost that might be set when commercially available products are available. Neither are
we making the assumption that NICE’s current EoL criteria would apply. Rather, the basis for setting the
price using the existing cost-effectiveness threshold was to enable different interested parties to better
understand the potential impact of other uncertainties (e.g. precision and maturity of evidence) within
NICE’s current decision-making process, identifying potential trade-offs that may exist and illustrating how
these uncertainties might be more explicitly addressed within different MEAs (i.e. evidence generation
and/or pricing schemes). Although it is clearly possible to examine a range of different possible prices
for the CAR T-cell therapy within the exemplar, it was considered that this approach may result in the
subsequent panel decision process becoming unmanageable (i.e. multiple pricing scenarios) and would
lessen the generalisability learning that the exemplar was developed to highlight.
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Chapter 8 Assessment of cost-effectiveness,
uncertainty and the value of alternative policy options
Overview
The exemplar in Chapter 7 was developed to highlight some of the specific challenges that may present
themselves to manufacturers and AGs in terms of developing and populating a cost-effectiveness model.
Consideration is now given to how such estimates could be presented and communicated to the
committee. In doing this, we consider the analyses routinely requested within NICE’s existing methods
guide122 but also consider whether further analyses may provide useful additional insights to help inform
subsequent committee deliberations.
Based on the scoping review reported in Chapter 3 (see Scoping review of potential cost-effectiveness
issues), we also considered analyses relating to some of the broader issues and approaches identified
previously (e.g. alternative payment mechanisms), which, although potentially outside the existing remit of
NICE, may provide additional insights to other interested bodies and manufacturers.
Importantly, the use of non-reference case approaches and additional analyses beyond those requested
within NICE’s existing process and methods guide is not intended to be prescriptive. Neither are they
comprehensive, given the multiplicity of issues and challenges raised. Instead, they have been provided
to help explore whether or not additional information and analyses may be helpful in informing the
committee’s deliberations and the nature of such analyses.
Consideration will subsequently be given to whether particular analyses helped to inform particular
considerations within NICE’s deliberations within the exemplar appraisal and to identify areas in which
further methodological and applied work may be required.
Acquisition costs of chimeric antigen receptor T-cell therapies
As noted in Chapter 7 (see Chimeric antigen receptor T-cell therapy), the acquisition cost for CAR T-cell
therapy in the exemplar was assumed to be based on a value-based approach from the manufacturer,
such that it would be priced at a level so that the ICER for CAR T-cell therapy would be close to the upper
limit of NICE’s EoL threshold range (circa £50,000 per QALY gained). Because of differences in the
projected survival benefits of treatment across the separate TPPs, the subsequent cost of CAR T-cell
therapy varied across the TPPs, with one-off acquisition costs of £356,100 assumed in the bridge to HSCT
scenario and £528,600 in the curative intent scenario.
A full summary of the CAR T-cell therapy acquisition costs assumed across the separate pricing scenarios
described in subsequent sections (one-off fixed cost, monthly leasing price, discounted list price via PASs) is
provided in Table 23.
TABLE 23 Estimated acquisition costs for CAR T-cell therapies (excluding costs for conditioning therapy
and leukapheresis)
Scenario
One-off acquisition
cost per patient (£)
Monthly leasing
price (£)
Discounted list price
(10%) per patient (£)
Bridge to HSCT 356,100 2756.27 320,490
Curative intent 528,600 3282.66 475,740
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Bridge to haematopoietic stem cell transplantation target
product profile
Per-patient analyses: minimum evidence set
The sequence of assessments starts with a conventional assessment of cost-effectiveness at the patient
level based on the minimum evidence set reported in Chapter 5. Disaggregated costs and outcomes are
presented in Table 24.
The mean incremental cost of CAR T-cell therapy compared with standard of care over a patient’s lifetime
was estimated to be £373,166, with CAR T-cell therapy resulting in an additional 7.46 QALYs. The
incremental cost per QALY gained over a lifetime horizon was £49,995 (Table 25), which can be compared
against the cost-effectiveness threshold. This can also be expressed as the per-patient net health effect
(NHE), including benefits, harms and NHS/Personal Social Services costs. The NHE is the difference between
any health gained with the intervention and the health forgone elsewhere in the health-care system and
can be expressed in both monetary and QALY terms. With an ICER of approximately £50,000 per QALY,
TABLE 24 Summary of costs and outcomes in the bridge to HSCT TPP: minimum evidence set
Outcome CAR T-cell therapy Standard of care Increment
Costs (£)
Course of treatment (including conditioning) 358,057 43,200 314,857
Hospitalisation for treatment 13,012 7180 5832
Adverse event costs 2750 442 2308
HSCT and related follow-up costs 71,918 21,380 50,538
Non-HSCT follow-up costs 3391 3759 –368
Total costs 449,128 75,962 373,166
QALYs
Decision tree 0.14 0.11 0.03
Post HSCT MRD negative 8.82 0.30 8.52
Post HSCT MRD positive 0.00 0.16 –0.16
Post HSCT no remission 0.00 0.72 –0.72
No HSCT remission 0.06 0.03 0.03
No HSCT no remission 0.07 0.11 –0.04
QALY loss from HSCT –0.27 –0.08 –0.19
Total QALYs 8.82 1.36 7.46
Total life-years 10.60 1.77 8.83
Proportion of patients receiving HSCT (undiscounted) 48% 15% 33%
TABLE 25 Expected cost-effectiveness of CAR T-cell therapy per patient treated (lifetime horizon): bridge to HSCT
TPP – minimum evidence set
Per-patient level Cost-effectiveness threshold of £50,000 per QALY gained
Treatment Cost (£) QALYs ICER (£) NHE, QALYs (£) Incremental NHE, QALYs (£)
CAR T-cell therapy 449,128 8.82 49,995 –0.158 (–7919) 0.001 (41)
Standard of care 75,962 1.36 –0.159 (–7960) –
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the incremental NHE at a threshold of £50,000 is close to zero (i.e. 0.001 QALYs or £41 per patient), that
is, the additional health gained with the intervention is almost exactly offset by health forgone elsewhere.
Given the uncertainties surrounding longer-term outcomes, it may also be informative to consider how
incremental NHEs accumulate over time or the ‘investment profile’ with CAR T-cell therapy, shown in
Figure 11. The initial per-patient cost for CAR T-cell patients is attributable to the additional acquisition
and administration costs of the CAR T-cells and associated HSCT costs. The ‘kink’ in the curve that appears
early on represents the associated HSCT costs, which are assumed to be incurred at day 28. These negative
NHEs are gradually offset by positive NHEs in later periods resulting from the ongoing mortality benefits
assumed from successfully bridging to HSCT. However, it is only after 60 years that the initial losses are
sufficiently compensated for by later gains, that is, CAR T-cell therapy appears to be close to breaking even
(i.e. NHE ≥ 0).
Population-level analyses: minimum evidence set
Net health effects can also be presented for a population of patients over time. Although the presentation
of population NHEs is not formally requested within the existing NICE methods guide,122 population-based
analyses are requested to be submitted to assess population impacts within Section 5.12 (Impact on the
NHS). In addition, Section 6.4.1. states that in situations in which the evidence of clinical effectiveness is
‘absent, weak or uncertain’, the committee is requested to ‘balance the potential net benefits to current
NHS patients of a recommendation not restricted to research with the potential net benefits to both
current and future NHS patients of being able to produce guidance and base clinical practice on a more
secure evidence base’ (p. 69-71).122
Analyses of population NHEs may therefore provide additional information to help inform the committee’s
deliberations regarding possible research recommendations (Section 6.4 of the current methods guide122).
Analyses of population NHEs require information about the prevalence and future incidence of the target
population and a judgement about the time horizon over which the technology will be used in clinical
practice. As outlined in Appendix 8, the expected incidence of eligible cases for the exemplar was estimated
to be approximately 38 per annum. The technology time horizon was set to 10 years in the base case.
Table 26 reports the population NHE for CAR T-cell therapy over the 10-year technology time horizon.
Over this period, the use of CAR T-cell therapy is estimated to generate an additional 2356 QALYs
(discounted values) within the population considered compared with the current standard of care.
However, as the additional lifetime cost of £117.78M (£141.75M – £23.97M; discounted values) requires
other treatments to be displaced and health to be forgone by other patients in the NHS, overall the
additional QALYs are exactly offset by health forgone elsewhere. Hence, the incremental population NHE
at a £50,000 per QALY threshold is 0.26 QALYs (£12,813).
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FIGURE 11 Investment profile: bridge to HSCT TPP.
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A series of one-way sensitivity analyses was undertaken to assess the sensitivity of the model results to
changes in assumptions. The results of these sensitivity analyses are presented in Table 27.
The one-way sensitivity analyses indicate that the results of the evaluation are sensitive to assumptions
regarding the potential for retreatment with CAR T-cell therapy and the assumed discounting rate for
health effects in the model. The results of the evaluation are less sensitive to assumptions about the
discounting rate for costs, to the impact of remission status on survival in non-HSCT patients and to
reducing the cost of standard of care treatment to values consistent with treatment using FLAG-IDA
(assuming similar efficacy to that of clofarabine).
If the committee was to consider the criteria met for applying the non-reference case discount rate of
1.5% for both costs and health effects (i.e. when treatment restores people who would otherwise die or
have a very severely impaired life to full or near full health and when this is sustained over a very long
period, normally at least 30 years), then the ICER would reduce to £35,162 per QALY and CAR T-cell
therapy would be associated with an additional population NHE equivalent to 994 QALYs (£49.72M) in
comparison to health forgone elsewhere.
TABLE 26 Expected cost-effectiveness of CAR T-cell therapy at the population level (including incident patients):
bridge to HSCT TPP – minimum evidence set
Population level Cost-effectiveness threshold of £50,000 per QALY gained
Treatment Cost (£) QALYs ICER (£) NHE, QALYs (£) Incremental NHE, QALYs (£)
CAR T-cell therapy 141,751,559 2785.04 49,995 –49.99 (–2,499,490) 0.26 (12,813)
Standard of care 23,974,719 429.25 –50.25 (–2,512,303)
TABLE 27 Results of the one-way sensitivity analyses at the population level: bridge to HSCT TPP – minimum
evidence set
Scenario
Incremental
cost (£)
Incremental
QALYs ICER (£)
Incremental NHE at
willingness to pay of
£50,000, QALYs (£)
Base case (0% repeat CAR T-cell treatment) 117,776,840 2355.79 49,995 0.26 (12,813)
Repeat CAR T-cell treatment – monthly probability
of 0.5%
193,649,693 2355.79 82,201 –1517.20 (–75,860,040)
Repeat CAR T-cell treatment – monthly probability
of 0.1%
132,951,410 2355.79 56,436 –303.24 (–15,161,757)
Discounting – 0% costs and health effects 117,863,631 4608.43 25,576 2251.16 (112,557,826)
Discounting – 6% costs and health effects 117,718,706 1662.50 70,808 –691.87 (–34,593,729)
Discounting – 0% costs and 6% health effects 117,863,631 1662.50 70,895 –694.77 (–34,738,654)
Discounting – 6% costs and 0% health effects 117,718,706 4608.43 25,544 2254.06 (112,702,751)
Discounting – 1.5% costs and 1.5% health effects 117,825,625 3350.89 35,162 994.38 (49,718,835)
Discounting – UK Treasury-recommended step
discounting of 3.5% up to year 30, 3% thereafter
(both costs and health effects)
117,776,840 2374.47 49,601 18.94 (946,799)
Standard of care costs based on FLAG-IDA 130,211,131 2355.79 55,273 –248.43 (–12,421,478)
Hazard rate for death in non-remission no-HSCT
patients increased from 0.2425 (mean time to
death 0.34 years) to 0.6075 (mean time to death
0.14 years)
117,775,723 2363.47 49,832 7.95 (397,705)
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Employing the stepwise discounting recommended by the UK Treasury210 to all public sector bodies makes
only a small difference to the ICER (£49,601 vs. £49,995), with the incremental population NHE increasing
to 18.94 QALYs (£946,799).
Although the results of the evaluation appear to be sensitive to assumptions about the potential for
retreatment with CAR T-cell therapy, this was not considered to represent such a challenge in this TPP.
CAR T-cell therapy was assumed to be used as a one-off therapy to induce remission and to improve the
likelihood and outcomes of HSCT. It was assumed that patients would not receive a repeat treatment in
the event of not achieving remission; nor would patients who were successfully treated with HSCT receive
further treatments with CAR T-cell therapy.
Probabilistic analysis
The results of the probabilistic analysis are shown in Table 28.
The probabilistic ICER increased to £55,090 because of the model non-linearities. Consequently, the
population NHE is now negative, with an overall loss to the health system of 215.9 QALYs (£10.79M). At a
£50,000 cost-effectiveness threshold, the probability that CAR T-cell therapy is the most cost-effective
option is 26.1%.
The cost-effectiveness acceptability planes and curves are presented in Figures 12 and 13, respectively.
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FIGURE 12 Cost-effectiveness acceptability plane: bridge to HSCT TPP – minimum evidence set. WTP, willingness
to pay.
TABLE 28 Results of the base-case probabilistic analysis at the population level: bridge to HSCT TPP – minimum
evidence set
Population level Cost-effectiveness threshold of £50,000 per QALY gained
Treatment Cost (£) QALYs ICER (£)
NHE, QALYs
(£)
Incremental
NHE, QALYs
(£)
Probability
cost-effective
(%)
Consequences
of decision
uncertainty,
QALYs (£)
CAR T-cell
therapy
141,556,652 2716.4 55,090 –114.8
(–5,738,274)
–215.9
(–10,794,902)
26.1 56.3
(2,813,197)
Standard of
care
24,728,297 595.7 101.1
(5,056,627)
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In addition to considering how uncertain a decision is to approve or reject a technology based on expected
cost-effectiveness, an assessment of the scale of the likely consequences may also be potentially informative
to the committee, particularly in deliberations related to possible research recommendations. An assessment
of the potential consequences of uncertainty is important because it indicates the scale of the population
NHEs that could be gained if uncertainty surrounding this decision could be resolved immediately.128 This
estimate also represents an expected upper bound to the benefits of more research. This may help to
inform subsequent research recommendations. For example, if the maximum potential benefits of further
research are considered unlikely to sufficiently justify the research costs, then it may not be worthwhile to
issue further research recommendations.
These same consequences are referred to using the term ‘payer uncertainty burden’ (PUB) in the DSU report
on managed access.211 Elsewhere in the literature, these have been defined as the expected value of perfect
information (EVPI) and the overall expected opportunity loss. Within the DSU report they are further defined
as the value of the risk of making a particular decision because of uncertainty (expressed in either monetary
or health units), combining two key concepts: first, the probability that the strategy with the highest
expected NHE may not be the optimal strategy (i.e.1 – probability that the intervention is cost-effective
based on the probabilistic results) and, second, the consequences of a ‘wrong’ decision in terms of QALYs
and NHS costs that could have been saved if the truly optimal strategy had been selected instead.
Assuming a 10-year technology horizon, the consequences of decision uncertainty in the minimum data set
are estimated to be 56.3 QALYs (£2.83M). Figure 14 shows how the scale of the consequences of decision
uncertainty varies across different cost-effectiveness thresholds, reaching a peak at a £55,000 threshold.
A summary of the population-level incremental NHEs, net monetary benefits, probability of cost-effectiveness
and consequences of decision uncertainty across a range of willingness-to-pay thresholds is presented in
Table 29.
At conventional cost-effectiveness thresholds between £20,000 and £30,000 per QALY gained, the
probability that CAR T-cell therapy is cost-effective compared with standard of care is 0%. Consequently,
because of the high certainty that CAR T-cell therapy is not cost-effective at conventional thresholds
(i.e. assuming that EoL criteria do not apply), there are no consequences of decision uncertainty. At a
cost-effectiveness threshold of £50,000 per QALY gained, the probability that CAR T-cell therapy is
cost-effective compared with standard of care is 26.1%. In this case, the expected population health
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FIGURE 13 Cost-effectiveness acceptability curve: bridge to HSCT TPP – minimum evidence set.
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consequence of decision uncertainty is 56.3 QALYs. These expected consequences can be interpreted as
an estimate of the population NHE that could be gained if the uncertainty surrounding this decision could
be resolved immediately and provide an expected upper bound on the benefits of more research. The
corresponding expected monetary cost of decision uncertainty is approximately £2.8M. At thresholds of
£75,000 and £100,000 per QALY gained, the probability that CAR T-cell therapy is cost-effective increases to
> 94%. Because there is now high certainty that CAR T-cell therapy is cost-effective at these thresholds, the
corresponding consequences of decision uncertainty reduce to < 10 QALYs (or < £1M in monetary terms).
Alternative pricing scenarios probabilistic analysis
A series of alternative pricing schemes has been generated to explore their potential impact on cost-effectiveness
and decision uncertainty. These schemes were selected to reflect the possible approaches that have been
suggested to address the potential HTA challenges, as highlighted previously in Chapter 3 (seeMethods). The
schemes considered were:
l A leasing scheme approach based on the approach outlined by Edlin et al.137 In this scenario, the
technology is assumed to be leased from the company. The monthly ‘lease’ payment was established
by calculating a stream of payments over the expected survival duration of the patients that has the
same expected net present value as the agreed price. Hence, payment was assumed to continue on a
monthly basis while a patient remained alive.
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FIGURE 14 Consequences of decision uncertainty: bridge to HSCT TPP – minimum evidence set.
TABLE 29 Consequences of decision uncertainty across different willingness-to-pay thresholds: bridge to HSCT
TPP – minimum evidence set
Cost-effectiveness
threshold (£)
Incremental
NHE, QALYs
Incremental
NMB (£)
Probability
cost-effective (%)
Consequences of decision
uncertainty, QALYs (£)
20,000 –3720.75 –74,414,973 0 0 (0)
30,000 –1773.61 –53,208,283 0 0 (0)
50,000 –215.90 –10,794,902 26.1 56.3 (2,813,197)
75,000 562.96 42,221,825 94.1 9.5 (710,894)
100,000 952.39 95,238,551 99.3 0.6 (63,592)
NMB, net monetary benefit.
DOI: 10.3310/hta21070 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 7
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Hettle et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
109
l A pay for performance scheme in which payment is made retrospectively only for patients who achieve
remission (CR) within a specified period (e.g. 28 days). Alternatively, an initial upfront payment could
be made for all, with a separate ‘clawback’ agreed for patients who do not achieve remission.
l A more conventional PAS providing a fixed percentage discount (e.g. 10%).
The probabilistic results based on alternative hypothetical pricing scenarios are shown in Table 30. The
scatterplots showing each iteration of incremental costs and incremental effects considered in the
probabilistic sensitivity analysis are provided in Figure 15.
The impact of the different pricing schemes on the sampled outputs of the probabilistic sensitivity analysis
is shown graphically in Figure 15. In the base case (fixed cost for CAR T-cell therapy), the cloud of
simulated outcomes from the probabilistic sensitivity analysis is flat, such that there is considerable
variability around the QALY gains of treatment, but little relative variability around the incremental costs.
By introducing a leasing method, the cost of CAR T-cell therapy becomes more closely linked to the
effectiveness of treatment, such that the cloud of simulated outcomes from the probabilistic sensitivity
analysis is reoriented around the willingness-to-pay threshold. With both the remission and discounted
schemes, the cost-effectiveness of treatment is improved and the cloud of simulated outcomes is shifted
downwards on the chart.
A comparison plot of the consequences of decision uncertainty across the alternative pricing scenarios for
different cost-effectiveness thresholds is shown in Figure 16.
Under a fixed one-off acquisition cost approach, assumed in the main analyses, the NHS bears all of the
risks associated with uncertainty surrounding whether the expected benefits of therapy will be realised in
routine clinical practice. Hence, the consequences of decision uncertainty to the NHS appear highest with
this scheme (56.3 QALYs, £2.81M). The alternative schemes result in reductions in decision uncertainty and
associated consequences to the NHS. However, the impact of this and the mechanism by which it is
achieved differ across the separate approaches.
The leasing approach results in only a minor difference in the ICER. Similar levels of decision uncertainty
also remain (i.e. the probability that the intervention is cost-effective is similar to that under a fixed one-off
acquisition cost approach). However, the scale of the consequences of the uncertainty to the NHS is
significantly reduced under this scheme. This scheme limits the risk to the NHS of overpaying for a
technology that does not achieve the expected outcomes, significantly lowering the consequences of
decision uncertainty to 22.5 QALYs (£1.12M).
The use of a pay for performance scheme improves the expected cost-effectiveness and, as a result,
reduces both the level of decision uncertainty and the scale of the consequences of this uncertainty.
Restricting payment to only patients who achieve remission improves expected cost-effectiveness
(£36,430 per QALY), leading to a higher probability of being cost-effective (96.8%), thereby reducing the
consequences of uncertainty to 3.9 QALYs (£195,000). The use of a more conventional PAS, based on an
assumed 10% reduction in the acquisition cost, works in a similar manner by improving both expected
cost-effectiveness (£49,857 per QALY) and the likelihood that the treatment is cost-effective (51.8%).
However, as the ICER now lies closer to the threshold in absolute terms, the consequences are increased to
131.2 QALYs (£6.56M).
The comparison plot more clearly shows the impact of the alternative pricing schemes. The alternative
schemes affect both the shape of the distribution of the consequences across the separate cost-effectiveness
thresholds as well as their position.
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FIGURE 15 Scatterplots of incremental costs and incremental effectiveness across the four pricing scenarios:
bridge to HSCT TPP. (a) Base case; (b) leasing method; (c) payment for remission only; and (d) fixed discount.
Blue box=mean of the probabilistic sensitivity analysis values. WTP, willingness to pay. (continued )
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Alternative evidence sets probabilistic analysis
All of the analyses reported previously have been based on the minimum evidence set. The impact of the
alternative evidence sets on expected cost-effectiveness, the level of decision uncertainty and the scale of
the consequences is reported in Table 31 and Figure 17.
As highlighted in Chapter 5, the use of a separate structural/surrogate link within the bridge to HSCT TPP
was employed to allow the incorporation of external evidence on the relationship between remission MRD
and HSCT status. A limitation of our analysis is that the same external evidence is then used across each of
the separate evidence sets. This means that the additional follow-up assumed in both the intermediate and
the mature evidence sets is not adequately reflected in the results. Consequently, the ICER and associated
decision uncertainty are identical across the minimum and intermediate data sets. Furthermore, the
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FIGURE 15 Scatterplots of incremental costs and incremental effectiveness across the four pricing scenarios:
bridge to HSCT TPP. (a) Base case; (b) leasing method; (c) payment for remission only; and (d) fixed discount.
Blue box=mean of the probabilistic sensitivity analysis values. WTP, willingness to pay.
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differences in results between these evidence sets and the mature evidence set is driven entirely by the
increased precision (i.e. because of higher patient numbers) in the short-term remission, MRD and HSCT
rates, as opposed to the additional maturity of follow-up data that may be available.
In practice, the additional follow-up reported in more mature studies could either replace the existing
surrogate relationship employed here or be synthesised and combined with the external evidence.
Hence, the value that the additional follow-up brings in terms of either confirming an assumed surrogate
relationship or increasing the precision around this relationship is not adequately captured in these analyses.
Despite these limitations, the separate evidence sets may still provide an important comparison for the
committee to consider, specifically in relation to how its deliberations might be affected in situations in
which the same ICER and decision uncertainty are reported but under different circumstances, that is,
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FIGURE 17 Scatterplots of incremental costs and incremental effectiveness across evidence sets: bridge to HSCT TPP.
(a) Minimum and intermediate evidence sets; and (b) mature evidence set. Blue box=mean of the probabilistic
sensitivity analysis values. WTP, willingness to pay.
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situations in which the results are based entirely on external surrogate relationships compared with
situations in which the results are based on actual observed data from a longer-term trial or follow-up.
As expected, the health consequence of decision uncertainty in the mature evidence set (48.1 QALYs,
£2.41M) is lower than that reported in the minimum set (56.2 QALYs, £2.81M) at a threshold of £50,000
per QALY gained. These consequences are reduced by the increased precision associated with the larger
sample in terms of the short-term remission, MRD and HSCT rates.
A comparison plot of the consequences of decision uncertainty between the minimum/intermediate
evidence sets and the mature evidence set across a range of cost-effectiveness thresholds is provided in
Figure 18.
Presentation of the scale of consequences using population NHEs allows some important comparisons to
be made across the separate pricing approaches and the different evidence sets. Specifically, these
comparisons could provide a more explicit basis for considering the value of direct price reductions that
might be realised through a conventional PAS (or less conventional schemes that work by indirectly
lowering the effective price) compared with the provision of additional evidence (both precision and
maturity) in terms of reducing decision uncertainty and its consequences.
In the bridge to HSCT TPP, significant reductions in the level and scale of the consequences of decision
uncertainty (i.e. the risk faced by the NHS) appear to be achieved by more innovative pricing approaches
such as pay for performance and leasing approaches than those that might be realised by the provision
of further evidence. Such information might provide an important basis for discussions between
manufacturers and NICE in terms of how the existing uncertainties that exist might be appropriately
managed, ensuring that risks and benefits are more appropriately shared.
Curative intent target product profile
A similar sequence of assessments and analyses was conducted based on the curative intent TPP. In
contrast to the bridge to HSCT TPP, differences in the results across the evidence sets are more evident, as
the results are directly informed by the data assumed within these rather than by employing evidence from
external sources.
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FIGURE 18 Comparison plot of the consequences of decision uncertainty across alternative evidence sets: bridge to
HSCT TPP.
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Per-patient analyses: minimum evidence set
Again, the sequence of assessments starts with a conventional assessment of cost-effectiveness at the
patient level based on the minimum evidence set. Disaggregated costs and outcomes are presented in
Table 32. The mean incremental cost of CAR T-cell therapy over an individual patient’s lifetime was
estimated to be £503,256 and CAR T-cell therapy resulted in an additional 10.07 QALYs.
The expected cost-effectiveness of CAR T-cell therapy and the per-patient NHEs are shown in Table 33.
In common with the previous TPP, the acquisition cost was set such that the ICER (£49,994) was close to
the upper limit of NICE’s EoL threshold range (circa £50,000 per QALY gained).
The accumulation of NHEs over time, or, equivalently, the ‘investment profile’ per patient, is shown in
Figure 19.
At the start of the time horizon, the initial high costs of treatment are far in excess of the immediate
health benefits of treatment, leading to a negative NHE. Over time, the initial negative NHEs are gradually
offset by the accrual of the residual health benefits of treatment (i.e. cure). In common with the bridge to
HSCT TPP, it is only after approximately 60 years that the initial losses are sufficiently compensated for by
later gains such that CAR T-cell therapy appears to be close to breaking even (i.e. NHE ≥ 0).
TABLE 32 Summary of costs and outcomes in the curative intent TPP: minimum evidence set
Outcome CAR T-cell therapy Standard of care Increment
Costs (£)
Course of treatment (including conditioning) 530,557 43,200 487,357
Hospitalisation for treatment 13,012 7180 5832
Adverse event costs 20,513 442 20,070
HSCT and related follow-up costs 15,092 22,267 –7175
Non-HSCT follow-up costs 4189 7016 –2827
Total costs 583,362 80,106 503,256
QALYs
Event free 10.62 0.83 9.79
Recurrent disease 0.62 0.37 0.25
Adverse events 0.00 0.00 0.00
QALY loss from HSCT –0.06 –0.08 0.03
Total QALYs 11.18 1.11 10.07
Total life-years 13.42 1.47 11.95
TABLE 33 Expected cost-effectiveness of CAR T-cell therapy per patient treated (lifetime horizon): curative intent
TPP – minimum evidence set
Patient level Cost-effectiveness threshold of £50,000 per QALY gained
Treatment Cost (£) QALYs ICER (£) NHE, QALYs (£) Incremental NHE, QALYs (£)
CAR T-cell therapy 583,362 11.18 49,994 –0.49 (–24,509) 0.001 (61)
Standard of care 80,106 1.11 –0.49 (–24,570) –
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The shape of the investment profile differs slightly across the separate TPPs, with the early kink that was
shown in the bridge to HSCT TPP not evident here. The lack of the kink is due to the small number of
patients who are assumed to receive HSCT in the curative intent TPP. Hence, the resulting investment
profile is smoother, although higher initial negative NHEs are reported because of the higher acquisition
cost assumed within this TPP.
Population-level analyses: minimum evidence set
The expected per-patient effects of treatment were also extended to a population level based on similar
assumptions concerning incidence (approximately 38 patients per annum) and the technology time horizon
(10 years).
Table 34 reports the population NHEs for CAR T-cell therapy over the 10-year technology time horizon.
Over this period, the use of CAR T-cell therapy is estimated to result in an additional 3177 QALYs
(discounted values) within the population considered compared with the current standard of care.
However, as the additional lifetime costs of £158.84M (discounted values) require other treatments to be
displaced and health to be forgone by other patients, overall the additional QALYs are almost exactly
offset by health forgone elsewhere. The resulting incremental population NHE is 0.39 QALYs expressed in
health terms and £19,269 expressed in monetary terms.
A series of one-way sensitivity analyses was conducted to assess the sensitivity of the model results to
changes in assumptions or model settings. The results of these sensitivity analyses are presented in
Table 35.
Again, the results of the one-way sensitivity analyses indicate that the results of the evaluation in the
curative intent TPP are sensitive to assumptions about the potential for retreatment with CAR T-cell
therapy and the assumed discounting rate for health effects in the model. The results of the evaluation are
relatively insensitive to assumptions about the discounting rate for costs, the use of a stepped discounting
rate (vs. constant discounting rates) and a reduction in the cost of standard of care treatment to values
consistent with treatment using FLAG-IDA (keeping the same efficacy).
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FIGURE 19 Investment profile: curative intent TPP.
TABLE 34 Expected cost-effectiveness of CAR T-cell therapy at the population level: curative intent TPP – minimum
evidence set
Population level Cost-effectiveness threshold of £50,000 per QALY gained
Treatment Cost (£) QALYs ICER (£) NHE, QALYs (£) Incremental NHE, QALYs (£)
CAR T-cell therapy 184,117,952 3527.65 49,994 –154.71 (–7,735,298) 0.39 (19,269)
Standard of care 25,282,579 350.56 –155.09 (–7,754,567)
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If the committee was to consider the criteria met for applying the non-reference case discount rate of
1.5% for both costs and health effects, then the ICER would reduce to £35,585 per QALY, and CAR T-cell
therapy would be associated with an additional population NHE equivalent to 1291 QALYs (£64.56M) in
comparison to health forgone elsewhere.
Employing the stepwise discounting recommended by the UK Treasury again makes only a small difference
to the ICER results (£49,606 vs. £49,994), with an incremental population NHE of 25 QALYs (£1.26M) in
comparison to health forgone elsewhere.
The sensitivity of the results to assumptions about the potential for retreatment with CAR T-cell therapy
was considered to represent a more important issue within this TPP, that is, the longer-term survival
benefits are directly linked to the curative potential of the CAR T-cells themselves rather than to an
intermediate treatment such as HSCT. Consequently, the potential need to re-administer CAR T-cell
therapy over a longer period represents an important additional source of uncertainty within this TPP,
particularly for the minimum data set with a relatively short follow-up period.
Probabilistic analysis
The results of the probabilistic analysis are shown in Table 36. The probabilistic ICER increased to £50,906
because of the model non-linearities. Consequently, the population NHE is now negative, with an overall
loss to the health system of 56 QALYs (£2.82M). At a £50,000 cost-effectiveness threshold, the probability
that CAR T-cell therapy is the most cost-effective option is 50.7%.
The cost-effectiveness acceptability planes and curves are presented in Figures 20 and 21, respectively.
TABLE 35 Results of one-way sensitivity analysis at the population level: curative intent TPP – minimum
evidence set
Scenario
Incremental
cost (£)
Incremental
QALYs ICER (£)
Incremental NHE,
QALYs (£)
Base case (0% repeat CAR T-cell treatment) 158,835,372 3177.09 49,994 0.39 (19,269)
Repeat CAR T-cell treatment – monthly
probability of 1%
429,511,483 3177.09 135,190 –5413.14 (–270,656,842)
Repeat CAR T-cell treatment – monthly
probability of 0.5%
294,173,428 3177.09 92,592 –2706.38 (–135,318,786)
Repeat CAR T-cell treatment – monthly
probability of 0.1%
185,902,983 3177.09 58,514 –540.97 (–27,048,342)
Discounting – 0% costs and health effects 160,095,703 6127.15 26,129 2925.24 (146,261,823)
Discounting – 6% costs and health effects 158,456,968 2272.68 69,723 –896.46 (–44,823,167)
Discounting – 0% costs and 6% health
effects
160,095,703 2272.68 70,444 –929.24 (–46,461,901)
Discounting – 6% costs and 0% health
effects
158,456,968 6127.15 25,861 2958.01 (147,900,557)
Discounting – 1.5% costs and 1.5% health
effects
159,368,09 4478.47 35,585 1291.1 (64,555,226)
Discounting – UK Treasury-recommended
step discounting of 3.5% up to year 30,
3% thereafter (both costs and health
effects)
158,853,044 3202.28 49,606 25.22 (1,260,898)
Standard of care costs based on FLAG-IDA 171,269,663 3177.09 53,908 –248.3 (–12,415,022)
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FIGURE 21 Cost-effectiveness acceptability curve: curative intent TPP – minimum evidence set.
TABLE 36 Results of the base-case probabilistic analysis at the population level: curative intent TPP – minimum
evidence set
Population level Cost-effectiveness threshold of £50,000 per QALY gained
Treatment E[Costs] (£) E[QALYs] ICER (£)
E[NHE],
QALYs (£)
Incremental
NHE, QALYs (£)
Probability
cost-effective (%)
Consequences
of decision
uncertainty,
QALYs (£)
CAR T-cell
therapy
183,931,590 3501.50 50,906 –177.13
(–8,856,695)
–56.4
(–2,823,943)
50.7 304.6
(15,229,876)
Standard
of care
25,270,727 384.76 –120.66
(–6,032,752)
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The consequences of decision uncertainty in the minimum evidence set are estimated to be 304.6 QALYs
(£15.23M). Figure 22 shows how the scale of the consequences of decision uncertainty varies across
different cost-effectiveness thresholds, reaching a peak at the £50,000 threshold.
A summary of the population-level incremental NHEs, net monetary benefits, probability of cost-effectiveness and
consequences of decision uncertainty across a range of cost-effectiveness thresholds is presented in Table 37.
At conventional thresholds of between £20,000 and £30,000 per QALY gained, the probability that
CAR T-cell therapy is cost-effective compared with standard of care is 0%. Consequently, there are no
consequences of decision uncertainty at these threshold values. At a willingness-to-pay threshold of £50,000
per QALY gained, the probability that CAR T-cell therapy is cost-effective compared with standard of care is
50.7%. In this case, the expected population health consequence of decision uncertainty is 305 QALYs
(10 years). The corresponding expected monetary cost of decision uncertainty is approximately £15.23M. At
thresholds of £75,000 and £100,000 per QALY gained, the probability that CAR T-cell therapy is cost-effective
increases to > 88%. Despite there being high certainty that CAR T-cell therapy is cost-effective at these
thresholds, the corresponding consequences of decision uncertainty remain relatively high at 66 QALYs
(£4.96M in monetary terms) and 23 QALYs (£2.34M), respectively.
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FIGURE 22 Consequences of decision uncertainty: curative intent TPP – minimum evidence set.
TABLE 37 Consequences of decision uncertainty across different willingness-to-pay thresholds: curative intent
TPP – minimum evidence set
Cost-effectiveness
threshold (£)
Incremental
NHE, QALYs
Incremental
NMB (£)
Probability
cost-effective (%)
Consequences of decision
uncertainty, QALYs (£)
20,000 –4816.30 –96,326,095 0.0 0 (0)
30,000 –2171.96 –65,158,711 0.0 0 (0)
50,000 –56.48 –2,823,943 50.7 304.6 (15,229,876)
75,000 1001.26 75,094,517 88.1 66.2 (4,963,418)
100,000 1530.13 153,012,977 94.8 23.4 (2,336,731)
NMB, net monetary benefit.
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Alternative pricing scenarios probabilistic analysis
The probabilistic results based on alternative hypothetical pricing scenarios are shown in Table 38.
The scatterplots showing the iterations of incremental costs and incremental effects for the four pricing
scenarios considered in the probabilistic sensitivity analysis are provided in Figure 23. A comparison plot of
the consequences of decision uncertainty across the alternative pricing scenarios is shown in Figure 24.
As observed in the previous analysis, the fixed one-off acquisition cost approach is associated with the
highest potential consequences because of decision uncertainty (304.6 QALYs, £15.23M). As before, the
alternative schemes result in reductions in decision uncertainty and associated consequences to the NHS.
However, the impact of these reductions and the mechanisms by which they are achieved differ across the
separate approaches.
The leasing approach results in only a minor difference in the ICER. Similar levels of decision uncertainty
also remain (i.e. the probability that the intervention is cost-effective is similar to that under a fixed one-off
acquisition cost approach). However, the scale of the consequences of the uncertainty to the NHS is
significantly reduced with this scheme. This scheme limits the risk to the NHS of overpaying for a technology
that does not achieve the expected outcomes, significantly lowering the consequences of decision uncertainty
from > 300 QALYs in the base case to 65.6 QALYs (£3.28M) with the leasing approach.
Alternative evidence sets probabilistic analysis
The results of the probabilistic analysis are shown in Table 39 and Figure 25. A comparison plot of the
consequences of decision uncertainty across the evidence sets is shown in Figure 26.
As expected, the health consequences of decision uncertainty in the mature evidence set (14.1 QALYs,
£707,000) are lower than those reported in the minimum evidence set (304.6 QALYs, £15.23M) at a
threshold of £50,000 per QALY gained. These consequences are reduced by the increased certainty
surrounding the trajectory of the parametric survival curves and the effect of increased maturity on
improving the cost-effectiveness of CAR T-cell therapy. As is evident from Figure 26, the increased
certainty over the longer-term survival benefits of treatment (represented by the longer follow-up assumed
in the intermediate and mature evidence sets) has a proportionately greater effect in reducing decision
uncertainties within the minimum evidence set than the increased precision of greater patient numbers
(i.e. reflected only in the mature evidence set).
Conclusions
The primary purpose of this chapter was to report the potential cost-effectiveness of CAR T-cell therapy
within the separate scenarios considered and to highlight key uncertainties surrounding these results.
An important aspect of this work was also to consider how these estimates could be presented and
communicated to the committee to inform its deliberations. In doing this, we presented analyses based on
approaches routinely requested within NICE’s existing methods guide.122 We also undertook additional
analyses that may provide useful additional insights to help inform subsequent committee deliberations
and the potential nature of such analyses.
The sequence of assessments presented started with a conventional assessment of cost-effectiveness at the
patient level based on the minimum evidence set. Disaggregated estimates of the costs and outcomes were
presented, together with resulting cost-effectiveness estimates based on the ICER. These results were also
expressed using NHEs, representing the difference between any health gained with the intervention and health
forgone elsewhere in the health-care system, expressed either in monetary or in QALY terms. The impact of
uncertainties was explored using conventional one-way sensitivity analyses (i.e. varying individual parameters
or specific assumptions) and probabilistic approaches (i.e. exploring the impact of joint uncertainty across all
parameters). Conventional scatterplots and acceptability curves were utilised to graphically show the impact of
parameter uncertainties and other more methodological uncertainties (e.g. the appropriate discount rate).
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FIGURE 23 Scatterplots of incremental costs and incremental effectiveness across the four pricing scenarios:
curative intent TPP. (a) Base case; (b) leasing method; (c) payment for remission only; and (d) fixed discount.
Blue box=mean of the probabilistic sensitivity analysis values. WTP, willingness to pay. (continued )
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FIGURE 23 Scatterplots of incremental costs and incremental effectiveness across the four pricing scenarios:
curative intent TPP. (a) Base case; (b) leasing method; (c) payment for remission only; and (d) fixed discount.
Blue box=mean of the probabilistic sensitivity analysis values. WTP, willingness to pay.
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The analyses also explored the potential impact if the committee considered the criteria met for applying the
non-reference case discount rate of 1.5% for costs and health effects.
In addition to the analyses undertaken using the conventional reference case approaches, a series of more
exploratory analyses was also undertaken. In particular, the per-patient assessments were subsequently
scaled up to population assessments, requiring an estimate of the number of potentially eligible patients
(assumed to be approximately 38 patients per annum) and an assessment of the ‘technology time horizon’,
that is, the period over which the therapy might be utilised within clinical practice (assumed to be 10 years
in the exemplar). Although the population-level analyses are not formally requested within the existing
NICE methods guide for reporting cost-effectiveness results,122 an assessment of population impact is
required within section 5.12 (Impact on the NHS). Hence, these exploratory analyses were considered to be
consistent with the requirement to consider the population impact and the specific requests within section
6.4.1 (Research recommendations) for the committee to balance the potential NHEs of current and future
NHS patients when considering making research recommendations.
The results of the population-based analyses were summarised in terms of incremental NHEs (both in terms
of QALYs and equivalent monetary value) together with an assessment of the probability that CAR T-cell
therapy was cost-effective. Alongside these more conventional assessments, an assessment of the scale of
the likely consequences was considered to be potentially informative to the committee, particularly in
deliberations related to possible research recommendations. An estimate of the consequences of existing
decision uncertainty was subsequently derived, reflecting the possible scale of NHEs that could be gained if
uncertainty surrounding this decision could be resolved.
Using the different analyses, the impact of alternative pricing scenarios was explored, including conventional
PASs (i.e. equivalent to a fixed price reduction) as well as more sophisticated schemes based on pay for
performance and leasing approaches. Similarly, the impact of the alternative evidence sets was explored to
establish the implications of increased precision and maturity assumed in the intermediate and mature
evidence sets.
An important consideration within this work is the extent to which current NICE methods and processes are
likely to appropriately quantify the potential uncertainties surrounding regenerative medicines and cell-based
therapies to ensure that appropriate policy decisions are made regarding the adoption and spread of
potentially promising technologies. Our findings show that the conventional assessments requested
within the current TA process may not be sufficient. Estimates of the ICER and associated uncertainty
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FIGURE 24 Comparison plot of consequences of decision uncertainty across alternative pricing schemes: curative
intent TPP – minimum evidence set.
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FIGURE 25 Comparison plot of the consequences of decision uncertainty across alternative evidence sets: curative
intent TPP.
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FIGURE 26 Scatterplots of incremental costs and incremental effectiveness across evidence sets: curative intent TPP.
(a) Base case; (b) intermediate evidence set; and (c) mature evidence set. Blue box=mean of the probabilistic
sensitivity analysis values. (continued )
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FIGURE 26 Scatterplots of incremental costs and incremental effectiveness across evidence sets: curative intent TPP.
(a) Base case; (b) intermediate evidence set; and (c) mature evidence set. Blue box =mean of the probabilistic
sensitivity analysis values.
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(e.g. probability that a technology is cost-effective) were shown to be similar in one of the TPPs despite
being based on three different evidence sets with varying levels of precision and maturity. Consequently, it is
unclear how these differences would be reflected within the current deliberative process. Although it is
acknowledged that different conclusions might be reached based on informal judgements, the importance
of ensuring transparency in subsequent decisions remains a key principle of NICE and appears to be critical
for manufacturers in developing appropriate R&D and pricing strategies.
The presentation of the scale of the consequences using population NHEs provided a clearer distinction
between the different evidence sets and the impact of alternative pricing schemes. Consequently, their
more routine application within the TA process for regenerative and cell-based therapies may be an
important consideration for NICE. Furthermore, such comparisons could also provide a more transparent
and explicit basis for considering the value of direct price reductions that might be realised using a
conventional PAS (or less conventional schemes that work by indirectly lowering the effective price)
compared with the provision of additional evidence (both precision and maturity) in terms of reducing
decision uncertainty and its consequences. Such information might provide an important basis for
discussions between manufacturers, NICE and other relevant parties in terms of how the existing
uncertainties that exist might be appropriately managed, ensuring that risks and benefits are more
appropriately shared.
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Chapter 9 Issues arising from the National
Institute for Health and Care Excellence
panel meeting
Aseparate panel and meeting were convened by NICE to discuss the findings from Chapters 1–8 of thereport. The panel included clinical experts and current and past NICE committee members and was
chaired by Professor Andrew Stevens (current chairperson of the NICE Technology Appraisal Committee).
A full list of panel members is provided in Appendix 9. The objective of the panel meeting was to assess
the clinical effectiveness and cost-effectiveness evidence informing the separate TPPs and to identify
potential issues and challenges for the NICE TA appraisal process and methods.
A summary of the clinical effectiveness and cost-effectiveness evidence was presented to the panel, together
with an overview of key technical and process issues for consideration. The panel was then presented with a
series of separate decision scenarios reflecting the two separate TPPs (bridge to HSCT and curative intent),
the three evidence sets (minimum, intermediate and mature) and the impact of different pricing approaches
based on the minimum evidence set. The panel was requested to deliberate on the scenarios and to provide
‘hypothetical’ decisions and outline the main considerations for these. The panel was requested to focus
particularly on the role of uncertainty (clinical effectiveness and cost-effectiveness) to (1) identify key areas
of uncertainty, (2) understand the nature of assessments/analyses that could help to inform deliberations and
(3) explore the impact of different pricing approaches and different evidence sets.
The main clinical effectiveness and cost-effectiveness issues discussed by the panel are summarised in the
following sections. This is followed by a summary of the panel discussions related to the separate scenarios.
Clinical issues
When asked for their thoughts, following a presentation of the clinical effectiveness and safety issues, the
panel clinical experts commented that, although the data for CAR T-cell therapies were limited, the results
nevertheless appeared to be very encouraging when T-cell therapy was compared with the best available
alternative (clofarabine). They added that manufacturers nevertheless need guidance on how to account
for the uncertainty of trial results, given the availability of only short-term data and the potential long-term
effects. It is likely that future cell therapies will be aimed at larger populations (which ties in with the
EMA’s adaptive pathways approach; see Chapter 2), and the panel members also highlighted that clarity
was needed around how data requirements might change according to the size of the population.
The clinical experts stated that knowledge is improving about which patients will have side effects from
CAR T-cell therapies. Knowledge on predictors of response (effect modifiers) was less developed, although
the panel thought that the possibility of ERGs having access to IPD during any assessment could be an
important step to help identify possible effect modifiers and to assess the reliability of submitted evidence.
For this assessment, it was suggested that there might be interest in whether relapsed patients responded
better than refractory patients.
The clinical experts were also asked about the potential variability in the efficacy and safety profiles of
these types of interventions as a result of manufacturing variability and heterogeneity in patient response.
It was considered that any differences in efficacy and safety because of variability in the manufacturing
process are likely to be largest early on, but will be optimised with time. Variability of efficacy and safety as
a result of individual patient heterogeneity is, however, likely to remain.
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In response to a question from the panel about the success rates when manufacturing individual treatments,
the clinicians said that, although the success rates for ‘expanding’ CAR T-cells is high for B-ALL patients,
it is difficult to tell which patients’ (cells) can be successfully expanded (i.e. successful manufacture of the
bespoke treatment). They stated that patients may die before the cell-based therapies can be produced and
administered. It was noted that it will, therefore, be very important that trials report data relating to the full
intention-to-treat population, including those patients for whom CAR T-cell expansion was not successful.
If any patients required retreatment this should also be clearly reported.
There were serious concerns from the panel regarding the level of uncertainty in the evidence base, in
particular that it was based on single-arm trials with possibly large unknown biases. There were concerns
from the panel that certain efficacy estimates, particularly for the minimum data set, might be too
optimistic, and questions were asked about whether any such biases could be quantified and adjusted for;
it would be useful to see the impact of more pessimistic efficacy estimates on the cost-effectiveness results.
There were concerns around the long-term benefit of the therapy and whether or not the estimate of OS in
the minimum data set really could be carried into the mature data set.
Another issue that was raised was the panel being provided with knowledge about what further
research had been mandated by the EMA (e.g. for conditional approvals). Understanding this may be
key to knowing how much present uncertainty, and at what cost, can be accepted. The difficulties of
decommissioning services once treatments are approved were also raised as potential problems.
Cost-effectiveness issues
A key issue regarding the cost-effectiveness results and implications for the ‘hypothetical’ decisions was
whether the panel considered that existing criteria considered within the TA process in relation to EoL and
1.5% discounting (applied to costs and health outcomes) could be applied. The panel accepted that,
based on the patient numbers, current prognosis and the likely treatment benefit, CAR T-cell therapy for
relapsed/refractory ALL would be likely to meet existing criteria for EoL. However, the panel also noted that
the existing criteria might need to be reconsidered more generally for therapies with curative potential.
It was argued by one panel member that the EoL criteria were developed to cover scenarios in which
people with conditions such as cancer with a short life expectancy were given some extension but whose
life expectancy was still short. It was suggested that different QALY weights might need to be considered
over a longer period of projected survival benefits for therapies that have curative potential.
The use of the 1.5% discounting was also discussed by the panel. Although it was noted that the existing
criteria had been developed in response to a similar decision context, the panel was also aware that the
criteria had been applied in only one previous appraisal (the TA for which it was developed212). The lack of
precedent was noted and the panel concluded that its application could generate significant debate in
future appraisals. Hence, no conclusion was reached during the panel meeting about its application to CAR
T-cell therapy. The use of stepped discounting recommended by the UK Treasury was discussed by the
panel but was considered to be more relevant for interventions that might have important intragenerational
impacts (e.g. immunisation) as opposed to longer-term intergenerational effects.
In addition to the concerns it noted in relation to the possible biases and additional uncertainty arising from
comparisons based on single-arm trials, the panel raised questions about whether or not there were wider
structural uncertainties relevant to regenerative medicines and cell-based therapies that were not fully captured
within the analyses presented. The panel concluded that identifying sources of potential bias and appropriately
reflecting structural sources of uncertainty would be important considerations in future appraisals, and
manufacturers would need to clearly report how these had been addressed within their submissions.
The panel discussed the sequence of assessments presented in the cost-effectiveness section and the
exploratory approaches to quantifying decision uncertainty based on an assessment of the scale of
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the consequences associated with each decision using population NHEs. The panel agreed that these
exploratory approaches provided a clearer and potentially important distinction between the different
evidence sets and the impact of alternative pricing schemes. The panel also acknowledged that such
assessments provided important information that could help to inform its deliberations. However, the
panel further noted that, although such assessments were helpful and represented a useful starting point
for deliberations, they were not necessarily sufficient to inform its final decisions. In particular, the panel
expressed difficulty in determining how to interpret the numbers presented without a formal reference
point to establish whether the consequences were sufficiently high to impact on their decisions and/or
potential research recommendations.
The panel acknowledged that the estimates of the consequences represented a theoretical upper bound to
the value of further research. However, the panel concluded that it would be important to explore these
consequences further, in terms of both the underlying distribution (as opposed to the expected mean value
of the consequences) and needing to decompose the overall estimate in relation to specific sources of
uncertainty. This latter aspect was considered particularly important in determining the extent to which
particular sources of uncertainty could be resolved by additional research, the type of research that might
be most appropriate and, finally, whether this research would be feasible following a positive approval.
The panel was also aware of the relevance of existing published work128 and work by the NICE DSU211 that
would be important to consider in any review of potential processes or methods.
Prior to a more detailed discussion of the specific decision scenarios, the panel outlined a number of more
general considerations related to the cost-effectiveness evidence and results:
1. In discussing the appropriate cost-effectiveness threshold for the purpose of NICE decision-making, the
panel was clear that £50,000 per QALY (assuming that the EoL criteria applied) represented an absolute
upper bound to the range that NICE would consider acceptable. The panel concluded that other
considerations (e.g. innovation) would not be applied in conjunction with the higher threshold considered
in an EoL appraisal. Furthermore, the panel also considered that the upper end of the range was unlikely
to be considered appropriate in the presence of significant evidential uncertainties.
2. The panel concluded that, if the hypothetical price of CAR T-cell therapy had been set using the
conventional cost-effectiveness threshold range (£20,000–30,000 per QALY), this could have mitigated
some of these uncertainties, increasing the likelihood of a positive recommendation.
3. The panel appreciated that there was a difference between the deterministic estimates of the ICER and the
probabilistic estimates of the ICER because of the non-linearity between the parameter inputs and the
model outputs (i.e. mean costs, QALYs and ICER). The panel also noted that, for some analyses, these
differences resulted in ICER estimates that could have a material impact on its decisions (i.e. situations in
which the deterministic and probabilistic estimates lie on either side of the cost-effectiveness threshold). The
panel concluded that the probabilistic estimates were the more appropriate basis for informing its decisions.
4. The panel raised issues regarding the possible nature and magnitude of any irrecoverable costs that
might be incurred by the NHS and the implications for its decisions. The panel concluded that an ‘exit
strategy’ for the NHS would be a key consideration for interventions that appear highly promising but
for which significant uncertainties and irrecoverable costs may exist.
5. The panel acknowledged that the different pricing schemes had important impacts both in terms of the ICER
and in terms of the allocation of any risk between the NHS and manufacturers. The concept of the ‘leasing
approach’ was identified as a potentially important option and there was consensus among the panel that
this warranted further exploration by NICE and manufacturers (e.g. logistics, costs and overall feasibility).
6. The panel recognised the various issues and challenges likely to be faced by the manufacturers of
regenerative medicines and cell-based therapies. The panel also noted that many of the issues and
implications identified did not appear to be specific to these types of therapies but were also apparent
in appraisals of more conventional products. However, the panel acknowledged that the challenges
may be faced more routinely by manufacturers of regenerative medicines and cell-based therapies and
that the resulting levels of uncertainty (and the potential scale of the consequences) may exceed those
that existing committees might conclude could be appropriately dealt with by existing processes and
the current methods guide.
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Panel discussion of the different scenarios
Following a general discussion of clinical effectiveness and cost-effectiveness issues, the panel was
presented with a series of ‘decision scenarios’ based on the results reported in Chapter 8. For each TPP,
the scenarios started with the minimum evidence set and a fixed acquisition cost for CAR T-cell therapy
(scenario 1). Scenario 2 explored the impact of alternative pricing approaches based on the same minimum
evidence set. Scenarios 3 and 4 were based on the results from the intermediate and mature evidence
sets, respectively, assuming a fixed acquisition cost.
For each scenario, the panel was presented with a summary of the deterministic ICER and the probabilistic,
population-level results, including an estimate of the ICER, an estimate of the incremental NHE (expressed
in monetary and QALY terms), the probability of CAR T-cell therapy being cost-effective and an assessment
of the scale of the consequences of decision uncertainty (again expressed in monetary and QALY terms).
A summary of the panel considerations is provided below:
l For scenario 1, the panel understood that the deterministic estimate of the ICER for CAR T-cell therapy
was close to the £50,000 upper bound of the ICER range considered acceptable currently when the
EoL criteria are met. However, the panel concluded that the probabilistic estimates of the ICER were
more appropriate given the model non-linearity. As the probabilistic ICER in the base case for both
TPPs exceeded the upper bound of the ICER range, the panel concluded that CAR T-cell therapy would
be unlikely to represent an efficient use of NHS resources in scenario 1. The panel concluded that,
although other aspects of innovation were discussed that were important considerations for CAR T-cell
therapy, additional weight should not be incorporated over and above that which had already been
permitted when applying the EoL criteria.
l For scenario 2, the panel acknowledged the different impacts of the alternative pricing schemes on the
ICER, the scale of the consequences of decision uncertainty and the apportionment of any risk between
the NHS and a manufacturer. The panel noted that the lifetime leasing scheme resulted in a significant
reduction in the scale of decision uncertainty compared with a fixed acquisition cost. The panel also
acknowledged that the leasing scheme could also provide an important exit strategy for the NHS given
the high uncertainties that were evident. There was consensus among panel members that innovative
financing schemes could be an important consideration in future appraisals.
l The panel also noted that there were important differences in the scale of the consequences of
decision uncertainty across the separate TPPs, with significantly higher consequences reported in the
curative intent TPP. The panel understood that the use of an external surrogate relationship between
MRD, HSCT and remission status in the bridge to HSCT TPP had an important impact on reducing the
scale of the decision consequences over the modelled time horizon.
l The panel found it difficult to determine the policy significance of the estimates reported for decision
uncertainty without further analyses and an appropriate reference point. However, the panel also
acknowledged in the bridge to HSCT TPP that the magnitude of the incremental NHE (i.e. the NHE that
might be gained from immediate approval) significantly exceeded the scale of the consequences of
decision uncertainty for the pricing schemes formed on a pay for performance approach based on
achieving remission. The panel understood that the higher incremental NHE reported in these scenarios
(and reduction in the consequences of decision uncertainty) was driven by the lower ICER as a result
of the direct or indirect impact on the acquisition cost of CAR T-cell therapy and that this had an
important impact on the scale of the consequences of decision uncertainty.
l Faced with the high levels of uncertainty, the panel concluded that schemes that reduced the ICER to
significantly below the upper bound of the EoL range and closer to the more conventional ICER range
(£20,000–30,000 per QALY) would increase the likelihood of approval.
l The panel also acknowledged that the reduction in the consequences of decision uncertainty in the
leasing and pay for performance schemes arose because of the risks being shared between the NHS
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and manufacturers. Although the ICER of the lifetime leasing method exceeded the upper bound of
the EoL range, the panel concluded that it may have looked more favourably on a combined scheme
involving a fixed price discount and a leasing element in the bridge to HSCT TPP. However, in the
absence of being provided with a formal assessment of this scheme, the panel felt that it was not
possible to make a clear recommendation.
l The panel was less clear on potential recommendations across the different pricing schemes for the
curative intent TPP. Although the panel acknowledged that the consequences of decision uncertainty
were reduced by each of the alternative pricing approaches, it remained concerned at the scale of the
consequences that remained. Again, the panel concluded that it may have looked more favourably on
a combined scheme involving a fixed price discount and a leasing element but noted that it had not
been presented with results from such a scenario.
l The panel was also aware that different prices were assumed across the separate TPPs, reflecting the
different effectiveness estimates reported in the different studies used in each TPP. The panel indicated
that, if the same price that was used in the bridge to HSCT TPP had been applied in the curative intent
TPP, this would have potentially significantly improved the ICER and lowered the consequences of
decision uncertainty.
l Faced with higher consequences in the curative intent TPP, the panel concluded that the combination
of using the same price as in the bridge to HSCT TPP and a leasing scheme would potentially improve
the ICER and lower the consequences of decision uncertainty to a level that could potentially be
acceptable. Again, in the absence of being provided with a formal assessment of such a scheme,
the panel felt that it was not possible to make a clear recommendation.
l The panel discussed the additional evidence sets that had been generated for each TPP (scenarios 3
and 4). The panel acknowledged that these estimates were generated using a series of assumptions
and hence remained subject to various additional uncertainties. However, the panel understood the
principles that were being considered and that there were important differences across the evidence
sets for the separate TPPs. The panel understood that the difference across the TPPs was primarily the
use of an external surrogate relationship in the bridge to HSCT TPP. The panel acknowledged that
greater uncertainty could arise in situations in which a robust surrogate relationship had not been
demonstrated and that ensuring that evidence is sufficiently robust (i.e. in terms of precision and/or
maturity) for decision-making would be an important consideration. The panel noted that the
consequences of decision uncertainty in the intermediate evidence set for the curative intent TPP were
significantly reduced compared with those in the minimum evidence set and were closer to the scale of
those reported for the minimum evidence set for the bridge to HSCT TPP, for which a surrogate
relationship had been assumed.
l The panel understood that the scale of the consequences was further reduced in the mature evidence
sets because of increased precision (compared with the intermediate data set) and maturity (compared
with the minimum evidence set) and that this was most evident in the curative intent TPP because
additional surrogate evidence had not been included.
l The panel acknowledged the challenges and difficulties of generating mature evidence at the point at
which a product is launched. However, the panel considered that the principles outlined through the
different assessments would be important in informing future deliberations. In particular, the panel
noted that a comparison of the magnitude of the incremental NHE and the consequences of decision
uncertainty provided an important starting point for deliberations regarding the scale of the NHE that
could be achieved by immediate approval and that which might be achieved by further research.
l The panel noted that further assessments could be helpful to inform (1) whether a positive approval
decision might alter incentives to undertake the type of research necessary to resolve the main sources
of uncertainty and (2) the full opportunity costs of approval and rejection decisions. The panel
concluded that further information concerning the distribution of the consequences and further
exploration of the main sources of these consequences would provide important additional information.
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Additional exploratory analyses undertaken after the
panel discussion
Following the panel meeting, a series of additional exploratory analyses was undertaken to capture some
of the specific requests and considerations that were identified during the panel discussions. These
analyses are not intended to be comprehensive but rather to reflect on some of the main points raised and
to consider any further implications.
Information on the distribution of consequences is shown in Figure 27 based on the minimum evidence
set of the curative intent TPP. The most common outcome (50.7%) is for CAR T-cell therapy to be
cost-effective at a willingness-to-pay threshold of £50,000. Consequently, there are no negative
consequences to the NHS in these instances. However, in 49.3% of iterations (1 – probability of CAR
T-cell therapy being cost-effective), the decision to recommend CAR T-cell therapy may be incorrect (at a
willingness-to-pay threshold of £50,000). The consequences of making an incorrect decision are expressed
in terms of the NHEs forgone. In this analysis, most of the negative consequences are < 1000 QALYs
(probability of 36.4%). The probability that the negative consequences exceed 1000 and 3000 QALYs is
12.9% and 0.1%, respectively.
The panel was also interested in exploring the impact of a number of alternative pricing schemes on the
cost-effectiveness of CAR T-cell therapy and associated decision uncertainty. These schemes included the
application of the bridge to HSCT fixed acquisition cost to the curative intent TPP, as well as a lifetime
leasing approach with or without an additional 10% price discount.
Applying both a lifetime leasing method and a 10% discount to the cost of CAR T-cell therapy to the
minimum evidence set analysis for the curative intent TPP improved the ICER (£45,502 per QALY), resulting
in a large decrease in the consequences of decision uncertainty and an increase in the probability of
cost-effectiveness, as shown in Table 40.
Applying the bridge to HSCT fixed acquisition cost of CAR T-cell therapy (£356,100) to the minimum
evidence set analysis for the curative intent TPP significantly improved the cost-effectiveness of curative CAR
T-cell therapy, resulting in an ICER of £34,337 per QALY (see Table 40). With improved cost-effectiveness,
the expected consequences of decision uncertainty are also improved, decreasing from 304 QALYs
(£15.23M) in the base case to 73.1 QALYs (£3.66M). Applying a lifetime leasing method resulted in further
reductions in the consequences of decision uncertainty to 2.3 QALYs (£0.11M). By applying an additional
10% discount alongside the leasing and bridge to HSCT acquisition cost, it was possible to eliminate the
potential consequences of decision uncertainty (at a willingness-to-pay threshold of £50,000).
These additional analyses further reinforce the importance of considering the implications of decision
uncertainty for the ICER as well as the scale of the consequences. A key finding from these additional
analyses is that the consequences of decision uncertainty in the minimum evidence set can be significantly
lowered by reductions in price or the application of alternative pricing schemes. Indeed, the additional
exploratory analyses reveal that the scale of the consequences might be reduced to a similar or even
lower magnitude than that which could be resolved through the provision of further evidence alone.
Furthermore, by reducing the opportunity costs of early approval, increased flexibility in pricing and pricing
approaches would allow more patients to receive early access to potentially innovative regenerative
medicines and cell-based therapies.
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Chapter 10 Discussion
Implications for the National Institute for Health and Care
Excellence technology appraisal process
Modifications (which may sometimes be informed by methods research) might be considered to update
the methods guidance provided to manufacturers and ERGs in the following areas.
Use of surrogate end points
The choice of surrogate end points used by manufacturers in their submissions must be researched, explicit
and justified. Ideally, a systematic review should be performed to evaluate the strength of the association
between the surrogate and the patient-relevant outcome, and the evidence on surrogate validation should
be presented according to an explicit hierarchy.
Pivotal study design and the use of historical control data sets
For manufacturer submissions, consideration should be given to the benefits of producing recommendations
and/or minimum reporting requirements in terms of the methods used to obtain and analyse single-arm trial
data when they are compared with historical control data. When single-arm trial data form the main basis of
an assessment, a clear rationale should be given for the type of comparisons made (implicit or explicit) and
for the choice of the historical control data that were selected. For example, the gold standard for historical
data might be matched data obtained from a patient database (rather than relying on published studies,
which might not fit the trial population being studied well enough). When designing trials, manufacturers
should bear in mind that multicentre trials are likely to produce more reliable and generalisable results than
single-centre trials.
Evidence Review Groups might benefit from using checklists when appraising how historical control data
were identified and analysed by manufacturers.
Efficacy estimates
Submission of IPD might be beneficial for ERGs, especially when data sets are small. Use of multivariate
meta-analysis can lead to reduced uncertainty around the effectiveness parameter. By allowing all of the
relevant data to be incorporated in estimating clinical effectiveness outcomes – including data from
surrogate outcomes – multivariate meta-analysis can improve the estimation of health utilities through
mapping methods.
Manufacturers should report the data for the full trial population, that is, all eligible patients, including
patients who died before they could receive treatment and patients for whom a bespoke (autologous)
treatment could not be produced.
The role of any further mandatory trial evidence
Manufacturers should provide details of mandated further studies (e.g. those related to conditional
approvals or approvals made through the EMA’s adaptive pathways approach). Future reports from the
ADAPT SMART project should provide details about how the use of development plans across target
populations agreed upfront with the EMA is working. Guidance may be needed regarding methodological
approaches to utilising ‘confirmatory’ trial data in a related indication to update the decision that NICE
made for the original indication.
Consideration is also needed regarding the precise role that NICE will have in EMA adaptive pathways processes.
For example, what will be the mechanisms by which the EMA updates NICE with new efficacy and safety data
for conditionally approved ATMPs (in a timely way) and how will NICE deal with the new data (process wise)?
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Extrapolation approaches
Given the inevitable uncertainties that are likely to exist regarding the longer-term benefits of regenerative
medicines and cell-based therapies, further methodological research could be usefully undertaken to help
inform how these uncertainties might be appropriately quantified in a transparent manner to inform
cost-effectiveness analyses. Further research may be particularly helpful to determine the appropriateness
of alternative survival modelling approaches to regenerative medicines and cell-based therapies, including
more flexible survival models and cure fraction models.
The level of data maturity is an important factor in deriving robust survival projections that are required
for cost-effectiveness assessments. When follow-up is immature, a single ‘best-fitting’ survival distribution
may not adequately characterise uncertainties over the longer-term extrapolation period. Although the
robustness of the ICER estimates to alternative distributions can be explored through separate sensitivity
analyses or scenarios, the transparency of the process may be impacted if the weighting of these is not
explicitly considered in subsequent policy decisions. The feasibility and appropriateness of model-averaging
approaches may also need to be considered more formally. The advantage of these approaches is that the
parametric uncertainty associated within each distribution and the uncertainty (or weights) surrounding the
choice of preferred method can be more explicitly characterised. However, given the potential complexity
in both undertaking these analyses and communicating the results, efforts will need to be made to ensure
that models are developed so that informal judgements can be explicitly incorporated in a timely and
transparent manner.
Irrecoverable costs and possible learning curve effects
Given the complexity of the treatment pathways that may be required for regenerative medicines and
cell-based therapies, manufacturers will need to report clearly the resource and cost assumptions of the
different processes required to determine whether the full costs to the NHS have been included and
any aspects for which uncertainties may exist. Issues of irrecoverable costs may need to be considered
more formally, particularly if a new technology could impose additional infrastructure requirements on the
health system. If reimbursement decisions about the technology change before the end of the lifetime of
the equipment (e.g. approval is withdrawn), then these costs may not be recovered and hence need to be
explicitly considered.
The existence and possible impact of learning curves may also be an important issue for clinical
effectiveness and cost-effectiveness assessments. Although the existence of learning curves has received
attention in the clinical literature, the relevance of recent work in this area in the context of assessing the
cost-effectiveness of medical devices should be considered.133
Quantification of decision uncertainty
Presentation of the scale of the consequences of decision uncertainty using population NHEs may provide
an important additional approach to quantifying decision uncertainty to the assessments already routinely
specified within the existing TA methods guide.122 The implications of existing research128 and research by
the DSU211 will also need to be considered by NICE to determine whether further changes to its processes
or methods may be helpful for informing the nature of any additional assessments that may be required.
Such assessments could provide a more transparent and explicit basis for discussions between manufacturers,
NICE and other relevant stakeholders in terms of how the existing uncertainties might be appropriately
managed, ensuring that risks and benefits are more appropriately shared. Broader consideration will also need
to be given to approaches that may extend beyond NICE’s existing remit, for example alternative payment
schemes. Consequently, other bodies and manufacturers themselves may also have an important role in
identifying more innovative approaches to seeking reimbursement that recognise the inherent uncertainties and
lead to a more efficient sharing of associated risk.
DISCUSSION
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Existing criteria
The National Institute for Health and Care Excellence’s existing processes also make separate provision for
specific disease and technology characteristics that may be relevant to many regenerative medicines and
cell-based therapies. Although NICE’s current EoL criteria allow the committee to explore a QALY weighting
that is different from that of the reference case, the appropriateness of these criteria may need to be
considered in relation to treatments that have curative potential. Further methodological research may also
be important to determine whether an alternative weighting approach might be more appropriate for
curative therapies. Existing research has identified a potential disconnect between individual and societal
preferences concerning valuation of treatment compared with preventative interventions. Further research
that is more specifically focused on the concept of cure may provide important additional insights.
Although the NICE methods guide permits the use of a non-reference case discount to be applied in
specific contexts, it remains unclear whether regenerative medicines and cell-based therapies would meet
the existing criteria (e.g. uncertainties over the projected benefits and/or potentially significant irrecoverable
costs). Consequently, NICE may need to provide additional guidance to ensure that manufacturers
understand the likelihood of meeting these criteria.
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Appendix 1 Regenerative medicines licensed by
the European Medicines Agency
TABLE 41 Regenerative medicines that are (or that have been) licensed by the EMA
Glybera (alipogene tiparvovec): EMA assessment (CAT and CHMP) 201218
EMA marketing authorisation under exceptional circumstances
Nature of the disease
Indication The indication initially applied for was (p. 11):18
Glybera is indicated for the long term correction of lipoprotein lipase deficiency,
to control or abolish symptoms and prevent complications in adult patients
clinically diagnosed with lipoprotein lipase deficiency (LPLD)
The indication for which a licence was granted is more restricted (p. 98):18
Glybera is indicated for adult patients diagnosed with familial lipoprotein lipase
deficiency (LPLD) and suffering from at least one pancreatitis episode despite
dietary fat restriction. The diagnosis of LPLD has to be confirmed by genetic
testing. The indication is restricted to patients with detectable levels of LPL protein
Orphan status? Yes
Is this a rare condition? The calculated prevalence of this condition was reported to be 0.02 per 10,000
What is the natural history of the
disease without this treatment/
with current treatment?
LPLD is a rare autosomal recessive inherited condition caused by homozygosity or
compound heterozygosity for mutations in the LPL gene. The condition may become
evident only after several episodes of pancreatitis in adolescence or adulthood.
Laboratory investigation reveals genuine lactescent plasma (lipaemia) because of the
increased chylomicron concentrations. The symptom severity is proportional to the
degree of chylomicronaemia and the most severe complication associated with LPLD is
pancreatitis. Pancreatitis in a LPLD subject may lead to admission to an intensive care
unit. In severe cases, patients may eventually develop chronic pancreatitis, ultimately
resulting in endocrine and exocrine pancreatic insufficiency. Treatment of LPLD patients
currently consists of severe reductions in dietary fat to < 20% of caloric intake.
Compliance with this dietary regimen is very difficult and, even with good compliance,
the diet is often ineffective at reducing chylomicronaemia and triglyceride levels.
Currently, no triglyceride-lowering drug is available. Enzyme replacement therapy is not
expected to be effective because of the short intravascular half-life of the LPL protein
Nature of the medicine
How does it work? Glybera is a replication-deficient adeno-associated viral vector designed to deliver and
express the human LPL gene variant LPLS447X. Transduction of part of the skeletal
muscle mass is expected to restore a level of LPL activity that is sufficient to hydrolyse
the triglyceride-rich lipoproteins and influence lipid homoeostasis and thus lead to
clinical improvement or stabilisation
Is it claiming to meet an
otherwise unmet need?
Yes, the therapeutic aim of Glybera was to control symptoms of LPLD and prevent
complications in adult patients clinically diagnosed with LPLD
How is it given? A sterile solution for injection presented as single-use vials. Each vial contains 3 × 1012
genomic copies (gcs) of alipogene tiparvovec (AAV1-LPLS447X) in 1 ml of a
phosphate-based formulation buffer containing 5% sucrose. Glybera is to be
administered once at multiple sites intramuscularly at a dose of 1 × 1012 gcs/kg of
body weight. Note that Glybera is intended as a single procedure but with multiple
injections (up to 60 injection sites) administered under regional or spinal anaesthesia.
All 27 patients reported adverse events related to the injection procedure
Are there any comparator
treatments?
Reducing chylomicronaemia and triglyceride levels by reducing dietary fat to < 20% of
caloric intake
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TABLE 41 Regenerative medicines that are (or that have been) licensed by the EMA (continued )
Glybera (alipogene tiparvovec): EMA assessment (CAT and CHMP) 201218
Is there any mention of the
intervention evolving over time?
The applicant uses two different company codes to differentiate between the current
production system (AMT-011) and the previous production system (AMT-010). There
were changes during the development phases but the CHMP felt that issues relating to
these had been resolved and ‘consistency of product quality throughout development
has been shown’ (p. 14)18
Is there any mention of
persistence of the treatment
within the patient?
Negative effects of persistence – it is considered that, although recombinant
adeno-associated virus has a potential integration risk, the risk of a consequent cancer
is minimal. In the context of treating patients with this disease, these data suggest an
acceptable safety profile.18 Overall, the CAT and CHMP agreed that the data do not
substantiate a concern for tumourigenicity
Positive effects of persistence – the post-treatment observation period was insufficient
for conclusions to be made about a rate of change of pancreatitis events long term.
The totality of evidence derived from all studies combined suggested that AMT-011
may temporarily reduce mean fasting triglyceride levels but the proposed single
treatment was insufficient to provide a durable and measurable effect
Trial design
Trial description
Study number
Dose
(gc/kg)
Number
of patients
Duration of
monitoring
Duration of
follow-up Status
PREPARATION-01 None 18 13–78
weeks
– Completed
CT-AMT-010–01 1 × 1011 4 12 weeks 5 years Active phase
completed,
follow-up
ongoing
3 × 1011 4
PREPARATION-02 None 22 2–83 weeks – Completed
CT-AMT-011–01 3 × 1011 6 12 weeks 5 year Active phase
completed,
follow-up
ongoing
1 × 1012 8
CT-AMT-011–02 1 × 1012 5 18 weeks
(including
4 weeks’
run-in)
1 year Completed
Two observational preparation studies were carried out to collect baseline data
(no treatment control)
Glybera was studied in three uncontrolled, open-label interventional studies
(CT-AMT-010–01, CT-AMT-011–01 and CT-AMT-011–02) with a combined total
sample size of 27. Three different dose regimens were evaluated in CT-AMT-010–01,
CT-AMT-011–01 and CT-AMT-011–02. CT-AMT-011–02 was a safety and efficacy
trial; initially planned as a controlled study it was subsequently amended to an
uncontrolled study because of difficulties in identifying patients with a high baseline
risk of pancreatitis. It should be noted that a different Glybera product was used in the
AMT-010 and AMT-011 trials because of a change in the manufacturing process. The
first cohort in the AMT-011 trials (n= 2 subjects) was administered 3 × 1011 gc/kg of
AMT-011 to serve as a bridging arm to gauge the similarity in the safety and efficacy
of AMT-011 relative to AMT-010. CT-AMT-011–01 and CT-AMT-011–02 included an
immunosuppressive regimen. CT-AMT-011–01 included a combination of ciclosporin A
(3 mg/kg/day) and mycophenolate mofetil (2 g/day) given over 12 weeks. The regimen
in CT-AMT-011–02 was the same as that in CT-AMT-011–01 but also included a
single bolus of methylprednisolone (single intravenous bolus of 1 mg/kg) given half an
hour before administration of ciclosporin A and mycophenolate mofetil. Efficacy was
assessed over 12 weeks, with long-term follow up planned for 5 years. The analysis of
pancreatitis events was attempted post hoc by examining the number of events or
admissions to an intensive care unit retrospectively as this was not a prespecified
analysis
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TABLE 41 Regenerative medicines that are (or that have been) licensed by the EMA (continued )
Glybera (alipogene tiparvovec): EMA assessment (CAT and CHMP) 201218
Trial population (adults/children/
all); any further specifics of
disease not covered in ‘Indication’
PREPARATION-01: 18 LPL-deficient patients aged ≥ 18 years with type I
hyperchylomicronaemia, post-heparin LPL activity < 25% of the normal level and
plasma concentration of triglycerides > 95th percentile for age and sex. Seventeen
subjects completed the study; one subject died of a cardiac arrest
CT-AMT-010–01: 8/18 patients from the PREPARATION-01 cohort with confirmed
homozygotic and compound heterozygotic LPL gene mutations
PREPARATION-02: 22 subjects with LPLD, LPL activity ≤ 20% of normal, LPL mass
> 5% of normal and fasting plasma triglyceride concentration > 10mmol/l. Twenty
subjects completed the study; two subjects withdrew
CT-AMT-011–01: 15/22 subjects from PREPARATION-02 cohort; one subject was
withdrawn and thus 14 subjects entered the study long term. Follow-up extended up
to 5 years
CT-AMT-011–02: five patients enrolled to examine postprandial chylomicron
metabolism, fasting triglyceride level, serum LPL activity and pancreatitis; only one
patient provided data
Trial size/total trial population Combined total n = 27
Length of follow-up See table above
Control/comparator used The two observational studies (PREPARATION-01 and PREPARATION-02), which included
patients receiving only diet reduction and no active treatment, acted as the control for
the active treatment studies. Note: some patients (not all) from the PREPARATION-01
and PREPARATION-02 studies took part in the active treatment studies
How is the control/comparator
constructed?
See previous section
Outcomes
Response outcome 1 PREPARATION studies – fasting plasma triglyceride levels and disease complications in
LPL-deficient subjects on a low-fat diet
Active treatment studies – across the three studies a measure of the reduction in
fasting plasma triglyceride levels to < 10mmol/l or to 40% of the starting level was
either a primary or a secondary outcome
Response outcome 2 PREPARATION studies – to record the incidence of pancreatic events in the context of
the safety evaluation
Active treatment studies – a reduction in frequency and/or severity of clinical signs
and symptoms related to LPL deficiency (i.e. eruptive xanthomas, lipaemia retinalis,
pancreatitis, episodes of abdominal pain, plasma lactescence, lack of energy/fatigue
and quality of life and diabetes management). The incidence of pancreatitis was the
most clinically meaningful end point
Response outcome 3 Other measures of the effect of active treatment [e.g. clearance of chylomicrons and
other determinants of the biological activity of the LPL (LPLS447X) transgene product]
Adverse events Overall, Glybera was well tolerated by all patients during the initial 12-week
observational period and during the long-term phase of observation (up to 3 years
with CT-AMT-010–01). All reactions were self-limiting and mild in nature. There were
no obvious serious adverse events seemingly related to Glybera
Surrogate or intermediate clinical
outcome?
Yes – the effect on lipid profiles, such as a reduction in fasting triglycerides to
< 10mmol/l or a > 40% reduction in fasting triglycerides, is a surrogate marker of LPL
activity-related clinical benefit. A reduction in post-prandial chylomicronaemia has been
proposed as an alternative surrogate marker and, subject to clinical validation, a
reduction in post-prandial chylomicronaemia could be accepted as a surrogate marker
for efficacy
Real clinical outcome? Yes (a reduction in pancreatitis events was suggested using retrospective data)
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TABLE 41 Regenerative medicines that are (or that have been) licensed by the EMA (continued )
Glybera (alipogene tiparvovec): EMA assessment (CAT and CHMP) 201218
Summary of efficacy evidence
Overall evidence base provided CT-AMT-011–02 was the only study yielding data allowing the possibility of making a link
between surrogate and clinical end points (pp-CM metabolism, fasting triglyceride levels,
serum LPL activity, pancreatitis). Only one patient out of five responded to the treatment
The presented data set in relation to the restricted indication included 12 out of 27 patients
treated with Glybera, who were aged 40–70 years of age and were diagnosed with LPLD
relatively late in life
The reduction in post-prandial chylomicronaemia as an alternative surrogate marker for
efficacy, although not validated at present, was considered biologically plausible and
acceptable. The data on pancreatitis remain very limited and include a very small
number of patients (n= 12) with limitations acknowledged in the statistical analysis
In summary, the evidence generated by the reduction in pancreatitis events and
severity of attacks, although hampered by statistical limitations and by fluctuations in
the occurrence of pancreatitis, suggested that Glybera leads to a clinically relevant
reduction in pancreatitis risk, at least in some patients. This is also supported by the
reduction in hospital admissions and intensive care unit stays. Of particular note is the
fact that, although about half of the 17 patients required an intensive care unit stay
because of pancreatitis events before treatment, no intensive care unit stay was
recorded in the same patients after treatment, compared with non-treated patients
Estimate of effect on HRQoL The reduction in SF-36 scores (from both the physical functioning and the mental
domains) in three out of five patients in the CT-AMT-011–02 study at week 14
following treatment was of major concern. The applicant explained the quality-of-life
reduction by adverse events and immunosuppression. However, the data on quality of
life from later time points (up to week 52) and from all other studies conducted with
Glybera are not available
Other issues
Any issues of scale-up for the
product?
1. During the development of the AMT-011 process a number of changes have been
made during scale-up
2. A two-tiered system has been established for commercial drug substance
production based on master and working cell banks (MCB, WCB) and master and
working viral seed stocks (MSV, WSV)
Is further evidence requested for
approval?
1. The marketing authorisation holder shall set up a long-term surveillance
programme/disease register before launch of the product in each country to collect
information on the epidemiology of the disease and the demographics and safety
and effectiveness outcomes of patients treated with Glybera. The patients enrolled
in clinical studies (CT-AMT-010–01, CT-AMT-011–01, CT-AMT-011–02) should be
followed up in the LPLD registry
2. Assessment of postprandial chylomicron metabolism in at least 12 patients, before
and 12 months after treatment with Glybera, to be carried out in addition to
assessment of the patients included in the CT-AMT-011–02 study and eight healthy
subjects in the second cohort. Assessment of immune response at baseline,
6 months and 12 months in at least 12 newly treated patients. The study should
start by July 2013 and should enrol at least four patients per year
3. Re-evaluation of immune responses from all patients enrolled in the CT-AMT-011–01
study by using a validated assay method should also be provided
4. To improve the virus safety profile of the product
5. To complete the validation of the residual infectious baculovirus assay
Notes Given the rarity of LPLD (prevalence in the EU of 2 in 1,000,000), the uncontrolled
study design applied in all three clinical trials using subjects as their own control was
accepted and in line with the scientific advice given. Development of studies was
hampered by difficulties in the recruitment of sufficient numbers of patients
The Scientific Advisory Group considered that it is not possible to exclude completely
the hypothesis that the reduction in the incidence of pancreatitis in some patients
is due to the inherent temporal rarity of pancreatitis events. Issues inherent to
retrospective data assessment in comparison to prospective data assessment were
highlighted by the CAT
Across the three active treatment trials the primary and secondary outcomes were not
the same
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TABLE 41 Regenerative medicines that are (or that have been) licensed by the EMA (continued )
MACI: EMA assessment (CHMP and CAT) 2013,19 NICE multiple technology appraisal 201420
EMA marketing authorisation in April 2013, which was subsequently suspended in September 2014 (an authorised
manufacturing site no longer existed)
Nature of the disease
Indication MACI is to be used in skeletally mature patients for the repair of symptomatic cartilage
defects of the knee (grades III and IV of the arthroscopic staging of osteochondral
lesions as described by the modified Outerbridge scale)
Orphan status? No
Is this a rare condition? No. Cartilage injuries were observed in 5–11% of diagnostic knee arthroscopies in
predominantly young adult populations with knee pain
What is the natural history of the
disease without this treatment/
with current treatment?
Cartilage defects of the knee occur along a spectrum of disease and severity. Larger,
more chronic lesions are often symptomatic, may contribute to joint misalignment and
can cause disabling symptoms such as pain, catching, locking and swelling. Focal
chondral lesions that are left untreated may progress to debilitating joint pain,
dysfunction and degenerative arthritis
Nature of the medicine
How does it work? It is the first advanced-therapy medicine to be combined with a medical device – in this
case the cells are embedded in a biodegradable matrix. It attempts to generate hyaline
or hyaline-like cartilage. ACI requires two surgical procedures, first to harvest
autologous chondrocytes, which are then grown extracorporeally, and then to
transplant the cultivated cells back into the lesions. The benefit of ACI over other
restoration techniques is that larger lesions can be treated
Is it claiming to meet an
otherwise unmet need?
No, other treatment options (such as microfracture) exist and clinical practice varies
How is it given? Autologous chondrocytes are seeded onto a collagen membrane of porcine origin, which
is secured into the lesion with fibrin glue. At implantation, the membrane is trimmed to
the correct size and shape and implanted cell-side down into the base of the defect; the
implant is secured in place using fibrin sealant. The recommended dose of MACI implant
is 500,000–1,000,000 cells/cm2 of defect. The dose is the same for all patients, regardless
of age
Are there any comparator
treatments?
Repair techniques such as microfracture aim at marrow stimulation and induce the
formation of fibrocartilage repair tissue to treat patients with focal chondral defects in
the knee. These techniques penetrate the subchondral bone and cause release of
marrow components into the defect site. The reparative response produced from these
procedures is one that may generate primarily fibrocartilage. Single-stage restoration
techniques such as osteochondral autograft, mosaicplasty and osteochondral allograft
attempt to replace the cartilage defect with host or donor articular cartilage
Is there any mention of the
intervention evolving over time?
Yes – MACI is a third-generation ACI product. ERG report (for NICE) stated that ‘There is
a general problem when long-term results are needed but the technology continues to
evolve’ (p. 148)20
Is there any mention of
persistence of the treatment
within the patient?
In concept, the MACI implant would contribute to the repair of articular cartilage
defects through proliferation of seeded chondrocytes, resulting in synthesis of
hyaline-like repair tissue
Trial design
Trial description The clinical data consist of the pivotal Superiority of MACI Versus Microfracture Treatment
(SUMMIT) multicentre, randomised, open-label parallel-group trial (MACI00206)
supported by several clinical studies reported in the literature.19 The internal study reports
were small-scale, non-randomised prospective studies. The aim of the SUMMIT trial
was to demonstrate the superiority of the MACI implant compared with arthroscopic
microfracture for the treatment of symptomatic articular cartilage defects of the femoral
condyle, including the trochlea
Trial population (adults/children/
all); any further specifics of
disease not covered in
‘Indication’
Male and female patients aged between 18 and 55 years (inclusive) with at least one
symptomatic Outerbridge grade III or IV focal cartilage defect on the medial femoral
condyle, lateral femoral condyle and/or trochlea (defect size ≥ 3.0 cm2 irrespective of
location)
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TABLE 41 Regenerative medicines that are (or that have been) licensed by the EMA (continued )
MACI: EMA assessment (CHMP and CAT) 2013,19 NICE multiple technology appraisal 201420
Trial size/total trial population 144 patients: 72 patients MACI, 72 patients microfracture
Length of follow-up 2-year follow-up data already collected from the MACI00206 study (5-year follow-up
planned)
Control/comparator used Microfracture treatment
How is the control/comparator
constructed?
RCT
Outcomes
Response outcome 1 Co-primary end point of Knee Injury and Osteoarthritis Outcome Score (KOOS) for pain
and function (sports and recreational activities)
Response outcome 2 Secondary end point: histology of cartilage forming (histological evaluation of
structural repair of evaluable biopsies harvested from the core of the index lesion
during arthroscopy)
Response outcome 3 Magnetic resonance imaging (MRI) of cartilage – MRI assessments of structural repair
parameters
Adverse events Most adverse events were thought to be surgery related rather than product related
Surrogate or intermediate clinical
outcome?
Yes – structural and functional repair of cartilage defects as measured by MRI or
histology scoring
Real clinical outcome? Yes – KOOS
Summary of evidence
Overall evidence base provided A clinically and statistically significant difference in improvement from baseline to week
104 was seen for the co-primary end point of KOOS for pain and function in patients
treated with MACI over the comparator (p= 0.001). Significantly more patients treated
with MACI (87.50%) met the responder analysis criteria than patients treated with
microfracture (68.06%), which is considered clinically relevant. The primary efficacy end
point was corroborated by several other patient-reported outcome measures and a
responder analysis of the primary efficacy measures demonstrated superior clinical efficacy
for patients treated with MACI compared with microfracture
Estimate of HRQoL Knee-related quality of life is one of the five key dimensions of KOOS, although the
NICE report highlighted the ‘lack of good quality of life data’ (p. 60)20
Other issues
Any issues of scale-up for the
product?
The manufacture of the product is patient specific (autologous). Production will be
centralised at one site
Is further evidence requested for
EMA/FDA approval?
1. As part of the ongoing monitoring of MACI, the EMA requested the 5-year
follow-up data from the main clinical study, which will provide information on the
sustainability of the cartilage repair and maintenance of the effect of MACI
compared with microfracture over time, as well as the long-term safety of
the medicine
2. Periodic safety update reports for this product within 6 months following
authorisation and a risk management plan
3. Education pack for surgeons
Any additional information
provided?
1. The applicant sought advice from the EMA/CHMP regarding the design of the trial
2. MACI has now been recommended for licensing as the first advanced-therapy
medicine to be combined with a medical device
3. Surgical skill was identified as being an important issue; MACI will probably be
available from only a few specialised centres
The marketing authorisation for MACI was suspended in September 2014 as an
authorised manufacturing site no longer existed (the developer closed the site)
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
166
TABLE 41 Regenerative medicines that are (or that have been) licensed by the EMA (continued )
ChondroCelect – characterised viable autologous cartilage cells expanded ex vivo expressing specific marker
proteins: EMA assessment 2009,22 NICE multiple technology appraisal 201420
EMA marketing authorisation
Nature of the disease
Indication The indication for ChondroCelect is repair of single symptomatic cartilaginous defects
of the femoral condyle of the knee [International Cartilage Repair Society (ICRS) grade
III or IV] in adults
Orphan status? No
Is this a rare condition? No
What is the natural history of the
disease without this treatment/
with current treatment?
The healing capacity of articular cartilage is poor and damaged articular cartilage is
thought to be a precursor to the development of osteoarthritis. Damaged articular
cartilage can result in pain, loss of joint function and disability. An early intervention on
symptomatic cartilage lesions may prevent or delay irreversible changes in the joint
surface. Currently, there is no uniform approach to managing significant knee cartilage
defects
Nature of the medicine
How does it work? ChondroCelect is a suspension of approximately 10,000 autologous cartilage cells per
microlitre of medium for autologous use. The cells have been obtained by ex vivo
expansion of chondrocytes isolated from a biopsy of the articular cartilage from the
patient’s knee. The active substance is a centrifuged pellet of 4–12 million cells that were
expanded ex vivo, harvested and washed. The expansion process is designed to preserve
the integrity and function of the cells and particularly to maintain the cells’ ability to
produce hyaline cartilage
Is it claiming to meet an
otherwise unmet need?
No. Other treatment options exist and clinical practice varies
How is it given? In the first step a cartilage biopsy is obtained arthroscopically from healthy articular
cartilage from a lesser weight-bearing area of the patient’s knee, approximately
4 weeks prior to implantation. Chondrocytes are isolated from the biopsy by enzymatic
digestion, expanded in vitro, characterised and delivered as a suspension of 1 × 104
cells/µl for implantation in the same patient. During the second step of the procedure
the expanded chondrocyte suspension is implanted during open-knee surgery
Are there any comparator
treatments?
Repair techniques such as microfracture aim at marrow stimulation and induce the
formation of fibrocartilage repair tissue to treat patients with focal chondral defects in the
knee. These techniques penetrate the subchondral bone and cause release of marrow
components into the defect site. The reparative response produced from these
procedures is one that may generate primarily fibrocartilage. Single-stage restoration
techniques such as osteochondral autograft, mosaicplasty and osteochondral allograft
attempt to replace the cartilage defect with host or donor articular cartilage
Is there any mention of the
intervention evolving over time?
Yes – ChondroCelect is a third-generation ACI product
Is there any mention of
persistence of the treatment
within the patient?
Implanted cells become a structural part of newly formed cartilage
Trial design
Trial description Study TIG/ACT/01/2000 is a Phase III, multicentre RCT to compare ChondroCelect with
microfracture in the repair of symptomatic single cartilaginous lesions of the femoral
condyles of the knee. Supportive study: prospective, long-term follow-up study of patients in
the Belgian Armed Forces treated with ChondroCelect (TIG/ACT/02)22
Trial population (adults/children/
all); any further specifics of
disease not covered in
‘Indication’
TIG/ACT/01/2000: patients aged between 18 and 50 years who had a single
symptomatic cartilage lesion of between 1 and 5 cm2 of the femoral condyles met the
inclusion criteria
TIG/ACT/02: this study is a prospective, non-comparative, open-label study of
2–5 years’ duration in 20 patients with single and multiple symptomatic cartilage
defects, in any location of the knee, who underwent chondrocyte implantaton using
ChondroCelect
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TABLE 41 Regenerative medicines that are (or that have been) licensed by the EMA (continued )
ChondroCelect – characterised viable autologous cartilage cells expanded ex vivo expressing specific marker
proteins: EMA assessment 2009,22 NICE multiple technology appraisal 201420
Trial size/total trial population TIG/ACT/01/2000: 118 participants: n= 57 ChondroCelect, n= 61 microfracture
TIG/ACT/02: Of all reported lesions, 80% were reported to be of ICRS Grade III or IV.
Of 24 femoral lesions reported in 19 patients, 21 were treated with CCI
Length of follow-up TIG/ACT/01/2000: 12 months, extended to 36 months for adverse events
TIG/ACT/02: 5 years
Control/comparator used Microfracture is considered an effective standard treatment for smaller femoral cartilage
lesions according to currently available literature and is an acceptable control therapy
How is the control/comparator
constructed? Source of
comparative data? Confounding?
RCT
Outcomes
Response outcome 1 Knee Injury and Osteoarthritis Outcome Score (KOOS)
Response outcome 2 Structural repair
Adverse events The overall safety summary showed that the main difference in treatment-related adverse
events between ChondroCelect and microfracture was related to the open knee surgery
(arthrotomy), which caused an increase in joint swelling and possible joint effusion.
Cartilage hypertrophy can be reduced by using a biomembrane to cover the lesion and
will therefore not pose a major safety concern in future applications of ChondroCelect.
However, a higher number of patients in the microfracture arm have a treatment failure
and require a subsequent surgical intervention. Therefore, the short- and long-term
complication rate is not higher for ChondroCelect than for microfracture
Surrogate or intermediate clinical
outcome?
Yes – structural repair (histological analysis)
Real clinical outcome? Yes – KOOS
Summary of efficacy evidence
Overall evidence base provided The mean change in overall KOOS from baseline to the average of 12–18 months was
slightly higher for patients in the ChondroCelect group than for patients in the
microfracture group. The results fulfil the predefined criteria for non-inferiority and changes
are clinically relevant. The results of the histological analysis of structural repair at 12 months
favoured ChondroCelect and the difference was statistically significant for both qualitative
and quantitative analyses. It was, however, acknowledged that this end point was not in
compliance with good clinical practice as it was developed during the conduct of the study
as the original a priori determined primary efficacy point was considered invalid
Estimate of HRQoL Knee-related quality of life is one of the five key dimensions of KOOS, although the
NICE report highlighted the ‘lack of good quality of life data’ (p. 60)20
Other issues
Any issues of scale-up for the
product?
The manufacture of the product is patient specific (autologous). Production will be
centralised at one site
Is further evidence requested for
approval?
The good clinical practice inspection highlighted the number of missing data on the
structural end point and the change to the ICRS II readout in the pivotal study as major
concerns. The CAT considered the following particular causes for concern:
l there were deficiencies in the conduct of the pre-authorisation studies and
uncertainties related to the results of the submitted single pivotal trial
l there is unknown long-term durability of product efficacy
l the benefit/risk profile of the product is significantly influenced by the level of
compliance with the defined procedures throughout treatment with
ChondroCelect, from biopsy harvest to receiving correct physiotherapy
The CAT also considered that performance of post-authorisation studies will need to
be part of the pharmacovigilance plan and efficacy follow-up plan presented in the risk
management plan. The CHMP agreed with the above
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TABLE 41 Regenerative medicines that are (or that have been) licensed by the EMA (continued )
Holoclar – ex vivo expanded autologous human corneal epithelial cells containing stem cells: EMA assessment
(CHMP, CAT, Committee for Orphan Medicinal Products) 201423
EMA conditional marketing authorisation
Nature of the disease
Indication Corneal lesions, with associated (limbal) stem cell deficiency (LSCD), as a result of ocular
burns. The clinical spectrum of LSCD includes pain, photophobia, inflammation, corneal
neovascularisation and eventually the reduction or complete loss of visual acuity
Orphan status? Designated as an orphan medicinal product (2008) in the following indications: corneal
lesions with associated LSCD as a result of ocular burns
Is this a rare condition? The condition is considered to be rare, with an estimated prevalence of 0.34 per 10,000
What is the natural history of the
disease without this treatment/
with current treatment?
If left untreated, the condition may progress to a stage whereby persistent epithelial
defects present with an associated high risk for the development of bacterial keratitis,
corneal perforation and blindness
Nature of the medicine
How does it work? Holoclar is specifically ex vivo expanded autologous human corneal epithelial cells
containing stem cells and replaces damaged corneal epithelium cells and creates a
reservoir of limbic stem cells (LSCs) in LSC-deficient areas of the cornea for continuous
regeneration. It consists of a transparent circular sheet of living tissue containing
autologous human corneal epithelial cells, limbal stem cells and derived transient
amplifying cells
Is it claiming to meet an
otherwise unmet need?
Yes, the product claims to respond to an unmet medical need by providing a new
active substance to treat patients with irreversible and extensive damage as a result of
an ocular burn. At the time of application, no medicinal products had been approved
in the EU/European Economic Area (EEA) for this indication and there was no gold
standard treatment
How is it given? Single topical placement without systemic effect
Are there any comparator
treatments?
Limbal allografts, which have an associated risk of rejection and which require
long-term systemic immunosuppression. Non-expanded limbal autografts from the
healthy fellow eye, which may lead to iatrogenic induction of LSCD in the donor eye
Is there any mention of the
intervention evolving over time?
No
Is there any mention of
persistence of the treatment
within the patient?
Negative effects of persistence – possible risks include systemic distribution of cells
derived from Holoclar that are tumour forming, accelerated immune response or
transmission of adventitious agents. The cells are not expected to migrate beyond the
ocular surface or to produce systemic effects. Tumourigenicity was investigated in vivo
and results suggested a low risk
Positive effects of persistence – some information on the potential for biodistribution was
derived from a historical data set: data from a histological and morphological evaluation
of corneal material collected from 26 patients who had undergone perforating
keratoplasty post LSC transplantation with Holoclar. Available long-term follow-up data
up to 10 years after autologous cultivated limbal stem cells transplantation, although
limited, supported persistence of treatment success beyond 12 months. Additional
long-term efficacy data will be collected in the margins of a post-authorisation safety
study to confirm this outcome
Trial design
Trial description Multicentre retrospective observational case series
Primary efficacy/safety study and supportive study
HLSTM01 (1998–2007) HLSTM02 (1998–2007) HLSTM04 (2008–2013)
Trial population (adults/children/
all); any further specifics of
disease not covered in
‘Indication’
Male or female with
moderate/severe LSCD;
median age 49 years,
mostly adults
Male or female with
moderate/severe LSCD;
median age 43.5 years,
mostly adults
15 patients treated from
2008 (from additional
centres not originally
provided as part of
HLSTM01)
continued
DOI: 10.3310/hta21070 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 7
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Hettle et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
169
TABLE 41 Regenerative medicines that are (or that have been) licensed by the EMA (continued )
Holoclar – ex vivo expanded autologous human corneal epithelial cells containing stem cells: EMA assessment
(CHMP, CAT, Committee for Orphan Medicinal Products) 201423
Trial size/total trial population 104 patients with
moderate/severe LSCD;
two centres
29 patients with
moderate/severe LSCD;
seven centres
15 patients with
moderate/severe LSCD;
three centres
Length of follow-up 12 months post-intervention assessment, max. 10 years’ follow-up: 28% of patients
1–2 years, 22% of patients 2–3 years, 12% of patients ≥ 5 years to a maximum of
10 years post transplantation
After year 5, only five patients had long-term follow-up data, of whom four were
reported to have continued treatment success
Control/comparator used Patients acted as their own controls – outcomes were compared with baseline data
How is the control/comparator
constructed? Source of
comparative data?
Confounding?
See above. The assumption that the condition would not heal was accepted, so any
healing could be ascribed to Holoclar
Outcome
Response outcome 1 Successful transplant at 12 months based on the co-presence of clinical signs:
(1) a superficial corneal neovascularisation classified as ‘none’ or ‘mild’ and
(2) epithelial defects classified as ‘none’ or ‘trace’
Response outcome 2 Symptomatic relief (pain, burning, photophobia)
Response outcome 3 Improvement in visual acuity or visual stabilisation at month 12 compared with
baseline
Surrogate or intermediate clinical
outcome?
Yes – corneal epithelial integrity and absence of significant corneal neovascularisation
Real clinical outcome? Yes – improved visual acuity
Adverse events Eye-related disorders were the most commonly observed adverse events, occurring in
57% of the safety population. Overall, the rate of serious adverse events was low.
Out of a total of 11 serious adverse events, three were judged as related to the
administration of Holoclar
Summary of efficacy evidence
Overall evidence base provided 1. Significant decrease (p< 0.001) in ocular symptoms (reduction from 40 patients to
12 patients with ocular symptoms)
2. No change in inflammation by the 12-month end point: 32 pre-surgical patients,
33 post-surgical patients
3. Superficial corneal neovascularisation evaluated before and after the
transplantation: 73.1% of patients showed an improvement at 12 months post
transplantation and there was a significant decrease in corneal neovascularisation
from baseline to 12 months post surgery (p< 0.001)
4. 83.6% showed a reduced epithelial defect of none or trace
5. An improvement in visual acuity was noted in 51 (49%) patients
6. The majority of patients required only one transplant for a successful outcome
7. Persistent success of limbal cell transplantation after keratoplasty: 14 patients had
one previous transplants and two patients had two previous transplants.
8. 57 patients had keratoplasty subsequent to the Holoclar graft and success was
achieved in 24 patients
9. The results of impression cytology in a subset of patients in the pivotal studies
showed an increase in the percentage of keratinocytes and a decrease in the
percentage of conjunctival cells after Holoclar treatment, thus providing evidence
that Holoclar enables corneal-type epithelialisation of the ocular surface and exerts
a regenerative effect
Estimate of HRQoL Not assessed
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TABLE 41 Regenerative medicines that are (or that have been) licensed by the EMA (continued )
Holoclar – ex vivo expanded autologous human corneal epithelial cells containing stem cells: EMA assessment
(CHMP, CAT, Committee for Orphan Medicinal Products) 201423
Other issues
Any issues of scale-up for the
product?
Clinical success depends on factors unique to cell therapies, including manufacturing
procedures, clinical and pharmacological standardisation of protocols and regulation.
Manufacture of the active substance is patient specific and the manufacturing process is
state of the art and highly complex. As such, the applicant implemented a training
programme for surgeons to ensure collection of seed material and a structured approach
to manufacturing consisting of many monitored stages and substage in-process controls.
The applicant was also required to provide further evidence on the stability of the product
(integrity and viability) and transport information
Is further evidence requested for
EMA/FDA approval?
A multinational, multicentre, prospective, open-label, uncontrolled interventional study
to assess the efficacy and safety of autologous cultivated LSC grafting for restoration
of corneal epithelium in patients with LSCD caused by ocular burns was required by
December 2020. A major objection was raised with regard to the proliferation of
irradiated cells and further validation was requested. Evidence was provided in the
form of a demonstration of several methods to show that the irradiated cells do not
proliferate. Paediatric application was deferred at the time of submission pending
further measures
Notes At the time of the application > 200 patients had already been treated with Holoclar in
clinical practice (since 1998); however, many clinics declined the request to provide data.
The assessors considered that this may introduce bias but felt that the supporting
literature and the similarity of the findings reported to those in the published articles
provided some confidence in the numbers and, therefore, they were happy to allow the
data. Supportive data from published articles were also considered by the CAT and this
appears to have had a strong influence on the decision-making process, although only
supportive information was provided. As the condition was considered to have a low
incidence the small sample size was considered to be acceptable. The CAT noted that at
baseline the majority of patients already presented with no or only trace epithelial
defects and as such already presented with a successful treatment outcome. However,
they considered that LSCD is a condition with impaired ability to maintain or restore an
intact corneal epithelium and so defects over the follow-up period were considered
clinically relevant. The fact that the studies were uncontrolled and not randomised
further added to the uncertainties of the validity of the data set, but this was considered
inevitable because of the lack of a suitable comparator, considering that there is neither
an approved treatment for LSCD nor a ubiquitous accepted standard of care. As this
condition would not heal spontaneously, the single-arm, uncontrolled design was
considered acceptable by the CAT
PROVENGE (sipuleucel-T/autologous peripheral blood mononuclear cells activated with prostatic acid
phosphatase–granulocyte-macrophage colony-stimulating factor): EMA assessment 2013 (CAT and CHMP),24
NICE STA 2014,26 FDA assessment 200925
EMA marketing authorisation in June 2013, which was withdrawn in May 2015 at the request of the manufacturer for
commercial reasons
Nature of the disease
Indication Asymptomatic or minimally symptomatic metastatic (non-visceral) hormone-relapsed
prostate cancer in men for whom chemotherapy is not yet clinically indicated
Orphan status? No
Is this a rare condition? Hormone-refractory metastatic prostate cancer affects around 5000 patients per year
in the UK
What is the natural history of the
disease without this treatment/
with current treatment?
Asymptomatic patients have a median OS of 18–24 months. Patients with
symptomatic disease have a median OS of 9–16 months
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TABLE 41 Regenerative medicines that are (or that have been) licensed by the EMA (continued )
PROVENGE (sipuleucel-T/autologous peripheral blood mononuclear cells activated with prostatic acid
phosphatase–granulocyte-macrophage colony-stimulating factor): EMA assessment 2013 (CAT and CHMP),24
NICE STA 2014,26 FDA assessment 200925
Nature of the medicine
How does it work? Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate
an antigen (CD59) immune response to prostate cancer. Patients’ peripheral blood
mononuclear cells are incubated with a recombinant fusion protein, the prostate protein
prostatic acid phosphatase
Is it claiming to meet an
otherwise unmet need?
No
How is it given? Following blood sampling leukapheresis is performed (day 1) after which sipuleucel-T
is manufactured at a central facility (days 2–3) and then infused into the patient
(day 3 or 4). This process happens three times, at approximately 2-week intervals
Are there any comparator
treatments?
Best supportive care (radiotherapy, bisphosphonates, steroids, analgesics, active
surveillance), abiraterone acetate
Is there any mention of the
intervention evolving over time?
No
Is there any mention of
persistence of the treatment
within the patient?
No. The achievement and maintenance of the antigen response was assessed –
maximum duration tested was 26 weeks in one trial. There was no clear indication of
whether or not persistence was required for benefit. No adverse effects related to
persistence of antigen response were mentioned
Trial design
Trial description D9902B (IMPACT)24 D9902A24 D990124
Multicentre RCT (with
crossover allowed after
progression) using a 2 : 1
ratio (favouring allocation to
sipuleucel-T)
As for IMPACT trial As for IMPACT trial
Trial population (adults/children/
all); any further specifics of
disease not covered in
‘Indication’
Asymptomatic or minimally
symptomatic metastatic
hormone-relapsed prostate
cancer
Asymptomatic metastatic
hormone-relapsed prostate
cancer
Asymptomatic metastatic
hormone-relapsed prostate
cancer
Trial size/total trial population 512 98 127
Length of follow up 3 years [follow-up was
planned to continue until
the number of events
(deaths) reached that
required by the analysis
plan]
3 years 3 years
Control/comparator used Placebo, consisting of
one-third of the patient’s
cells being reinfused, but
the cells had not been
activated with the fusion
protein; the remaining
two-thirds were
cryopreserved
As for IMPACT study As for IMPACT study
How is the control/comparator
constructed? Source of
comparative data?
Confounding?
Following confirmation of
disease progression,
placebo patients could
receive activated cells
(i.e. very similar to
sipuleucel-T) derived from
their cryopreserved cells.
Open-label phase
As for IMPACT study As for IMPACT study
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TABLE 41 Regenerative medicines that are (or that have been) licensed by the EMA (continued )
PROVENGE (sipuleucel-T/autologous peripheral blood mononuclear cells activated with prostatic acid
phosphatase–granulocyte-macrophage colony-stimulating factor): EMA assessment 2013 (CAT and CHMP),24
NICE STA 2014,26 FDA assessment 200925
Outcomes
Response outcome 1 OS Time to disease
progression
Time to disease
progression
Response outcome 2 Time to objective disease
progression
OS Time to onset of
disease-related pain
Response outcome 3 Safety Time to objective disease
progression
Grade 3 adverse events
Surrogate or intermediate clinical
outcome?
TTP. Antigen response was also measured. Note: this did not correlate with the OS
results
Real clinical outcome? OS
Adverse events Overall, the leukapheresis procedure and PROVENGE infusions were well tolerated.
The main risks identified were acute infusion reactions, toxicities (e.g. citrate toxicity)
associated with the leukapheresis procedure and infections (principally associated with
catheters). Treatment with PROVENGE may lead to unwanted long-term immunological
effects in the body system. This potential risk is adequately addressed in the risk
management plan. Additional data will become available to further characterise the
long-term safety profile of PROVENGE through registries
Summary of efficacy evidence
Overall evidence base provided For the IMPACT trial, OS was significantly improved with sipuleucel-T (HR 0.8, 95% CI
0.61 to 0.98; p = 0.03) but there was no difference in time to objective disease
progression (HR 0.95, 95% CI 0.77 to 1.17; p = 0.63). Two trials reported a significant
advantage in terms of OS favouring sipuleucel-T, although no significant differences in
time to disease progression were seen in any of the three trials. The RCTs had a low
risk of bias, but only up to the point of disease progression, after which crossover from
placebo to active intervention was permitted. No analyses were performed to adjust
for crossover. In addition, the lack of significant effect on PFS may also have been
because of a delay in effect
Estimate of HRQoL Not assessed
Other issues
Any issues of scale-up for the
product?
Yes, patients’ cells must be transferred from their local hospital to a central
manufacturing facility and then back again to the local hospital. The final product has
a short shelf life
Is further evidence requested for
approval?
Periodic safety update reports
Notes Thirteen members of the CHMP did not agree with the CHMP’s recommendation
and the granting of a marketing authorisation. The objections were based around
whether the differences in OS resulted from a true and clinically relevant effect of
sipuleucel-T. The effect was not supported by either the PFS results or the TTP results.
Importantly, in case of disagreement between these outcomes the efficacy evidence
should be particularly convincing and ideally corroborated by other secondary end points,
which was not the case. A lower proportion of patients were treated with docetaxel in
the placebo group and also underwent delayed treatment with docetaxel in the placebo
group (in the pivotal trial), which may have had an effect on OS. Confounding may also
have been caused by the crossover from placebo to the active treatment (sipuleucel-T
prepared from cryopreserved cells); as stated above, no analyses were performed to
adjust for crossover and, therefore, the treatment effect may have been underestimated
‘Lack of consistency’ between TTP and OS, and possible confounding of the OS results by
non-randomised post-progression post-blinding treatment, was also noted in the ERG
report for NICE (appraisal now withdrawn). A possible reason for the lack of association
between OS and TTP was that current clinical metrics of progression assessed in bone are
inadequate. In addition, immune responses may require time to develop and the lack of
difference in progression could result from such a delayed anti-tumour response
FDA analyses of docetaxel treatment following randomisation did not provide evidence
continued
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TABLE 41 Regenerative medicines that are (or that have been) licensed by the EMA (continued )
PROVENGE (sipuleucel-T/autologous peripheral blood mononuclear cells activated with prostatic acid
phosphatase–granulocyte-macrophage colony-stimulating factor): EMA assessment 2013 (CAT and CHMP),24
NICE STA 2014,26 FDA assessment 200925
that the survival difference between the two arms was attributable to docetaxel. The FDA
statistician based these analyses on the following assumption, which was thought very
likely to be true: more patients with good prognosis were in the placebo arm than in the
sipuleucel-T arm in the subgroup receiving docetaxel. This implies that more patients with
poor prognosis were in the placebo arm in the sipuleucel-T arm in which patients did not
receive docetaxel, as overall the two treatments were comparable
In May 2015 the EU marketing authorisation for PROVENGE was withdrawn at the
request of the manufacturer (Dendreon) for commercial reasons
ReCell Spray-On Skin system: NICE Medical Technologies Evaluation Programme (MTEP) 201427
Authorisation granted in 2005 under Medical Devices Directive 93/42/EEC28
Nature of the disease
Indication Adults or children treated in burns units or centres for (1) partial-thickness burns
including scalds caused by hot water for which mesh grafting is not required and
(2) large-area burns – full-thickness or deep partial-thickness burns including where
mesh grafting is required
Orphan status? No
Is this a rare condition? No
What is the natural history of the
disease without this treatment/
with current treatment
The treatment of burns can be considered in two phases: acute and reconstructive.
The acute phase is the initial management of the injury with the intention that burn
wound healing will occur with minimal scarring and physical limitation. The
reconstructive phase aims to improve the functional or visual impact of scarring,
usually by surgical means, and may be carried out months or years after the initial
injury. Full-thickness burns of > 1 cm in diameter need skin grafts because the
regenerative components of the skin have been lost. Healing can occur only from the
edges of the wound; without a graft the skin contracts, leading to a poor cosmetic
outcome and reduced mobility. Deep dermal burns are unlikely to heal within 3 weeks
and will therefore often need grafting
Nature of the medicine
How does it work? ReCell is a stand-alone autologous cell harvesting device that enables a thin
split-thickness skin biopsy to be processed to produce a mixed cell population for
immediate delivery onto a prepared wound surface
Is it claiming to meet an
otherwise unmet need?
No
How is it given? The ReCell device allows a small, thin split-thickness shave biopsy to be physically and
enzymatically broken down, yielding a viable suspension of mixed keratinocytes,
fibroblasts and melanocytes that can be immediately sprayed or dripped on to the
de-epithelialised area. The process is rapid – around 30 minutes – and does not require
specialist skills or facilities to carry out. A cell suspension derived from a 1-cm2 biopsy is
sufficient to treat an area of around 80 cm2, making it particularly valuable for patients
with limited available healthy donor sites
Are there any comparator
treatments?
Partial-thickness burns: biosynthetic dressings or standard dressings; large-area burns:
skin mesh graft alone or skin mesh graft plus biosynthetic dressing
Is there any mention of the
intervention evolving over time?
No
Is there any mention of
persistence of the treatment
within the patient?
No
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TABLE 41 Regenerative medicines that are (or that have been) licensed by the EMA (continued )
ReCell Spray-On Skin system: NICE Medical Technologies Evaluation Programme (MTEP) 201427
Trial design
Trial description Eleven studies were included in the submission to NICE:27 three RCTs and eight
observational studies. Two of the RCTs were pilot studies with very small sample sizes
(n = 13 and 14). All but one of the observational studies were also small (range 5–40
patients) case series. The two main studies are summarised below
Gravante et al.213 Park et al.214
Single-centre RCT Retrospective cohort study (three groups)
Trial population (adults/children/
all); any further specifics of
disease not covered in
‘Indication’
Adults with deep partial-
thickness burns (< 320 cm2)
Burns treated with skin grafting or replacement; all
ages
Trial size/total trial population? 82 767
Length of follow-up 6 months Not reported
Control/comparator used Split-thickness skin grafting ReCell Spray-On Skin system plus standard skin graft
and standard skin graft alone
How is the control/comparator
constructed? Source of
comparative data?
Confounding?
RCT Both the intervention and the two comparators used
historical data. Multiple regression was used, although
sex and type of burn agent were not included in the
model input variables. Burn depth was greater in
patients treated with a standard skin graft than in
patients treated with ReCell alone, although burn
depth was controlled for in the multiple regression
Outcomes
Response outcome 1 Time to complete
epithelialisation
Wound infection
Response outcome 2 Aesthetic and functional
quality of the scar
Graft loss
Response outcome 3 Wound infections
Response outcome 4 Postoperative pain
Surrogate or intermediate clinical
outcome?
No No
Real clinical outcome? Yes Yes
Adverse events None reported None reported
Summary of efficacy evidence
Overall evidence base provided The RCT found ReCell and standard skin graft to be comparable in terms of wound
healing time and long-term aesthetics, but ReCell was significantly less painful and the
mean size of the donor site was significantly smaller. These results were reflected in
the large cohort study, which also found no difference in terms of wound infection.
The remaining evidence was supportive, indicating a range of patients who can be
treated with ReCell. The External Assessment Centre concluded that ReCell may be
a clinically suitable alternative to the use of split-thickness skin grafts in mid-deep
partial-thickness burns. There was no clinical evidence examining the use of ReCell
in partial-thickness burns, which are considered not to require skin grafting. There
was also no evidence demonstrating improved outcomes for the use of ReCell plus
split-thickness skin grafts compared with split-thickness skin grafts alone
Estimate of effect HRQoL Not reported
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TABLE 41 Regenerative medicines that are (or that have been) licensed by the EMA (continued )
ReCell Spray-On Skin system: NICE Medical Technologies Evaluation Programme (MTEP) 201427
Other issues
Any issues of scale-up for the
product?
No
Is further evidence requested for
approval?
NICE concluded that despite the potential benefits of the ReCeII Spray-On Skin system
in terms of helping improve healing of acute burns, there was limited evidence
regarding its use in clinical practice to curently support routine use in the NHS.27 NICE
recommended research to address uncertainties about the claimed patient and system
benefits of the ReCell Spray-On Skin system. Clinical outcomes should include time to
95% healing, length of hospital stay, cosmetic appearance of the scar and function of
the burned area with ReCell compared with standard care
Notes Note: within the NICE assessment the claimed benefits of ReCell in the case for
adoption presented by the sponsor were:
l a reduction in the size and depth of the skin graft donor site
l shorter healing time, fewer complications and reduced morbidity at the donor site
l shorter healing time at the recipient site, leading to:
¢ improved aesthetic results for burn wounds, with a reduced likelihood
of scarring
¢ reduced likelihood of later readmission to hospital for corrective surgery as a
result of improved aesthetic results
l repopulation of melanocytes to reduce hypopigmentation and improve skin colour
match in healed wounds
l reduced frequency of dressing changes to weekly rather than daily, allowing for a
shorter stay in hospital and outpatient management
l reduced need for dressing changes under anaesthetic
l a reduction in the need for external technical laboratory support
This long list of potential benefits was not supported by robust evidence
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Appendix 2 Adjustment for bias in
non-randomised studies
Methods developed to adjust effect estimates obtained from NRSs for potential biases have taken twobroad approaches: adjust at the study level or adjust as part of the process of evidence synthesis.
These approaches are discussed separately in the following sections.
Adjusting for bias in the evidence synthesis process
The review of the literature on methods to adjust for bias in the evidence synthesis process identified
10 relevant studies.44–53 These articles included two comprehensive reviews44,45 as well as individual articles,
all of which were identified in the review articles. Many of the techniques described in Verde and
Ohmann44 and Doi,45 however, have limited applicability to regenerative medicine (i.e. when only limited
evidence from a small number of studies is available), as they require significant numbers of studies or data
from RCTs to be applied. A small number of these techniques can, however, be applied when only a single
study or a small number of studies is available. These methods are outlined in the following sections.
Adjusting using external data
Welton et al.50 present a Bayesian hierarchical model to model bias in RCTs that are at high risk of bias.
The authors developed a mixed-effects model in which treatment effects are considered as fixed and bias
effects are considered as random. Estimates of bias in any given meta-analysis were given as a function of
the prior distribution, which was estimated from published meta-analyses of RCTs and data from the current
meta-analysis. When a meta-analysis contained no information about the size and magnitude of the bias,
that is, when there were only high-risk studies, the estimate of bias was based on the prior distribution
alone. This method allows treatment effect estimates to include information from the high-risk studies,
accounting for the uncertainty in the magnitude of the bias in any particular meta-analysis. This technique
was designed with adjustment of RCTs in mind but is extendable to the adjustment of NRSs whereby
RCTs represent the low-risk studies and NRSs represent the high-risk studies. An appropriate library of
meta-analyses combining data from RCTs and NRSs would, however, be necessary to apply this technique.
Elicitation
Turner et al.,53 recognising the practical limitations of basing adjustment on external empirical data,
proposed an alternative approach in which the direction and magnitude of biases are elicited by reviewers.
This method can deal with multiple sources and types of bias including both internal validity bias and
external validity bias. In brief, Turner et al.53 proposed that authors design an idealised study aimed at
answering the specific question in mind. This study may not be feasible to carry out and is simply a tool
for exploring bias in the completed studies. To identify the potential biases, the completed studies are
compared with the idealised study considering a number of potential sources of bias. For each form of bias
identified, assessors then elicit the likely magnitude and variance of the bias. These estimates of the
magnitude and variance of the potential biases can then be used to adjust treatment effect estimates
accounting for both the magnitude and the uncertainty of any potential bias identified. External empirical
evidence of bias can be included in the analysis rather than relying on eliciting values, but it is assumed
that these data will be largely unavailable.
Adjusting for bias at the study level
There are a number of established statistical methods for analysing NRSs that attempt to minimise the
potential bias from confounding. Each of these methods is briefly described in the following sections and is
followed by a brief review of the literature discussing the efficacy of these methods.
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Regression analysis
Confounding bias occurs in the context of estimating clinical effectiveness when individual patient
characteristics, such as age, sex and disease duration, that influence efficacy outcomes are also correlated
with treatment received. Regression analysis seeks to directly adjust for these potential confounding
variables by building a statistical model54 of the form:
Outcome variable = f (control variables + treatment decision). (7)
Regression models therefore allow the estimation of the treatment effect conditional on these
confounding variables. There are many types of regression model. The choice of any particular model
depends on the characteristics of the outcome variable (i.e. continuous or categorical) and on the way that
it is mathematically related to the explanatory variables. Typically, for dichotomous outcomes, a logistic
regression model is used. For continuous outcomes a linear regression model is used and for time-to-event
data a proportional hazards regression (Cox regression) model is used.
Theoretically, regression models can be used to entirely eliminate bias attributable to confounding as
long as the appropriate parameters are included with a regression equation. However, in reality, either
confounding factors will be unobserved, preventing their inclusion in the regression model, or a lack of
understanding of the disease process will mean that we do not know to include them in the regression
model. When such unobserved confounders are not included in the regression model, confounding bias
can persist. Regression techniques can be used in conjunction with other methods for adjusting of
confounding, including propensity scoring and instrumental variables.54 Regression models also require
a minimum number of participants per additional explanatory variable, with a useful rule of thumb
being at least 10 observations per explanatory variable.55 This requirement may limit their application to
regenerative medicine where effectiveness estimates can be based on relatively small studies.
Stratification
Stratification involves the division of participants into subgroups with respect to categorical (or categorised
quantitative) prognostic factors, for example classifying age into decades or weight into quartiles. The
intervention effect is then estimated in each stratum and a pooled estimate is calculated across strata. This
procedure can be interpreted as a meta-analysis at the level of an individual study. Major limitations are that it
is feasible and meaningful only when effects are consistent across strata and that it can usually be employed
for only few variables, as strata increase exponentially in keeping with the number of stratification factors.54
As such, stratification can only minimise rather than completely remove the bias resulting from confounding.
Matching
Matching involves selecting participants with similar values for important prognostic factors to make the
control and treatment groups more similar so that any differences between the treatment group and
the control group cannot be a result of differences in the matched variables. Matching can be carried out
both prospectively or retrospectively. Matching prospectively can, however, cause significant recruitment
problems. Matching retrospectively can also cause problems as it is not always possible to match individuals.
In large studies it is often easier to use an unmatched control group and to use regression analysis to adjust
for what would have been matched on.56 Matching can, however, be useful in small studies when there are
insufficient participants to adjust for multiple variables at once.56 As such, matching may be a potentially
useful technique for controlling for confounding when using historical controls with the small single-arm
studies that have typified regenerative medicine clinical evidence. Although matching can be used to reduce
confounding bias, it is unlikely to completely account for all difference because of unobserved confounding.
Instrumental variables analysis
Instrumental variables techniques attempt to approximate the experimental approach by using an instrument
variable or variables. A parameter is considered a valid instrument if it meets the following two conditions:
1. the instrument must be correlated with the receiving of treatment (or exposure)
2. the instrumental variable must be independent of (uncorrelated with) unobserved confounders.
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When a valid instrument exists the instrumental variables approach leads to unbiased estimates equivalent
to those from a randomised study. Indeed, randomisation can be thought of as the perfect instrumental
variable as it is by definition perfectly associated with treatment allocation and independent of unobserved
heterogeneity. The problem with the instrumental variables approach, however, is that identification of a
valid instrument is often difficult. Furthermore, although the first requirement of a valid instrument is easily
tested, the second requirement is essentially untestable and therefore we can never be certain that an
instrument is valid. The application of an instrumental variables approach also leads to significant reduction
in the power to detect a difference, particularly when the instrumental variable is poorly correlated with
treatment allocation. This issue may be particular problematic in regenerative medicine where studies are
often small with a low power to detect differences between alternative treatments.
Propensity scoring
Propensity scoring, rather than being a single method, is a suite of methods that considers confounding
bias as a form of selection bias in which treatment allocation is acknowledged to be non-random and
which considers that treatment selection is often influenced by a patient’s characteristics.57 All propensity
scoring methods seek to model this process of treatment selection and estimate the propensity to receive
treatment based on baseline patient characteristics. Conditional on the propensity score the distribution of
baseline characteristics will be similar in both the treatment group and the control group. Therefore, in
patients with similar propensity scores patient characteristics will be the same, independent of whether
treatment was received. The propensity is typically estimated using a logistic regression model, although
other methods have been applied. The estimated propensity score can be used to remove the effects
of confounding in four different ways.57 These are described very briefly below:
1. Matching – the propensity score is used to match participants in the treatment and control groups who
have similar values of the propensity score.
2. Stratification – subjects are ranked on the propensity score and stratified into groups, typically quintiles.
Stratum-specific mean differences are then calculated and these differences are effectively
meta-analysed to estimate an overall difference in means.
3. Inverse probability of treatment weighting (IPTW) – this involves using the propensity score as a weight
such that an individual participant’s weight is equal to the inverse of the probability of receiving
the treatment.
4. Covariate – the propensity score is added as a covariate within a regression equation. The propensity
score can be added either with or without additional explanatory variables.
A number of studies have sought to compare propensity scoring methods to ascertain which is the most
effective at removing confounding bias.57–61 These studies have shown matching and IPTW to be more
effective than stratification or covariate adjustment.58–61 The principal advantage of propensity scoring over
other adjustment methods such as regression analysis is that it can be used even with small sample sizes
and therefore may be particularly relevant to regenerative medicine. Propensity scoring also has a number
of disadvantages. First, propensity scoring controls only for differences in observed variables and does
nothing to remove bias resulting from unobserved characteristics. Second, including variables that affect
whether a treatment is received but not the outcome of interest increases the variance of the estimated
treatment effect without a concomitant reduction in bias. This is problematic as sometimes it can be
difficult to establish which variables will impact only on which treatment is received.57
Effectiveness of adjustment methods
Our review identified a total of nine studies: eight studies62–69 compared the results of regression analysis,
instrumental variables and propensity scoring and a further study70 discussed the relative merits of the
alternative methods of adjustment. Two of these studies were systematic reviews: Shah et al.66 reviewed
comparisons between propensity scoring and regression methods and Shah et al.66 and Laborde-Castérot
et al.69 reviewed comparisons between propensity scoring and instrumental variable analyses.
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Propensity scoring compared with regression analysis
Six studies62,64–68 compared propensity scoring with regression analysis. The conclusions from these studies
were inconsistent. Two studies66,68 concluded that estimates obtained from regression analysis are similar
to those obtained using propensity scoring. However, two studies64,67 also came to the opposite
conclusion, that estimates obtained from regression analysis and propensity scoring differ significantly.
One simulation study65 comparing the two methods considered propensity scoring to be the superior
method, whereas another study62 found that propensity scoring is superior when the number of events
per confounder is low. The disparate results of these studies means that it is difficult to draw conclusions
regarding the relative performance of the different approaches, but Kurth et al.64 make an important
observation that potentially explains these different results. Kurth et al.64 note that each method of
adjustment answers subtly different questions as it makes different assumptions. This inevitably means that
different methods of adjustment will yield different results. Kurth et al.64 advise that researchers need to
consider carefully the population for which an overall treatment estimate is most appropriate.
Regression analysis compared with instrumental variables analysis
Only two studies compared regression analysis with instrumental variable methods.63,67 Crosby et al.63
found that results from regression analysis and instrumental variable methods differed somewhat and
suggested that instrumental variable methods are potentially superior. Stukel et al.67 compared all three
methods of adjustment (regression analysis, instrumental variables and propensity scoring) and concluded
that instrumental variables may lead to less biased estimates of treatment effects. Although the evidence
on instrumental variables is limited it nevertheless suggests that instrumental variables may offer
advantages over other methods and may produce the least biased estimates.
Propensity scoring compared with instrumental variables analysis
A recently published systematic review found 55 comparisons (37 studies) between propensity scoring
and instrumental variables analysis.69 The review found there to be a slight/fair agreement between the
methods (Cohen’s kappa coefficient = 0.21, 95% CI 0.00 to 0.41). In 23 cases (42%) the results were
non-significant using one method but significant using the other method; using instrumental variables
methods the results were non-significant in most cases (87%). The study authors recommended caution
when interpreting the results of these analyses and that further research is needed to clarify the roles of
these methods.
In addition to the seven empirical studies identified,62–67,69 a discussion paper by Biondi-Zoccai et al.70
provides a useful overview of the alternative methods of adjustment. Biondi-Zoccai et al.70 concluded that
there is no clearly superior method, noting that ‘both standard multivariable methods and propensity
scores have key limitations, and none is able to take into account unknown confounders’ (p. 736).
Biondi-Zoccai et al.,70 however, go on to suggest that propensity scoring methods may have advantages
over regression methods when the sample size is small and that, although instrumental variables methods
are not without their limitations, they are the only methods that allow for unobserved confounding to be
adjusted for.
Adjustment methods applied specifically to single-arm trials
Hamre et al.71 carried out a study aimed at improving methods to minimise bias in single-arm studies.
Four bias factors were suppressed stepwise: attrition bias (by replacing missing values with the baseline
value carried forward), bias from natural recovery (by sample restriction to patients with disease duration
of 12 months), regression to the mean because of symptom-driven self-selection (by replacing baseline
scores with scores 3 months before enrolment) and bias from adjunctive therapies (by sample restriction
to patients not using adjunctive therapies). In the cohort analysed, these four bias factors could together
explain a maximum of 37% of the 0- to 6-month improvement in disease score. However, this method has
not been widely tested on other cohorts.
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Appendix 3 Studies comparing bias adjustment
methods
TABLE 43 Studies comparing bias adjustment methods
Study Objective Methods compared Summary of findings
Biondi-Zoccai et al.,
201170
Discussion piece comparing
relative merits of alternative
methods of adjusting for
confounding bias in NRSs
Regression analysis,
propensity scoring and
instrumental variables
Propensity scoring may have
advantages over other methods of
adjustment, but all methods have
important limitations
Cepeda et al.,
200362
Simulations study comparing
logistic regression with
propensity scoring in terms of
bias, precision, empirical
coverage probability, empirical
power and robustness
Propensity scoring and
logistic regression
Logistic regression is superior to
propensity scoring when the
number of events is greater than
eight per confounder
Crosby et al.,
201063
To assess the potential
usefulness of instrumental
variables and ordinary least
squares regression for addressing
biases that can confound causal
inferences in child-care research
Regression analysis and
instrumental variables
Some discrepancies in results
obtained using regression analysis
and instrumental variables.
Suggested that instrumental
variables may be superior to
regression analysis as a method of
accounting for confounding bias
Kurth et al., 200664 To assess the utility of different
techniques to adjust for
confounding
Propensity scoring and
logistic regression
Different methods to control for
confounding yielded extremely
different treatment effect
estimates. This disparity is
suggested to be a result of each
analysis answering a different
question implicit or explicit to that
method of adjustment
Laborde-Castérot
et al., 201569
Systematic review of studies
comparing the performance of
propensity scoring with that of
instrumental variables analysis
Propensity scoring and
instrumental variables
analysis
There was slight/fair agreement
between the methods (Cohen’s
kappa coefficient = 0.21, 95% CI
0.00 to 0.41). In 42% of cases the
results were non-significant using
one method but significant using
the other method; using
instrumental variables methods the
results were non-significant in 87%
of cases
Martens et al.,
200865
Simulation study comparing the
treatment effect estimates from
propensity scoring and logistic
regression
Propensity scoring and
logistic regression
On average, estimates from
propensity scoring are closer to the
true marginal treatment effects
than those generated by logistic
regression
Shah et al., 200566 Systematic review: to determine
whether adjusting for
confounder bias in observational
studies using propensity scores
gives different results from
traditional regression modelling
Propensity scoring and
standard regression
analysis
Observational studies had similar
results whether using traditional
regression or propensity scores to
adjust for confounding. Propensity
scoring produced modestly more
conservative estimates of effect on
average
continued
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TABLE 43 Studies comparing bias adjustment methods (continued )
Study Objective Methods compared Summary of findings
Stukel et al., 200767 To compare four analytical
methods for removing the
effects of selection bias in
observational studies
Regression analysis,
propensity scoring (via
matching and covariate
adjustment) and
instrumental variables
Estimates of the observational
association of cardiac
catheterisation with long-term
acute myocardial infarction
mortality are highly sensitive
to analytical method used.
Compared with standard
modelling, instrumental variables
analysis may produce less biased
estimates of treatment effects
Sturmer et al.,
200668
To examine the use of
propensity scoring methods and
whether results obtained using
propensity scoring differ
substantially from those
obtained using standard
regression techniques
Propensity scoring and
standard regression
analysis
Little evidence that propensity
scoring yielded substantially
different estimates from those
obtained using conventional
multivariable methods
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Appendix 4 Studies on surrogate end points
TABLE 44 Review and data extraction of the literature on the use of surrogate measures as clinical end points in
therapeutic trials
Study Description/aim Summary/findings
Use of surrogate measures as clinical end points
Davis et al.,
201294
The aim of the review was to
examine the evidence available
on the relationship between
PFS/TTP and OS to support
surrogate end points in
advanced cancer
PFS and TTP are sometimes regarded as valid surrogate outcomes in
the absence of a mature data set, but an estimate of OS is still needed
within the economic analysis. The relationship between surrogate and
OS can be used to populate the economic model. Unfortunately, when
comparing studies, the lack of a standardised methodology or
approach made it difficult for the authors to establish a relationship.
The findings support Taylor and Elston89 in that any cost-effectiveness
analysis based on a surrogate relationship between PFS and OS should
be supported with a transparent explanation of how the relationship is
quantified and presented alongside appropriate validation analysis and
supporting literature
Katz 200496 An article presenting the FDA
regulatory context in relation to
problems of interpretation of
data from clinical trials in which
unvalidated surrogate markers
are used as primary outcomes
From a regulatory standpoint, the use of biomarkers and surrogate
outcomes is supported when used in the appropriate context and they
can be ‘shown to confer a clinical benefit to patients’ (p. 190). In research
in which there are few if any available alternative treatment options,
accelerated approval on the basis of the drug product having an effect
on a surrogate end point may be granted by the FDA. The surrogate end
point is expected to be based on research evidence other than survival or
irreversible morbidity. Important points to note with regard to the
regulation of surrogate outcome use in research include (p. 190):
l FDA regulation requires the effect on the surrogate to be only
‘reasonably likely’ to predict clinical benefit
l The regulation applies to use of an ‘unvalidated’ surrogate marker
in definitive effectiveness trials (to provide unequivocal evidence of
a treatment’s tangible benefit to the patient)
l An unvalidated surrogate is described as ‘reasonably likely’ to
provide a measure of clinical benefit in circumstances in which
evidence of a clinical effect is immature
l Only for proposed treatments for serious and life-threatening conditions
l Ongoing research must be continued after marketing. If research is
not continued or if continued but efforts to validate the surrogate
fail the drug must be withdrawn
Bucher et al.,
1999100
The JAMA (Journal of the
American Medical Association)
Evidence-Based Medicine
Working Group’s thoughts on
the validity of surrogate
outcome measures
For a surrogate to be valid there must be ‘no important effects of that
intervention on the outcome of interest that are not mediated through,
or captured by, the surrogate’ (p. 772). ‘Reliance on surrogate end
points may be beneficial or harmful’ (p. 771) and the clinician needs to
assess more than a single study to be confident that a surrogate end
point is an adequate measure of outcome
Fleming and
DeMets,
1996102
The most commonly used
guidance on the validity of
surrogate end points
For the surrogate to be a reliable outcome measure it must be on the
causal pathway from the intervention to the clinical outcome; this is
the ‘setting that provides the greatest potential for the surrogate end
point to be valid’ (p. 606). Reasons for failure when using surrogate
outcomes include (p. 606):
l the surrogate is not on the causal pathway from intervention to
clinical outcome
l the intervention affects only the pathway mediated by the surrogate
l the intervention does not affect the surrogate
l the action of the intervention is independent of the disease process
continued
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TABLE 44 Review and data extraction of the literature on the use of surrogate measures as clinical end points in
therapeutic trials (continued )
Study Description/aim Summary/findings
Health technology assessment and regulation
Elston and
Taylor,
200988
Paper published prior to the
following HTA programme
report by Taylor and Elston89
that specifically discusses the
use of surrogate outcomes in
cost-effectiveness models
This key discussion paper on the role of surrogate outcomes in
cost-effectiveness models is often cited as such and includes the
following recommendations (pp. 12–13):
When it is not possible to base the clinical effectiveness and
cost-effectiveness of the health technology on final patient outcome
data and there is a requirement to use a surrogate outcome, the
following should be undertaken:
1. a systematic review of evidence to validate the surrogate/final
outcome relationship
2. the evidence should be presented as follows:
i. level 1 – evidence demonstrating the effect of the intervention
on the surrogate is following the clinical pathway of the
patient-related outcome
ii. level 2 – evidence demonstrating a consistent association
between surrogate outcome and final patient-related outcome
iii. level 3 – evidence of a biological relationship between the
surrogate and the final patient-related outcome
3. a cost-effectiveness model based on a surrogate outcome should be
considered when there is level 1 or level 2 validation evidence
When a cost-effectiveness model analysis based on a surrogate
outcome is undertaken the authors recommend the following:
1. provide a transparent explanation as to how the relationship of
the surrogate and final outcome is quantified within the
cost-effectiveness model
2. explicitly explore and discuss the uncertainty associated with use of
the surrogate outcome
3. specific research recommendations should specifically address the
need for future research on the relationship between the surrogate
and final clinical outcome
4. the impact of the surrogate outcome on decision uncertainty may
be quantified by a value of information analysis
5. include the term ‘surrogate outcome’ in the report executive
summary/abstract to assist bibliographic identification
EUnetHTA
201387
Recommendations for end
points used in REAs of
pharmaceuticals. EUnetHTA
summarised its findings into
eight recommendations for end
points used in REAs of
pharmaceuticals (pp. 6–7)
EUnetHTA summarised its findings into eight recommendations for end
points used in REAs of pharmaceuticals (p. 6):
1. the REA of pharmaceuticals should be based whenever possible on
final patient-relevant clinical end points (e.g. morbidity, overall
mortality)
2. biomarkers and intermediate end points must reliably substitute for
a clinical end point and predict its clinical benefit
3. surrogate end points should be adequately validated
4. demonstration of surrogate validation both within and across drug
classes should be thoroughly justified
5. evidence on safety outcomes should always be reported
6. the absence of data on clinical end points might be acceptable
when a clinical end point is difficult or impossible to study;
however, these exceptions need to be carefully argued and agreed
in advance
7. reassessment requirements for further data should be clearly
defined when a REA has been previously made based on surrogate
end points for the first assessment
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TABLE 44 Review and data extraction of the literature on the use of surrogate measures as clinical end points in
therapeutic trials (continued )
Study Description/aim Summary/findings
Taylor and
Elston,
200989
Full HTA programme report to
explore the use of surrogate
outcomes in HTA and provide a
basis for guidance for their
future use, validation and
reporting
The focus of this report was the use of surrogate outcomes in
cost-effectiveness models within UK HTA programme reports. HTA
programme reports were selected to examine the role of surrogate
outcomes on cost-effectiveness models within the UK between 2005
and 2006. Selection was based on treatment effectiveness/efficacy,
a cost-effectiveness model being included in the report and the
cost-effectiveness model being primarily based on a surrogate
outcome. Only one HTA reported the results of a systematic review
that presented the evidence base for the association between
surrogate and final outcomes. A key output from this work was the
design of a schema used to evaluate the cost-effectiveness ratio of a
surrogate for use in HTA reports
Key publications
Aziz et al.,
201591
A review of the current
evidence for the treatment of
metastatic castration-resistant
prostate cancer and the
advantages of using prognostic
and/or predictive markers as
surrogate end points in clinical
trials
This review aimed to address the prospects for the future application
and clinical use of biomarkers in the field of metastatic castration-
resistant prostate cancer, including highlighting possible obstacles and
solutions: ‘Suitable parameters serving as surrogates for intermediate
and long-term endpoints and reflecting individual benefit, respectively,
need to be identified and proven’ (p. 649)
Bujkiewicz
et al., 2014116
A study to examine the
possibility of reducing the
uncertainty around the clinical
utility using multivariate
meta-analysis
In the areas of highest priority in health care, decisions are required to
be made on a short time scale. Therefore, alternative clinical outcomes,
including surrogate end points, are increasingly being considered for
use in evidence synthesis as part of economic evaluation
p. 109
The results of this research suggest that multivariate meta-analysis can
improve the estimation of health utilities through mapping methods;
however, more research is needed to determine the circumstances
under which uncertainty is reduced
Buyse et al.,
2007215
In this study the authors
examine the relationship
between PFS and OS in a set of
historical trials of colorectal
cancer
The end point for trials assessing chemotherapy for advanced cancer
was OS. This study examined the relevance of PFS as a surrogate end
point in studies with prolonged follow-up periods
The rank correlation coefficient between PFS and OS was equal to
0.82 (95% CI, 0.82 to 0.83). The correlation coefficient between
treatment effects on PFS and on OS ranged from 0.99 (95% CI,
0.94 to 1.04) when all trials were considered to 0.74 (95% CI,
0.44 to 1.04)
p. 5218
Data are presented that suggest that additional measures are required
to validate PFS as a surrogate for OS in colorectal cancer studies.
Recommendations include a comparison between the effects of
treatment on the true end point and the effects of treatment on the
surrogate at the population level as well as quantifying the association
between the true and the surrogate end points after taking treatment
into account at the individual level
Ciani et al.,
201398
The aim of this research was
to quantify and compare the
treatment effect and risk of bias
of trials reporting biomarkers
or intermediate outcomes
(surrogate outcomes) vs. trials
using final patient-relevant
primary outcomes
This meta-epidemiological study examined 84 trials using surrogate
outcomes and 101 using patient-relevant outcomes:
The preliminary results suggest trials reporting surrogate primary
outcomes are more likely to report larger treatment effects than
trials reporting final patient relevant primary outcomes
p. 346
continued
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TABLE 44 Review and data extraction of the literature on the use of surrogate measures as clinical end points in
therapeutic trials (continued )
Study Description/aim Summary/findings
As the study characteristics of the two trial types (surrogate outcomes
and those reporting patient-relevant outcome) were well balanced and
there were no differences in risk of bias, the authors conclude that the
findings could not be explained by these factors
Ciani and
Taylor,
201393
Letter to the editor
commenting on analytical
approaches discussed by
Hawkins et al.216 with regard to
the use of surrogates in HTA
and cost-effectiveness models
Presents opinion on the three main issues raised by Hawkins et al.216
with regard to best practice for the use of surrogate outcomes in HTA
and cost-effectiveness models:
1. the need for a new definition of surrogate outcome that fits not
only regulatory and licensing needs but also the evaluation of
treatment for HTA
2. to recognise the need for pragmatic, high-level evidence, preferably
from meta-analyses and regression modelling using both surrogate
and final outcomes
3. the need for systematic evidence that proves a link between the
surrogate and final outcome measures allowing a calculation of
the ICER
Oviana et al.,
2013217
This case study aimed to
illustrate the validation of
complete cytogenic response
(CCyR) and major molecular
response (MMR) as surrogate
outcomes for OS in chronic
myelogenous leukaemia (CML)
and how this evidence was
used to inform NICE’s
recommendation on the public
funding of first-line treatments
A case study to provide insight into the use of surrogate outcome
evidence in HTA. It is often a requirement that surrogate outcome data
be based on the findings of RCTs and that the link between the
treatment effects be apparent for both the surrogate outcome and the
final outcome. The findings from this case study suggest that a lower
level of evidence (i.e. observational association) may be acceptable
Ciani et al.,
2014107
The authors state that it is
essential that candidate
surrogate end points be
properly validated but that
there is no consensus on
statistical methods for such
validation. This study proposed
a method for validation
A review of three statistical approaches to surrogate–end point
validation (Elston and Taylor’s88 framework, the IQWiG framework and
BSES3) was performed. The findings suggest that the strength of the
association between two surrogates, PFS and TTP, and OS was
generally low. The authors discuss the challenges of surrogate–end
point validation and emphasise the importance of building consensus
on the development of evaluation frameworks
Ciani et al.,
2015108
To examine the treatment
effects on three surrogate end
points vs. OS based on a
meta-analysis of RCTs of drug
interventions in advanced
colorectal cancer (aCRC)
Univariate and multivariate random-effects meta-analyses were used to
estimate pooled summary treatment effects reported in RCTs of
pharmacological therapies in aCRC over a 10-year period. The
treatment effects on PFS, TTP and tumour response rate were all
compared with those for OS. The authors found larger treatment
effects for the surrogate end points than for OS, with differences in
median PFS/TTP higher than differences in OS by an average of
0.5 months. The authors conclude that the surrogacy relationships
observed between PFS and TTP vs. OS in selected settings may not
apply across other clinical classes or lines of therapy
De Gruttola
et al., 1997218
In this study the authors
consider why surrogate end
points can be unreliable and
illustrate the importance of
variability in evaluating the
reliability of surrogates, with
specific focus on HIV/AIDS
treatment
In order for a marker to be a valid surrogate by the ‘Prentice’
definition (Prentice 1989), it must capture all of a treatment's
beneficial and harmful effects
[Although] partial surrogate markers that capture some of a
treatment’s effect may provide insight into biologic mechanisms,
analyses of the degree of surrogacy must be regarded with caution
p. 243
Ellenberg and
Hamilton
1989219
A review of surrogate end
points in clinical trials with a
special focus on cancer
The authors argue that a surrogate end point is usually proposed on
the basis of a biological rationale. Overall, the paper describes how, in
cancer studies with survival time as the primary end point, the
surrogate outcomes often used are tumour response, TTP and time to
reappearance of disease, as these events occur earlier
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TABLE 44 Review and data extraction of the literature on the use of surrogate measures as clinical end points in
therapeutic trials (continued )
Study Description/aim Summary/findings
Fleming et al.,
1994220
In this paper the authors
discuss the applicability of
surrogate end point criteria,
with an emphasis on cancer
and AIDS research settings
The authors conclude that using biological markers as axillary end
points appears to provide an improvement in efficiency when assessing
treatment effect, although only a modest improvement:
There is potential for data on pertinent intermediate endpoints to
play an auxiliary role in strengthening true endpoint analyses
The gains will be particularly evident when sufficient follow-up
occurs to observe both auxiliary and true endpoints
p. 965
aFleming and
DeMets,
1996102
This paper provides examples
to illustrate how surrogate end
points may provide misleading
assessments of actual effects of
treatment on the health of
patients
In theory, for a surrogate end point to be an effective substitute for
the clinical outcome, effects of the intervention on the surrogate
must reliably predict the overall effect on the clinical outcome
p. 605
The authors argue that in reality this is not always the case and believe
that, although surrogate end points have value in guiding decisions
about whether the intervention is promising enough to justify a large
definitive trial with clinically meaningful outcomes, in definitive Phase III
trials, unless the surrogate end point has already been rigorously
established, the primary end point should be the clinical outcome used
Freedman
et al., 1992221
In this paper the authors
expand on the work of
Prentice222 with respect to the
criteria for validation of
intermediate variables or
surrogate end points, by
describing and discussing the
statistical implementation of
these criteria and by using the
example of serum cholesterol
as an intermediate end point
for coronary heart disease
The authors state that a major obstacle in the study of the aetiology
of chronic diseases and the development of effective prevention is
the long latent period between the initiation of the disease and its
diagnosis. Intermediate end points or surrogate end points are of
interest in the study of several diseases as they can usually be observed
prior to the clinical appearance of disease. In this paper an attempt
is made to clarify the criteria that may be used to validate an
intermediate end point. The authors found that the original general
criteria were difficult to test in practice and as such found that the
validation analysis would require some aspect of statistical modelling
Gøtzsche
et al., 199695
In this paper the authors review
the justification for the use of
surrogates and conclude that
‘reliance on them may be
harmful’
Surrogate outcomes can be any measurable event or value related to
the disease and true outcome of interest. A surrogate in one trial may
be the true outcome in another, depending on the purpose of the
study. The authors discuss the risk of making assumptions based on
surrogate outcome measures using a bone mineral density study as an
example. They report that, although clinically relevant interventions
would be expected to improve clinical outcomes, measures made on
surrogate outcomes may be unreliable as a true measure of a positive
effect
Herson
1989223
An introduction to a series of
papers that were presented at
a meeting in 1989 to address
the interest and controversy
around surrogate end points
Long completion times are not only a component of overall cost,
but also frequently result in the intervention under investigation
being rendered obsolete by the time the trial terminates . . . The use
of surrogate endpoints constitutes an effort to control the cost and
completion time for clinical trials
p. 403
Holloway and
Dick, 2002224
The authors hypothesise that
therapeutic uncertainty in
certain areas of clinical research
exists because of the use of
surrogate outcome measures in
clinical trials
many of the clinical trial end points have been surrogate outcome
measures rather than end points with clear and convincing value
to patients
Consequences of using surrogate outcomes that have not been
validated include ambiguous evidence and wasted resources as well
as patient harm and missed opportunities
p. 679
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TABLE 44 Review and data extraction of the literature on the use of surrogate measures as clinical end points in
therapeutic trials (continued )
Study Description/aim Summary/findings
Lerche la
Cour et al.,
201097
The authors assessed RCT
reports to evaluate the authors’
use of surrogate outcome
measures
Of 626 published RCTs, 109 used a surrogate as a primary outcome.
Of these trials, 62 clearly reported that the primary outcome was a
surrogate. Only 38 also discussed the validity of the surrogate. The
authors discuss the ‘shortcomings of surrogates’ in research and the
use of such surrogates as primary outcomes in about one-fifth of
published RCTs
Lessere et al.,
2007103
Review of biomarkers and
surrogates to systematically
evaluate the surrogacy status of
such measures
The result of this research was a recommendation for a new
quantitative surrogate validation level of evidence schema designed to
evaluate the criteria for biomarkers and surrogate end points:
Scores derived from 3 domains – the Target that the marker is
being substituted for, the Design of the (best) evidence, and the
Statistical strength – are additive. Penalties are then applied if there
is serious counterevidence
Most stakeholders agreed that this operationalization of the
National Institutes of Health definitions of biomarker, surrogate
endpoint, and clinical endpoint was useful
p. 607
Prentice
1989222
The operational criteria for
using surrogate end points in
clinical trials are discussed
A criterion for surrogate use is proposed:
In order that treatment comparisons based on a surrogate response
variable have a meaningful implication for the corresponding true
endpoint treatment comparison, a rather restrictive criterion is
proposed for use of the adjective ‘surrogate’
p. 431
Operationally, it is suggested that the surrogate ‘capture’ any
relationship between the clinical intervention and the true end point
Schievink
et al., 2014101
The authors consider the
opinions of different
stakeholders concerning the
use of surrogate end points in
the regulation of medicines
Online questionnaire of various stakeholder groups and medical
specialties to inquire under what conditions a surrogate end point
should be used:
out of four proposed surrogates (blood pressure (BP), HbA1c,
albuminuria, CRP) for cardiovascular outcomes or end-stage renal
disease, only use of BP for cardiovascular outcomes was deemed
moderately accurate (mean: 3.6, SD: 1.1). Specialists in cardiology
or nephrology tended to be more positive about the use of
surrogate endpoints
p. 1
Wilson et al.,
201590
Review of the benefits and
limitations of ‘alternative’ trial
end points in use for cancer
research
Considers the issue of who defines what is a clinically meaningful
outcome in cancer treatment: patients, clinicians or regulatory bodies
and also highlights the variation in opinion between these groups
Zee et al.,
2015225
A study to assess and validate
treatment effects with
surrogate survival outcomes
The authors conclude that the resulting method is able to account for
the uncertainty of surrogate outcomes. The proposed estimator is
thought to outperform standard semiparametric survival analysis
methods, saving on trial costs and leading to improvements in
detecting treatment effects
a Repeated in table as paper covers many subjects.
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Appendix 5 Licensed treatments for relapsed/
refractory B-cell acute lymphoblastic leukaemia
TABLE 45 Licensed treatments for relapsed/refractory B-ALL
Clofarabine: EMA,170 AWMSG – Evoltra;171 FDA – Clolar226
Nature of the disease and medicine
Indication(s) Relapsed or refractory paediatric ALL patients after receiving at least two
previous regimens and when there is no other treatment option that is
anticipated to result in a durable response
How does it work? Clofarabine is a purine nucleoside antimetabolite (affects DNA elongation,
synthesis and repair)
Is it claiming to meet an otherwise
unmet need?
Yes (indicated in patients in whom no other durable treatment options exist)
How is it given? Intravenous infusion for 5 consecutive days every 2–6 weeks. Dose for
paediatrics is 52 mg/m2 over 2 hours
Are there any comparator treatments? Not at the time of evaluation (other than palliative care)
Is there any mention of the intervention
evolving over time?
No (not a regenerative medicine)
Is there any mention of persistence of
the treatment within the patient?
No (not a regenerative medicine)
Trial design Only a single efficacy trial available
Trial description CLO 212: multicentre single-arm Phase II trial170
Trial population (adults/children/all); any
further specifics of disease not covered
in ‘Indication’
Paediatric patients aged from ≥ 1 to ≤ 21 years
Trial size/total trial population 61 patients
Length of follow-up Data cut-off point was 2 years after the start of recruitment
Control/comparator used Results for clofarabine were compared with rates expected by expert clinical
evaluation. No suitable published studies were available to provide appropriate
comparator data
How is the control/comparator
constructed? Source of comparative
data? Confounding?
Median survival of 9–10 weeks was estimated (using German and Dutch cancer
registries)
Outcomes
Response outcome 1 Overall remission rate (incorporates CR and CR without platelet recovery
Response outcome 2 PR
Response outcome 3 Duration of remission
Response outcome 4 OS
Adverse events Nausea and vomiting in around two-thirds of patients and febrile neutropenia in
around one-third. Two patients stopped treatment because of a serious adverse
event, although four deaths were considered to be related to clofarabine
Surrogate or intermediate clinical
outcome?
Remission outcomes
Real clinical outcome? OS
continued
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TABLE 45 Licensed treatments for relapsed/refractory B-ALL (continued )
Clofarabine: EMA,170 AWMSG – Evoltra;171 FDA – Clolar226
Summary of evidence The overall remission rate was 12/61 (20%). In total, 10/61 patients (16%)
went on to receive HSCT. Median survival (all patients) was 17.7 weeks. For
the seven patients achieving a CR, the median OS was 66.6 weeks (95% CI
53.7 to 89.4 weeks). The effect in terms of remission and facilitating HSCT was
considered to be clinically significant and may have a significant impact on
long-term treatment outcome; 8/18 responders received HSCT
Overall evidence base provided: trial result summary
Estimate of HRQoL No information reported
Product information and registration
Any issues of scale-up for the product? No – not a regenerative medicine
Is further evidence requested for
EMA/FDA approval?
Specific risk-minimisation activities were required. Prescribers were also
encouraged to participate in a voluntary adverse event reporting system. In
particular, monitoring of systemic inflammatory response syndrome was
important
Any additional information provided? The EMA review stated that, given the efficacy seen early on in the clinical
programme, studies using a placebo comparator were considered to be clinically
unethical. Active comparator studies were not appropriate as there were no
other recognised therapeutic options available. ‘The indication is encountered so
rarely that the applicant cannot reasonably be expected to provide comprehensive
data on clinical efficacy and safety’ (p. 35).170 Marketing authorisation was
therefore granted ‘under exceptional circumstances’. The AWMSG recommended
use only if the intended use was as a bridge to HSCT (should not be used with
palliative intent)
Blincyto (blinatumomab): FDA assessment227
Nature of the disease and medicine
Indication(s) Ph– relapsed or refractory B-cell precursor ALL
How does it work? Blinatumomab is a monoclonal antibody (a type of protein) that has been
designed to specifically recognise and attach to CD19 proteins and to the T-cell
receptor/CD3 complex, which is responsible for the activation of some cells of
the immune system (the body’s natural defences) called T-cells. By attaching to
the cancer cells and the T-cell receptor/CD3 complex blinatumomab is expected
to stimulate the T-cells to kill the cancer cells
Is it claiming to meet an otherwise
unmet need?
Clofarabine and Marqibo already exist as current treatments, although
blinatumomab might be a significant alternative because it works in a different
way from existing treatments
How is it given? Intravenous infusion over 4 weeks, with 2-week interval between each
treatment cycle
Are there any comparator treatments? Yes, clofarabine and Marqibo have been granted accelerated approval by the
FDA for a similar indication prior to blinatumomab
Is there an issue of the intervention
evolving over time?
No (not a regenerative medicine)
Is there an issue of persistence? No (not a regenerative medicine)
Trial design Trial MT103–211 (with supporting data from MT103–206)227
Trial description Single-arm pivotal Phase II trial (MT103–211)
Trial population (adults/children/all); any
further specifics of disease not covered
in ‘Indication’
Adults, mean age 39 years
Trial size/total trial population n= 189 (MT103–211) + 36 (MT103–206)
Length of follow-up 24 months
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
194
TABLE 45 Licensed treatments for relapsed/refractory B-ALL (continued )
Blincyto (blinatumomab): FDA assessment227
Control/comparator used Historical controls
How is the control/comparator
constructed? Source of comparative
data? Confounding?
Analysis of patient-level data from 694 historical controls: the CR+ CRh rate
was 24%
Outcomes Trial MT103–211 (with supporting data from MT103–206)
Response outcome 1 Rate of CR + CRh
Response outcome 2 RFS
Response outcome 3 OS
Response outcome 4 HSCT
Adverse events Boxed warning for CRS and neurological toxicities (including seizures)
Surrogate or intermediate clinical
outcome
CR+ CRh, RFS
Real clinical outcome OS
Summary of evidence
Overall evidence base provided CR+ CRh rate was 42% (95% CI 34% to 49%). Median RFS was 6.7 months
(95% CI < 0.1 to 16.5 months)
HRQoL measure No data
Product information and registration
Any issues of scale-up for the product? No (not a regenerative medicine)
Is further evidence requested for EMA/
FDA approval?
A confirmatory Phase III RCT comparing blinatumomab with standard care
chemotherapy in the same population was ongoing at the time of
submission.180 Randomisation method used will ensure a 2 : 1 treatment ratio
(i.e. more patients will receive blinatumomab than will receive standard care).
OS is the primary end point. In addition, there are four post-marketing
commitments to test the stability of the product once stored
Any additional information provided?
Marqibo (vincristine sulphate liposomes injection): FDA assessment173
Nature of the disease and medicine
Indication(s) Adult ALL patients with Ph– second or greater relapse or who are refractory to
treatment
How does it work? Targeted delivery of vincristine is achieved through encapsulating it in
nanoparticle liposomes. This allows increased vincristine doses to be achieved
without the associated increases in toxicity (dose-limiting neuropathy)
Is it claiming to meet an otherwise
unmet need?
Yes (no other durable treatment options existed at the time for this indication)
How is it given? Intravenously for 1 hour every week. Four doses= one course of treatment
Are there any comparator treatments? Not at the time of evaluation (other than palliative care)
Is there any mention of the intervention
evolving over time?
No
Is there any mention of persistence of
the treatment within the patient?
No
Trial design Only one trial using the correct dose (HBS407). Supporting evidence from a
Phase I/II, multicentre, dose-escalation study (VSLI-06) was also submitted173
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TABLE 45 Licensed treatments for relapsed/refractory B-ALL (continued )
Marqibo (vincristine sulphate liposomes injection): FDA assessment173
Trial description HBS407: multicentre, single-arm, Phase II trial (minimax two-stage design used
for sample size)
Trial population (adults/children/all); any
further specifics of disease not covered
in ‘Indication’
Adults only. All patients had previously been treated with standard vincristine
Trial size/total trial population 65 patients
Length of follow-up Up to 5 years (planned)
Control/comparator used Data from relevant patients included in a retrospective study were identified and
used as a historical control group. Median OS was < 3 months
How is the control/comparator
constructed? Source of comparative
data? Confounding?
Outcomes
Response outcome 1 Rate of CR + CR with incomplete blood count recovery (CRi)
Response outcome 2 Duration of CR+ Cri
Response outcome 3 OS
Adverse events Most frequent were constipation (57%) and nausea (52%). Around one-third of
patients had a neuropathy adverse event ≥ grade 3
Surrogate or intermediate clinical
outcome
CR, Cri
Real clinical outcome OS
Summary of evidence
Overall evidence base provided: trial
result summary
10/65 patients (15%) achieved CR or CRi. Five of the eight FDA-confirmed
CR+ CRi patients had a duration of response of < 1 month (median duration
of response for these eight patients was 28 days). Five patients who lived for
≥ 1 year were considered potential long-term survivors; two of the five did not
respond to Marqibo. In total, 12 patients received a stem cell transplant; seven
patients did not achieve CR or CRi with Marqibo but six of these received other
chemotherapy and had a subsequent stem cell transplant
Estimate/measure of effect (HRQoL) No information
Product information and registration
Any issues of scale-up for the product? No
Is further evidence requested for
EMA/FDA approval?
Post-approval confirmatory commitment study: a multicentre, open-label RCT
of standard vincristine vs. Marqibo in adults aged > 60 years with newly
diagnosed, untreated Ph– ALL. Proposed sample size of 348
Any additional information provided? ‘Accelerated approval’ regulations were used. Final vote was ‘yes’, n= 7; ‘no’,
n= 4; ‘abstain’, n= 2. Members discussed the liposomal formulation of the
product and its possible impact on the effectiveness of the drug; they
consistently stated that the proposed Phase III trial was critical in assessing the
benefit of Marqibo. Some members indicated that the trial should be completed
before approval, whereas several indicated that accelerated approval may be
appropriate but with the expectation that this approval would be withdrawn if
the Phase III trial failed to confirm clinical benefit. One member stated that the
‘yes’ vote was more an indictment of the lack of other options than enthusiasm
about Marqibo
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Appendix 6 Summary of patient characteristics in
previously published multivariate prognostic models
of acute lymphocytic (lymphoblastic) leukaemia
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Appendix 7 Review of previous economic
evaluations in acute lymphocytic (lymphoblastic)
leukaemia
Database
Ovid MEDLINE In-Process & Other Non-Indexed Citations and Ovid MEDLINE (1946 to present).
Search strategy
1. acute lymphoblastic leukaemia.ti,ab. (4080)
2. acute lymphoblastic leukaemia.ti,ab. (19,141)
3. Leukaemia, Lymphocytic, Chronic, B-Cell/ (12,539)
4. 1 or 2 or 3 (35,395)
5. ‘ALL R3’.ti,ab. (7)
6. ALLR3.ti,ab. (2)
7. ‘ALL R2’.ti,ab. (31)
8. ALLR2.ti,ab. (0)
9. 5 or 6 or 7 or 8 (39)
10. 4 or 9 (35,431)
11. economics/ (26,627)
12. exp ‘costs and cost analysis’/or Cost Allocation/or Cost-Benefit Analysis/or Cost Control/or Cost of
Illness/or Cost Sharing/or Health Care Costs/or Health Expenditures/ (188,408)
13. economics, dental/ (1861)
14. exp ‘economics, hospital’/or Hospital Charges/or Hospital Costs/ (20,315)
15. economics, medical/ (8619)
16. economics, nursing/ (3916)
17. economics, pharmaceutical/ (2575)
18. (economic$or cost$or price or prices or pricing or pharmacoeconomic$).tw. (536,282)
19. (expenditure$not energy).tw. (20,070)
20. (value adj1 money).tw. (27)
21. budget$.tw. (20,416)
22. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 (665,721)
23. ((energy or oxygen) adj cost).ti,ab. (3059)
24. (metabolic adj cost).ti,ab. (925)
25. ((energy or oxygen) adj expenditure).ti,ab. (18,354)
26. or/23–25 (21,563)
27. 22 not 26 (660,845)
28. letter.pt. (882,177)
29. editorial.pt. (379,418)
30. historical article.pt. (317,175)
31. 28 or 29 or 30 (1,563,299)
32. 27 not 31 (630,599)
33. exp animals/not humans/ (4,056,152)
34. 32 not 33 (586,163)
35. 10 and 34 (489)
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Appendix 8 Incidence of relevant population
estimate
To estimate the budget impact associated with CAR T-cell therapy it is necessary to estimate the incidentpopulation eligible for treatment per year. No observed estimates were available because of the small
numbers of patients involved and the late stage of treatment; therefore, an estimate was constructed
based on a three-step calculation:
1. estimate of new ALL diagnoses per year in the UK in the age range of interest
2. adjustment for B-ALL
3. adjustment for patients who have relapsed (with no further planned curative chemotherapy or HSCT) or
who are refractory to standard chemotherapy.
The ONS publishes registrations of newly diagnosed cases of cancer, shown for ALL in England in Table 47.233
The population of relevance is assumed to be those aged from birth to 30 years inclusive, consistent with the
definition of children and young adults in the study by Lee et al.,164 giving an annual incidence estimate of 460.
Of these ALL incident cases, an estimated 80–85% are B-ALL.234 For simplicity, we assumed that 82.5%
are B-ALL, giving a B-ALL incidence of 379.5. Finally, Fuster157 estimated that 20% of children experience
relapse after current frontline therapy. In addition, Fuster157 finds that, of this population, 50% will not
respond to salvage therapy or will suffer a second relapse, giving a population incidence of relevance of
37.95 per annum in England.
TABLE 47 Incidence of new ALL diagnoses in 2013233
Sex
Age (years)
Total< 1 1–4 5–9 10–14 15–19 20–24 25–29
Male 6 87 60 36 33 10 14 246
Female 9 102 48 22 18 6 9 214
Total 15 189 108 58 51 16 23 460
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Appendix 9 Full list of advisory group and
National Institute for Health and Care Excellence
panel members
TABLE 48 Members of the advisory group for the project
Andrew Stevens (chairperson) Professor of Public Health, University of Birmingham
Natalie Mount Chief Clinical Officer, Cell Therapy Catapult
Ian McKay Senior Scientific Officer, Genomics Science and Emerging Therapies, Department of Health
Nick Crabb Programme Director Scientific Affairs, NICE
Robert Hawkins Professor of Medical Oncology, University of Manchester
Panos Kefalas Head of Health Economics and Market Access, Cell Therapy Catapult
Matthew Taylor Director of York Health Economics Consortium, University of York
Philip Newsome Professor of Experimental Hepatology, University of Birmingham
Chris Mason Professor of Regenerative Medicine Bioprocessing, UCL
Angela Blake Head of Health and Value, Pfizer UK
Andrew Webster Director of the Science and Technology Studies Unit, University of York
Paul Catchpole Director of Value and Access, ABPI
Michael Hunt Chief Financial Officer, ReNeuron
Siobhan Connor Clinical Effectiveness Executive, BUPA
Holger Mueller Senior Vice President, Commercial Operations, Cell Medica
Ahmed Syed NHS England
Claude Schmitt Head of Market Access, Rare Diseases, GSK
Angela Crossman Global Market Access Director, Gene Therapy, GSK
Helen Tayton-Martin Chief Operating Officer, Adaptimmune
Matthew Durdy Chief Business Officer, Cell Therapy Catapult
ABPI, Association of the British Pharmaceutical Industry; BUPA, British United Provident Association; GSK, GlaxoSmithKline.
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TABLE 49 National Institute for Health and Care Excellence panel meeting participantsa
Andrew Stevens
(chairperson of the panel)
Chair of Appraisal Committee C, Professor of Public Health, University of Birmingham
Peter Jackson Consultant Physician and Honorary Reader in Clinical Pharmacology and Therapeutics,
Sheffield Teaching Hospitals NHS Foundation Trust
Gary McVeigh Professor of Cardiovascular Medicine, Queen’s University Belfast, and Consultant Physician,
Belfast Health and Social Care Trust
Peter Selby Consultant Physician, Central Manchester University Hospitals NHS Foundation Trust
Jonathan Michaels Honorary Professor of Clinical Decision Science, University of Sheffield
Mark Sculpher Professor of Health Economics, University of York
Allan Wailoo Professor of Health Economics and Director of NICE DSU, University of Sheffield
John Cairns Professor of Health Economics, Public Health and Policy, London School of Hygiene and
Tropical Medicine
Norman Waugh Professor of Public Health, Warwick Medical School
Paul Miller Director, Payer Evidence, AstraZeneca
Chris O’Regan Head of Health Technology and Outcomes Research, Merck Sharp & Dohme
Danielle Preedy Assistant Director, NIHR Evaluation, Trials and Studies Coordinating Centre
David Chandler Chief Executive, nominated by Psoriasis and Psoriatic Arthritis Alliance
a The panel meeting took place on the 29 October 2015 at NICE (Manchester).
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